[
  {
    "text": "Machine learning-based prediction of disease-free survival in breast cancer",
    "entities": []
  },
  {
    "text": "patients with non-pathological complete response after neoadjuvant chemotherapy:",
    "entities": []
  },
  {
    "text": "a retrospective multicenter cohort study.",
    "entities": []
  },
  {
    "text": "Author information:",
    "entities": []
  },
  {
    "text": "(1)Department of Breast Diseases, Jiaxing Women and Children's Hospital, Wenzhou",
    "entities": [
      {
        "text": "Breast Diseases",
        "label": "ORG"
      },
      {
        "text": "Jiaxing Women and Children's Hospital",
        "label": "ORG"
      },
      {
        "text": "Wenzhou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Medical University Jiaxing 314000, Zhejiang, P. R. China.",
    "entities": [
      {
        "text": "Medical University Jiaxing 314000",
        "label": "ORG"
      },
      {
        "text": "Zhejiang",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "This study aimed to construct a robust machine learning (ML) model for",
    "entities": [
      {
        "text": "ML",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "predicting the disease-free survival (DFS) and risk stratification of breast",
    "entities": []
  },
  {
    "text": "cancer (BC) patients with non-pathological complete response (non-PCR) after",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "neoadjuvant chemotherapy (NAC). The model will facilitate the initiation of",
    "entities": [
      {
        "text": "NAC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "early interventions for high-risk patients. This retrospective multicenter",
    "entities": []
  },
  {
    "text": "cohort study included BC patients from two hospitals in China who received NAC",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      },
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "NAC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "but did not achieve PCR. Four ML algorithms were utilized to construct models",
    "entities": [
      {
        "text": "PCR",
        "label": "ORG"
      },
      {
        "text": "Four",
        "label": "CARDINAL"
      },
      {
        "text": "ML",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "based on patients' clinicopathological data, followed by a performance",
    "entities": []
  },
  {
    "text": "evaluation of these models. To improve the interpretability of the model, the",
    "entities": []
  },
  {
    "text": "shapley additive explanation (SHAP) method was employed to analyze the",
    "entities": [
      {
        "text": "SHAP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "contribution of each feature to the predictive outcomes. A total of 463 non-PCR",
    "entities": [
      {
        "text": "463",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "patients were included in the study. Of these, 385 patients were from Ruijin",
    "entities": [
      {
        "text": "385",
        "label": "CARDINAL"
      },
      {
        "text": "Ruijin",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Hospital, affiliated with Shanghai Jiao Tong University, and were randomly split",
    "entities": [
      {
        "text": "Shanghai Jiao Tong University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "into a training cohort and an internal validation cohort in a 3:1 ratio for",
    "entities": [
      {
        "text": "3:1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "model development and preliminary performance evaluation. In addition, 78",
    "entities": [
      {
        "text": "78",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "patients enrolled from Jiaxing Women and Children's Hospital were assigned to",
    "entities": [
      {
        "text": "Jiaxing Women and Children's Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the external validation cohort to evaluate the model's generalizability.",
    "entities": []
  },
  {
    "text": "Univariate and multivariate Cox regression analyses demonstrated that age,",
    "entities": []
  },
  {
    "text": "residual tumor size, Ki67 change, molecular subtype, and axillary lymph node",
    "entities": []
  },
  {
    "text": "metastasis were independent factors influencing DFS. Among the four ML models,",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      },
      {
        "text": "ML",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the random survival forest (RSF) model showed the best performance, with a",
    "entities": [
      {
        "text": "RSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "concordance index of 0.820 in the training cohort, 0.642 in the internal",
    "entities": [
      {
        "text": "0.820",
        "label": "CARDINAL"
      },
      {
        "text": "0.642",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "validation cohort, and 0.689 in the external validation cohort. Further analysis",
    "entities": [
      {
        "text": "0.689",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "revealed that the RSF model had excellent discriminative ability with a high",
    "entities": [
      {
        "text": "RSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "area under curve value, while its low Brier score indicated excellent",
    "entities": [
      {
        "text": "Brier",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "calibration. Decision curve analysis indicated that the RSF model offered a",
    "entities": [
      {
        "text": "RSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "higher clinical net benefit at various time points and effectively stratified",
    "entities": []
  },
  {
    "text": "risk, successfully identifying high-risk patients. SHAP analysis underscored",
    "entities": []
  },
  {
    "text": "residual tumor size as the most influential predictive feature. The RSF model",
    "entities": [
      {
        "text": "RSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "can effectively predict DFS and risk of BC patients with non-PCR following NAC,",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      },
      {
        "text": "non-PCR",
        "label": "NORP"
      },
      {
        "text": "NAC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "offering a critical reference for developing individualized treatment",
    "entities": []
  },
  {
    "text": "AJCR Copyright \u00a9 2025.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The authors declare that the research was",
    "entities": []
  },
  {
    "text": "conducted in the absence of any commercial or financial relationships that could",
    "entities": []
  },
  {
    "text": "be construed as a potential conflict of interest.",
    "entities": []
  },
  {
    "text": "Erratum: Baicalein suppress EMT of breast cancer by mediating tumor-associated",
    "entities": [
      {
        "text": "Baicalein",
        "label": "PERSON"
      },
      {
        "text": "EMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "macrophages polarization.",
    "entities": []
  },
  {
    "text": "(1)Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong",
    "entities": [
      {
        "text": "The Second Affiliated Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University 157 West Fifth Street, Xi'an 710004, Shaanxi, P. R. China.",
    "entities": [
      {
        "text": "Xi'an 710004",
        "label": "ORG"
      },
      {
        "text": "Shaanxi",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)The Second Department of Thoracic Surgery, The First Affiliated Hospital of",
    "entities": [
      {
        "text": "Second Department",
        "label": "ORG"
      },
      {
        "text": "The First Affiliated Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Xi'an Jiaotong University 277 West Yanta Road, Xi'an 710061, Shaanxi, P. R.",
    "entities": [
      {
        "text": "Xi'an Jiaotong University",
        "label": "ORG"
      },
      {
        "text": "Shaanxi",
        "label": "GPE"
      },
      {
        "text": "P. R.\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(3)Institute of Traditional Chinese medicine, Hunan University of Chinese",
    "entities": [
      {
        "text": "Traditional",
        "label": "NORP"
      },
      {
        "text": "Chinese",
        "label": "NORP"
      },
      {
        "text": "Hunan University of Chinese\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine 300 Xueshi Street, Changsha 410208, Hunan, P. R. China.",
    "entities": [
      {
        "text": "300",
        "label": "CARDINAL"
      },
      {
        "text": "Changsha",
        "label": "GPE"
      },
      {
        "text": "410208",
        "label": "DATE"
      },
      {
        "text": "Hunan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Blood, The Chengdu Military Command General Hospital of Kunming",
    "entities": [
      {
        "text": "Blood",
        "label": "GPE"
      },
      {
        "text": "The Chengdu Military Command General Hospital",
        "label": "ORG"
      },
      {
        "text": "Kunming",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Medical University 212 West Daguan Road, Kunming 650032, Yunnan, P. R. China.",
    "entities": [
      {
        "text": "Medical University",
        "label": "ORG"
      },
      {
        "text": "212",
        "label": "CARDINAL"
      },
      {
        "text": "Yunnan",
        "label": "GPE"
      },
      {
        "text": "P. R. China",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Am J Cancer Res. 2018 Aug 01;8(8):1528-1540.",
    "entities": [
      {
        "text": "2018",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "[This corrects the article on p. 1528 in vol. 8, PMID: 30210921.].",
    "entities": [
      {
        "text": "1528",
        "label": "DATE"
      },
      {
        "text": "8",
        "label": "CARDINAL"
      },
      {
        "text": "30210921",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "ESRP1 drives subtype-specific breast cancer progression through ER-regulated",
    "entities": [
      {
        "text": "ESRP1",
        "label": "PRODUCT"
      },
      {
        "text": "ER",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "transcriptional programs and EMT-related splicing switch.",
    "entities": [
      {
        "text": "EMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Cancer Center, The Affiliated Dongguan Songshan Lake Central Hospital,",
    "entities": [
      {
        "text": "Center",
        "label": "ORG"
      },
      {
        "text": "The Affiliated Dongguan Songshan Lake Central Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Guangdong Medical University Dongguan, Guangdong, The People's Republic of",
    "entities": [
      {
        "text": "Guangdong Medical University Dongguan",
        "label": "ORG"
      },
      {
        "text": "Guangdong",
        "label": "GPE"
      },
      {
        "text": "The People's Republic",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Pathology, School of Basic Medicine, Guangdong Medical",
    "entities": [
      {
        "text": "2)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Pathology, School of Basic Medicine",
        "label": "ORG"
      },
      {
        "text": "Guangdong Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University Zhanjiang, Guangdong, The People's Republic of China.",
    "entities": [
      {
        "text": "University Zhanjiang",
        "label": "PERSON"
      },
      {
        "text": "Guangdong",
        "label": "GPE"
      },
      {
        "text": "The People's Republic of China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)The First Clinical Medical College, Guangdong Medical University Zhanjiang,",
    "entities": [
      {
        "text": "First Clinical Medical College",
        "label": "ORG"
      },
      {
        "text": "Guangdong Medical University Zhanjiang",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Guangdong, The People's Republic of China.",
    "entities": [
      {
        "text": "Guangdong",
        "label": "GPE"
      },
      {
        "text": "The People's Republic of China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Pathology, The Affiliated Hospital of Guangdong Medical",
    "entities": [
      {
        "text": "Pathology",
        "label": "ORG"
      },
      {
        "text": "The Affiliated Hospital of Guangdong Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Thyroid and Breast Surgery, Dongguan Songshan Lake Central",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Thyroid",
        "label": "ORG"
      },
      {
        "text": "Breast Surgery",
        "label": "PERSON"
      },
      {
        "text": "Dongguan Songshan Lake Central",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hospital, Guangdong Medical University Dongguan, Guangdong, The People's",
    "entities": [
      {
        "text": "Guangdong Medical University Dongguan",
        "label": "ORG"
      },
      {
        "text": "Guangdong",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Republic of China.",
    "entities": []
  },
  {
    "text": "Epithelial Splicing Regulatory Protein 1 (ESRP1), an epithelial splicing",
    "entities": [
      {
        "text": "Epithelial Splicing Regulatory",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "regulator, influences the invasiveness and metastasis of breast cancer cells,",
    "entities": []
  },
  {
    "text": "yet its prognostic significance and interaction with estrogen receptors are not",
    "entities": [
      {
        "text": "estrogen",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "fully understood. Our findings indicate that ESRP1 is significantly up-regulated",
    "entities": [
      {
        "text": "ESRP1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "in breast cancer tissues and correlates positively with adverse clinical",
    "entities": []
  },
  {
    "text": "outcomes, particularly in estrogen receptor (ER) positive breast cancer. In",
    "entities": [
      {
        "text": "ER",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "vitro experiments with cells demonstrated a dual regulatory mechanism: in",
    "entities": []
  },
  {
    "text": "ER-positive breast cancer cells, reduced expression of ESRP1 suppresses tumor",
    "entities": [
      {
        "text": "ER",
        "label": "GPE"
      },
      {
        "text": "ESRP1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cell proliferation but does not significantly affect tumor cell invasion and",
    "entities": []
  },
  {
    "text": "migration; conversely, in ER-negative breast cancer cells, ESRP1 hinders tumor",
    "entities": [
      {
        "text": "ER",
        "label": "GPE"
      },
      {
        "text": "ESRP1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "progression by regulating the alternative splicing of epithelial-mesenchymal",
    "entities": []
  },
  {
    "text": "transition (EMT)-related genes. To investigate whether the presence of ER is a",
    "entities": [
      {
        "text": "ER",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "decisive factor in ESRP1's role, we treated ER-positive breast cancer cells with",
    "entities": [
      {
        "text": "ESRP1",
        "label": "ORG"
      },
      {
        "text": "ER",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "an ER inhibitor to induce EMT, followed by the knockdown of ESRP1, which further",
    "entities": [
      {
        "text": "ER",
        "label": "ORG"
      },
      {
        "text": "EMT",
        "label": "ORG"
      },
      {
        "text": "ESRP1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "promoted the EMT process and enhanced the cells' invasive and migratory",
    "entities": [
      {
        "text": "EMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "abilities. This study demonstrates that ESRP1 is a potential breast cancer",
    "entities": [
      {
        "text": "ESRP1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "prognostic marker with subtype specificity and its value as a molecular target",
    "entities": []
  },
  {
    "text": "needs to be accurately assessed in the context of breast cancer subtypes, as",
    "entities": []
  },
  {
    "text": "ESRP1 function may be highly dependent on the ER background.",
    "entities": [
      {
        "text": "ESRP1",
        "label": "PERSON"
      },
      {
        "text": "ER",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: None.",
    "entities": []
  },
  {
    "text": "Super-resolution microscopy reveals distinct epigenetic states regulated by",
    "entities": []
  },
  {
    "text": "estrogen receptor activity.",
    "entities": [
      {
        "text": "estrogen",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "Akhshi T, Hu SS, Wheeler E, Hellriegel C, Richardson DS, Cayting N, Mvula W,",
    "entities": [
      {
        "text": "Hu SS",
        "label": "PERSON"
      },
      {
        "text": "Hellriegel C",
        "label": "PERSON"
      },
      {
        "text": "Richardson DS",
        "label": "PERSON"
      },
      {
        "text": "Mvula W",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Ahmed B, Jeselsohn R, Zang C, Brown M.",
    "entities": [
      {
        "text": "Ahmed B",
        "label": "PERSON"
      },
      {
        "text": "Jeselsohn R",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Changes in gene expression regulated by ligand-dependent transcription factors",
    "entities": []
  },
  {
    "text": "such as estrogen receptor-\u03b1 (ER\u03b1) involves the recruitment of coactivators",
    "entities": [
      {
        "text": "estrogen",
        "label": "ORDINAL"
      },
      {
        "text": "ER\u03b1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "including p300 that acetylates histone H3 at lysine 27 (H3K27ac). While H3K27ac",
    "entities": [
      {
        "text": "H3",
        "label": "PRODUCT"
      },
      {
        "text": "27",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "marks active enhancers, the detailed chromatin architecture of enhancers remains",
    "entities": []
  },
  {
    "text": "unclear. Using super-resolution microscopy, we reveal distinct structural states",
    "entities": []
  },
  {
    "text": "of H3K27ac modified chromatin in response to ER\u03b1 activation. In estradiol",
    "entities": []
  },
  {
    "text": "(E2)-treated cells, H3K27ac modified chromatin adopts open, elongated structures",
    "entities": []
  },
  {
    "text": "associated with active enhancers, while ER\u03b1 inhibition induces compact,",
    "entities": []
  },
  {
    "text": "spherical H3K27ac modified chromatin conformations linked to repression. A",
    "entities": []
  },
  {
    "text": "constitutively active ER\u03b1 mutation linked to endocrine therapy resistance in",
    "entities": []
  },
  {
    "text": "breast cancer maintains open chromatin states independent of ligand, suggesting",
    "entities": []
  },
  {
    "text": "sustained transcriptional activity. Our findings provide the first direct",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "visualization of H3K27ac associated chromatin structural dynamics, challenging",
    "entities": []
  },
  {
    "text": "the assumption that H3K27ac modification alone is sufficient to lead to enhancer",
    "entities": []
  },
  {
    "text": "activation. By demonstrating that H3K27ac architecture is dynamically regulated",
    "entities": []
  },
  {
    "text": "by ER\u03b1, we establish a new paradigm for understanding epigenetic regulation and",
    "entities": [
      {
        "text": "ER\u03b1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "highlight potential therapeutic targets for endocrine therapy resistant cancers.",
    "entities": []
  },
  {
    "text": "Integrated Omics Approach to Delineate the Mechanisms of Doxorubicin-Induced",
    "entities": [
      {
        "text": "Integrated Omics Approach",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cardiotoxicity.",
    "entities": []
  },
  {
    "text": "Dabour MS, Abdelgawad IY, Sadaf B, Daniel MR, Grant MKO, Blaes AH, Jacobson PA,",
    "entities": [
      {
        "text": "Dabour MS",
        "label": "PERSON"
      },
      {
        "text": "Abdelgawad IY",
        "label": "PERSON"
      },
      {
        "text": "Sadaf B",
        "label": "ORG"
      },
      {
        "text": "Daniel MR",
        "label": "ORG"
      },
      {
        "text": "Grant MKO",
        "label": "PERSON"
      },
      {
        "text": "Blaes AH",
        "label": "ORG"
      },
      {
        "text": "Jacobson PA",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Doxorubicin (DOX) is an effective chemotherapy whose clinical utility is limited",
    "entities": [
      {
        "text": "Doxorubicin",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "by cardiotoxicity. To investigate underlying mechanisms, we employed a",
    "entities": []
  },
  {
    "text": "multi-omics approach integrating transcriptomic and proteomic profiling",
    "entities": []
  },
  {
    "text": "leveraging established mouse models of chronic DOX- induced cardiotoxicity.",
    "entities": []
  },
  {
    "text": "Five-week-old male mice received weekly DOX (4 mg/kg) or saline injections for",
    "entities": [
      {
        "text": "Five-week-old",
        "label": "DATE"
      },
      {
        "text": "weekly",
        "label": "DATE"
      },
      {
        "text": "4 mg/kg",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "six weeks, with heart tissues harvested 4 days post-treatment. Differentially",
    "entities": [
      {
        "text": "six weeks",
        "label": "DATE"
      },
      {
        "text": "4 days",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "expressed genes (DEGs) and proteins (DEPs) were identified by bulk RNA-seq and",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "proteomics, validated via qPCR and western blot, respectively Key DEPs were",
    "entities": [
      {
        "text": "qPCR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "validated in plasma samples from DOX-treated breast cancer patients.",
    "entities": []
  },
  {
    "text": "Additionally, a temporal comparison was conducted between DEPs in the mice",
    "entities": []
  },
  {
    "text": "hearts 4 days and 6 weeks post-DOX. RNA-seq revealed upregulation of",
    "entities": [
      {
        "text": "4 days",
        "label": "DATE"
      },
      {
        "text": "6 weeks",
        "label": "DATE"
      },
      {
        "text": "post-DOX",
        "label": "EVENT"
      }
    ]
  },
  {
    "text": "stress-responsive genes ( Phlda3, Trp53inp1 ) and circadian regulators ( Nr1d1",
    "entities": []
  },
  {
    "text": "), with downregulation of Apelin and Cd74 . Proteomics identified upregulation",
    "entities": [
      {
        "text": "Apelin",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "of serpina3n, thrombospondin-1, and epoxide hydrolase 1. Plasma SERPINA3",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "Plasma SERPINA3",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "concentrations were significantly elevated in breast cancer patients 24 hours",
    "entities": [
      {
        "text": "24 hours",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "post-DOX. Gene set enrichment analysis (GSEA) revealed upregulated pathways",
    "entities": [
      {
        "text": "post-DOX",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "including p53 signaling, apoptosis, and unfolded protein response. Integrated",
    "entities": []
  },
  {
    "text": "omics analysis revealed 2,089 gene-protein pairs. GSEA of concordant",
    "entities": [
      {
        "text": "2,089",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "gene-protein pairs implicated p53 signaling, apoptosis, and",
    "entities": []
  },
  {
    "text": "epithelial-mesenchymal transition in upregulated pathways, while oxidative",
    "entities": []
  },
  {
    "text": "phosphorylation and metabolic pathways were downregulated. Temporal comparison",
    "entities": []
  },
  {
    "text": "with a delayed timepoint (6 weeks post-DOX) uncovered dynamic remodeling of",
    "entities": [
      {
        "text": "6 weeks",
        "label": "DATE"
      },
      {
        "text": "post-DOX",
        "label": "EVENT"
      }
    ]
  },
  {
    "text": "cardiac signaling, with early response dominated by inflammatory and apoptotic",
    "entities": []
  },
  {
    "text": "responses, and delayed response marked by cell cycle and DNA repair pathway",
    "entities": []
  },
  {
    "text": "activation. This integrated-omics study reveals key molecular pathways and",
    "entities": []
  },
  {
    "text": "temporal changes in DOX-induced cardiotoxicity, identifying potential biomarkers",
    "entities": []
  },
  {
    "text": "CDH1 loss remodels gene expression and lineage identity in human mammary",
    "entities": []
  },
  {
    "text": "epithelial cells.",
    "entities": []
  },
  {
    "text": "Musick M, Ufondu CA, Rowland CE, Sottnik JL, Shackleford MT, Nesiba CS,",
    "entities": [
      {
        "text": "Musick M",
        "label": "PERSON"
      },
      {
        "text": "Ufondu CA",
        "label": "PERSON"
      },
      {
        "text": "Rowland CE",
        "label": "GPE"
      },
      {
        "text": "Sottnik JL",
        "label": "PERSON"
      },
      {
        "text": "Shackleford MT",
        "label": "ORG"
      },
      {
        "text": "Nesiba CS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Invasive lobular carcinoma (ILC) is a common subtype of breast cancer that is",
    "entities": []
  },
  {
    "text": "defined in part by genetic loss of CDH1 caused by mutation or deletion, leading",
    "entities": []
  },
  {
    "text": "to loss of cell adhesion protein E-cadherin in >90% of ILC. Genetic loss of CDH1",
    "entities": [
      {
        "text": "90%",
        "label": "PERCENT"
      },
      {
        "text": "ILC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "is an early event in ILC oncogenesis, yet the mechanisms by which CDH1/",
    "entities": []
  },
  {
    "text": "E-cadherin acts as a tumor suppressor are not well understood. To study how",
    "entities": []
  },
  {
    "text": "early CDH1 loss drives ILC oncogenesis, we used a series of non-transformed",
    "entities": []
  },
  {
    "text": "human mammary epithelial cell (HMEC) models to target CDH1 /E-cadherin,",
    "entities": [
      {
        "text": "HMEC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "inhibiting extracellular E-cadherin signaling using antibodies versus modeling",
    "entities": []
  },
  {
    "text": "genetic CDH1 loss using siRNA or knockout via CRISPR/Cas9. Through transcriptome",
    "entities": [
      {
        "text": "CRISPR/Cas9",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "analyses across four HMEC models, we found that the mode of E-cadherin loss or",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      },
      {
        "text": "HMEC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "suppression is critical for the subsequent phenotype. Antibody-mediated",
    "entities": []
  },
  {
    "text": "inhibition of cell-cell contacts induced gene signatures of",
    "entities": []
  },
  {
    "text": "epithelial-mesenchymal transition (EMT), consistent with the role of E-cadherin",
    "entities": [
      {
        "text": "EMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "suppression during the EMT process. Conversely, genetic CDH1 loss - as in ILC",
    "entities": [
      {
        "text": "EMT",
        "label": "ORG"
      },
      {
        "text": "ILC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "oncogenesis - repressed EMT signatures, and instead remodeled gene expression",
    "entities": [
      {
        "text": "EMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "toward a luminal epithelial phenotype. Using single cell transcriptomics and",
    "entities": []
  },
  {
    "text": "flow cytometry analyses of cell lineage markers, we found that genetic loss of",
    "entities": []
  },
  {
    "text": "CDH1 reprogrammed cells to a luminal progenitor-like phenotype. By isolating",
    "entities": []
  },
  {
    "text": "luminal versus basal cells prior to CDH1 knockout, we found that CDH1 loss led",
    "entities": []
  },
  {
    "text": "to remodeling of lineage identity in both populations, converging on a new",
    "entities": []
  },
  {
    "text": "lineage homeostasis with a luminal progenitor-like phenotype. Consistent with",
    "entities": []
  },
  {
    "text": "increased progenitor features, CDH1 loss enhanced proliferative capacity over",
    "entities": []
  },
  {
    "text": "the finite lifespan of the HMECs, highlighting a feature of early CDH1 loss that",
    "entities": []
  },
  {
    "text": "may contribute to clonal advantage during tumor initiation. Our findings support",
    "entities": []
  },
  {
    "text": "that inhibition of E-cadherin results in different transcriptional response",
    "entities": []
  },
  {
    "text": "compared to CDH1 loss, with the latter driving a transcriptional and phenotypic",
    "entities": []
  },
  {
    "text": "state characteristic of a luminal progenitor-like population, which offers new",
    "entities": []
  },
  {
    "text": "insight into early events in ILC oncogenesis.",
    "entities": []
  },
  {
    "text": "A microfluidic gradient and parallel-track system uncovers spatial control of",
    "entities": []
  },
  {
    "text": "endocytosis and adhesion formation in breast cancer cell migration.",
    "entities": []
  },
  {
    "text": "Chan ET, Jones TH, Thompson CM, Kannan H, D'Souza MW, Ali MM, Kural C, Song JW.",
    "entities": [
      {
        "text": "Chan ET",
        "label": "ORG"
      },
      {
        "text": "Jones TH",
        "label": "PERSON"
      },
      {
        "text": "Thompson CM",
        "label": "ORG"
      },
      {
        "text": "Kannan H",
        "label": "PERSON"
      },
      {
        "text": "D'Souza MW",
        "label": "PERSON"
      },
      {
        "text": "Ali MM",
        "label": "PERSON"
      },
      {
        "text": "Kural C",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Cell migration through confined spaces is a critical step in cancer metastasis,",
    "entities": []
  },
  {
    "text": "yet the spatial regulation of endocytosis and adhesion dynamics during this",
    "entities": []
  },
  {
    "text": "process remains poorly understood. To address this, we developed a microfluidic",
    "entities": []
  },
  {
    "text": "platform that generates stable, spatially linear biochemical gradients across 5",
    "entities": [
      {
        "text": "linear",
        "label": "ORG"
      },
      {
        "text": "5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "\u03bcm-tall migration channels while limiting confounding flow-induced shear stress",
    "entities": []
  },
  {
    "text": "(<0.05 dyn/cm 2 ). COMSOL simulations and optical calibration using FITC-dextran",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "FITC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "confirmed that gradients form reliably within 5 minutes. The microdevice also",
    "entities": [
      {
        "text": "5 minutes",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "supports long-term live imaging and is compatible with both spinning disk",
    "entities": []
  },
  {
    "text": "confocal and total internal reflection fluorescence structured illumination",
    "entities": []
  },
  {
    "text": "microscopy modalities, enabling high-resolution visualization of adhesion and",
    "entities": []
  },
  {
    "text": "endocytic structures. Localized application of the endocytic inhibitor Dyngo-4a",
    "entities": [
      {
        "text": "Dyngo-4a",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "to the front or rear of migrating cells revealed that front-targeted inhibition",
    "entities": []
  },
  {
    "text": "significantly increased the enrichment of paxillin and the clathrin adaptor AP-2",
    "entities": [
      {
        "text": "paxillin",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "at the leading edge, whereas rear-targeted inhibition completely abolished their",
    "entities": []
  },
  {
    "text": "front-rear asymmetry. These changes were accompanied by enhanced migration speed",
    "entities": []
  },
  {
    "text": "and persistence, particularly under front-targeted inhibition. Together, these",
    "entities": []
  },
  {
    "text": "findings highlight the critical role of spatially coordinated endocytosis in",
    "entities": []
  },
  {
    "text": "sustaining polarized adhesion and persistent cell movement. Our platform offers",
    "entities": []
  },
  {
    "text": "a powerful tool for dissecting subcellular mechanisms of migration under",
    "entities": []
  },
  {
    "text": "confinement and provides a broadly applicable framework for probing spatially",
    "entities": []
  },
  {
    "text": "localized signaling in engineered microenvironments.",
    "entities": []
  },
  {
    "text": "Anthracyclines induce global changes in cardiomyocyte chromatin accessibility",
    "entities": []
  },
  {
    "text": "that overlap with cardiovascular disease loci.",
    "entities": []
  },
  {
    "text": "Matthews ER, Abodunrin RO, Hurley JD, Guti\u00e9rrez JA, Ward MC.",
    "entities": [
      {
        "text": "Matthews ER",
        "label": "LOC"
      },
      {
        "text": "Abodunrin RO",
        "label": "GPE"
      },
      {
        "text": "Hurley JD",
        "label": "PERSON"
      },
      {
        "text": "Guti\u00e9rrez JA",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Breast cancer drugs including anthracyclines (ACs) and Trastuzumab increase the",
    "entities": [
      {
        "text": "Trastuzumab",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "risk for cardiovascular diseases (CVDs) such as atrial fibrillation (AF) and",
    "entities": []
  },
  {
    "text": "heart failure (HF) that ultimately affect the heart muscle. These CVDs are",
    "entities": []
  },
  {
    "text": "associated with hundreds of genetic variants in non- coding regions of the",
    "entities": [
      {
        "text": "hundreds",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "genome. However, how these drugs affect the regulatory potential of the",
    "entities": []
  },
  {
    "text": "non-coding genome of the heart and CVD risk loci is unknown. We therefore",
    "entities": [
      {
        "text": "CVD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "measured global chromatin accessibility across iPSC-derived cardiomyocytes from",
    "entities": []
  },
  {
    "text": "four individuals treated with the ACs, Doxorubicin, Epirubicin, and",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      },
      {
        "text": "Doxorubicin, Epirubicin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Daunorubicin, a related non-AC, Mitoxantrone, and the monoclonal antibody",
    "entities": [
      {
        "text": "non-AC",
        "label": "ORG"
      },
      {
        "text": "Mitoxantrone",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Trastuzumab, or a vehicle control for three and 24 hours. We identified 155,557",
    "entities": [
      {
        "text": "Trastuzumab",
        "label": "GPE"
      },
      {
        "text": "three and 24 hours",
        "label": "TIME"
      },
      {
        "text": "155,557",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "high-confidence regions of open chromatin across 48 samples where the major",
    "entities": [
      {
        "text": "48",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "sources of variation are associated with drug type and time. Jointly modeling",
    "entities": []
  },
  {
    "text": "the data revealed three accessibility response signatures denoted as",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "early-acute, early-sustained, and late that correspond to 67,329 regions that",
    "entities": [
      {
        "text": "67,329",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "open or close in response to drug treatment. Sequences associated with",
    "entities": []
  },
  {
    "text": "drug-induced chromatin opening contain motifs for DNA damage-associated",
    "entities": []
  },
  {
    "text": "transcription factors including p53 and ZBTB14, and associate with increases in",
    "entities": [
      {
        "text": "transcription",
        "label": "CARDINAL"
      },
      {
        "text": "ZBTB14",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "active histone acetylation and gene expression. 21 AF- and HF-associated SNPs",
    "entities": [
      {
        "text": "21",
        "label": "CARDINAL"
      },
      {
        "text": "HF-associated SNPs\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "directly overlap with regions associated with drug-induced opening. A shared",
    "entities": []
  },
  {
    "text": "intronic HF and AF SNP, rs3176326, that is also an eQTL for CDKN1A in heart",
    "entities": [
      {
        "text": "SNP",
        "label": "ORG"
      },
      {
        "text": "rs3176326",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "tissue, associates with increased chromatin accessibility, histone acetylation,",
    "entities": []
  },
  {
    "text": "and CDKN1A expression in response to all ACs. Our results demonstrate",
    "entities": []
  },
  {
    "text": "large-scale changes in chromatin accessibility in cardiomyocytes treated with",
    "entities": []
  },
  {
    "text": "ACs, which correspond to several regions harboring CVD risk loci.",
    "entities": []
  },
  {
    "text": "AUTHOR SUMMARY: Anthracyclines are a widely used class of breast cancer drugs",
    "entities": []
  },
  {
    "text": "that are linked to cardiac toxicity and the development of heart disease in some",
    "entities": []
  },
  {
    "text": "women. There are hundreds of genetic variants that associate with risk for heart",
    "entities": [
      {
        "text": "hundreds",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "disease; however their role and mechanism of action in drug- induced toxicity is",
    "entities": []
  },
  {
    "text": "unclear given that most reside in the non-coding genome. We therefore tested the",
    "entities": []
  },
  {
    "text": "effects of five breast cancer drugs on genome-wide chromatin accessibility using",
    "entities": [
      {
        "text": "five",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "induced pluripotent stem cell-derived cardiomyocytes. We found tens of thousands",
    "entities": [
      {
        "text": "tens of thousands",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "of chromatin regions that change in accessibility after drug treatment. Regions",
    "entities": []
  },
  {
    "text": "with increased accessibility contain sequences that have been shown to bind DNA",
    "entities": []
  },
  {
    "text": "damage-associated transcription factors, and associate with increases in nearby",
    "entities": [
      {
        "text": "transcription",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "gene expression. We find 21 heart disease-associated genetic variants in regions",
    "entities": [
      {
        "text": "21",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "that increase in chromatin accessibility following treatment. This suggests that",
    "entities": []
  },
  {
    "text": "cancer drugs have large effects on the non-coding genome of heart cells",
    "entities": []
  },
  {
    "text": "including at regions associated with heart disease. This research contributes to",
    "entities": []
  },
  {
    "text": "our understanding of how genetic variants associated with disease exert their",
    "entities": []
  },
  {
    "text": "effects.",
    "entities": []
  },
  {
    "text": "Soluble E-cadherin Drives Brain Metastasis in Inflammatory Breast Cancer.",
    "entities": [
      {
        "text": "Drives Brain Metastasis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hu X, Xiong Y, Villodre ES, Zhang H, Song J, Fowlkes N, Krishnamurthy S,",
    "entities": [
      {
        "text": "Hu X",
        "label": "PERSON"
      },
      {
        "text": "Xiong Y",
        "label": "PERSON"
      },
      {
        "text": "Villodre ES",
        "label": "PERSON"
      },
      {
        "text": "Zhang H",
        "label": "ORG"
      },
      {
        "text": "Fowlkes N",
        "label": "ORG"
      },
      {
        "text": "Krishnamurthy S",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Rylander M, Bartholomeusz C, Tripathy D; MDACC Inflammatory Breast Cancer Team;",
    "entities": [
      {
        "text": "Rylander M",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The brain is a common site of relapse in inflammatory breast cancer (IBC), an",
    "entities": []
  },
  {
    "text": "E-cadherin positive, aggressive form of breast cancer. We found that elevated",
    "entities": []
  },
  {
    "text": "serum levels of soluble E-cadherin (sEcad), an 80-kDa fragment of E-cadherin, in",
    "entities": [
      {
        "text": "80-kDa",
        "label": "QUANTITY"
      }
    ]
  },
  {
    "text": "patients with metastatic IBC correlated with poorer outcomes and increased rates",
    "entities": [
      {
        "text": "IBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of brain metastases. In our effort to understand the underlying mechanism, we",
    "entities": []
  },
  {
    "text": "discovered that sEcad binds to XIAP, an inhibitor of cell death, activating the",
    "entities": [
      {
        "text": "sEcad",
        "label": "NORP"
      },
      {
        "text": "XIAP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "pro-survival NF-k\u03b2 signaling in tumor cells. We also discovered that sEcad",
    "entities": []
  },
  {
    "text": "affects the tumor cell microenvironment by enhancing cancer cell adhesion to",
    "entities": []
  },
  {
    "text": "endothelial cells and inducing reactive astrocytosis in the brain. In addition,",
    "entities": []
  },
  {
    "text": "we found that sEcad-mediated reactive astrocytosis relies on the",
    "entities": []
  },
  {
    "text": "CXCL1/CXCL8-CXCR2 axis and treatment with a brain-permeable CXCR2 antagonist",
    "entities": [
      {
        "text": "CXCL1",
        "label": "ORG"
      },
      {
        "text": "CXCL8-CXCR2",
        "label": "PERSON"
      },
      {
        "text": "CXCR2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "reduced brain metastatic burden and prolonged survival. These findings implicate",
    "entities": []
  },
  {
    "text": "sEcad in brain metastasis and provide new insights into potential therapeutic",
    "entities": []
  },
  {
    "text": "HIGHLIGHTS: High serum sEcad levels correlate clinically with poor survival",
    "entities": []
  },
  {
    "text": "outcomes and development of brain metastasissEcad drives IBC brain metastasis",
    "entities": []
  },
  {
    "text": "growth in mouse modelssEcad binds XIAP to activate NFkB and promote anoikis",
    "entities": [
      {
        "text": "XIAP",
        "label": "ORG"
      },
      {
        "text": "NFkB",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "resistance and invasion of IBC cells sEcad activates reactive astrocytes and",
    "entities": []
  },
  {
    "text": "induces CXCR2 expression on tumor cells in vitro and in vivo CXCR2-IN-1, a",
    "entities": [
      {
        "text": "CXCR2",
        "label": "PERSON"
      },
      {
        "text": "CXCR2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "brain-permeable CXCR2 antagonist, reduces metastasis and improves survival in",
    "entities": [
      {
        "text": "CXCR2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Exosomes are specialized vehicles to induce fibronectin assembly.",
    "entities": []
  },
  {
    "text": "Fibronectin is a key stromal matrix molecule whose assembly into fibrils is",
    "entities": [
      {
        "text": "Fibronectin",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "thought to require cells. In contrast, we find that small exosome-type",
    "entities": []
  },
  {
    "text": "extracellular vesicles (EVs) are critical initiators of fibronectin assembly.",
    "entities": []
  },
  {
    "text": "Fibroblasts engineered to be deficient in exosome secretion showed greatly",
    "entities": []
  },
  {
    "text": "reduced assembly of fibronectin and other stromal matrix molecules in 2D, 3D,",
    "entities": [
      {
        "text": "fibronectin",
        "label": "ORG"
      },
      {
        "text": "2D",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and in vivo environments, and led to reduced tumor growth and lung metastasis by",
    "entities": []
  },
  {
    "text": "breast cancer cells. Furthermore, transgenic mice with defects in exosome",
    "entities": []
  },
  {
    "text": "secretion had greatly reduced lung fibrosis after treatment with bleomycin. In a",
    "entities": []
  },
  {
    "text": "direct test of exosome function, we find that the addition of purified small EVs",
    "entities": []
  },
  {
    "text": "to purified soluble fibronectin in a cell-free system is sufficient to induce",
    "entities": []
  },
  {
    "text": "fibronectin assembly. The EV-induced fibronectin assembly requires the presence",
    "entities": [
      {
        "text": "EV",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "of fibronectin-binding integrins and Syndecan-1 in the EVs. We propose a new",
    "entities": []
  },
  {
    "text": "model in which secreted exosomes directly drive stromal matrix assembly and",
    "entities": []
  },
  {
    "text": "Radiosensitizers in Cancer Therapy: A Global Bibliometric Analysis.",
    "entities": []
  },
  {
    "text": "BACKGROUND/OBJECTIVES: Radiosensitizers are compounds given concurrently with",
    "entities": []
  },
  {
    "text": "radiotherapy to enhance the killing of cancer cells while sparing healthy",
    "entities": []
  },
  {
    "text": "tissue. Radiosensitization research has involved a diverse range of therapeutic",
    "entities": []
  },
  {
    "text": "agents. In the present study, we aimed to investigate international trends in",
    "entities": []
  },
  {
    "text": "the development of radiosensitizers across the most common cancer types.",
    "entities": []
  },
  {
    "text": "METHODS: A bibliometric analysis was performed of the field of radiosensitizer",
    "entities": []
  },
  {
    "text": "research from 1956 to 2024. Individual author impacts and trends, collaborations",
    "entities": [
      {
        "text": "1956 to 2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "between and productivity of countries, and themes/keywords were analyzed.",
    "entities": []
  },
  {
    "text": "RESULTS: Our search yielded 12,690 results. The most highly represented",
    "entities": [
      {
        "text": "12,690",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "countries were the United States of America, China, and Germany. Radiosensitizer",
    "entities": [
      {
        "text": "the United States of America",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "studies for breast cancers demonstrated the highest rate of annual growth in",
    "entities": [
      {
        "text": "annual",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "record count by comparison with other cancer types, while publications for",
    "entities": []
  },
  {
    "text": "gynecological cancers showed the slowest growth. The most common",
    "entities": []
  },
  {
    "text": "radiosensitizers investigated included ATM kinase inhibitors, chemotherapies,",
    "entities": [
      {
        "text": "ATM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "gold nanoparticles, mTOR inhibitors, natural compounds such as caffeine or",
    "entities": [
      {
        "text": "mTOR",
        "label": "LAW"
      }
    ]
  },
  {
    "text": "curcumin, and poly (ADP-ribose) polymerase inhibitors.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: The United States, Germany, and China were the most productive",
    "entities": [
      {
        "text": "The United States",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "countries during the study period, with China demonstrating the greatest",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "increase in annual publication rate. Additionally, pre-clinical studies",
    "entities": [
      {
        "text": "annual",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "primarily investigated gold particles and targeted therapies. By comparison,",
    "entities": []
  },
  {
    "text": "clinical studies focused on radiosensitizing chemotherapies.",
    "entities": []
  },
  {
    "text": "Modeling the role of urokinase plasminogen activator, uPA, and circulating",
    "entities": []
  },
  {
    "text": "Cancer-Associated Fibroblasts (cCAFS) in breast cancer cell extravasation.",
    "entities": [
      {
        "text": "Cancer-Associated Fibroblasts",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Circulating Cancer-Associated Fibroblasts (cCAFs) have been discovered in",
    "entities": [
      {
        "text": "Circulating Cancer-Associated Fibroblasts",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "circulating tumor cell clusters from all stages of disease progression in breast",
    "entities": []
  },
  {
    "text": "cancer patients. We have shown that CAFs promote lung metastases in the mouse",
    "entities": []
  },
  {
    "text": "tail vein model when they are clustered with triple negative breast cancer",
    "entities": [
      {
        "text": "tail vein",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(TNBC) MDA-MB231 cells. Following on this observation, we saw that",
    "entities": [
      {
        "text": "MDA-MB231",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "MDA-MB231-luciferase labeled cells persist at higher levels when present in",
    "entities": [
      {
        "text": "MDA-MB231",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CAF23/MDA-MB231 co-clusters compared to MDA-MB231 mono-clusters within the first",
    "entities": [
      {
        "text": "MDA-MB231",
        "label": "PRODUCT"
      },
      {
        "text": "MDA-MB231",
        "label": "ORG"
      },
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "3 days after tail vein injection. This prompted us to investigate whether CAFs",
    "entities": [
      {
        "text": "3 days",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "aid cancer cell extravasation from capillary venules into the lung parenchyma,",
    "entities": []
  },
  {
    "text": "which would impart better survival and faster seeding of metastases. Ex vivo",
    "entities": []
  },
  {
    "text": "lung extravasation assays showed that within the first 8-24 hrs after tail vein",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "injection, more cells from CAF23/MDA-MB231 co-clusters extravasated than cells",
    "entities": [
      {
        "text": "MDA-MB231",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "from MDA-MB231 mono-clusters. Using in vitro endothelial binding assays, we",
    "entities": [
      {
        "text": "MDA-MB231",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "determined that CAF/TNBC co-clusters bind to HUVEC endothelial cells better than",
    "entities": [
      {
        "text": "CAF",
        "label": "ORG"
      },
      {
        "text": "HUVEC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "TNBC mono-clusters. Single Cell RNA-seq identified several genes in the",
    "entities": []
  },
  {
    "text": "fibrinolysis pathway whose expression increases in TNBC cells when they are",
    "entities": []
  },
  {
    "text": "clustered with CAFs. One of these genes is PLAU , which encodes the",
    "entities": [
      {
        "text": "One",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "urokinase-type plasminogen activator, uPA. siRNA knockdown of PLAU decreased in",
    "entities": []
  },
  {
    "text": "vitro TNBC-endothelial cell interactions and ex vivo extravasation of MDA-MB231",
    "entities": [
      {
        "text": "MDA-MB231",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "mono-clusters, revealing a role for uPA/PLAU in breast cancer cell",
    "entities": []
  },
  {
    "text": "extravasation. Our data helps to define the role of CAFs in breast cancer",
    "entities": []
  },
  {
    "text": "extravasation and highlights the importance of our previous work showing that",
    "entities": []
  },
  {
    "text": "CAFs promote tumor cell dissemination and metastasis.",
    "entities": []
  },
  {
    "text": "Paclitaxel-induced mitotic arrest results in a convergence of apoptotic",
    "entities": []
  },
  {
    "text": "dependencies that can be safely exploited by BCL-X (L) degradation to overcome",
    "entities": [
      {
        "text": "BCL-X (L",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Qin X, Presser A, Johnson L, Matoba Y, Shay BS, Xu W, Choiniere J, Fraser C,",
    "entities": [
      {
        "text": "Qin X",
        "label": "PERSON"
      },
      {
        "text": "Presser A",
        "label": "PERSON"
      },
      {
        "text": "Johnson L",
        "label": "PERSON"
      },
      {
        "text": "Matoba Y",
        "label": "PERSON"
      },
      {
        "text": "Xu W",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Paclitaxel and other microtubule-targeting agents are cornerstone therapies for",
    "entities": []
  },
  {
    "text": "diverse cancers, including lung, breast, cervical, pancreatic, and ovarian",
    "entities": []
  },
  {
    "text": "malignancies. Paclitaxel induces tumor cell apoptosis during mitosis by",
    "entities": []
  },
  {
    "text": "disrupting microtubule dynamics required for chromosome segregation. However,",
    "entities": []
  },
  {
    "text": "despite initial responsiveness, many tumors develop resistance, limiting",
    "entities": []
  },
  {
    "text": "therapeutic durability. Here, we used high-grade serous ovarian carcinoma",
    "entities": []
  },
  {
    "text": "(HGSOC), the most common and lethal subtype of ovarian cancer, as a model to",
    "entities": [
      {
        "text": "HGSOC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "dissect the mechanisms underlying this resistance. We find that",
    "entities": []
  },
  {
    "text": "paclitaxel-induced mitotic arrest triggers degradation of the pro-survival",
    "entities": []
  },
  {
    "text": "protein MCL-1 and upregulation of BCL-XL, followed by inactivating",
    "entities": [
      {
        "text": "MCL-1",
        "label": "ORG"
      },
      {
        "text": "BCL-XL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "phosphorylation of BCL-XL at Ser62 to promote apoptosis. In resistant cells,",
    "entities": [
      {
        "text": "BCL-XL",
        "label": "ORG"
      },
      {
        "text": "Ser62",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "this MCL-1 downregulation is insufficient to commit cells to apoptosis but",
    "entities": [
      {
        "text": "MCL-1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "instead results in a transient convergence of apoptotic dependencies by forcing",
    "entities": []
  },
  {
    "text": "BCL-X L to sequester the pro-apoptotic proteins BIM, BAX, and BAK. During this",
    "entities": [
      {
        "text": "BIM",
        "label": "PERSON"
      },
      {
        "text": "BAX",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "state, BCL-XL inhibition induces synergistic apoptosis, even in chemoresistant",
    "entities": [
      {
        "text": "BCL-XL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cells. Surprisingly, we also discover that loss of substrate attachment",
    "entities": []
  },
  {
    "text": "recapitulates this apoptotic convergence both in vitro and in vivo, with HGSOC",
    "entities": [
      {
        "text": "HGSOC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cells growing in metastasis-promoting malignant ascites displaying heightened",
    "entities": []
  },
  {
    "text": "apoptotic priming and dependence on BCL-XL relative to solid tumors. In HGSOC",
    "entities": [
      {
        "text": "BCL-XL",
        "label": "ORG"
      },
      {
        "text": "HGSOC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "xenografts, targeted degradation of BCL-XL using the platelet-sparing",
    "entities": [
      {
        "text": "xenografts",
        "label": "PERSON"
      },
      {
        "text": "BCL-XL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "proteolysis-targeting chimera (PROTAC) DT2216 matches the efficacy of paclitaxel",
    "entities": []
  },
  {
    "text": "monotherapy while avoiding the chronic thrombocytopenia induced by BCL-XL",
    "entities": [
      {
        "text": "BCL-XL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "inhibitors such as navitoclax (ABT-263). Strikingly, combination therapy",
    "entities": []
  },
  {
    "text": "leveraging the synergy between paclitaxel and DT2216 leads to complete",
    "entities": [
      {
        "text": "DT2216",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "eradication of HGSOC cell line and patient-derived xenografts. Moreover, DT2216",
    "entities": [
      {
        "text": "HGSOC",
        "label": "ORG"
      },
      {
        "text": "DT2216\n",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "treatment blunts the rapid apoptotic adaptation caused by other BCL-X L",
    "entities": []
  },
  {
    "text": "inhibitors, indicating that targeted degradation of pro-survival proteins may",
    "entities": []
  },
  {
    "text": "yield more durable responses than inhibition alone. These findings uncover a",
    "entities": []
  },
  {
    "text": "mechanistic framework for safely exploiting the apoptotic dependency convergence",
    "entities": []
  },
  {
    "text": "caused by mitotic arrest and substrate detachment and support the clinical",
    "entities": []
  },
  {
    "text": "development of BCL-XL-targeting PROTACs to overcome chemoresistance in ovarian",
    "entities": [
      {
        "text": "BCL-XL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cancer and other solid tumors.",
    "entities": []
  },
  {
    "text": "Transient chromatin decompaction by histone deacetylation inhibition",
    "entities": []
  },
  {
    "text": "preferentially radiosensitizes cancerous breast epithelial cells at lower",
    "entities": []
  },
  {
    "text": "Radiation therapy plays a prominent role in breast cancer treatment, but the",
    "entities": []
  },
  {
    "text": "high doses of radiation damage both healthy and cancerous cells. Therefore,",
    "entities": []
  },
  {
    "text": "additional research is needed into combination therapies that could",
    "entities": []
  },
  {
    "text": "preferentially radiosensitize cancer cells compared to surrounding healthy",
    "entities": []
  },
  {
    "text": "tissue without causing deleterious side effects. Histone deacetylase inhibitor",
    "entities": []
  },
  {
    "text": "drugs (HDACis) have been tested as radiosensitizers in both basic research and",
    "entities": []
  },
  {
    "text": "clinical trials, but the long exposure usually used in these treatments and lack",
    "entities": []
  },
  {
    "text": "of examination of effects on matched healthy cells leave aspects of their",
    "entities": []
  },
  {
    "text": "mechanism of action unclear. Here, we show that transient (2 hour) trichostatin",
    "entities": [
      {
        "text": "2 hour",
        "label": "TIME"
      },
      {
        "text": "trichostatin\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "A (TSA) treatment of cancerous and non-tumorigenic breast epithelial cell lines",
    "entities": [
      {
        "text": "TSA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "increases immediate DNA damage and decreases long-term cell survival in both",
    "entities": []
  },
  {
    "text": "cell types at high radiation doses. At an intermediate radiation dose (1 Gy),",
    "entities": []
  },
  {
    "text": "however, TSA treatment selectively radiosensitizes the cancer as compared to the",
    "entities": [
      {
        "text": "TSA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "non-cancer cell line. The radiosensitizing action of short-term TSA treatment,",
    "entities": [
      {
        "text": "TSA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "which by itself has no impact on cell viability, suggests that chromatin",
    "entities": []
  },
  {
    "text": "decompaction is an important part of the mechanism of radiosensitization by",
    "entities": []
  },
  {
    "text": "HDACis.",
    "entities": []
  },
  {
    "text": "Cerebellum metastasis model of HER2-positive breast cancer unveils key role of",
    "entities": [
      {
        "text": "HER2",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "IL34-induced Arg1+ macrophages.",
    "entities": []
  },
  {
    "text": "Cheng X, Patel KK, Zhou B, Fu Y, Cleary R, Highkin M, Hsia J, Jin X, Kohn B,",
    "entities": [
      {
        "text": "Cheng X",
        "label": "PERSON"
      },
      {
        "text": "Patel KK",
        "label": "PERSON"
      },
      {
        "text": "Zhou B",
        "label": "PERSON"
      },
      {
        "text": "Fu Y",
        "label": "PERSON"
      },
      {
        "text": "Highkin M",
        "label": "PERSON"
      },
      {
        "text": "Hsia J",
        "label": "PERSON"
      },
      {
        "text": "Jin X",
        "label": "PERSON"
      },
      {
        "text": "Kohn B",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Jain V, Gregory S, Kim A, Bose R.",
    "entities": [
      {
        "text": "Jain V",
        "label": "PERSON"
      },
      {
        "text": "Gregory S",
        "label": "ORG"
      },
      {
        "text": "Kim A",
        "label": "PERSON"
      },
      {
        "text": "Bose R.\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Brain metastases occur in up to 40% of Stage IV breast cancer patients. The",
    "entities": [
      {
        "text": "Brain",
        "label": "ORG"
      },
      {
        "text": "up to 40%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "cerebellum is a frequent location for metastases in HER2-positive breast cancer",
    "entities": [
      {
        "text": "HER2",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "patients, but the mechanisms for this are unknown. Here, we developed a",
    "entities": []
  },
  {
    "text": "syngeneic, immunocompetent mouse model for breast cancer brain metastases by",
    "entities": [
      {
        "text": "syngeneic",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "stereotactically injecting mouse HER2-overexpressing breast cancer organoids",
    "entities": []
  },
  {
    "text": "into the cerebellum. Growth of these cerebellar metastases was monitored by MRI",
    "entities": []
  },
  {
    "text": "and trastuzumab optical imaging using a near-infrared fluorophore conjugated to",
    "entities": []
  },
  {
    "text": "trastuzumab. Spatial transcriptomics identified interleukin-34 production by",
    "entities": [
      {
        "text": "interleukin-34",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "breast cancer cells inducing ARG1+ macrophages at the invading edge of the",
    "entities": []
  },
  {
    "text": "metastasis. Treatment with a blocking antibody to interleukin-34's receptor,",
    "entities": [
      {
        "text": "interleukin-34",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "CSF1R, produced tumor shrinkage. These findings have immediate translation",
    "entities": []
  },
  {
    "text": "potential as a CSF1R-blocking antibody is FDA-approved. Further, it demonstrates",
    "entities": [
      {
        "text": "FDA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "that cancer-associated inflammation bordering the brain metastasis promotes",
    "entities": []
  },
  {
    "text": "metastatic growth and offers a molecularly targeted strategy to treat",
    "entities": []
  },
  {
    "text": "inflammation in brain metastasis.",
    "entities": []
  },
  {
    "text": "Sulindac modulates the response of triple negative breast cancer to anti-PD-L1",
    "entities": [
      {
        "text": "anti-PD-L1",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "immunotherapy.",
    "entities": []
  },
  {
    "text": "Teriple-negative breast cancer (TNBC) is a heterogeneous tumor, and there is a",
    "entities": []
  },
  {
    "text": "lack of effective therapies. Immune checkpoint inhibitors (ICIs) therapy has",
    "entities": []
  },
  {
    "text": "been widely used to treat a variety of human cancers including TNBC. Despite the",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "FDA's approval of therapies like Atezolizumab (anti- PD-L1) and Pembrolizumab",
    "entities": [
      {
        "text": "FDA",
        "label": "ORG"
      },
      {
        "text": "Atezolizumab",
        "label": "PERSON"
      },
      {
        "text": "Pembrolizumab",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(anti-PD-1) for certain TNBC cases, more than half of all TNBC patients,",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      },
      {
        "text": "more than half",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "especially those with low PD-L1 levels and in advanced stages, remain",
    "entities": []
  },
  {
    "text": "unresponsive. Therefore, there is urgent clinical need to find other innovative",
    "entities": []
  },
  {
    "text": "combination therapy strategy for these TNBC patients. In this study, we examined",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the efficacy of sulindac to enhance the response of TNBC to anti-PD-L1",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "immunotherapy. We utilized a 4T1 syngeneic mouse tumor model to compare the",
    "entities": [
      {
        "text": "4T1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "inhibitory effects of PD-L1 antibody, sulindac, and their combination on 4T1",
    "entities": [
      {
        "text": "4T1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "tumor growth. We found that mice treated with combination therapy showed a",
    "entities": []
  },
  {
    "text": "significant reduction in tumor volume, along with increased infiltration of",
    "entities": []
  },
  {
    "text": "activated T lymphocytes (Granzyme B+/CD8+ T cells) in the tumor tissues. We also",
    "entities": [
      {
        "text": "Granzyme",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "established a PBMC humanized mouse model to further confirmed that combination",
    "entities": [
      {
        "text": "PBMC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "therapy could significantly reduce the tumor size of TNBC patient-derived",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "xenografts (56S) and the combination group were found to have the most",
    "entities": [
      {
        "text": "xenografts",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "infiltrating activated human T lymphocytes (Granzyme B+/CD8+ T cells) in the",
    "entities": [
      {
        "text": "Granzyme",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "tumor tissues. Immunofluorescent staining of organoids also confirmed that",
    "entities": []
  },
  {
    "text": "organoids from combination group have more CD8+ T cell and the results of",
    "entities": []
  },
  {
    "text": "organoid cell viability assay in vitro indicated that combination of sulindac",
    "entities": []
  },
  {
    "text": "with PD-L1 antibody together with activated human PBMC significantly reduce 56S",
    "entities": [
      {
        "text": "56S",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "organoid cell viability, which is consistent with in vivo study. When",
    "entities": []
  },
  {
    "text": "investigating the mechanism of action, first we found sulindac could",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "downregulate exosomal PD-L1 by decreasing expression of nsMase2 which is a major",
    "entities": [
      {
        "text": "nsMase2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "regulator in production of exosomal PD-L1. Second, we demonstrated that sulindac",
    "entities": [
      {
        "text": "PD-L1",
        "label": "GPE"
      },
      {
        "text": "Second",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "could downregulate PD-L1 by blocking Stat3 signaling and enhancing the",
    "entities": []
  },
  {
    "text": "expression of miR-570-3p which can potentially target PD-L1, which in turn led",
    "entities": [
      {
        "text": "miR-570-3p",
        "label": "ORG"
      },
      {
        "text": "PD-L1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "to a further decrease in exosomal PD-L1. Previous study showed that PD-L1",
    "entities": []
  },
  {
    "text": "antibody could be bound and consumed by exosomal PD-L1 in the blood circulation.",
    "entities": []
  },
  {
    "text": "Therefore, in combination therapy, sulindac downregulating exosomal PD-L1 leads",
    "entities": []
  },
  {
    "text": "to increased availability of PD-L1 Ab, which potentially improves the overall",
    "entities": [
      {
        "text": "PD-L1 Ab",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "efficacy of anti-PD-L1 therapy. In conclusion, our findings provide unique",
    "entities": [
      {
        "text": "anti-PD-L1",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "insights into the mechanism of action and efficacy for sulindac as an",
    "entities": []
  },
  {
    "text": "immunomodulatory agent in combination with anti-PD-L1 therapy for the treatment",
    "entities": []
  },
  {
    "text": "of TNBC.",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of ER+ breast",
    "entities": [
      {
        "text": "NCAM1",
        "label": "PRODUCT"
      },
      {
        "text": "FGFR1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "cancer brain metastases in young and aged hosts.",
    "entities": []
  },
  {
    "text": "Cittelly DM.",
    "entities": []
  },
  {
    "text": "proportion of BC brain metastasis (BCBM) but remains understudied. Here, we",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "report that FGFR1-amplification, a well-established driver of ER+ BC endocrine",
    "entities": [
      {
        "text": "FGFR1",
        "label": "ORG"
      },
      {
        "text": "ER+ BC",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "resistance, promotes ER+ BCBM colonization in young and aged mice, through",
    "entities": []
  },
  {
    "text": "brain-dependent mechanisms. FGFR1-dependent brain colonization in young and aged",
    "entities": []
  },
  {
    "text": "interactions. Astrocytic FGF2-mediated paracrine activation of FGFR1 promoted",
    "entities": [
      {
        "text": "FGFR1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "BCBMs in estrogen-treated young mice, but FGF2 signaling decreased in the brain",
    "entities": []
  },
  {
    "text": "with aging and estrogen-depletion. Neuronal and glial NCAM1, which remain",
    "entities": [
      {
        "text": "NCAM1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "unchanged in young and aged brains, promoted adhesion to neurons and migration",
    "entities": []
  },
  {
    "text": "of ER+ BC cells, suggesting that interactions with astrocytes and neurons",
    "entities": [
      {
        "text": "ER+ BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "facilitate early ER+ BCBM colonization through FGFR1. Importantly, FDA-approved",
    "entities": [
      {
        "text": "FGFR1",
        "label": "PRODUCT"
      },
      {
        "text": "FDA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "FGFR inhibitors effectively blocked early but not late metastatic progression",
    "entities": []
  },
  {
    "text": "only in young mice, suggesting limited efficacy of FGFR inhibitors to block",
    "entities": [
      {
        "text": "FGFR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "18. Health Sci Rep. 2025 Jul 15;8(7):e71062. doi: 10.1002/hsr2.71062. eCollection",
    "entities": [
      {
        "text": "18",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "10.1002",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Assessment of ESR1, PGR, ERBB2, and MKI67 mRNA in Hormone Receptor-Positive",
    "entities": [
      {
        "text": "PGR",
        "label": "ORG"
      },
      {
        "text": "ERBB2",
        "label": "PERSON"
      },
      {
        "text": "Hormone Receptor",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Early Breast Cancer: A Cross-Sectional Study.",
    "entities": []
  },
  {
    "text": "(1)Department of Hematology-Oncology Shahid Beheshti University of Medical",
    "entities": [
      {
        "text": "Hematology-Oncology Shahid Beheshti University of Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sciences Tehran Iran.",
    "entities": [
      {
        "text": "Tehran",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Cancer Research Center Shahid Beheshti University of Medical Sciences Tehran",
    "entities": [
      {
        "text": "Research Center Shahid Beheshti University of Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Tehran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND AND AIMS: Hormone receptors are expressed in 70% of breast cancers",
    "entities": [
      {
        "text": "70%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "and are the major biomarkers for tailoring treatment in early-stage breast",
    "entities": []
  },
  {
    "text": "cancer. In clinical routine, immunohistochemistry (IHC) is used to assess",
    "entities": [
      {
        "text": "IHC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "expression. However, IHC procedure is challenged with pre-analytical and",
    "entities": [
      {
        "text": "IHC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "analytical variability. Pathologist interpretation of IHC results can vary, and",
    "entities": [
      {
        "text": "IHC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "discordant results between local and reference laboratories have been reported.",
    "entities": []
  },
  {
    "text": "Using mRNA-based tests may be a more robust, reliable, and standardized method",
    "entities": []
  },
  {
    "text": "to assess these important breast cancer biomarkers. This study aimed to assess",
    "entities": []
  },
  {
    "text": "the concordance between real-time PCR and IHC results.",
    "entities": [
      {
        "text": "PCR",
        "label": "ORG"
      },
      {
        "text": "IHC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: In this study, we analyzed 178 early-stage hormone receptor-positive",
    "entities": [
      {
        "text": "178",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "breast tumors. IHC for ER, PR, HER2, and Ki67 had been previously performed for",
    "entities": [
      {
        "text": "IHC",
        "label": "ORG"
      },
      {
        "text": "ER",
        "label": "ORG"
      },
      {
        "text": "PR",
        "label": "GPE"
      },
      {
        "text": "HER2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "the study samples at local laboratories. For samples with HER2 IHC score 2+,",
    "entities": [
      {
        "text": "2+",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Fluorescence In Situ Hybridization was performed. ESR1 (encoding ER), PGR",
    "entities": [
      {
        "text": "Fluorescence In Situ Hybridization",
        "label": "WORK_OF_ART"
      },
      {
        "text": "ER",
        "label": "ORG"
      },
      {
        "text": "PGR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(encoding PR), ERBB2 (encoding HER2), and MKI67 (encoding Ki67) mRNA expression",
    "entities": [
      {
        "text": "ERBB2",
        "label": "PERSON"
      },
      {
        "text": "HER2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "were determined using TaqMan gene expression assays.",
    "entities": []
  },
  {
    "text": "RESULTS: The overall concordance between mRNA expression results and their",
    "entities": []
  },
  {
    "text": "corresponding IHC markers was 95.9% for ESR1/ER, 79.3% for PGR/PR, and 100% for",
    "entities": [
      {
        "text": "IHC",
        "label": "ORG"
      },
      {
        "text": "95.9%",
        "label": "PERCENT"
      },
      {
        "text": "79.3%",
        "label": "PERCENT"
      },
      {
        "text": "PGR/PR",
        "label": "ORG"
      },
      {
        "text": "100%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "ERBB2/HER2. There was a moderate correlation between MKi67 mRNA values and Ki67",
    "entities": [
      {
        "text": "ERBB2/HER2",
        "label": "ORG"
      },
      {
        "text": "MKi67",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "IHC. ESR1 expression was significantly lower in tumors of younger patients",
    "entities": [
      {
        "text": "IHC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(p < 0.001). No statistically significant correlation between age at cancer",
    "entities": []
  },
  {
    "text": "diagnosis and ER IHC was identified. Higher ESR1 and MKI67 mRNA expression was",
    "entities": [
      {
        "text": "IHC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "associated with worse pathological characteristics.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: PCR-based classification of breast tumors in a central laboratory",
    "entities": []
  },
  {
    "text": "may be used to confirm the available IHC results performed at local laboratories",
    "entities": [
      {
        "text": "IHC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and add valuable information for patient management. mRNA-based biomarkers may",
    "entities": []
  },
  {
    "text": "be promising for more standardized breast cancer management.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 The Author(s). Health Science Reports published by Wiley Periodicals LLC.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Wiley Periodicals",
        "label": "ORG"
      },
      {
        "text": "LLC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The authors declare no conflicts of interest.",
    "entities": []
  },
  {
    "text": "19. APL Bioeng. 2025 Jul 14;9(3):036104. doi: 10.1063/5.0230800. eCollection 2025",
    "entities": [
      {
        "text": "19",
        "label": "CARDINAL"
      },
      {
        "text": "Bioeng",
        "label": "PERSON"
      },
      {
        "text": "10.1063/5.0230800",
        "label": "CARDINAL"
      },
      {
        "text": "eCollection",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Microwave-assisted immunostaining for rapid labeling of matrix-embedded",
    "entities": []
  },
  {
    "text": "(1)Cancer Early Detection Advanced Research Center, Knight Cancer Institute,",
    "entities": [
      {
        "text": "Early Detection Advanced Research Center",
        "label": "ORG"
      },
      {
        "text": "Knight Cancer Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Oregon Health and Science University, Portland, Oregon 97201, USA.",
    "entities": [
      {
        "text": "Oregon Health and Science University",
        "label": "ORG"
      },
      {
        "text": "Portland",
        "label": "GPE"
      },
      {
        "text": "Oregon 97201",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Immunofluorescence staining of cell proteins is essential to understanding",
    "entities": []
  },
  {
    "text": "biomolecular interactions within three-dimensional (3D) hydrogel cell cultures.",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "However, the scaffold material limits passive diffusion of antibodies through",
    "entities": []
  },
  {
    "text": "thick 3D matrices, prolonging staining and washing steps and resulting in",
    "entities": []
  },
  {
    "text": "processing times that can last for several days. Microwave irradiation has",
    "entities": [
      {
        "text": "several days",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "previously been shown to enhance penetration of fixatives in a variety of soft",
    "entities": []
  },
  {
    "text": "tissues by increasing the rate of diffusion through the sample, yet it is",
    "entities": []
  },
  {
    "text": "unknown if microwave irradiation can improve immunofluorescence staining of",
    "entities": []
  },
  {
    "text": "cells in 3D hydrogel cultures. Here, we demonstrate a microwave-assisted",
    "entities": []
  },
  {
    "text": "immunostaining technique that rapidly labels cells within spheroid structures",
    "entities": []
  },
  {
    "text": "embedded within thick intact hydrogels. These results show that",
    "entities": []
  },
  {
    "text": "collagen-embedded breast epithelial spheroids can be efficiently labeled with",
    "entities": []
  },
  {
    "text": "primary antibodies in less than 3.5 h. We show significantly enhanced staining",
    "entities": [
      {
        "text": "less than 3.5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and greater depth penetration with microwave-assisted staining compared to",
    "entities": []
  },
  {
    "text": "conventional benchtop staining methods. We demonstrate staining of",
    "entities": []
  },
  {
    "text": "collagen-embedded breast cancer spheroids with complete staining achieved in",
    "entities": []
  },
  {
    "text": "less than 2.5 h via the microwave, which outperforms conventional staining",
    "entities": [
      {
        "text": "less than 2.5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "techniques. Moreover, we demonstrate enhanced staining of spheroids embedded in",
    "entities": []
  },
  {
    "text": "basement membrane-derived Matrigel matrices with the microwave method compared",
    "entities": [
      {
        "text": "Matrigel",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "to benchtop techniques. Finally, we directly compare 2-h microwave-assisted",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "staining to conventional 15-h longform benchtop staining and show that microwave",
    "entities": [
      {
        "text": "15",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "staining increases depth penetration and intensity of stains compared to the",
    "entities": []
  },
  {
    "text": "longform staining. This work develops a microwave-assisted staining protocol",
    "entities": []
  },
  {
    "text": "that provides a rapid and reproducible method to label a variety of cell types",
    "entities": []
  },
  {
    "text": "within various 3D hydrogel cell culture systems.",
    "entities": []
  },
  {
    "text": "\u00a9 2024 Author(s).",
    "entities": [
      {
        "text": "2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The authors have no conflicts to disclose.",
    "entities": []
  },
  {
    "text": "Paraneoplastic Amyopathic Dermatomyositis Associated With a Bone and Medullary",
    "entities": []
  },
  {
    "text": "Location of Breast Adenocarcinoma.",
    "entities": []
  },
  {
    "text": "(1)Department of Medical Oncology, Centre Hospitalo-Universitaire Mohammed VI,",
    "entities": [
      {
        "text": "Medical Oncology",
        "label": "ORG"
      },
      {
        "text": "Mohammed VI",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(2)Department of Medical Oncology, Cadi Ayyad University, Marrakesh, MAR.",
    "entities": [
      {
        "text": "Medical Oncology",
        "label": "ORG"
      },
      {
        "text": "Cadi Ayyad University",
        "label": "ORG"
      },
      {
        "text": "Marrakesh",
        "label": "GPE"
      },
      {
        "text": "MAR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Paraneoplastic amyopathic dermatomyositis (ADM) is a rare connective tissue",
    "entities": [
      {
        "text": "ADM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "disease presenting with characteristic dermatomyositis-like skin findings in the",
    "entities": []
  },
  {
    "text": "absence of muscle involvement. It is associated with malignancies in 15%-30% of",
    "entities": [
      {
        "text": "15%-30%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "cases and may portend a fatal outcome, especially when linked to advanced",
    "entities": []
  },
  {
    "text": "cancers. We report the case of a 58-year-old woman who presented with",
    "entities": [
      {
        "text": "58-year-old",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "progressive low back pain and erythroderma. Imaging revealed diffuse bone",
    "entities": []
  },
  {
    "text": "metastases, and bone biopsy confirmed a poorly differentiated adenocarcinoma of",
    "entities": []
  },
  {
    "text": "erythema and other cutaneous findings consistent with ADM. The patient was",
    "entities": [
      {
        "text": "ADM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "started on endocrine therapy with palbociclib and letrozole, along with",
    "entities": []
  },
  {
    "text": "improvement. However, within six months of diagnosis, she developed severe",
    "entities": [
      {
        "text": "six months",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "COVID-19 pneumonia, complicated by pancytopenia and sepsis, and ultimately",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "succumbed to multiorgan failure despite intensive care support. This case",
    "entities": []
  },
  {
    "text": "underlines the importance of recognizing paraneoplastic ADM as an initial",
    "entities": [
      {
        "text": "ADM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "manifestation of malignancy. A multidisciplinary approach is key, but the",
    "entities": []
  },
  {
    "text": "prognosis largely depends on the cancer's burden and complications such as",
    "entities": []
  },
  {
    "text": "treatment-induced immunosuppression.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025, Haboub et al.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "al.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Human subjects: Informed consent for treatment",
    "entities": []
  },
  {
    "text": "and open access publication was obtained or waived by all participants in this",
    "entities": []
  },
  {
    "text": "study. Conflicts of interest: In compliance with the ICMJE uniform disclosure",
    "entities": [
      {
        "text": "ICMJE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "form, all authors declare the following: Payment/services info: All authors have",
    "entities": []
  },
  {
    "text": "declared that no financial support was received from any organization for the",
    "entities": []
  },
  {
    "text": "submitted work. Financial relationships: All authors have declared that they",
    "entities": []
  },
  {
    "text": "have no financial relationships at present or within the previous three years",
    "entities": [
      {
        "text": "the previous three years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "with any organizations that might have an interest in the submitted work. Other",
    "entities": []
  },
  {
    "text": "relationships: All authors have declared that there are no other relationships",
    "entities": []
  },
  {
    "text": "or activities that could appear to have influenced the submitted work.",
    "entities": []
  },
  {
    "text": "Updates on Breast Cancer in Oman: Challenges and Promising Frontiers.",
    "entities": [
      {
        "text": "Oman",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(1)Department of Pathology and Blood Bank, Sohar Hospital, Sohar, OMN.",
    "entities": [
      {
        "text": "Pathology",
        "label": "ORG"
      },
      {
        "text": "Blood Bank",
        "label": "ORG"
      },
      {
        "text": "Sohar Hospital",
        "label": "ORG"
      },
      {
        "text": "Sohar",
        "label": "GPE"
      },
      {
        "text": "OMN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Breast cancer is a significant public health concern in Oman, with increasing",
    "entities": [
      {
        "text": "Oman",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "incidence rates over the past few decades. This literature review explores the",
    "entities": [
      {
        "text": "the past few decades",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "epidemiology, risk factors, cultural influences, screening practices, treatment",
    "entities": []
  },
  {
    "text": "outcomes, research, and role of non-profit organizations in breast cancer",
    "entities": []
  },
  {
    "text": "awareness in Oman. The review highlights the unique challenges faced by Omani",
    "entities": [
      {
        "text": "Oman",
        "label": "GPE"
      },
      {
        "text": "Omani",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "women, including late-stage diagnosis, cultural stigma, and limited awareness of",
    "entities": []
  },
  {
    "text": "screening programs. While efforts have been made to improve early detection and",
    "entities": []
  },
  {
    "text": "treatment, there is a need for more comprehensive public health strategies to",
    "entities": []
  },
  {
    "text": "address the growing burden of breast cancer in Oman. This review synthesizes",
    "entities": [
      {
        "text": "Oman",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "recent studies to provide a comprehensive overview of the current state of",
    "entities": []
  },
  {
    "text": "breast cancer in Oman and suggests directions for future research and policy",
    "entities": [
      {
        "text": "Oman",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "interventions.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025, Al Khan et al.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Al Khan",
        "label": "PERSON"
      },
      {
        "text": "al.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Conflicts of interest: In compliance with the",
    "entities": []
  },
  {
    "text": "ICMJE uniform disclosure form, all authors declare the following:",
    "entities": []
  },
  {
    "text": "Payment/services info: All authors have declared that no financial support was",
    "entities": []
  },
  {
    "text": "received from any organization for the submitted work. Financial relationships:",
    "entities": []
  },
  {
    "text": "All authors have declared that they have no financial relationships at present",
    "entities": []
  },
  {
    "text": "or within the previous three years with any organizations that might have an",
    "entities": [
      {
        "text": "the previous three years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "interest in the submitted work. Other relationships: All authors have declared",
    "entities": []
  },
  {
    "text": "that there are no other relationships or activities that could appear to have",
    "entities": []
  },
  {
    "text": "influenced the submitted work.",
    "entities": []
  },
  {
    "text": "Identification and validation of genes related to stem cells and telomere",
    "entities": []
  },
  {
    "text": "maintenance mechanisms as biomarkers for breast cancer.",
    "entities": []
  },
  {
    "text": "(1)Department of Breast Surgery, Department of General Surgery, The First",
    "entities": [
      {
        "text": "Breast Surgery",
        "label": "ORG"
      },
      {
        "text": "Department of General Surgery",
        "label": "ORG"
      },
      {
        "text": "First",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "Affiliated Hospital with Nanjing Medical University, Nanjing, China.",
    "entities": [
      {
        "text": "Affiliated Hospital",
        "label": "ORG"
      },
      {
        "text": "Nanjing Medical University",
        "label": "ORG"
      },
      {
        "text": "Nanjing",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(#)Contributed equally",
    "entities": []
  },
  {
    "text": "BACKGROUND: Stem cell-related genes (SCRGs) and telomere maintenance",
    "entities": [
      {
        "text": "SCRGs",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mechanism-related genes (TMMRGs) are pivotal in breast cancer (BC) pathogenesis",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "by facilitating tumor cell proliferation and self-renewal. This study employed",
    "entities": []
  },
  {
    "text": "integrated transcriptomic and single-cell RNA sequencing (scRNA-seq) analyses to",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "investigate SCRGs and TMMRGs as potential biomarkers for BC and to elucidate",
    "entities": [
      {
        "text": "SCRGs",
        "label": "ORG"
      },
      {
        "text": "TMMRGs",
        "label": "ORG"
      },
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "their underlying cellular mechanisms.",
    "entities": []
  },
  {
    "text": "METHODS: Total RNA was extracted from eight BC tumor samples and eight matched",
    "entities": [
      {
        "text": "eight",
        "label": "CARDINAL"
      },
      {
        "text": "BC",
        "label": "ORG"
      },
      {
        "text": "eight",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "adjacent non-tumorous tissues. Differential expression profiling,",
    "entities": []
  },
  {
    "text": "protein-protein interaction (PPI) network construction, and Molecular Complex",
    "entities": [
      {
        "text": "Molecular Complex",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Detection (MCODE) were conducted. Biomarker candidates were identified using the",
    "entities": []
  },
  {
    "text": "least absolute shrinkage and selection operator (LASSO) algorithm, followed by",
    "entities": [
      {
        "text": "LASSO",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "pathway enrichment and immunological analyses. Publicly available scRNA-seq",
    "entities": []
  },
  {
    "text": "datasets were utilized to delineate BC cell types, with emphasis on cellular",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "subsets exhibiting differential biomarker expression. Heterogeneity,",
    "entities": []
  },
  {
    "text": "communication, and pseudo-temporal analyses of key cells were examined.",
    "entities": []
  },
  {
    "text": "Biomarker expression was further validated by reverse transcription-quantitative",
    "entities": []
  },
  {
    "text": "polymerase chain reaction (RT-qPCR).",
    "entities": [
      {
        "text": "RT-qPCR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: JUN, NFKB1, and SP1 were significantly downregulated in BC, potentially",
    "entities": [
      {
        "text": "JUN",
        "label": "PERSON"
      },
      {
        "text": "NFKB1",
        "label": "PERSON"
      },
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "modulating disease progression through mechanisms involving extracellular matrix",
    "entities": []
  },
  {
    "text": "(ECM) remodeling, intracellular signaling, oxidative stress response, and",
    "entities": [
      {
        "text": "ECM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "translational regulation. Activated B cells and natural killer (NK) cells",
    "entities": []
  },
  {
    "text": "demonstrated elevated infiltration levels, accompanied by increased expression",
    "entities": []
  },
  {
    "text": "of immune checkpoint molecules CD200, CD274, TIGIT, TNFRSF25, and TNFSF15. Nine",
    "entities": [
      {
        "text": "CD200",
        "label": "GPE"
      },
      {
        "text": "CD274",
        "label": "GPE"
      },
      {
        "text": "TIGIT",
        "label": "GPE"
      },
      {
        "text": "Nine",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "distinct cellular lineages were annotated, among which mesenchymal cells",
    "entities": []
  },
  {
    "text": "exhibited pronounced biomarker expression differences and enhanced",
    "entities": []
  },
  {
    "text": "differentiation potential, designating them as key cellular mediators.",
    "entities": []
  },
  {
    "text": "Interactions between mesenchymal subpopulations (MSC1, MSC2, MSC3) and other",
    "entities": [
      {
        "text": "MSC2",
        "label": "ORG"
      },
      {
        "text": "MSC3",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cell types were markedly reduced in BC, despite an overall expansion in",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mesenchymal cell numbers during disease progression. MSC1 emerged as the",
    "entities": []
  },
  {
    "text": "predominant subtype. RT-qPCR analyses corroborated the downregulation of JUN,",
    "entities": [
      {
        "text": "RT-qPCR",
        "label": "PERSON"
      },
      {
        "text": "JUN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "NFKB1, and SP1 in BC tissues.",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSION: JUN, NFKB1, and SP1 were identified as potential biomarkers for BC.",
    "entities": [
      {
        "text": "JUN",
        "label": "PERSON"
      },
      {
        "text": "NFKB1",
        "label": "PERSON"
      },
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "These findings highlight the critical role of mesenchymal cells in tumor biology",
    "entities": []
  },
  {
    "text": "and suggest potential therapeutic targets.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Zhen, Huang, Zhu, Chen, Wang and Zha.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Zhen",
        "label": "GPE"
      },
      {
        "text": "Huang",
        "label": "PERSON"
      },
      {
        "text": "Zhu",
        "label": "PERSON"
      },
      {
        "text": "Chen",
        "label": "PERSON"
      },
      {
        "text": "Wang",
        "label": "PERSON"
      },
      {
        "text": "Zha",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Genomic and immune profiling of prognostic risk groups in IgM gammopathy reveals",
    "entities": [
      {
        "text": "IgM",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "novel biomarkers beyond MYD88 L265P.",
    "entities": [
      {
        "text": "MYD88 L265P.",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Cl\u00ednic de",
    "entities": [
      {
        "text": "Myeloma Unit",
        "label": "ORG"
      },
      {
        "text": "Department of Hematology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Barcelona, University of Barcelona, Barcelona, Spain.",
    "entities": [
      {
        "text": "Barcelona,",
        "label": "ORG"
      },
      {
        "text": "University of Barcelona",
        "label": "ORG"
      },
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University of Barcelona, Barcelona, Spain.",
    "entities": [
      {
        "text": "University of Barcelona",
        "label": "ORG"
      },
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Institute of Cancer and Blood Diseases, Barcelona, Spain.",
    "entities": [
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Reveal Genomics, Barcelona, Spain.",
    "entities": [
      {
        "text": "Genomics",
        "label": "ORG"
      },
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Hematopathology Unit, Department of Pathology, Hospital Cl\u00ednic de Barcelona,",
    "entities": [
      {
        "text": "Unit,",
        "label": "ORG"
      },
      {
        "text": "Department of Pathology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Breast Cancer Unit, Institute of Oncology (IOB)-Quir\u00f3nSalud,",
    "entities": [
      {
        "text": "Cancer Unit",
        "label": "ORG"
      },
      {
        "text": "Institute of Oncology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Barcelona, Spain.",
    "entities": [
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: MYD88 L265P is an early mutation in IgM monoclonal gammopathy of",
    "entities": []
  },
  {
    "text": "undetermined significance (MGUS) and asymptomatic Waldenstr\u00f6m macroglobulinemia",
    "entities": [
      {
        "text": "Waldenstr\u00f6m",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(WM). Given the high prevalence of the MYD88 mutation observed in",
    "entities": [
      {
        "text": "MYD88",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "epidemiological studies, its presence is not sufficient to drive disease",
    "entities": []
  },
  {
    "text": "progression. In fact, a recent risk model of progression reported that the",
    "entities": []
  },
  {
    "text": "impact of other laboratory biomarkers was superior to the MYD88 mutation's",
    "entities": [
      {
        "text": "MYD88",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "presence. Due to the low incidence of these clinicopathological entities, there",
    "entities": []
  },
  {
    "text": "is a need for a better characterization of tumor and immune cells that can help",
    "entities": []
  },
  {
    "text": "to identify novel biomarkers. We hypothesize that the characterization of the",
    "entities": []
  },
  {
    "text": "risk groups in asymptomatic patients could improve the discovery of drivers of",
    "entities": []
  },
  {
    "text": "METHODS: We characterized the genomic and immune landscape of the most recent",
    "entities": []
  },
  {
    "text": "prognostic risk categories in 19 IgM MGUS and 17 asymptomatic WM patients. We",
    "entities": [
      {
        "text": "19 IgM MGUS",
        "label": "MONEY"
      },
      {
        "text": "17",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "performed targeted next generation sequencing (NGS) on CD19+ cells from bone",
    "entities": [
      {
        "text": "NGS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "marrow samples at diagnosis using a panel of 54 lymphoma-driver genes. Whole",
    "entities": [
      {
        "text": "54",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "bone marrow samples were also used to measure mRNA gene expression in tumor and",
    "entities": []
  },
  {
    "text": "immune cells using the PanCancer ImmuneProfiling panel on the nCounter platform",
    "entities": [
      {
        "text": "PanCancer ImmuneProfiling",
        "label": "ORG"
      },
      {
        "text": "nCounter",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: We observed that low-risk patients were only characterized by the",
    "entities": []
  },
  {
    "text": "presence of MYD88 L265P, while intermediate- and high-risk groups harbored",
    "entities": [
      {
        "text": "MYD88",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "additional mutations on CXCR4, KMT2D, ARID1A and EP300. Regarding the mRNA",
    "entities": [
      {
        "text": "CXCR4",
        "label": "GPE"
      },
      {
        "text": "KMT2D",
        "label": "ORG"
      },
      {
        "text": "EP300",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "expression analyses, we found an increased proportion of myeloid cells in the",
    "entities": [
      {
        "text": "myeloid",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "low-risk group, with monocytes having a significant decrease in low versus",
    "entities": []
  },
  {
    "text": "high-risk patients. The high-risk group also upregulated genes involved in the",
    "entities": []
  },
  {
    "text": "activation of NF-\u03baB and B-cell receptor (BCR) signaling, while low-risk patients",
    "entities": [
      {
        "text": "NF-\u03baB",
        "label": "ORG"
      },
      {
        "text": "BCR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "upregulated genes associated with an alternative activation of B cells or a",
    "entities": []
  },
  {
    "text": "decrease of the BCR signaling, such as TOLLIP, CEACAM1 and CR1.",
    "entities": [
      {
        "text": "BCR",
        "label": "ORG"
      },
      {
        "text": "TOLLIP",
        "label": "ORG"
      },
      {
        "text": "CEACAM1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: Beyond the MYD88 mutation, we described novel molecular mechanisms",
    "entities": [
      {
        "text": "MYD88",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "associated with high-risk patients, as an effort moving towards easy-to use new",
    "entities": []
  },
  {
    "text": "biomarkers in IgM gammopathy.",
    "entities": [
      {
        "text": "IgM",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: DM received travel grants and honoraria from",
    "entities": []
  },
  {
    "text": "Janssen. FN received honoraria from Janssen, AbbVie, AstraZeneca, and SOPHiA",
    "entities": [
      {
        "text": "Janssen",
        "label": "DATE"
      },
      {
        "text": "Janssen, AbbVie",
        "label": "DATE"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GENETICS, and research funding from Gilead. FN licensed the use of the protected",
    "entities": [
      {
        "text": "GENETICS",
        "label": "ORG"
      },
      {
        "text": "Gilead",
        "label": "ORG"
      },
      {
        "text": "FN",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "IgCaller algorithm for SOPHiA GENETICS and Diagn\u00f3stica Longwood. CF consulted",
    "entities": [
      {
        "text": "GENETICS",
        "label": "ORG"
      },
      {
        "text": "Diagn\u00f3stica Longwood",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "and received honoraria from GSK, Sanofi, Pfizer, BeiGene, Amgen, BMS, and",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "Pfizer",
        "label": "ORG"
      },
      {
        "text": "BeiGene",
        "label": "ORG"
      },
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "BMS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Janssen and received research funding from GSK, Amgen, and Janssen. JB received",
    "entities": [
      {
        "text": "Janssen",
        "label": "PERSON"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "Janssen",
        "label": "GPE"
      },
      {
        "text": "JB",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "honoraria for lectures from Janssen and Sanofi. NT received honoraria for",
    "entities": [
      {
        "text": "Janssen",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "lectures from Pfizer. FB-M. refers a part-time employment from Reveal Genomics.",
    "entities": [
      {
        "text": "Pfizer",
        "label": "ORG"
      },
      {
        "text": "Reveal Genomics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "AP reports advisory and consulting fees from AstraZeneca, Roche, Pfizer,",
    "entities": [
      {
        "text": "AP",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Roche",
        "label": "ORG"
      },
      {
        "text": "Pfizer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Novartis, Daiichi Sankyo, Ona Therapeutics, and Peptomyc, lecture fees from",
    "entities": [
      {
        "text": "Daiichi Sankyo",
        "label": "PERSON"
      },
      {
        "text": "Ona Therapeutics",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "AstraZeneca, Roche, Novartis, and Daiichi Sankyo, institutional financial",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Roche",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Daiichi Sankyo",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "interests from AstraZeneca, Novartis, Roche, and Daiichi Sankyo; and is a",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Roche",
        "label": "ORG"
      },
      {
        "text": "Daiichi Sankyo",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "stockholder and employee of Reveal Genomics. LR received honoraria for lectures",
    "entities": [
      {
        "text": "Reveal Genomics",
        "label": "ORG"
      },
      {
        "text": "LR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "received honoraria and travel grants from Janssen, Amgen, BMS, GSK, Menarini",
    "entities": [
      {
        "text": "Janssen",
        "label": "DATE"
      },
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "BMS",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Menarini",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Stemline, and Sanofi. MC received honoraria from Amgen and Janssen. AD received",
    "entities": [
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "Janssen",
        "label": "LANGUAGE"
      }
    ]
  },
  {
    "text": "honoraria for lectures from Janssen, travel grants from Sanofi and Binding Site.",
    "entities": [
      {
        "text": "Janssen",
        "label": "DATE"
      },
      {
        "text": "Sanofi",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "The remaining authors declare that the research was conducted in the absence of",
    "entities": []
  },
  {
    "text": "any commercial or financial relationships that could be construed as a potential",
    "entities": []
  },
  {
    "text": "conflict of interest. The author(s) declared that they were an editorial board",
    "entities": []
  },
  {
    "text": "member of Frontiers, at the time of submission. This had no impact on the peer",
    "entities": [
      {
        "text": "Frontiers",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "review process and the final decision.",
    "entities": []
  },
  {
    "text": "10.1021/acsmedchemlett.5c00125. eCollection 2025 Jul 10.",
    "entities": [
      {
        "text": "10.1021",
        "label": "CARDINAL"
      },
      {
        "text": "10",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Exploring the Ligandability of 53BP1 through Fragment-Based Approaches.",
    "entities": [
      {
        "text": "53BP1",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Chiew B(1), Gunzburg MJ(1)(2), Foley CA(2)(3), Zeng H(4), Dong A(4), Brown",
    "entities": [
      {
        "text": "Gunzburg MJ(1)(2",
        "label": "ORG"
      },
      {
        "text": "Foley CA(2)(3",
        "label": "ORG"
      },
      {
        "text": "Zeng",
        "label": "PERSON"
      },
      {
        "text": "Dong A(4",
        "label": "PERSON"
      },
      {
        "text": "Brown",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "PJ(4), The J(4), Norris-Drouin JL(3), Cholensky SH(3), Mohanty B(1)(2), Scanlon",
    "entities": [
      {
        "text": "Norris-Drouin",
        "label": "ORG"
      },
      {
        "text": "Cholensky SH(3",
        "label": "PERSON"
      },
      {
        "text": "Mohanty B(1)(2",
        "label": "PERSON"
      },
      {
        "text": "Scanlon",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "MJ(1)(2), Headey SJ(1)(2), Doak BC(1)(2), James LI(3).",
    "entities": [
      {
        "text": "Headey SJ(1)(2",
        "label": "PERSON"
      },
      {
        "text": "Doak BC(1)(2",
        "label": "PERSON"
      },
      {
        "text": "James LI(3",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash",
    "entities": [
      {
        "text": "Chemistry, Monash Institute of Pharmaceutical Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Parkville, Victoria 3052, Australia.",
    "entities": [
      {
        "text": "Parkville",
        "label": "GPE"
      },
      {
        "text": "Victoria 3052",
        "label": "PERSON"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Monash Fragment Platform, Monash Institute of Pharmaceutical Sciences, Monash",
    "entities": [
      {
        "text": "2)Monash",
        "label": "CARDINAL"
      },
      {
        "text": "Monash Institute of Pharmaceutical Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Center for Integrative Chemical Biology and Drug Discovery, Division of",
    "entities": [
      {
        "text": "Integrative Chemical Biology and Drug Discovery",
        "label": "ORG"
      },
      {
        "text": "Division of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy,",
    "entities": [
      {
        "text": "Chemical Biology and Medicinal Chemistry",
        "label": "ORG"
      },
      {
        "text": "UNC Eshelman School of Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of North Carolina, Chapel Hill, North Carolina 27599, United States.",
    "entities": [
      {
        "text": "University of North Carolina",
        "label": "ORG"
      },
      {
        "text": "Chapel Hill",
        "label": "GPE"
      },
      {
        "text": "North Carolina 27599",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Structural Genomics Consortium, University of Toronto, Toronto, Ontario,",
    "entities": [
      {
        "text": "Genomics Consortium",
        "label": "ORG"
      },
      {
        "text": "University of Toronto",
        "label": "ORG"
      },
      {
        "text": "Toronto",
        "label": "GPE"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "53BP1 is a DNA damage response protein recruited to sites of double strand",
    "entities": [
      {
        "text": "53BP1",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "breaks through recognition of dimethylated lysine on histone 4 by its tandem",
    "entities": [
      {
        "text": "4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Tudor domains. Like 53BP1, BRCA-1 plays a role in the regulation of DNA repair",
    "entities": [
      {
        "text": "Tudor",
        "label": "PERSON"
      },
      {
        "text": "53BP1",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "pathways, and BRCA-1 mutations have been strongly linked to breast and ovarian",
    "entities": []
  },
  {
    "text": "cancer. Interestingly, mice null for 53BP1 and BRCA-1 genes display minimal",
    "entities": [
      {
        "text": "53BP1",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "tumor formation, suggesting that the effects of deleterious BRCA-1 mutations",
    "entities": []
  },
  {
    "text": "could be prevented with potent 53BP1 small molecule antagonists. Herein, we",
    "entities": [
      {
        "text": "53BP1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "describe a fragment screen that was used to identify compounds that bind to the",
    "entities": []
  },
  {
    "text": "53BP1 Tudor domain and a chemoinformatic workflow to select near-neighbor",
    "entities": [
      {
        "text": "53BP1",
        "label": "DATE"
      },
      {
        "text": "Tudor",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "analogues and establish structure activity relationships for these binders. The",
    "entities": []
  },
  {
    "text": "marked affinity improvements of the analogues over their parent fragments",
    "entities": []
  },
  {
    "text": "highlights the developability of these series and the utility of this approach",
    "entities": []
  },
  {
    "text": "in discovering novel hit compounds for 53BP1 and other methyl-lysine reader",
    "entities": [
      {
        "text": "53BP1",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "\u00a9 2025 American Chemical Society.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "American Chemical Society",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DOI: 10.1021/acsmedchemlett.5c00125",
    "entities": [
      {
        "text": "10.1021",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "25. Front Psychiatry. 2025 Jul 1;16:1615271. doi: 10.3389/fpsyt.2025.1615271.",
    "entities": [
      {
        "text": "25",
        "label": "CARDINAL"
      },
      {
        "text": "Front Psychiatry",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.3389",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Psychological capital mediates the relationship between medication adherence and",
    "entities": []
  },
  {
    "text": "cancer-related fatigue in breast cancer patients undergoing long-term treatment.",
    "entities": []
  },
  {
    "text": "(1)Department of Oncology, The Third Xiangya Hospital of Central South",
    "entities": [
      {
        "text": "Central South",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "University, Changsha, Hunan, China.",
    "entities": [
      {
        "text": "Changsha",
        "label": "GPE"
      },
      {
        "text": "Hunan",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Nursing, The Third Xiangya Hospital of Central South",
    "entities": [
      {
        "text": "Central South",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "(3)School of Basic Medicine, Changsha Medical University, Changsha,",
    "entities": [
      {
        "text": "Basic Medicine",
        "label": "ORG"
      },
      {
        "text": "Changsha Medical University",
        "label": "ORG"
      },
      {
        "text": "Changsha",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Breast cancer is one of the most prevalent malignant tumors among",
    "entities": [
      {
        "text": "one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "women worldwide. Although long-term pharmacological treatment has substantially",
    "entities": []
  },
  {
    "text": "improved survival rates, it is often accompanied by psychological burdens,",
    "entities": []
  },
  {
    "text": "including cancer-related fatigue (CRF) and diminished adherence to therapy. CRF",
    "entities": []
  },
  {
    "text": "is a pervasive and debilitating symptom that adversely affects physical",
    "entities": []
  },
  {
    "text": "functioning and emotional well-being. Psychological capital (PsyCap), a",
    "entities": [
      {
        "text": "PsyCap",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "construct encompassing self-efficacy, hope, optimism, and resilience, has been",
    "entities": []
  },
  {
    "text": "shown to enhance treatment engagement and promote mental health. However, its",
    "entities": []
  },
  {
    "text": "role as a potential psychological mediator between medication adherence and CRF",
    "entities": [
      {
        "text": "CRF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "is yet to be thoroughly investigated.",
    "entities": []
  },
  {
    "text": "OBJECTIVE: To investigate the mediating role of PsyCap in the relationship",
    "entities": [
      {
        "text": "PsyCap",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "between medication adherence and CRF in patients with breast cancer undergoing",
    "entities": [
      {
        "text": "CRF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "long-term treatment.",
    "entities": []
  },
  {
    "text": "METHODS: A total of 100 breast cancer patients admitted between June 2022 and",
    "entities": [
      {
        "text": "100",
        "label": "CARDINAL"
      },
      {
        "text": "between June 2022",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "June 2024 were recruited using convenience sampling. Data from 90 valid",
    "entities": [
      {
        "text": "June 2024",
        "label": "DATE"
      },
      {
        "text": "90",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "responses were analyzed. Participants completed the PsyCap Questionnaire",
    "entities": [
      {
        "text": "PsyCap",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(PCQ-24), Self-Reported Medication Adherence Rating Scale (SR-MARS), and CRF",
    "entities": [
      {
        "text": "Self-Reported Medication Adherence Rating Scale",
        "label": "ORG"
      },
      {
        "text": "CRF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Scale (CFS). Pearson's correlation analysis was used to assess associations",
    "entities": [
      {
        "text": "Pearson",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "among variables. A mediation analysis was conducted using the bootstrap method",
    "entities": []
  },
  {
    "text": "with 5,000 resamples.",
    "entities": [
      {
        "text": "5,000",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "RESULTS: The mean scores for PsyCap, medication adherence, and CRF were 86.65 \u00b1",
    "entities": [
      {
        "text": "PsyCap",
        "label": "ORG"
      },
      {
        "text": "CRF",
        "label": "ORG"
      },
      {
        "text": "86.65",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "8.37, 5.36 \u00b1 1.12, and 36.77 \u00b1 5.98, respectively. PsyCap was positively",
    "entities": [
      {
        "text": "8.37",
        "label": "CARDINAL"
      },
      {
        "text": "5.36",
        "label": "DATE"
      },
      {
        "text": "1.12",
        "label": "DATE"
      },
      {
        "text": "36.77",
        "label": "CARDINAL"
      },
      {
        "text": "5.98",
        "label": "DATE"
      },
      {
        "text": "PsyCap",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "correlated with medication adherence (r = 0.994, p < 0.05) and negatively",
    "entities": [
      {
        "text": "0.994",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "correlated with CRF (r = -0.992, p < 0.05). Medication adherence was also",
    "entities": [
      {
        "text": "CRF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "negatively correlated with CRF (r = -0.994, p < 0.05). Mediation analysis",
    "entities": [
      {
        "text": "CRF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "confirmed that PsyCap significantly mediated the relationship between medication",
    "entities": [
      {
        "text": "PsyCap",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "adherence and CRF (indirect effect = 0.357, 95% CI did not include zero),",
    "entities": [
      {
        "text": "CRF",
        "label": "ORG"
      },
      {
        "text": "0.357",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "zero",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "accounting for 55.68% of the total effect.",
    "entities": [
      {
        "text": "55.68%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "CONCLUSION: PsyCap partially mediated the association between medication",
    "entities": [
      {
        "text": "PsyCap",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "adherence and CRF. Interventions aimed at enhancing PsyCap may improve adherence",
    "entities": [
      {
        "text": "CRF",
        "label": "ORG"
      },
      {
        "text": "PsyCap",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and reduce CRF in breast cancer patients receiving long-term pharmacotherapy.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Yan and Chu.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Yan",
        "label": "PERSON"
      },
      {
        "text": "Chu",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The remaining authors declare that the research",
    "entities": []
  },
  {
    "text": "was conducted in the absence of any commercial or financial relationships that",
    "entities": []
  },
  {
    "text": "could be construed as a potential conflict of interest.",
    "entities": []
  },
  {
    "text": "26. Breast Care (Basel). 2025 Jun 12. doi: 10.1159/000546089. Online ahead of",
    "entities": [
      {
        "text": "26",
        "label": "CARDINAL"
      },
      {
        "text": "Basel",
        "label": "GPE"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "Jun",
        "label": "PERSON"
      },
      {
        "text": "12",
        "label": "CARDINAL"
      },
      {
        "text": "10.1159/000546089",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "The Risk of Cardiovascular Disease following Aromatase Inhibitor Therapy for",
    "entities": [
      {
        "text": "The Risk of Cardiovascular Disease",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Breast Cancer in Postmenopausal Women: A Systematic Review and Meta-Analysis.",
    "entities": [
      {
        "text": "Breast Cancer",
        "label": "PERSON"
      },
      {
        "text": "Meta-Analysis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.",
    "entities": [
      {
        "text": "1)Sydney Medical School",
        "label": "ORG"
      },
      {
        "text": "The University of Sydney",
        "label": "ORG"
      },
      {
        "text": "Sydney",
        "label": "GPE"
      },
      {
        "text": "NSW",
        "label": "GPE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Surgery, Nepean Clinical School, The University of Sydney,",
    "entities": [
      {
        "text": "Surgery",
        "label": "GPE"
      },
      {
        "text": "Nepean Clinical School",
        "label": "ORG"
      },
      {
        "text": "The University of Sydney",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Kingswood, NSW, Australia.",
    "entities": [
      {
        "text": "Kingswood",
        "label": "ORG"
      },
      {
        "text": "NSW",
        "label": "ORG"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Nepean Institute of Academic Surgery, Nepean Clinical School, The University",
    "entities": [
      {
        "text": "3)Nepean Institute of Academic Surgery",
        "label": "ORG"
      },
      {
        "text": "Nepean Clinical School",
        "label": "ORG"
      },
      {
        "text": "The University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Sydney, Kingswood, NSW, Australia.",
    "entities": [
      {
        "text": "Sydney",
        "label": "GPE"
      },
      {
        "text": "Kingswood",
        "label": "GPE"
      },
      {
        "text": "NSW",
        "label": "ORG"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: More women are recovering and living longer lives due to advancement",
    "entities": []
  },
  {
    "text": "in breast cancer therapies. Aromatase inhibitors (AIs) are one form of endocrine",
    "entities": [
      {
        "text": "one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "therapy for breast cancer that may have an impact on the risk of developing",
    "entities": []
  },
  {
    "text": "cardiovascular diseases later in life. This study investigated whether AI",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "therapy for breast cancer in postmenopausal women increases the risk of",
    "entities": []
  },
  {
    "text": "developing cardiovascular disease in comparison with tamoxifen therapy or no",
    "entities": []
  },
  {
    "text": "hormonal therapy.",
    "entities": []
  },
  {
    "text": "METHODS: Comparisons were made between tamoxifen and no hormonal therapy using",
    "entities": []
  },
  {
    "text": "PRISMA guidelines. We searched publicly available databases for studies",
    "entities": [
      {
        "text": "PRISMA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "including postmenopausal women who underwent AI therapy for breast cancer",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "investigating the risk ratio of specific cardiovascular outcomes and",
    "entities": []
  },
  {
    "text": "RESULTS: There was a significant increase in the risk of ischaemic heart disease",
    "entities": []
  },
  {
    "text": "(RR 1.59, 95% CI: 1.25-2.02, p < 0.05), myocardial infarction (RR 1.50, 95% CI:",
    "entities": [
      {
        "text": "1.59",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.25",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "1.13-1.99, p < 0.05), heart failure (RR 1.63, 95% CI: 1.14-2.32, p < 0.05), and",
    "entities": [
      {
        "text": "1.13",
        "label": "CARDINAL"
      },
      {
        "text": "1.63",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.14",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "other cardiovascular events (RR 1.26, 95% CI: 1.12-1.40, p < 0.05) in the AI",
    "entities": [
      {
        "text": "1.26",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.12-1.40",
        "label": "CARDINAL"
      },
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "group when compared to tamoxifen. However, there was a significant decrease in",
    "entities": []
  },
  {
    "text": "the risk of myocardial infarction (RR 0.77, 95% CI: 0.65-0.90, p < 0.05) in the",
    "entities": [
      {
        "text": "0.77",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.65",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "AI group when compared to no hormonal treatment.",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSION: There is an increased risk of cardiovascular disease for AI therapy",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "in comparison to tamoxifen therapy. However, further research is needed to",
    "entities": []
  },
  {
    "text": "establish the cardiovascular risk of AIs when compared to no hormonal therapy.",
    "entities": []
  },
  {
    "text": "Prognosis and survival of patients should be an important consideration in",
    "entities": [
      {
        "text": "Prognosis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "choosing between tamoxifen and AI therapy among patients receiving treatment for",
    "entities": [
      {
        "text": "tamoxifen",
        "label": "ORG"
      },
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "breast cancer. Regular monitoring is essential to facilitate personalized",
    "entities": []
  },
  {
    "text": "approaches aimed at mitigating the risk of cardiovascular toxicity.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: The authors declare that there is no conflict of",
    "entities": []
  },
  {
    "text": "interest regarding the publication of this article.",
    "entities": []
  },
  {
    "text": "Correction: Gut microbiota, metabolites, and cytokines in relation to the risk",
    "entities": []
  },
  {
    "text": "of prostate cancer in the Asian population.",
    "entities": [
      {
        "text": "Asian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "(1)Department of Urology, Shanghai Tenth People's Hospital, Clinical Medical",
    "entities": [
      {
        "text": "Urology",
        "label": "GPE"
      },
      {
        "text": "Shanghai Tenth People's Hospital, Clinical Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "College of Nanjing Medical University, Shanghai, China.",
    "entities": [
      {
        "text": "College of Nanjing Medical University",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Urology, Shanghai Tenth People's Hospital, School of Medicine,",
    "entities": [
      {
        "text": "Urology",
        "label": "GPE"
      },
      {
        "text": "Shanghai Tenth People's Hospital",
        "label": "ORG"
      },
      {
        "text": "School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Tongji University, Shanghai, China.",
    "entities": [
      {
        "text": "Tongji University",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai,",
    "entities": [
      {
        "text": "Cancer Institute",
        "label": "ORG"
      },
      {
        "text": "School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Tongji University",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital,",
    "entities": [
      {
        "text": "Breast",
        "label": "GPE"
      },
      {
        "text": "Thyroid Surgery",
        "label": "PERSON"
      },
      {
        "text": "Shanghai Tenth People's Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Tongji University School of Medicine, Shanghai, China.",
    "entities": [
      {
        "text": "Tongji University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Shanghai Center of Thyroid Diseases, Shanghai Tenth People's Hospital, Tongji",
    "entities": [
      {
        "text": "Shanghai Tenth People's Hospital",
        "label": "ORG"
      },
      {
        "text": "Tongji",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University School of Medicine, Shanghai, China.",
    "entities": [
      {
        "text": "University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "[This corrects the article DOI: 10.3389/fonc.2024.1466190.].",
    "entities": [
      {
        "text": "10.3389",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Impact of blood lipid levels on breast cancer prognosis: a systematic review and",
    "entities": []
  },
  {
    "text": "(1)The First Affiliated Hospital of Zhejiang Chinese Medical University,",
    "entities": [
      {
        "text": "First Affiliated Hospital of Zhejiang Chinese Medical University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Breast cancer has emerged as the predominant malignant neoplasm",
    "entities": []
  },
  {
    "text": "globally, with potential implications for patient prognosis based on blood lipid",
    "entities": []
  },
  {
    "text": "profiles. This study aims to systematically review and meta-analyze the",
    "entities": []
  },
  {
    "text": "influence of lipid levels on the prognostic outcomes of individuals with breast",
    "entities": []
  },
  {
    "text": "METHODS: A thorough search was performed across multiple academic databases,",
    "entities": []
  },
  {
    "text": "including Embase, Cochrane, PubMed, Web of Science, CNKI, and Wanfang Database,",
    "entities": [
      {
        "text": "Embase",
        "label": "PERSON"
      },
      {
        "text": "Cochrane",
        "label": "PRODUCT"
      },
      {
        "text": "PubMed",
        "label": "ORG"
      },
      {
        "text": "CNKI",
        "label": "ORG"
      },
      {
        "text": "Wanfang Database",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "up to March 2024. A meta-analysis was conducted to assess the impact of total",
    "entities": [
      {
        "text": "up to March 2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "cholesterol (TC), triglycerides (TG), low-density lipoprotein-cholesterol",
    "entities": [
      {
        "text": "TG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(LDL-C), and high-density lipoprotein-cholesterol (HDL-C) on the prognosis of",
    "entities": [
      {
        "text": "HDL-C",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Breast Cancer. The primary outcome measure was hazard ratios (HR) for overall",
    "entities": [
      {
        "text": "Breast Cancer",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "survival (OS) and/or disease-free survival (DFS).",
    "entities": []
  },
  {
    "text": "RESULTS: Eight studies meeting inclusion criteria from a total of 13,292 were",
    "entities": [
      {
        "text": "Eight",
        "label": "CARDINAL"
      },
      {
        "text": "13,292",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "included in the meta-analysis. The systematic review and meta-analysis",
    "entities": []
  },
  {
    "text": "demonstrate an association between lower HDL-C levels and poorer survival",
    "entities": [
      {
        "text": "HDL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "outcomes. However, the statistical analysis did not find significant",
    "entities": []
  },
  {
    "text": "associations between HDL-C, TG, and LDL-C levels and the prognosis of breast",
    "entities": [
      {
        "text": "HDL-C",
        "label": "ORG"
      },
      {
        "text": "TG",
        "label": "ORG"
      },
      {
        "text": "LDL-C",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSION: While our analysis reveals a link between reduced HDL-C levels and",
    "entities": [
      {
        "text": "HDL-C",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "unfavorable survival outcomes, the statistical evidence does not support",
    "entities": []
  },
  {
    "text": "significant connections between HDL-C, TG, and LDL-C concentrations and the",
    "entities": [
      {
        "text": "HDL-C",
        "label": "ORG"
      },
      {
        "text": "TG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "prognostic landscape for breast cancer patients. Further research is warranted",
    "entities": []
  },
  {
    "text": "to explore these relationships more comprehensively.",
    "entities": []
  },
  {
    "text": "CRD42021297118.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Song, Jin, Yu, Wu and Gao.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Song",
        "label": "PERSON"
      },
      {
        "text": "Jin",
        "label": "PERSON"
      },
      {
        "text": "Yu",
        "label": "PERSON"
      },
      {
        "text": "Wu",
        "label": "PERSON"
      },
      {
        "text": "Gao",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Expression characteristics, molecular mechanisms, and clinical significance of",
    "entities": []
  },
  {
    "text": "DICER1 in breast cancer.",
    "entities": []
  },
  {
    "text": "(1)Department of Breast Center, The Fourth Hospital of Hebei Medical University,",
    "entities": [
      {
        "text": "Breast Center",
        "label": "FAC"
      },
      {
        "text": "The Fourth Hospital of Hebei Medical University",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "(2)Department of Anaesthesia, The Fourth Hospital of Hebei Medical University,",
    "entities": [
      {
        "text": "2)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Anaesthesia",
        "label": "GPE"
      },
      {
        "text": "The Fourth Hospital of Hebei Medical University",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "OBJECTIVE: This study aims to investigate the expression patterns, molecular",
    "entities": []
  },
  {
    "text": "mechanisms, and clinical significance of DICER1 in breast cancer (BRCA),",
    "entities": [
      {
        "text": "DICER1",
        "label": "ORG"
      },
      {
        "text": "BRCA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "providing new biomarkers and therapeutic targets for prognosis assessment and",
    "entities": []
  },
  {
    "text": "personalized treatment of breast cancer.",
    "entities": []
  },
  {
    "text": "(TMB) data from The Cancer Genome Atlas (TCGA) database, as well as single-cell",
    "entities": [
      {
        "text": "TMB",
        "label": "ORG"
      },
      {
        "text": "The Cancer Genome Atlas",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "transcriptomic data from the Gene Expression Omnibus (GEO) database, we analyzed",
    "entities": [
      {
        "text": "the Gene Expression Omnibus",
        "label": "ORG"
      },
      {
        "text": "GEO",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "the expression characteristics of DICER1 in breast cancer. Weighted gene",
    "entities": [
      {
        "text": "DICER1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "co-expression network analysis (WGCNA) was used to identify gene modules",
    "entities": [
      {
        "text": "WGCNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "associated with the breast cancer phenotype, and gene set enrichment analysis",
    "entities": []
  },
  {
    "text": "(GSEA) was performed to explore their biological functions. Cellular experiments",
    "entities": []
  },
  {
    "text": "were conducted to verify the effects of DICER1 on the proliferation, migration,",
    "entities": [
      {
        "text": "DICER1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and invasion of breast cancer cells. A nomogram model was constructed based on",
    "entities": []
  },
  {
    "text": "clinical data to evaluate its prognostic value. Additionally, the effects of",
    "entities": []
  },
  {
    "text": "DICER1 expression levels on drug sensitivity and the tumor immune",
    "entities": [
      {
        "text": "DICER1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "microenvironment were analyzed.",
    "entities": []
  },
  {
    "text": "RESULTS: The expression of DICER1 in breast cancer tissues was significantly",
    "entities": [
      {
        "text": "DICER1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "lower than that in normal tissues, and was significantly correlated with tumor",
    "entities": []
  },
  {
    "text": "stage, T stage, and TMB levels. The expression level of DICER1 was an",
    "entities": [
      {
        "text": "TMB",
        "label": "ORG"
      },
      {
        "text": "DICER1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "independent prognostic factor for breast cancer patients. The nomogram model",
    "entities": []
  },
  {
    "text": "based on DICER1 expression and clinical features demonstrated good",
    "entities": [
      {
        "text": "DICER1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "discriminative ability in predicting patient survival probability. Drug",
    "entities": []
  },
  {
    "text": "sensitivity analysis revealed that the high-expression group of DICER1 exhibited",
    "entities": [
      {
        "text": "DICER1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "higher sensitivity to multiple drugs. Immune microenvironment analysis indicated",
    "entities": []
  },
  {
    "text": "that the low-expression group of DICER1 had higher immune-suppressive features",
    "entities": [
      {
        "text": "DICER1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and immune exclusion scores, suggesting potential resistance to immunotherapy.",
    "entities": []
  },
  {
    "text": "Single-cell transcriptomic analysis revealed heterogeneous expression of DICER1",
    "entities": [
      {
        "text": "DICER1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "in breast cancer cell populations and its potential role in cell-cell",
    "entities": []
  },
  {
    "text": "CONCLUSION: DICER1 plays an important regulatory role in breast cancer, with its",
    "entities": [
      {
        "text": "DICER1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "expression level closely related to tumor progression, the immune",
    "entities": []
  },
  {
    "text": "microenvironment, and drug sensitivity. DICER1 has the potential to become an",
    "entities": [
      {
        "text": "DICER1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "important biomarker for prognosis assessment in breast cancer and may provide",
    "entities": []
  },
  {
    "text": "new targets for future immunotherapy and targeted therapy.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Zhang, Yu and Geng.",
    "entities": [
      {
        "text": "2025 Zhang",
        "label": "PERCENT"
      },
      {
        "text": "Yu",
        "label": "PERSON"
      },
      {
        "text": "Geng",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Nanoformulations Downregulating METTL16 Combined with mRNA Tumor Vaccines",
    "entities": [
      {
        "text": "Nanoformulations Downregulating METTL16",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Suppress Triple-Negative Breast Cancer and Prevent Metastasis.",
    "entities": []
  },
  {
    "text": "(1)MOE Key Laboratory of Bio-Intelligent Manufacturing, School of",
    "entities": [
      {
        "text": "Key Laboratory",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Bioengineering, Dalian University of Technology, Dalian, Liaoning, 116024,",
    "entities": [
      {
        "text": "Dalian University of Technology",
        "label": "ORG"
      },
      {
        "text": "Dalian",
        "label": "GPE"
      },
      {
        "text": "Liaoning",
        "label": "GPE"
      },
      {
        "text": "116024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "People's Republic of China.",
    "entities": []
  },
  {
    "text": "(2)Department of International Medical Department, the Second Affiliated",
    "entities": [
      {
        "text": "International Medical Department",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hospital of Dalian Medical University, Dalian, Liaoning, 116021, People's",
    "entities": [
      {
        "text": "Hospital of Dalian Medical University",
        "label": "ORG"
      },
      {
        "text": "Dalian",
        "label": "GPE"
      },
      {
        "text": "Liaoning",
        "label": "GPE"
      },
      {
        "text": "116021",
        "label": "DATE"
      },
      {
        "text": "People's\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Hernia and Colorectal Surgery Department, the Second Affiliated Hospital of",
    "entities": [
      {
        "text": "Colorectal Surgery Department",
        "label": "ORG"
      },
      {
        "text": "the Second Affiliated Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Dalian Medical University, Dalian, Liaoning, 116023, People's Republic of China.",
    "entities": [
      {
        "text": "Dalian Medical University",
        "label": "ORG"
      },
      {
        "text": "Dalian",
        "label": "GPE"
      },
      {
        "text": "Liaoning",
        "label": "GPE"
      },
      {
        "text": "116023",
        "label": "DATE"
      },
      {
        "text": "People's Republic of China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "PURPOSE: Triple-negative breast cancer (TNBC) poses a significant threat to",
    "entities": [
      {
        "text": "PURPOSE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "women's health due to its high malignancy and recurrence. Traditional treatments",
    "entities": []
  },
  {
    "text": "such as surgical resection, radiotherapy, and chemotherapy are no longer",
    "entities": []
  },
  {
    "text": "sufficient to meet clinical needs. Based on prior research that identified",
    "entities": []
  },
  {
    "text": "METTL16 as a potential target for TNBC, this study aimed to develop a",
    "entities": [
      {
        "text": "METTL16",
        "label": "ORG"
      },
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "nanoformulation to mitigate the malignancy of TNBC by silencing METTL16. The",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      },
      {
        "text": "METTL16",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "integration of this formulation with emerging mRNA tumor vaccines aimed to",
    "entities": []
  },
  {
    "text": "effectively inhibit the growth and metastasis of TNBC.",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESEARCH METHODS: Using microfluidic technology, efficient siRNA encapsulation",
    "entities": []
  },
  {
    "text": "in lipid nanoparticle (LNP) yielded LNP/siMETTL16 and selective organ-targeting",
    "entities": [
      {
        "text": "LNP",
        "label": "ORG"
      },
      {
        "text": "LNP/siMETTL16",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "LNP/siMETTL16 (SORT-LNP/siMETTL16). Initially, the antitumor properties of",
    "entities": [
      {
        "text": "LNP/siMETTL16",
        "label": "ORG"
      },
      {
        "text": "SORT-LNP/siMETTL16",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "LNP/siMETTL16 were evaluated at the cellular level. Subsequently, the antitumor",
    "entities": [
      {
        "text": "LNP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "properties were explored in mouse subcutaneous TNBC models with LNP/siMETTL16",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      },
      {
        "text": "LNP/siMETTL16\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(intratumoral injection) and mRNA tumor vaccines (intramuscular injection). The",
    "entities": []
  },
  {
    "text": "combined inhibition of TNBC lung metastasis by SORT-LNP/siMETTL16 (intravenous",
    "entities": [
      {
        "text": "SORT-LNP/siMETTL16",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "injection) and mRNA vaccine (intramuscular injection) was also investigated.",
    "entities": []
  },
  {
    "text": "RESULTS: Cellular experiments demonstrated the efficient silencing effect of",
    "entities": []
  },
  {
    "text": "LNP/siMETTL16, leading to inhibition of tumor cell activity. The combination of",
    "entities": [
      {
        "text": "LNP/siMETTL16",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "LNP/siMETTL16 and LNP/mMUC1 significantly suppressed subcutaneous tumor growth,",
    "entities": [
      {
        "text": "LNP/siMETTL16",
        "label": "ORG"
      },
      {
        "text": "LNP",
        "label": "ORG"
      },
      {
        "text": "mMUC1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "achieving an inhibition rate of 66.0%. Furthermore, the combination of",
    "entities": [
      {
        "text": "66.0%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "SORT-LNP/siMETTL16 and mRNA tumor vaccines markedly alleviated TNBC lung",
    "entities": [
      {
        "text": "SORT-LNP/siMETTL16",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSION: This study provides evident support for the application and",
    "entities": []
  },
  {
    "text": "translation of METTL16 as a therapeutic target and offers a novel strategy for",
    "entities": [
      {
        "text": "METTL16",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "TNBC combined treatment in clinical settings.",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40665962 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665962",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Yufeng Zhang reports grants from Department of",
    "entities": [
      {
        "text": "Yufeng Zhang",
        "label": "PERSON"
      },
      {
        "text": "Department of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Science & Technology of Liaoning province, Dalian Municipal Science and",
    "entities": [
      {
        "text": "Science & Technology of Liaoning province",
        "label": "ORG"
      },
      {
        "text": "Dalian Municipal Science",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Technology Bureau, the Second Af\ufb01liated Hospital of Dalian Medical University",
    "entities": [
      {
        "text": "Technology Bureau",
        "label": "ORG"
      },
      {
        "text": "the Second Af\ufb01liated Hospital of Dalian Medical University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Ministry of Education of the People\u2019s Republic of China, during the conduct",
    "entities": [
      {
        "text": "Ministry of Education",
        "label": "ORG"
      },
      {
        "text": "the People\u2019s Republic of China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "of the study. The other authors report no conflicts of interest in this work.",
    "entities": []
  },
  {
    "text": "31. Ann Ital Chir. 2025 Jul 10;96(7):950-955. doi: 10.62713/aic.3888.",
    "entities": [
      {
        "text": "31",
        "label": "CARDINAL"
      },
      {
        "text": "Ann Ital Chir",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "Jul 10;96(7):950-955",
        "label": "PERSON"
      },
      {
        "text": "10.62713",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "18 Years Experience of an Italian Breast Unit Among Male Breast Cancer: A",
    "entities": [
      {
        "text": "18 Years",
        "label": "DATE"
      },
      {
        "text": "Italian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Retrospective Observational Study.",
    "entities": []
  },
  {
    "text": "(2)Breast Unit, Department of General Surgery, S. Andrea University Hospital,",
    "entities": [
      {
        "text": "2)Breast",
        "label": "CARDINAL"
      },
      {
        "text": "Unit,",
        "label": "ORG"
      },
      {
        "text": "Department of General Surgery",
        "label": "ORG"
      },
      {
        "text": "S. Andrea University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "00189 Rome, Italy.",
    "entities": [
      {
        "text": "Rome",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Italy.",
    "entities": [
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "AIM: Male breast cancer has increased by approximately 26% over the past 25",
    "entities": [
      {
        "text": "AIM",
        "label": "ORG"
      },
      {
        "text": "approximately 26%",
        "label": "PERCENT"
      },
      {
        "text": "the past 25",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "years, there is a need to research specific treatment options. Currently, there",
    "entities": [
      {
        "text": "years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "is no established standard treatment which is therefore based on female disease.",
    "entities": []
  },
  {
    "text": "The purpose of this study is to analyze the clinical characteristics, survival",
    "entities": []
  },
  {
    "text": "outcomes, and the need for tailored treatment strategies in male breast cancer",
    "entities": []
  },
  {
    "text": "METHODS: This is an observational, retrospective, single-center clinical study.",
    "entities": []
  },
  {
    "text": "The research involved 21 male patients who underwent surgery for breast cancer",
    "entities": [
      {
        "text": "21",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "from 2003 to 2020 in our hospital. In order to strengthen the statistical value",
    "entities": [
      {
        "text": "2003",
        "label": "DATE"
      },
      {
        "text": "2020",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "of the results obtained, the survival curves of three selected studies in the",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "literature were compared with that obtained in the present study.",
    "entities": []
  },
  {
    "text": "RESULTS: All our patients underwent total mastectomy and axillary lymph node",
    "entities": []
  },
  {
    "text": "dissection. Twenty patients were diagnosed with invasive ductal carcinoma, while",
    "entities": [
      {
        "text": "Twenty",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "only one patient with invasive lobular carcinoma. The 5-year survival was 71.4%",
    "entities": [
      {
        "text": "only one",
        "label": "CARDINAL"
      },
      {
        "text": "5-year",
        "label": "DATE"
      },
      {
        "text": "71.4%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "with a median survival for metastatic patients of 5.7 years. A statistically",
    "entities": [
      {
        "text": "5.7 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "significant difference was found when comparing 5-year survival with one of the",
    "entities": [
      {
        "text": "5-year",
        "label": "DATE"
      },
      {
        "text": "one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "other three studies (p = 0.048).",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      },
      {
        "text": "0.048",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: Our findings highlight the delayed clinical presentation of male",
    "entities": []
  },
  {
    "text": "breast cancer and a 5-year overall survival of 71.4%, underscoring the need for",
    "entities": [
      {
        "text": "5-year",
        "label": "DATE"
      },
      {
        "text": "71.4%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "targeted screening strategies to improve early diagnosis and outcomes.The lack",
    "entities": []
  },
  {
    "text": "of knowledge of this disease at sociocultural and health level is the main",
    "entities": []
  },
  {
    "text": "reason for delay in diagnosis, a factor that strongly affects the prognosis.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 The Author(s).",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "PMID: 40665951 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665951",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "32. Cancer Res Treat. 2025 Jul 14. doi: 10.4143/crt.2025.423. Online ahead of",
    "entities": [
      {
        "text": "32",
        "label": "CARDINAL"
      },
      {
        "text": "Cancer Res Treat",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "14",
        "label": "CARDINAL"
      },
      {
        "text": "10.4143",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Keratin 6A Overexpression in the Lymphovascular Invasion-Associated Tumor",
    "entities": [
      {
        "text": "Keratin 6A Overexpression",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Subgroup Promotes Progression of Triple-Negative Breast Cancer.",
    "entities": [
      {
        "text": "Subgroup Promotes Progression of Triple-Negative Breast Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer",
    "entities": [
      {
        "text": "Thyroid",
        "label": "ORG"
      },
      {
        "text": "Neck Tumor",
        "label": "GPE"
      },
      {
        "text": "Tianjin Medical University Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institute and Hospital, National Clinical Research Center for Cancer, Key",
    "entities": [
      {
        "text": "Institute and Hospital",
        "label": "ORG"
      },
      {
        "text": "National Clinical Research Center for Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center",
    "entities": [
      {
        "text": "Laboratory of Cancer Prevention",
        "label": "ORG"
      },
      {
        "text": "Therapy",
        "label": "GPE"
      },
      {
        "text": "Clinical Research Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "for Cancer, Tianjin, China.",
    "entities": [
      {
        "text": "Cancer",
        "label": "GPE"
      },
      {
        "text": "Tianjin",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Pancreas Center, Tianjin Medical University Cancer Institute and Hospital,",
    "entities": [
      {
        "text": "Tianjin Medical University Cancer Institute and Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "National Clinical Research Center for Cancer, State Key Laboratory of",
    "entities": [
      {
        "text": "National Clinical Research Center for Cancer",
        "label": "ORG"
      },
      {
        "text": "State Key Laboratory",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Druggability Evaluation and Systematic Translational Medicine, Tianjin Key",
    "entities": []
  },
  {
    "text": "Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer,",
    "entities": [
      {
        "text": "Tianjin",
        "label": "GPE"
      },
      {
        "text": "Clinical Research Center for Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)The First Department of Breast Cancer, Tianjin Medical University Cancer",
    "entities": [
      {
        "text": "First Department of Breast Cancer",
        "label": "ORG"
      },
      {
        "text": "Tianjin Medical University Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institute and Hospital, National Clinical Research Center for Cancer, Tianjin,",
    "entities": [
      {
        "text": "Institute and Hospital",
        "label": "ORG"
      },
      {
        "text": "National Clinical Research Center for Cancer",
        "label": "ORG"
      },
      {
        "text": "Tianjin",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical",
    "entities": [
      {
        "text": "4)Key Laboratory",
        "label": "ORG"
      },
      {
        "text": "Therapy, Tianjin Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Ministry of Education, Tianjin, China.",
    "entities": [
      {
        "text": "University, Ministry of Education",
        "label": "ORG"
      },
      {
        "text": "Tianjin",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "PURPOSE: Lymphovascular invasion (LVI) is a strong predictor of poor prognosis",
    "entities": [
      {
        "text": "PURPOSE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "in triple-negative breast cancer (TNBC), yet its molecular basis remains",
    "entities": []
  },
  {
    "text": "unclear. This study investigates epithelial regulators associated with LVI and",
    "entities": []
  },
  {
    "text": "their functional roles in TNBC progression.",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "MATERIALS AND METHODS: We utilized single-cell sequencing data to further",
    "entities": []
  },
  {
    "text": "characterize epithelial cell populations in TNBC, identifying dominant",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "epithelial clusters in LVI-positive TNBC tissues. The prognostic significance of",
    "entities": []
  },
  {
    "text": "dominant epithelial marker genes was explored through transcriptomic analysis",
    "entities": []
  },
  {
    "text": "and immunohistochemical staining of patient samples from our center.",
    "entities": []
  },
  {
    "text": "Additionally, the effects of the marker gene on TNBC cell invasion and",
    "entities": []
  },
  {
    "text": "RESULTS: Single-cell data analysis revealed nine distinct epithelial cell",
    "entities": [
      {
        "text": "nine",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "clusters within TNBC tissues. Among these, Cluster 4 was identified as the",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      },
      {
        "text": "Cluster 4",
        "label": "LAW"
      }
    ]
  },
  {
    "text": "dominant epithelial subpopulation in LVI-positive TNBC, marked by the prognostic",
    "entities": []
  },
  {
    "text": "gene KRT6A. Multiple datasets confirmed KRT6A as a crucial prognostic marker in",
    "entities": [
      {
        "text": "KRT6A",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "TNBC. Functional assays, including CCK8, wound healing, transwell assays, and",
    "entities": [
      {
        "text": "CCK8",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "animal experiments, demonstrated that KRT6A knockdown significantly impaired the",
    "entities": [
      {
        "text": "KRT6A",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "proliferation, invasion, and metastatic potential of TNBC cells.",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Mechanistically, KRT6A promoted epithelial-mesenchymal transition (EMT) and",
    "entities": [
      {
        "text": "KRT6A",
        "label": "PERSON"
      },
      {
        "text": "EMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "activated Wnt/\u03b2-catenin signaling by stabilizing \u03b2-catenin through GSK3\u03b2",
    "entities": [
      {
        "text": "Wnt",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "phosphorylation.",
    "entities": []
  },
  {
    "text": "CONCLUSION: KRT6A promotes EMT and metastasis in TNBC via Wnt/\u03b2-catenin",
    "entities": [
      {
        "text": "KRT6A",
        "label": "PERSON"
      },
      {
        "text": "EMT",
        "label": "ORG"
      },
      {
        "text": "Wnt",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "signaling, contributing to LVI and chemoresistance. It may serve as a prognostic",
    "entities": []
  },
  {
    "text": "biomarker and therapeutic target in TNBC.",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "33. Oncologist. 2025 Jul 15:oyaf205. doi: 10.1093/oncolo/oyaf205. Online ahead of",
    "entities": [
      {
        "text": "33",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1093",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Somatic Mutations in Middle East and North Africa (MENA) Breast Cancer Patients:",
    "entities": [
      {
        "text": "Middle East",
        "label": "LOC"
      },
      {
        "text": "North Africa",
        "label": "GPE"
      },
      {
        "text": "Breast Cancer",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "A Systematic Review.",
    "entities": []
  },
  {
    "text": "Abujamous L(1)(2), Ahmed I(3), Ahen Y(3), Alotaibi H(3), Al Moustafa AE(4), Mohd",
    "entities": [
      {
        "text": "Al Moustafa",
        "label": "PERSON"
      },
      {
        "text": "Mohd",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar",
    "entities": [
      {
        "text": "Basic Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "College of Medicine, QU Health",
        "label": "ORG"
      },
      {
        "text": "Qatar",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University, Doha, Qatar.",
    "entities": [
      {
        "text": "Doha",
        "label": "GPE"
      },
      {
        "text": "Qatar",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Office of Vice President for Research and Graduate Studies, Qatar University,",
    "entities": [
      {
        "text": "Qatar University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Biomedical Sciences, College of Health Science, QU Health,",
    "entities": [
      {
        "text": "Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "College of Health Science, QU Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Qatar University, Doha, Qatar.",
    "entities": [
      {
        "text": "Qatar University",
        "label": "ORG"
      },
      {
        "text": "Doha",
        "label": "GPE"
      },
      {
        "text": "Qatar",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Oncology Department, McGill University, Montreal, QC, . Canada.",
    "entities": [
      {
        "text": "Department",
        "label": "ORG"
      },
      {
        "text": "McGill University",
        "label": "ORG"
      },
      {
        "text": "Montreal",
        "label": "GPE"
      },
      {
        "text": "QC",
        "label": "ORG"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Breast cancer presents with distinct clinical and molecular",
    "entities": []
  },
  {
    "text": "characteristics in the Middle East and North Africa (MENA) region, where women",
    "entities": [
      {
        "text": "the Middle East",
        "label": "LOC"
      },
      {
        "text": "North Africa",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "are diagnosed at younger ages and with more aggressive disease compared to",
    "entities": []
  },
  {
    "text": "Western populations. Despite the global burden, genomic studies of breast cancer",
    "entities": []
  },
  {
    "text": "in MENA remain underrepresented. This systematic review provides the first",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "comprehensive analysis of somatic mutations in breast cancer patients across the",
    "entities": []
  },
  {
    "text": "METHODS: Following PRISMA guidelines, we analyzed 44 studies encompassing 13",
    "entities": [
      {
        "text": "44",
        "label": "CARDINAL"
      },
      {
        "text": "13",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "MENA countries, representing data from over 2,500 breast cancer patients.",
    "entities": [
      {
        "text": "over 2,500",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Studies were rigorously assessed using the Newcastle-Ottawa Scale, with mutation",
    "entities": [
      {
        "text": "Newcastle",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "data extracted, standardized, and classified according to pathogenicity using",
    "entities": []
  },
  {
    "text": "established databases. We employed multiple sequencing methodologies, including",
    "entities": []
  },
  {
    "text": "next-generation sequencing and targeted gene panels, to identify",
    "entities": []
  },
  {
    "text": "country-specific and region-wide mutation patterns.",
    "entities": []
  },
  {
    "text": "RESULTS: We identified 559 mutations across 104 genes, with TP53 (23.79%) and",
    "entities": [
      {
        "text": "559",
        "label": "CARDINAL"
      },
      {
        "text": "104",
        "label": "CARDINAL"
      },
      {
        "text": "23.79%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "PIK3CA (10.19%) emerging as the most frequently altered genes, followed by",
    "entities": [
      {
        "text": "10.19%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "significant mutations in BRCA1/2, ATM, ESR1, and PTEN. Nearly 43% of variants",
    "entities": [
      {
        "text": "BRCA1/2",
        "label": "GPE"
      },
      {
        "text": "ATM",
        "label": "ORG"
      },
      {
        "text": "PTEN",
        "label": "ORG"
      },
      {
        "text": "Nearly 43%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "were classified as pathogenic/likely pathogenic, while 23% remained variants of",
    "entities": [
      {
        "text": "23%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "uncertain significance. Missense mutations predominated (60.29%), followed by",
    "entities": [
      {
        "text": "60.29%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "frameshift variants (13.06%) and stop-gained mutations (10.91%). We discovered",
    "entities": [
      {
        "text": "13.06%",
        "label": "PERCENT"
      },
      {
        "text": "10.91%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "distinctive country-specific mutation profiles, including unique alterations in",
    "entities": []
  },
  {
    "text": "KLF6 (Turkey) and IL-1\u03b2 (Iraq), reflecting potential environmental and",
    "entities": [
      {
        "text": "Turkey",
        "label": "GPE"
      },
      {
        "text": "IL-1\u03b2",
        "label": "ORG"
      },
      {
        "text": "Iraq",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "hereditary influences unique to MENA populations. Notably, all 11 PIK3CA hotspot",
    "entities": [
      {
        "text": "11",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "mutations that predict sensitivity to alpelisib therapy were identified.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: This study reveals both shared and distinct somatic mutation",
    "entities": []
  },
  {
    "text": "patterns in MENA breast cancer patients compared to Western populations. The",
    "entities": []
  },
  {
    "text": "high prevalence of clinically actionable mutations, particularly in PIK3CA and",
    "entities": [
      {
        "text": "PIK3CA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "DNA repair genes, presents immediate opportunities for implementing targeted",
    "entities": []
  },
  {
    "text": "therapies across the region. Our findings underscore the urgent need for",
    "entities": []
  },
  {
    "text": "establishing a MENA Breast Cancer Genomics Consortium to standardize sequencing",
    "entities": []
  },
  {
    "text": "protocols, develop locally validated gene panels, and create regional variant",
    "entities": []
  },
  {
    "text": "databases that capture the unique mutation spectrum of these populations. This",
    "entities": []
  },
  {
    "text": "comprehensive genomic landscape of breast cancer in the MENA region addresses a",
    "entities": []
  },
  {
    "text": "critical gap in global cancer genomics, ultimately improving outcomes for a",
    "entities": []
  },
  {
    "text": "historically underrepresented patient population.",
    "entities": []
  },
  {
    "text": "\u00a9 The Author(s) 2025. Published by Oxford University Press.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Oxford University Press",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DOI: 10.1093/oncolo/oyaf205",
    "entities": [
      {
        "text": "10.1093",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "ahead of print.",
    "entities": []
  },
  {
    "text": "Breast cancer and large-cell neuroendocrine carcinoma harboring the same PIK3CA",
    "entities": []
  },
  {
    "text": "mutation: A case report.",
    "entities": []
  },
  {
    "text": "(1)Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di",
    "entities": [
      {
        "text": "Hematology",
        "label": "ORG"
      },
      {
        "text": "Azienda Ospedaliero-Universitaria",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Modena, Modena, Italy.",
    "entities": [
      {
        "text": "Modena",
        "label": "GPE"
      },
      {
        "text": "Modena",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Medical and Surgical Sciences, University of Modena and Reggio",
    "entities": [
      {
        "text": "Medical and Surgical Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Modena",
        "label": "ORG"
      },
      {
        "text": "Reggio",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "(5)Department of Oncology and Hemato-Oncology, University of Milan, Milan,",
    "entities": [
      {
        "text": "Oncology",
        "label": "ORG"
      },
      {
        "text": "Hemato-Oncology",
        "label": "ORG"
      },
      {
        "text": "University of Milan",
        "label": "ORG"
      },
      {
        "text": "Milan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: The distinction between a metastatic recurrence and the onset of a",
    "entities": []
  },
  {
    "text": "second primary malignancy can be diagnostically challenging. Precision medicine",
    "entities": [
      {
        "text": "second",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "can offer valuable support in this context.",
    "entities": []
  },
  {
    "text": "CASE PRESENTATION: A 34-year-old woman was diagnosed in 2012 with",
    "entities": [
      {
        "text": "34-year-old",
        "label": "DATE"
      },
      {
        "text": "2012",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "hormone-receptor positive (HR+), human epidermal growth factor receptor",
    "entities": []
  },
  {
    "text": "2-negative (HER2-) breast cancer in the left breast, with homolateral axillary",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "node involvement but no distant metastases. Following neoadjuvant chemotherapy,",
    "entities": [
      {
        "text": "node involvement",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "surgery (pathological stage was ypT1b ypN2a M0), adjuvant endocrine therapy and",
    "entities": []
  },
  {
    "text": "radiotherapy, she remained disease-free until 2021, when a positron emission",
    "entities": [
      {
        "text": "2021",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "tomography scan showed a mediastinal mass. Histology revealed a high-grade large",
    "entities": []
  },
  {
    "text": "cell neuroendocrine carcinoma (LCNEC) lacking breast cancer-specific markers",
    "entities": []
  },
  {
    "text": "(GATA3-, HR-, HER2-, mammoglobin-, GCDFP15-), with PD-L1 expression at 10% and a",
    "entities": [
      {
        "text": "HR-",
        "label": "PERSON"
      },
      {
        "text": "GCDFP15-",
        "label": "PERSON"
      },
      {
        "text": "10%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "tumor mutational burden (TMB) of 9.54 mut/MB. Chemotherapy (cisplatin plus",
    "entities": [
      {
        "text": "9.54",
        "label": "CARDINAL"
      },
      {
        "text": "cisplatin",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "etoposide) led to rapid disease progression, whereas second-line pembrolizumab",
    "entities": [
      {
        "text": "second",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "led to a remarkable and prolonged disease response. Treatment was discontinued",
    "entities": []
  },
  {
    "text": "in 2023 due to grade 3 immune-related colitis and, as of November 2024, the",
    "entities": [
      {
        "text": "2023",
        "label": "DATE"
      },
      {
        "text": "3",
        "label": "CARDINAL"
      },
      {
        "text": "November 2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "patient shows no clinical evidence of disease.Molecular analysis:Next-generation",
    "entities": []
  },
  {
    "text": "sequencing identified shared tumor PIK3CA pathogenic variants in both breast",
    "entities": []
  },
  {
    "text": "cancer and LCNEC tissues, suggesting a potential relationship as primary tumor",
    "entities": []
  },
  {
    "text": "and metastasis, rather than two distinct malignancies.",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: Molecular characterization of cancer enabled the identification of",
    "entities": []
  },
  {
    "text": "potential causal links between tumors with distinct histologies and locations,",
    "entities": [
      {
        "text": "potential causal",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "offering a deeper insight into an atypical clinical scenario.",
    "entities": []
  },
  {
    "text": "BRMS1 suppresses the PI3K/AKT/mTOR pathway to regulate autophagy in multiple",
    "entities": []
  },
  {
    "text": "(1)Department of Hematology, The First People's Hospital of Kashgar Region,",
    "entities": [
      {
        "text": "Hematology",
        "label": "ORG"
      },
      {
        "text": "The First People's Hospital of Kashgar Region",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Tuberculosis Department, Kashgar Tuberculosis Prevention and Control",
    "entities": [
      {
        "text": "2)Tuberculosis Department",
        "label": "ORG"
      },
      {
        "text": "Kashgar Tuberculosis Prevention",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institute and Kashgar Regional Pulmonary Hospital, Kashgar, China.",
    "entities": [
      {
        "text": "Kashgar Regional Pulmonary Hospital",
        "label": "PERSON"
      },
      {
        "text": "Kashgar",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Imaging Center, The First People's Hospital of Kashgar Region, Kashgar,",
    "entities": [
      {
        "text": "The First People's Hospital of Kashgar Region",
        "label": "ORG"
      },
      {
        "text": "Kashgar",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "This study investigates the role of breast cancer metastasis suppressor 1",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(BRMS1) in multiple myeloma (MM) progression. BRMS1 expression was significantly",
    "entities": [
      {
        "text": "MM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "reduced in MM patient samples and cell lines. Functional assays revealed that",
    "entities": [
      {
        "text": "MM",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BRMS1 overexpression suppressed MM cell proliferation, migration, and invasion",
    "entities": [
      {
        "text": "MM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "while enhancing apoptosis and autophagic flux. Conversely, BRMS1 knockdown",
    "entities": [
      {
        "text": "BRMS1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "promoted tumorigenic behaviors. Pharmacological inhibition or activation of",
    "entities": []
  },
  {
    "text": "autophagy confirmed that BRMS1's tumor-suppressive effects are",
    "entities": [
      {
        "text": "BRMS1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "autophagy-dependent. Mechanistic studies demonstrated that BRMS1 regulates",
    "entities": [
      {
        "text": "BRMS1",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "autophagy through the PI3K/AKT/mTOR signaling pathway. These findings establish",
    "entities": []
  },
  {
    "text": "BRMS1 as a potential tumor suppressor in MM, linking its function to autophagy",
    "entities": [
      {
        "text": "MM",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "and apoptosis regulation. Targeting BRMS1-mediated autophagy may provide a novel",
    "entities": [
      {
        "text": "Targeting BRMS1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "therapeutic approach for MM treatment and addressing disease progression. This",
    "entities": [
      {
        "text": "MM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "study offers new insights into MM pathogenesis and potential strategies for",
    "entities": [
      {
        "text": "MM",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "A literature review of radio-genomics in breast cancer: Lessons and insights for",
    "entities": []
  },
  {
    "text": "low and middle-income countries.",
    "entities": []
  },
  {
    "text": "(1)Department of Surgery, Aga Khan University Hospital and Cancer Foundation",
    "entities": [
      {
        "text": "Surgery",
        "label": "GPE"
      },
      {
        "text": "Aga Khan University Hospital and Cancer Foundation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Surgery, Aga Khan University Hospital Karachi, Sindh, Pakistan.",
    "entities": [
      {
        "text": "Surgery",
        "label": "PERSON"
      },
      {
        "text": "Aga Khan University Hospital Karachi",
        "label": "ORG"
      },
      {
        "text": "Sindh",
        "label": "GPE"
      },
      {
        "text": "Pakistan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Surgery, Dow University of Health Sciences Karachi, Sindh,",
    "entities": [
      {
        "text": "Surgery",
        "label": "ORG"
      },
      {
        "text": "Dow University of Health Sciences Karachi",
        "label": "ORG"
      },
      {
        "text": "Sindh",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Software Engineering, Bahria University Karachi, Pakistan.",
    "entities": [
      {
        "text": "Software Engineering",
        "label": "ORG"
      },
      {
        "text": "Bahria University Karachi",
        "label": "ORG"
      },
      {
        "text": "Pakistan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "To improve precision medicine in breast cancer (BC) decision-making,",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "radio-genomics is an emerging branch of artificial intelligence (AI) that links",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cancer characteristics assessed radiologically with the histopathology and",
    "entities": []
  },
  {
    "text": "genomic properties of the tumour. By employing MRIs, mammograms, and ultrasounds",
    "entities": []
  },
  {
    "text": "to uncover distinctive radiomics traits that potentially predict genomic",
    "entities": []
  },
  {
    "text": "abnormalities, this review attempts to find literature that links AI-based",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "models with the genetic mutations discovered in BC patients. The review's",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "findings can be used to create AI-based population models for low and",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "middle-income countries (LMIC) and evaluate how well they predict outcomes for",
    "entities": []
  },
  {
    "text": "our cohort.Magnetic resonance imaging (MRI) appears to be the modality employed",
    "entities": []
  },
  {
    "text": "most frequently to research radio-genomics in BC patients in our systemic",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "analysis. According to the papers we analysed, genetic markers and mutations",
    "entities": []
  },
  {
    "text": "linked to imaging traits, such as tumour size, shape, enhancing patterns, as",
    "entities": []
  },
  {
    "text": "well as clinical outcomes of treatment response, disease progression, and",
    "entities": []
  },
  {
    "text": "survival, can be identified by employing AI. The use of radio-genomics can help",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "LMICs get through some of the barriers that keep the general population from",
    "entities": []
  },
  {
    "text": "having access to high-quality cancer care, thereby improving the health outcomes",
    "entities": []
  },
  {
    "text": "for BC patients in these regions. It is imperative to ensure that emerging",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "technologies are used responsibly, in a way that is accessible to and affordable",
    "entities": []
  },
  {
    "text": "for all patients, regardless of their socio-economic condition.",
    "entities": []
  },
  {
    "text": "37. Nat Prod Res. 2025 Jul 15:1-14. doi: 10.1080/14786419.2025.2531162. Online",
    "entities": [
      {
        "text": "37",
        "label": "CARDINAL"
      },
      {
        "text": "Nat Prod Res",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "15:1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Highly efficient and catalyst-free ring-closing reaction of 2'-hydroxychalcones",
    "entities": [
      {
        "text": "2'-hydroxychalcones",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(1)Department of Organic Chemistry, University of Science, Vietnam National",
    "entities": [
      {
        "text": "Organic Chemistry",
        "label": "ORG"
      },
      {
        "text": "University of Science",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Ho Chi Minh City, Ho Chi Minh City, Vietnam.",
    "entities": [
      {
        "text": "Ho Chi Minh City",
        "label": "GPE"
      },
      {
        "text": "Ho Chi Minh City",
        "label": "GPE"
      },
      {
        "text": "Vietnam",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Ionic liquids are known as useful and eco-friendly solvents due to their low",
    "entities": []
  },
  {
    "text": "vaporisation and suitable physicochemical properties. The synthesis of",
    "entities": []
  },
  {
    "text": "flavanones via the reversible ring-closing reaction of 2'-hydroxychalcones with",
    "entities": [
      {
        "text": "2'-hydroxychalcones",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "or without catalysts in the presence of various ionic liquids has been studied.",
    "entities": []
  },
  {
    "text": "Under optimal conditions, seventeen flavanones were obtained in yields ranging",
    "entities": [
      {
        "text": "seventeen",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "from 38% to 88% in 1-8 h, depending on the substituents of 2'-hydroxychalcones.",
    "entities": [
      {
        "text": "38% to 88%",
        "label": "PERCENT"
      },
      {
        "text": "1-8",
        "label": "CARDINAL"
      },
      {
        "text": "2'-hydroxychalcones",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Besides, the high recyclability of [Bpy]Br, which could be recycled four times",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "without any significant decrease in yield, is an important highlight of the",
    "entities": []
  },
  {
    "text": "present method. Furthermore, seven of the synthesised flavanones were selected",
    "entities": [
      {
        "text": "seven",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "for testing their in vitro anticancer efficacy against lung (A549) and breast",
    "entities": [
      {
        "text": "A549",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "(MCF-7) cancer cells. The screening led to the identification of a potent",
    "entities": []
  },
  {
    "text": "inhibitor, 4'-hydroxy-3'-methoxyflavone, 2 m, for further testing against liver",
    "entities": [
      {
        "text": "4'-hydroxy-3'-methoxyflavone",
        "label": "CARDINAL"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(HepG2) and cervix (HeLa) cancer cells.",
    "entities": [
      {
        "text": "HeLa",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Estimates of cardiac implanted electronic device neutron dose for a pencil beam",
    "entities": []
  },
  {
    "text": "scanning proton therapy system.",
    "entities": []
  },
  {
    "text": "(1)Department of Radiation Oncology, University of Michigan Medical Center, Ann",
    "entities": [
      {
        "text": "Radiation Oncology",
        "label": "ORG"
      },
      {
        "text": "University of Michigan Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Arbor, Michigan, USA.",
    "entities": [
      {
        "text": "Arbor",
        "label": "GPE"
      },
      {
        "text": "Michigan",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Radiation Oncology, University of Kansas Medical Center, Kansas",
    "entities": [
      {
        "text": "Radiation Oncology",
        "label": "ORG"
      },
      {
        "text": "University of Kansas Medical Center",
        "label": "ORG"
      },
      {
        "text": "Kansas",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Cardiovascular Medicine, University of Kansas Medical Center,",
    "entities": [
      {
        "text": "Cardiovascular Medicine,",
        "label": "ORG"
      },
      {
        "text": "University of Kansas Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Radiation Oncology, Huntsman Cancer Institute, University of",
    "entities": [
      {
        "text": "Radiation Oncology",
        "label": "ORG"
      },
      {
        "text": "Huntsman Cancer Institute",
        "label": "ORG"
      },
      {
        "text": "University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: The presence of a cardiovascular implantable electronic device",
    "entities": []
  },
  {
    "text": "(CIED) is frequently viewed as a contraindication to proton therapy due to the",
    "entities": []
  },
  {
    "text": "creation of secondary neutrons that can potentially damage CIED electronics. As",
    "entities": []
  },
  {
    "text": "a result, photon therapy is typically recommended for patients with CIEDs.",
    "entities": []
  },
  {
    "text": "PURPOSE: The study aims to provide a method for estimating neutron dose to a",
    "entities": [
      {
        "text": "PURPOSE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CIED by measuring equivalent neutron dose at varying distances from isocenter",
    "entities": []
  },
  {
    "text": "and field edge. This estimation can be used to guide clinical decisions by",
    "entities": []
  },
  {
    "text": "balancing the risk of neutron-induced CIED damage against the therapeutic",
    "entities": []
  },
  {
    "text": "benefits of proton therapy.",
    "entities": []
  },
  {
    "text": "METHODS: Standardized three-dimensional measurement fields of varying dimensions",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "were delivered using the IBA ProteusONE (Ion Beam Applications SA, Walloon",
    "entities": [
      {
        "text": "IBA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Brabant, Belgium) pencil beam scanning proton therapy system, with each field",
    "entities": [
      {
        "text": "Belgium",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "delivering an RBE-weighted dose of 2 Gy. Baseline measurement included one",
    "entities": [
      {
        "text": "RBE",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "treatment field being delivered with a range shifter. BD-PND detectors (Bubble",
    "entities": []
  },
  {
    "text": "Technology Industries, Chalk River, ON) were placed at a defined distances from",
    "entities": [
      {
        "text": "Technology Industries",
        "label": "ORG"
      },
      {
        "text": "Chalk River",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "the surface mark of beam isocenter and field edge to record neutron doses.",
    "entities": []
  },
  {
    "text": "Additionally, clinical treatment plans including two prostate/pelvis plans, two",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "head & neck plans, two brain plans, and one breast plans were delivered, with",
    "entities": [
      {
        "text": "head & neck",
        "label": "ORG"
      },
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "detectors placed at positions corresponding to the location of a CIED.",
    "entities": []
  },
  {
    "text": "RESULTS: For fields without a range shifter, the measured neutron dose ranged",
    "entities": []
  },
  {
    "text": "from 0.11 \u00b5Sv/2 Gy for the smallest field at 50 cm from isocenter to 11.0",
    "entities": [
      {
        "text": "0.11",
        "label": "CARDINAL"
      },
      {
        "text": "50 cm",
        "label": "QUANTITY"
      },
      {
        "text": "11.0",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "\u00b5Sv/2 Gy for the largest field size at 10 cm from isocenter for fields. The",
    "entities": [
      {
        "text": "\u00b5Sv/2 Gy",
        "label": "PERSON"
      },
      {
        "text": "10 cm",
        "label": "QUANTITY"
      }
    ]
  },
  {
    "text": "addition of a range shifter to the 10 \u00d7 10 \u00d7 10 cm3 field increased the dose to",
    "entities": [
      {
        "text": "10",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "0.66 \u00b5Sv/2 Gy at 50 cm to 14.2 \u00b5Sv/2 Gy at 10 cm from isocenter. For clinical",
    "entities": [
      {
        "text": "0.66",
        "label": "CARDINAL"
      },
      {
        "text": "50 cm to",
        "label": "QUANTITY"
      },
      {
        "text": "10 cm",
        "label": "QUANTITY"
      }
    ]
  },
  {
    "text": "treatment plans, neutron doses ranging from 0.14 \u00b5Sv/2 Gy to 9.5 \u00b5Sv /2 Gy at",
    "entities": [
      {
        "text": "0.14 \u00b5Sv/2 Gy to",
        "label": "CARDINAL"
      },
      {
        "text": "9.5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "24-56 cm from isocenter.",
    "entities": [
      {
        "text": "24",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSION: These measurements provide a foundation for estimating neutron doses",
    "entities": []
  },
  {
    "text": "to CIEDs, enabling physicists and physicians to evaluate the feasibility of",
    "entities": []
  },
  {
    "text": "proton therapy for patients with CIEDs. The results support informed clinical",
    "entities": []
  },
  {
    "text": "decision-making by quantifying the risk of neutron-induced damage relative to",
    "entities": []
  },
  {
    "text": "the therapeutic benefits of proton therapy.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 American Association of Physicists in Medicine.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "American Association of Physicists in Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40665543 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665543",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Polygenic risk of coronary artery disease for long-term survivors of breast",
    "entities": []
  },
  {
    "text": "EM(6)(7), Chow EJ(3)(8), Lynch CF(9), Mellemkj\u00e6r L(10), Woods M(1), Liang X(1),",
    "entities": [
      {
        "text": "Chow EJ(3)(8",
        "label": "PERSON"
      },
      {
        "text": "Lynch CF(9",
        "label": "PERSON"
      },
      {
        "text": "Mellemkj\u00e6r L(10",
        "label": "ORG"
      },
      {
        "text": "Liang X(1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer",
    "entities": [
      {
        "text": "Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Center, New York, NY, USA.",
    "entities": [
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Division of Psychosocial Research and Epidemiology, the Netherlands Cancer",
    "entities": [
      {
        "text": "Psychosocial Research and Epidemiology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institute, Amsterdam, the Netherlands.",
    "entities": [
      {
        "text": "Amsterdam",
        "label": "GPE"
      },
      {
        "text": "Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Division of Public Health Sciences, Epidemiology Program, Fred Hutchinson",
    "entities": [
      {
        "text": "Public Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Epidemiology Program",
        "label": "ORG"
      },
      {
        "text": "Fred Hutchinson",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Cancer Center, Seattle, WA, USAs.",
    "entities": [
      {
        "text": "Cancer Center",
        "label": "PERSON"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      },
      {
        "text": "WA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Sinai Health, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada.",
    "entities": [
      {
        "text": "Health",
        "label": "ORG"
      },
      {
        "text": "Lunenfeld-Tanenbaum Research Institute",
        "label": "ORG"
      },
      {
        "text": "Toronto",
        "label": "GPE"
      },
      {
        "text": "ON",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Dalla Lana School of Public Health, University of Toronto, Toronto, ON,",
    "entities": [
      {
        "text": "Lana School of Public Health",
        "label": "ORG"
      },
      {
        "text": "University of Toronto",
        "label": "ORG"
      },
      {
        "text": "Toronto",
        "label": "GPE"
      },
      {
        "text": "ON",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Department of Epidemiology and Population Health, Stanford University School",
    "entities": [
      {
        "text": "Epidemiology and Population Health",
        "label": "ORG"
      },
      {
        "text": "Stanford University School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medicine, Stanford, CA, USA.",
    "entities": [
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Department of Medicine, Division of Oncology, Stanford University School of",
    "entities": [
      {
        "text": "Medicine, Division of Oncology",
        "label": "ORG"
      },
      {
        "text": "Stanford University School of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Stanford, CA, USA.",
    "entities": [
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Clinical Research Division, Fred Hutchison Cancer Center, Seattle, WA, USA.",
    "entities": [
      {
        "text": "Research Division",
        "label": "ORG"
      },
      {
        "text": "Fred Hutchison Cancer Center",
        "label": "PERSON"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      },
      {
        "text": "WA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Department of Epidemiology, University of Iowa, Iowa City, IA, USA.",
    "entities": [
      {
        "text": "Epidemiology, University of Iowa",
        "label": "ORG"
      },
      {
        "text": "Iowa City",
        "label": "GPE"
      },
      {
        "text": "IA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Danish Cancer Institute, Copenhagen, Denmark.",
    "entities": [
      {
        "text": "10)Danish",
        "label": "CARDINAL"
      },
      {
        "text": "Cancer Institute",
        "label": "ORG"
      },
      {
        "text": "Copenhagen",
        "label": "ORG"
      },
      {
        "text": "Denmark",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New",
    "entities": [
      {
        "text": "11)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Medical Physics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "York, NY, USA.",
    "entities": [
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "AIM: Cardiovascular disease is a leading cause of death for long-term breast",
    "entities": [
      {
        "text": "AIM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cancer survivors. We evaluated whether a polygenic risk score for coronary",
    "entities": []
  },
  {
    "text": "artery disease (CAD-PRS) was associated with the risk of incident CAD for",
    "entities": []
  },
  {
    "text": "survivors of unilateral or contralateral breast cancer.",
    "entities": []
  },
  {
    "text": "METHODS: The study included 1,307 women with breast cancer first diagnosed at",
    "entities": [
      {
        "text": "1,307",
        "label": "CARDINAL"
      },
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "age <55 years who participated in the WECARE Follow-up Study. The CAD-PRS was",
    "entities": [
      {
        "text": "55 years",
        "label": "DATE"
      },
      {
        "text": "CAD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "based on a PRS developed and validated in a separate population. We modelled the",
    "entities": [
      {
        "text": "PRS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "association between incident CAD and the CAD-PRS, adjusting for age, CAD risk",
    "entities": [
      {
        "text": "CAD",
        "label": "ORG"
      },
      {
        "text": "CAD",
        "label": "ORG"
      },
      {
        "text": "CAD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "factors, first (and second) breast cancer treatment, study recruitment phase,",
    "entities": [
      {
        "text": "second",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "and genetic population stratification. We also explored whether the risk of CAD",
    "entities": [
      {
        "text": "CAD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "depended on interactions between the CAD-PRS and cardiotoxic cancer treatment.",
    "entities": [
      {
        "text": "CAD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: There were 65 incident CAD diagnoses reported at a median of 16 years",
    "entities": [
      {
        "text": "65",
        "label": "CARDINAL"
      },
      {
        "text": "CAD",
        "label": "ORG"
      },
      {
        "text": "16 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "after breast cancer diagnosis. Participants with CAD-PRS\u2265median had a 2.48-times",
    "entities": [
      {
        "text": "2.48",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "increased risk of CAD (95%CI = 1.44-4.29) relative to participants with",
    "entities": [
      {
        "text": "CAD",
        "label": "ORG"
      },
      {
        "text": "1.44-4.29",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CAD-PRS<median. Anthracycline-based chemotherapy was associated with increased",
    "entities": [
      {
        "text": "Anthracycline",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CAD risk (HR = 2.04, 95%CI = 1.04-3.98), and the association was not modified by",
    "entities": [
      {
        "text": "2.04",
        "label": "CARDINAL"
      },
      {
        "text": "1.04",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "the CAD-PRS. The association between incident CAD and left-sided RT was",
    "entities": [
      {
        "text": "CAD",
        "label": "ORG"
      },
      {
        "text": "CAD",
        "label": "ORG"
      },
      {
        "text": "RT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "increased for those with CAD-PRS\u2265median (HR = 2.90, 95% CI = 1.26-6.68), but not",
    "entities": [
      {
        "text": "2.90",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.26-6.68",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "for those with CAD-PRS<median (HR = 0.96, 95% CI 0.32-2.88). There was evidence",
    "entities": [
      {
        "text": "0.96",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.32-2.88",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "of super-additive interaction between the CAD-PRS and left-sided RT (relative",
    "entities": [
      {
        "text": "CAD",
        "label": "ORG"
      },
      {
        "text": "RT (",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "excess risk due to interaction = 2.06, 95% CI 0.05-4.06).",
    "entities": [
      {
        "text": "2.06",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.05",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: A genome-wide CAD-PRS was associated with non-fatal CAD risk for",
    "entities": [
      {
        "text": "CAD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "long-term breast cancer survivors, providing potential utility for personalized",
    "entities": []
  },
  {
    "text": "\u00a9 The Author(s) 2025. Published by Oxford University Press. All rights reserved.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Oxford University Press",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "For commercial re-use, please contact reprints@oup.com for reprints and",
    "entities": []
  },
  {
    "text": "translation rights for reprints. All other permissions can be obtained through",
    "entities": []
  },
  {
    "text": "our RightsLink service via the Permissions link on the article page on our",
    "entities": [
      {
        "text": "Permissions",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "site\u2014for further information please contact journals.permissions@oup.com.",
    "entities": [
      {
        "text": "journals.permissions@oup.com",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "40. Breast Cancer Res. 2025 Jul 15;27(1):132. doi: 10.1186/s13058-025-02084-9.",
    "entities": [
      {
        "text": "40",
        "label": "CARDINAL"
      },
      {
        "text": "Breast Cancer Res",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Fibroblast growth factor receptor signaling modulates cholesterol storage in a",
    "entities": []
  },
  {
    "text": "SOAT1-dependent manner to promote mammary tumor cell invasion.",
    "entities": []
  },
  {
    "text": "Tuokkola JE(1), Reese LE(2), Wang Y(2), O'Connor CH(2)(3), VanTreeck JG(1),",
    "entities": [
      {
        "text": "Tuokkola",
        "label": "ORG"
      },
      {
        "text": "JE(1",
        "label": "PERSON"
      },
      {
        "text": "Reese LE(2",
        "label": "PERSON"
      },
      {
        "text": "Wang Y(2",
        "label": "PERSON"
      },
      {
        "text": "O'Connor CH(2)(3",
        "label": "PERSON"
      },
      {
        "text": "VanTreeck JG(1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Molecular Pharmacology and Therapeutics Graduate Program, University of",
    "entities": [
      {
        "text": "1)Molecular",
        "label": "CARDINAL"
      },
      {
        "text": "Pharmacology and Therapeutics Graduate Program, University of\n",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "(2)Department of Laboratory Medicine and Pathology, University of Minnesota,",
    "entities": [
      {
        "text": "Laboratory Medicine and Pathology",
        "label": "ORG"
      },
      {
        "text": "University of Minnesota",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Supercomputing Institute, University of Minnesota, University of Minnesota,",
    "entities": [
      {
        "text": "3)Supercomputing Institute, University of Minnesota,",
        "label": "ORG"
      },
      {
        "text": "University of Minnesota",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Laboratory Medicine and Pathology, University of Minnesota,",
    "entities": [
      {
        "text": "Laboratory Medicine and Pathology",
        "label": "ORG"
      },
      {
        "text": "University of Minnesota",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.",
    "entities": [
      {
        "text": "Cancer Center,",
        "label": "ORG"
      },
      {
        "text": "University of Minnesota",
        "label": "ORG"
      },
      {
        "text": "Minneapolis",
        "label": "GPE"
      },
      {
        "text": "MN,",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Center for Immunology, University of Minnesota, Minneapolis, MN, USA.",
    "entities": [
      {
        "text": "6)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Immunology, University of Minnesota",
        "label": "ORG"
      },
      {
        "text": "Minneapolis",
        "label": "GPE"
      },
      {
        "text": "MN,",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Signaling by fibroblast growth factor receptors (FGFRs) is active in up to 85%",
    "entities": [
      {
        "text": "up to 85%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "of breast cancers and results in enhanced proliferation, migration, and invasion",
    "entities": []
  },
  {
    "text": "of tumor cells. Here, we show that FGFR signaling regulates cholesterol",
    "entities": []
  },
  {
    "text": "metabolism in breast cancer. Specifically, we demonstrate that FGFR activation",
    "entities": [
      {
        "text": "FGFR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "promotes cellular cholesterol storage by upregulating expression of the enzyme",
    "entities": []
  },
  {
    "text": "sterol O-acyltransferase 1 (SOAT1). Moreover, we demonstrate that inhibition of",
    "entities": [
      {
        "text": "SOAT1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "SOAT1 attenuates FGFR-driven colony formation and invasion in tumor cells, which",
    "entities": [
      {
        "text": "SOAT1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "correlates with reduced expression of matrix metalloproteinase expression.",
    "entities": []
  },
  {
    "text": "Furthermore, genetic knockdown of SOAT1 decreases mammary tumor growth in vivo.",
    "entities": [
      {
        "text": "SOAT1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Taken together, these findings suggest a largely undiscovered metabolic role for",
    "entities": []
  },
  {
    "text": "FGFR signaling in regulating cholesterol metabolism in breast cancer and present",
    "entities": []
  },
  {
    "text": "a therapeutic vulnerability that could be targeted in FGFR-driven cancers.",
    "entities": []
  },
  {
    "text": "\u00a9 2025. The Author(s).",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "PMID: 40665359 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665359",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declarations. Ethics approval and consent to",
    "entities": []
  },
  {
    "text": "participate: All animal care and procedures were approved by the University of",
    "entities": [
      {
        "text": "the University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Minnesota IACUC under protocol 2208\u201340316 A and were in accordance with the",
    "entities": [
      {
        "text": "Minnesota",
        "label": "GPE"
      },
      {
        "text": "protocol 2208\u201340316",
        "label": "LAW"
      }
    ]
  },
  {
    "text": "procedures detailed in the Guide for the Care and Use of Laboratory Animals. No",
    "entities": [
      {
        "text": "the Guide for the Care and Use of Laboratory Animals",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "human subjects were used in this study. Consent for publication: Not applicable.",
    "entities": []
  },
  {
    "text": "Competing interests: The authors declare no competing interests.",
    "entities": []
  },
  {
    "text": "41. Breast Cancer Res. 2025 Jul 15;27(1):133. doi: 10.1186/s13058-025-02061-2.",
    "entities": [
      {
        "text": "41",
        "label": "CARDINAL"
      },
      {
        "text": "Breast Cancer Res",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "15;27(1):133",
        "label": "CARDINAL"
      },
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Multi-transcriptomics predicts clinical outcome in systemically untreated breast",
    "entities": []
  },
  {
    "text": "cancer patients with extensive follow-up.",
    "entities": []
  },
  {
    "text": "(1)Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.",
    "entities": [
      {
        "text": "Clinical Genetics,",
        "label": "ORG"
      },
      {
        "text": "Odense University Hospital",
        "label": "ORG"
      },
      {
        "text": "Denmark",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Unit of Human Genetics, Department of Clinical Research, University of",
    "entities": [
      {
        "text": "Human Genetics, Department of Clinical Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Present address: Institute of Pharmacology and Clinical Pharmacy, University",
    "entities": [
      {
        "text": "3)Present",
        "label": "CARDINAL"
      },
      {
        "text": "Institute of Pharmacology and Clinical Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Marburg, Marburg, Germany.",
    "entities": [
      {
        "text": "Marburg",
        "label": "GPE"
      },
      {
        "text": "Marburg",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Clinical Genome Center, University of Southern Denmark & Region of Southern",
    "entities": [
      {
        "text": "Genome Center,",
        "label": "ORG"
      },
      {
        "text": "University of Southern Denmark & Region of Southern\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Pathology, Odense University Hospital. Institute of Clinical",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Pathology, Odense University Hospital",
        "label": "ORG"
      },
      {
        "text": "Institute of Clinical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Research, University of Southern Denmark, Odense, Denmark.",
    "entities": [
      {
        "text": "Research, University of Southern Denmark, Odense, Denmark",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Danish Breast Cancer Cooperative Group & Department of Clinical Oncology",
    "entities": [
      {
        "text": "Breast Cancer Cooperative Group & Department of Clinical Oncology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Department of Surgical Pathology, Zealand University Hospital, Slagelse,",
    "entities": [
      {
        "text": "Surgical Pathology",
        "label": "ORG"
      },
      {
        "text": "Zealand University Hospital",
        "label": "ORG"
      },
      {
        "text": "Slagelse",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Epidemiology, Biostatistics, and Biodemography, Department of Public Health,",
    "entities": [
      {
        "text": "Biostatistics",
        "label": "ORG"
      },
      {
        "text": "Biodemography, Department of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Southern Denmark, Odense, Denmark.",
    "entities": [
      {
        "text": "University of Southern Denmark, Odense, Denmark",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(9)Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.",
    "entities": [
      {
        "text": "Clinical Genetics,",
        "label": "ORG"
      },
      {
        "text": "Odense University Hospital",
        "label": "ORG"
      },
      {
        "text": "Denmark",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Unit of Human Genetics, Department of Clinical Research, University of",
    "entities": [
      {
        "text": "Human Genetics,",
        "label": "ORG"
      },
      {
        "text": "Department of Clinical Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(11)Clinical Genome Center, University of Southern Denmark & Region of Southern",
    "entities": [
      {
        "text": "11)Clinical Genome Center, University of Southern Denmark & Region of Southern\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Prognostic tools for determining patients with indolent breast",
    "entities": []
  },
  {
    "text": "cancers (BCs) are far from optimal, leading to extensive overtreatment. Several",
    "entities": []
  },
  {
    "text": "studies have demonstrated mRNAs, lncRNAs and miRNAs to have prognostic potential",
    "entities": []
  },
  {
    "text": "information, we hypothesized that combining them would improve classification",
    "entities": []
  },
  {
    "text": "performance.",
    "entities": []
  },
  {
    "text": "METHODS: Our pair-matched design study included fresh frozen primary tumor",
    "entities": []
  },
  {
    "text": "samples from 160 lymph node negative and systemically untreated BC patients of",
    "entities": [
      {
        "text": "160",
        "label": "CARDINAL"
      },
      {
        "text": "node negative",
        "label": "ORG"
      },
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "which 80 developed recurrence while 80 remained recurrence-free (mean follow-up",
    "entities": [
      {
        "text": "80",
        "label": "CARDINAL"
      },
      {
        "text": "80",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "of 20.9 years). We integrated three classes of RNA and subsequently performed",
    "entities": [
      {
        "text": "20.9 years",
        "label": "DATE"
      },
      {
        "text": "three",
        "label": "CARDINAL"
      },
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "classification using seven machine learning methods followed by a voting scheme.",
    "entities": [
      {
        "text": "seven",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "RESULTS: Under the criteria of \u2265 90% sensitivity, individual classifications",
    "entities": [
      {
        "text": "\u2265",
        "label": "GPE"
      },
      {
        "text": "90%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "resulted in specificities ranging from 74-91% for the integrated dataset and",
    "entities": [
      {
        "text": "74-91%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "56-66%, 58-71% and 69-86% for mRNAs, lncRNAs and miRNAs individually. The",
    "entities": [
      {
        "text": "56-66%",
        "label": "PERCENT"
      },
      {
        "text": "58-71%",
        "label": "PERCENT"
      },
      {
        "text": "69-86%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "specificity level for the multi-transcriptomic dataset was 85% after voting",
    "entities": [
      {
        "text": "85%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "while it was 38%, 48% and 82% for mRNAs, lncRNAs and miRNAs, respectively. In",
    "entities": [
      {
        "text": "38%",
        "label": "PERCENT"
      },
      {
        "text": "48% and",
        "label": "PERCENT"
      },
      {
        "text": "82%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "the clinical setting, very high sensitivity may be requested. In the most",
    "entities": []
  },
  {
    "text": "stringent clinical setting with a sensitivity of 99%, the integrated dataset",
    "entities": [
      {
        "text": "99%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "also outperformed the others with a specificity of 41% compared to 0%, 9% and",
    "entities": [
      {
        "text": "41%",
        "label": "PERCENT"
      },
      {
        "text": "0%",
        "label": "PERCENT"
      },
      {
        "text": "9%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "28% for mRNAs, lncRNAs and miRNAs, respectively.",
    "entities": [
      {
        "text": "28%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "CONCLUSION: Our results strongly suggest an improvement of prognostic power for",
    "entities": []
  },
  {
    "text": "classification using an integrated dataset compared to individual classes of RNA",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and thus encourage researches to opt for an integration of datasets rather than",
    "entities": []
  },
  {
    "text": "analyzing them separately.",
    "entities": []
  },
  {
    "text": "PMID: 40665339 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665339",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "participate: Patient consent was waived because the tumor samples included in",
    "entities": []
  },
  {
    "text": "the study were collected from established biobanks at Odense University",
    "entities": [
      {
        "text": "Odense University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hospital, Denmark where utilization of these surplus samples has been approved",
    "entities": [
      {
        "text": "Denmark",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "by the Danish National Committee on Health Research Ethics. Patients who",
    "entities": [
      {
        "text": "the Danish National Committee on Health Research Ethics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "objected to the use of their tumor material via the Danish Tissue Utilization",
    "entities": [
      {
        "text": "the Danish Tissue Utilization",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Register were excluded from the study. Consent for publication: Not applicable.",
    "entities": []
  },
  {
    "text": "42. Breast Cancer. 2025 Jul 15. doi: 10.1007/s12282-025-01742-2. Online ahead of",
    "entities": [
      {
        "text": "42",
        "label": "CARDINAL"
      },
      {
        "text": "Breast Cancer",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Major anatomic variations of the lateral upper arm lymphatic pathway in a",
    "entities": []
  },
  {
    "text": "healthy female population.",
    "entities": []
  },
  {
    "text": "Fanning JE(1), Givant M(1), Chen A(1), Thomson S(1), Tillotson E(1), Fleishman",
    "entities": [
      {
        "text": "JE(1",
        "label": "PERSON"
      },
      {
        "text": "Chen",
        "label": "PERSON"
      },
      {
        "text": "Thomson S(1",
        "label": "ORG"
      },
      {
        "text": "Tillotson",
        "label": "ORG"
      },
      {
        "text": "Fleishman\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "A(1), Donohoe K(2), Singhal D(3).",
    "entities": [
      {
        "text": "Singhal D(3",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Division of Plastic and Reconstructive Surgery, Department of Surgery, Beth",
    "entities": [
      {
        "text": "Beth\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Israel Deaconess Medical Center, Harvard Medical School, 110 Francis St, Suite",
    "entities": [
      {
        "text": "Israel Deaconess Medical Center",
        "label": "ORG"
      },
      {
        "text": "Harvard Medical School",
        "label": "ORG"
      },
      {
        "text": "Francis St",
        "label": "PERSON"
      },
      {
        "text": "Suite",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "5A, Boston, MA, 02215, USA.",
    "entities": [
      {
        "text": "5A",
        "label": "CARDINAL"
      },
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "02215",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Nuclear Medicine, Beth Israel Deaconess Medical Center, Harvard",
    "entities": [
      {
        "text": "Beth Israel Deaconess Medical Center",
        "label": "ORG"
      },
      {
        "text": "Harvard",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medical School, Boston, MA, USA.",
    "entities": [
      {
        "text": "Medical School",
        "label": "ORG"
      },
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Division of Plastic and Reconstructive Surgery, Department of Surgery, Beth",
    "entities": [
      {
        "text": "Plastic",
        "label": "NORP"
      },
      {
        "text": "Beth\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "BACKGROUND: The lateral upper arm (LUA) pathway is a route of superficial",
    "entities": [
      {
        "text": "LUA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "lymphatic drainage that bypasses the axilla by draining to the deltopectoral,",
    "entities": []
  },
  {
    "text": "clavicular, and cervical lymph nodes. Despite the fact that anatomic variations",
    "entities": []
  },
  {
    "text": "of the LUA pathway have been implicated in breast cancer-related lymphedema",
    "entities": [
      {
        "text": "LUA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(BCRL) risk after axillary lymph node dissection (ALND), the incidence of the",
    "entities": [
      {
        "text": "BCRL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "LUA pathway variations in the healthy population has never been reported.",
    "entities": [
      {
        "text": "LUA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: Healthy female volunteers underwent bilateral lymphatic mapping of the",
    "entities": []
  },
  {
    "text": "upper extremities with indocyanine green (ICG) lymphography. ICG was injected in",
    "entities": []
  },
  {
    "text": "six standard sites in the hand/wrist and upper arm. Major anatomic variations of",
    "entities": [
      {
        "text": "six",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "the LUA pathway were recorded including bundle phenotype (long, short, or",
    "entities": [
      {
        "text": "LUA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "absent), proximal visualization sites, and forearm pathway continuation to the",
    "entities": []
  },
  {
    "text": "long bundle phenotype.",
    "entities": []
  },
  {
    "text": "RESULTS: 90 arms of 45 volunteers were included. The LUA pathway was present in",
    "entities": [
      {
        "text": "90",
        "label": "CARDINAL"
      },
      {
        "text": "45",
        "label": "CARDINAL"
      },
      {
        "text": "LUA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "99% of arms and a long-versus-short bundle phenotype was observed in 71% versus",
    "entities": [
      {
        "text": "99%",
        "label": "PERCENT"
      },
      {
        "text": "71%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "28% of arms. When the long bundle was present, it was formed by continuity with",
    "entities": [
      {
        "text": "28%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "(34%), or both channels (19%). The LUA pathway was traced proximally to the",
    "entities": [
      {
        "text": "34%",
        "label": "PERCENT"
      },
      {
        "text": "19%",
        "label": "PERCENT"
      },
      {
        "text": "LUA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "deltopectoral groove in 89% of arms and to the axilla in 11% of arms.",
    "entities": [
      {
        "text": "89%",
        "label": "PERCENT"
      },
      {
        "text": "11%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: We observed similar proportions of arms with long and short bundle",
    "entities": []
  },
  {
    "text": "phenotypes in comparison to our previous report of the LUA pathway in breast",
    "entities": [
      {
        "text": "LUA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cancer patients with nodal disease. Defining the incidence of the LUA pathway",
    "entities": [
      {
        "text": "LUA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "with its variations in the general population is important as variations in this",
    "entities": []
  },
  {
    "text": "pathway may have implications for an individual's risk of developing BCRL.",
    "entities": [
      {
        "text": "BCRL",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "\u00a9 2025. The Author(s), under exclusive licence to The Japanese Breast Cancer",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Japanese",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declarations. Conflict of interest: Research",
    "entities": []
  },
  {
    "text": "reported in this publication was supported in part by the National Heart, Lung,",
    "entities": [
      {
        "text": "the National Heart",
        "label": "ORG"
      },
      {
        "text": "Lung",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "and Blood Institute of the National Institutes of Health under award number",
    "entities": [
      {
        "text": "Blood Institute of the National Institutes of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "R01HL157991 (D.S.) and the NIH Common Fund under award number U54HL165440",
    "entities": [
      {
        "text": "R01HL157991",
        "label": "ORG"
      },
      {
        "text": "D.S.",
        "label": "GPE"
      },
      {
        "text": "the NIH Common Fund",
        "label": "ORG"
      },
      {
        "text": "U54HL165440",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(D.S.). James Fanning and Angela Chen are supported by the 2024 JOBST Lymphatic",
    "entities": [
      {
        "text": "D.S.",
        "label": "GPE"
      },
      {
        "text": "James Fanning",
        "label": "PERSON"
      },
      {
        "text": "Angela Chen",
        "label": "PERSON"
      },
      {
        "text": "2024",
        "label": "DATE"
      },
      {
        "text": "JOBST Lymphatic",
        "label": "EVENT"
      }
    ]
  },
  {
    "text": "Research Grant awarded by the Boston Lymphatic Symposium, Inc. Madeleine Givant",
    "entities": [
      {
        "text": "the Boston Lymphatic Symposium",
        "label": "ORG"
      },
      {
        "text": "Madeleine Givant",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "is supported by the 2025 JOBST Lymphatic Research Grant awarded by the Boston",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "JOBST Lymphatic Research Grant",
        "label": "ORG"
      },
      {
        "text": "Boston",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Lymphatic Symposium, Inc. All other authors have no financial disclosures to",
    "entities": [
      {
        "text": "Lymphatic Symposium, Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "report (S.T., E.T., A.F., and K.D.). Research involving human participants:",
    "entities": [
      {
        "text": "S.T.",
        "label": "NORP"
      },
      {
        "text": "E.T.",
        "label": "ORG"
      },
      {
        "text": "A.F.",
        "label": "GPE"
      },
      {
        "text": "K.D.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Institutional review board approval was obtained (protocol #2021P-000209). All",
    "entities": [
      {
        "text": "2021P-000209",
        "label": "MONEY"
      }
    ]
  },
  {
    "text": "procedures performed in studies involving human participants were in accordance",
    "entities": []
  },
  {
    "text": "with the ethical standards of the institutional and/or national research",
    "entities": [
      {
        "text": "the institutional and/or national research\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "committee and with the 1964 Helsinki declaration and its later amendments or",
    "entities": [
      {
        "text": "1964",
        "label": "DATE"
      },
      {
        "text": "Helsinki",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "comparable ethical standards. Informed consent: Informed consent was obtained",
    "entities": []
  },
  {
    "text": "from all individual participants included in the study. All volunteers provided",
    "entities": []
  },
  {
    "text": "informed verbal and written consent prior to study enrollment. Volunteers were",
    "entities": []
  },
  {
    "text": "informed on the study purpose, study procedures, risk and benefits, and the",
    "entities": []
  },
  {
    "text": "collection and handling of confidential data. Volunteers were free to withdraw",
    "entities": []
  },
  {
    "text": "at any time, without reason and without cost. Volunteers provided informed",
    "entities": []
  },
  {
    "text": "consent that no identifiable information would be used in publications regarding",
    "entities": []
  },
  {
    "text": "data generated from the study.",
    "entities": []
  },
  {
    "text": "43. Clin Transl Oncol. 2025 Jul 15. doi: 10.1007/s12094-025-03983-1. Online ahead",
    "entities": [
      {
        "text": "43",
        "label": "CARDINAL"
      },
      {
        "text": "Clin Transl Oncol",
        "label": "PERSON"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "of print.",
    "entities": []
  },
  {
    "text": "Effect of exercise during chemotherapy infusion on symptomatology and quality of",
    "entities": []
  },
  {
    "text": "life in women with breast cancer: a randomized controlled trial.",
    "entities": []
  },
  {
    "text": "(1)State University of Londrina, Celso Garcia Cid Highway, Pr 445 Km 380,",
    "entities": [
      {
        "text": "University of Londrina",
        "label": "ORG"
      },
      {
        "text": "Garcia Cid Highway",
        "label": "PERSON"
      },
      {
        "text": "445",
        "label": "CARDINAL"
      },
      {
        "text": "380",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "University Campus, Postal Box 10.011, Londrina, PR, CEP 86.057-970, Brazil.",
    "entities": [
      {
        "text": "University Campus",
        "label": "ORG"
      },
      {
        "text": "Londrina",
        "label": "GPE"
      },
      {
        "text": "86.057",
        "label": "CARDINAL"
      },
      {
        "text": "Brazil",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)State University of Londrina, Celso Garcia Cid Highway, Pr 445 Km 380,",
    "entities": [
      {
        "text": "University of Londrina",
        "label": "ORG"
      },
      {
        "text": "Garcia Cid Highway",
        "label": "PERSON"
      },
      {
        "text": "445",
        "label": "CARDINAL"
      },
      {
        "text": "380",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(3)Central-West State University, Paran\u00e1, Brazil.",
    "entities": [
      {
        "text": "Paran\u00e1",
        "label": "GPE"
      },
      {
        "text": "Brazil",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Bishop's University, Sherbrooke, QC, Canada.",
    "entities": [
      {
        "text": "University,",
        "label": "ORG"
      },
      {
        "text": "Sherbrooke",
        "label": "GPE"
      },
      {
        "text": "QC",
        "label": "ORG"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "OBJECTIVE: To evaluate the effects of aerobic exercise performed during",
    "entities": []
  },
  {
    "text": "chemotherapy infusion on symptom burden and quality of life in women with breast",
    "entities": []
  },
  {
    "text": "METHODS: This single-blind randomized controlled trial included 39 women with",
    "entities": [
      {
        "text": "39",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "breast cancer undergoing chemotherapy at a specialized oncology hospital in",
    "entities": []
  },
  {
    "text": "Brazil. Participants were randomly assigned to an exercise group (n = 18) or",
    "entities": [
      {
        "text": "Brazil",
        "label": "GPE"
      },
      {
        "text": "18",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "control group (n = 21). The intervention group performed low-intensity aerobic",
    "entities": [
      {
        "text": "control group",
        "label": "ORG"
      },
      {
        "text": "21",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "cycling with a portable ergometer for 20 min during infusion sessions 2 through",
    "entities": [
      {
        "text": "20",
        "label": "CARDINAL"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "6. Fatigue (Cancer Fatigue Scale) and quality of life (EORTC QLQ-C30) were",
    "entities": [
      {
        "text": "6",
        "label": "CARDINAL"
      },
      {
        "text": "Fatigue",
        "label": "PERSON"
      },
      {
        "text": "Cancer Fatigue Scale",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "assessed before the second and after the sixth infusion. Chemotherapy-related",
    "entities": [
      {
        "text": "second",
        "label": "ORDINAL"
      },
      {
        "text": "sixth",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "symptoms were also monitored via telephone recall 48-72 h post-infusion. Data",
    "entities": [
      {
        "text": "48-72",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "were analyzed using GEE for symptom scores and repeated measures ANOVA for",
    "entities": [
      {
        "text": "GEE",
        "label": "ORG"
      },
      {
        "text": "ANOVA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "fatigue and quality of life outcomes.",
    "entities": []
  },
  {
    "text": "RESULTS: Of the 51 breast cancer patients recruited, 39 completed the study. No",
    "entities": [
      {
        "text": "51",
        "label": "CARDINAL"
      },
      {
        "text": "39",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "significant baseline differences were found between the intervention (exercise)",
    "entities": []
  },
  {
    "text": "and control groups. There were no significant changes in quality of life or",
    "entities": []
  },
  {
    "text": "fatigue scores (EORTC-QLQ-C30 and CFS) over time between groups. However, the",
    "entities": [
      {
        "text": "EORTC-QLQ-C30",
        "label": "ORG"
      },
      {
        "text": "CFS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "intervention group showed a significant reduction in the severity of alopecia",
    "entities": []
  },
  {
    "text": "between chemotherapy sessions, which was not observed in the control group.",
    "entities": []
  },
  {
    "text": "CONCLUSION: While exercise during chemotherapy did not significantly impact",
    "entities": []
  },
  {
    "text": "overall quality of life or fatigue, it may help reduce the perceived severity of",
    "entities": []
  },
  {
    "text": "certain treatment-related symptoms such as alopecia.",
    "entities": []
  },
  {
    "text": "DOI: 10.1007/s12094-025-03983-1",
    "entities": [
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declarations. Conflict of interest: The authors",
    "entities": []
  },
  {
    "text": "have no conflicts of interest to disclose.",
    "entities": []
  },
  {
    "text": "New benzimidazole-triazole glycoconjugates as anti-cancer agents and EGFR",
    "entities": [
      {
        "text": "EGFR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "inhibitors.",
    "entities": []
  },
  {
    "text": "(1)Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries",
    "entities": [
      {
        "text": "Therapeutic Chemistry",
        "label": "ORG"
      },
      {
        "text": "Pharmaceutical and Drug Industries",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Research Institute, National Research Centre, Dokki, Giza, 12622, Egypt.",
    "entities": [
      {
        "text": "Research Institute",
        "label": "ORG"
      },
      {
        "text": "National Research Centre",
        "label": "ORG"
      },
      {
        "text": "Dokki",
        "label": "GPE"
      },
      {
        "text": "Giza",
        "label": "GPE"
      },
      {
        "text": "12622",
        "label": "DATE"
      },
      {
        "text": "Egypt",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Chemistry, College of Science, Qassim University, Buraidah,",
    "entities": [
      {
        "text": "Chemistry, College of Science, Qassim University",
        "label": "ORG"
      },
      {
        "text": "Buraidah",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Photochemistry Department, National Research Centre, Dokki, Giza, 12622,",
    "entities": [
      {
        "text": "3)Photochemistry Department",
        "label": "ORG"
      },
      {
        "text": "National Research Centre",
        "label": "ORG"
      },
      {
        "text": "Dokki",
        "label": "GPE"
      },
      {
        "text": "Giza",
        "label": "GPE"
      },
      {
        "text": "12622",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(4)Chemistry of Natural and Microbial Products Department, Pharmaceutical and",
    "entities": [
      {
        "text": "Natural",
        "label": "ORG"
      },
      {
        "text": "Microbial Products Department",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Drug Industries Research Institute, National Research Centre, Dokki, Giza,",
    "entities": [
      {
        "text": "Drug Industries Research Institute",
        "label": "ORG"
      },
      {
        "text": "National Research Centre",
        "label": "ORG"
      },
      {
        "text": "Dokki",
        "label": "GPE"
      },
      {
        "text": "Giza",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(5)Tanning Materials and Leather Technology Department, National Research",
    "entities": [
      {
        "text": "Materials and Leather Technology Department",
        "label": "WORK_OF_ART"
      },
      {
        "text": "National Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah",
    "entities": [
      {
        "text": "Pharmaceutical Sciences",
        "label": "ORG"
      },
      {
        "text": "College of Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Department of Chemistry, College of Science, Northern Border University,",
    "entities": [
      {
        "text": "Chemistry, College of Science, Northern Border University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "A new series of glycosyl heterocyclic scaffolds, 5a-10b with N-glycosidic",
    "entities": [
      {
        "text": "5a-10b",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "linkage, were synthesized, starting with 2-acetyl-1H-benzimidazole as a",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "precursor of the propargyl-derived substrates (2) and (3), which were then",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "converted to the target 1,2,3-triazole glycosides (8a-10b) bearing unprotected",
    "entities": [
      {
        "text": "1,2,3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "hydroxyl groups. The new chemical entities have been assessed for their",
    "entities": []
  },
  {
    "text": "cytotoxic properties on diverse human cancer cell lines, namely HepG-2 (human",
    "entities": []
  },
  {
    "text": "liver cancer), HCT-116 (human colorectal), and MCF-7 (human breast cancer), in",
    "entities": []
  },
  {
    "text": "addition to a human normal cell line (BJ-1), following the LDH assay and with",
    "entities": [
      {
        "text": "BJ-1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "erlotinib and doxorubicin as the standard references. Most of the tested",
    "entities": []
  },
  {
    "text": "compounds demonstrated potent activity, particularly the triazole glycosides 6b,",
    "entities": [
      {
        "text": "6b",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "7b, 8b, 9a, 9b, 10a, and 10b. Compound 9a was the best against all targeted cell",
    "entities": [
      {
        "text": "7b",
        "label": "CARDINAL"
      },
      {
        "text": "8b",
        "label": "DATE"
      },
      {
        "text": "9a",
        "label": "CARDINAL"
      },
      {
        "text": "9b",
        "label": "DATE"
      },
      {
        "text": "10a",
        "label": "DATE"
      },
      {
        "text": "10b",
        "label": "DATE"
      },
      {
        "text": "9a",
        "label": "MONEY"
      }
    ]
  },
  {
    "text": "lines, particularly HepG-2 and HCT-116, by IC50 values of 1.64 \u00b1 0.11 and",
    "entities": [
      {
        "text": "1.64",
        "label": "CARDINAL"
      },
      {
        "text": "0.11",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "5.00 \u00b1 0.51 \u00b5M, superior to that of erlotinib, IC50 = 2.07 \u00b1 0.07 and",
    "entities": [
      {
        "text": "5.00",
        "label": "CARDINAL"
      },
      {
        "text": "0.51",
        "label": "CARDINAL"
      },
      {
        "text": "2.07",
        "label": "CARDINAL"
      },
      {
        "text": "0.07",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "5.14 \u00b1 0.33 \u00b5M, respectively. Furthermore, it showed a safe profile against the",
    "entities": [
      {
        "text": "5.14",
        "label": "CARDINAL"
      },
      {
        "text": "0.33",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "tested normal cell line BJ-1. The triazole glycosides 8a-10b were investigated",
    "entities": [
      {
        "text": "BJ-1",
        "label": "ORG"
      },
      {
        "text": "8a-10b",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "to assess their capability to inhibit EGFR. Remarkably, 9a and 9b exhibited",
    "entities": [
      {
        "text": "EGFR",
        "label": "ORG"
      },
      {
        "text": "9a",
        "label": "CARDINAL"
      },
      {
        "text": "9b",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "noteworthy inhibitory activity against EGFR (IC50 = 0.069 \u00b1 0.003 and",
    "entities": [
      {
        "text": "EGFR",
        "label": "PERSON"
      },
      {
        "text": "0.069",
        "label": "CARDINAL"
      },
      {
        "text": "0.003",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "0.075 \u00b1 0.003 \u00b5M, respectively) in comparison with erlotinib, the reference drug",
    "entities": [
      {
        "text": "0.075",
        "label": "CARDINAL"
      },
      {
        "text": "0.003",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(0.048 \u00b1 0.002 \u00b5M). Molecular docking confirmed these findings, suggesting that",
    "entities": [
      {
        "text": "0.048",
        "label": "CARDINAL"
      },
      {
        "text": "0.002",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "the incorporation of the \u03b1,\u03b2-unsaturated ketone function enhances compounds'",
    "entities": []
  },
  {
    "text": "stability within the EGFR active site. Thus, these results indicate that",
    "entities": [
      {
        "text": "EGFR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "compounds 9a and 9b disclosed potential anti-cancer agents targeting EGFR",
    "entities": [
      {
        "text": "9a",
        "label": "CARDINAL"
      },
      {
        "text": "9b",
        "label": "CARDINAL"
      },
      {
        "text": "EGFR",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "DOI: 10.1038/s41598-025-96675-3",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40665148 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665148",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declarations. Competing interests: The authors",
    "entities": []
  },
  {
    "text": "Design, synthesis and evaluation of benzodioxole and bromofuran tethered",
    "entities": []
  },
  {
    "text": "1,2,4-triazole hybrids as potential anti breast cancer agents with computational",
    "entities": [
      {
        "text": "1,2,4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "insights.",
    "entities": []
  },
  {
    "text": "(1)Department of Chemistry, Manipal Institute of Technology, Manipal Academy of",
    "entities": [
      {
        "text": "Chemistry, Manipal Institute of Technology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Biotechnology, Manipal Institute of Technology Bengaluru,",
    "entities": [
      {
        "text": "Biotechnology, Manipal Institute of Technology Bengaluru",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.",
    "entities": [
      {
        "text": "Manipal Academy of Higher Education",
        "label": "ORG"
      },
      {
        "text": "Manipal",
        "label": "GPE"
      },
      {
        "text": "Karnataka",
        "label": "GPE"
      },
      {
        "text": "576104",
        "label": "DATE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Physics, Sri Jayachamarajendra College of Engineering, JSS",
    "entities": [
      {
        "text": "Physics",
        "label": "ORG"
      },
      {
        "text": "Sri Jayachamarajendra College of Engineering",
        "label": "ORG"
      },
      {
        "text": "JSS",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Technical Institutions Campus, JSS Science and Technology University, Mysuru,",
    "entities": [
      {
        "text": "Mysuru",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Chemistry, Manipal Institute of Technology, Manipal Academy of",
    "entities": [
      {
        "text": "Chemistry, Manipal Institute of Technology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "1,2,4-Triazole derivatives are the focus of extensive research in medicinal",
    "entities": [
      {
        "text": "1,2,4",
        "label": "CARDINAL"
      },
      {
        "text": "Triazole",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "chemistry because of their diverse biological activities, particularly their",
    "entities": []
  },
  {
    "text": "potential as anticancer agents. In this study, we designed and synthesized six",
    "entities": [
      {
        "text": "six",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "compounds featuring benzo[d][1,3]dioxole and 5-bromofuran tethered to",
    "entities": [
      {
        "text": "5-bromofuran",
        "label": "QUANTITY"
      }
    ]
  },
  {
    "text": "1,2,4-triazole hybrids. This was achieved through an efficient four-step",
    "entities": [
      {
        "text": "1,2,4",
        "label": "CARDINAL"
      },
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "protocol with reproducible results. The characterization of the 1,2,4-triazoles",
    "entities": [
      {
        "text": "1,2,4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "was conducted via various analytical techniques, including FTIR, 1H NMR, 13C",
    "entities": [
      {
        "text": "FTIR",
        "label": "ORG"
      },
      {
        "text": "1H",
        "label": "CARDINAL"
      },
      {
        "text": "NMR",
        "label": "ORG"
      },
      {
        "text": "13C",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "NMR, and mass spectrometry. The in vitro anti-breast cancer activities of",
    "entities": [
      {
        "text": "NMR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "synthesized 1,2,4-triazols were evaluated against the MCF-7 cell line using the",
    "entities": [
      {
        "text": "1,2,4",
        "label": "CARDINAL"
      },
      {
        "text": "MCF-7",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "MTT assay. Among all the synthesized compounds, compound 12b demonstrated an",
    "entities": [
      {
        "text": "MTT",
        "label": "ORG"
      },
      {
        "text": "12b",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "excellent IC50 value of 3.54 \u00b1 0.265 \u00b5g/mL. Additionally, in silico studies,",
    "entities": [
      {
        "text": "3.54",
        "label": "CARDINAL"
      },
      {
        "text": "0.265",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "such as molecular docking to predict the orientation of the compounds, molecular",
    "entities": []
  },
  {
    "text": "dynamics simulations to evaluate binding stability with the target protein,",
    "entities": []
  },
  {
    "text": "of three, DFT analysis to determine the energy gap of the frontier molecular",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      },
      {
        "text": "DFT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "orbitals (FMOs) and the molecular electrostatic potential (MEP) for identifying",
    "entities": [
      {
        "text": "MEP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "sites of nucleophilic and electrophilic attacks, were also conducted.",
    "entities": [
      {
        "text": "nucleophilic",
        "label": "ORG"
      },
      {
        "text": "electrophilic",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "DOI: 10.1038/s41598-025-09420-1",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40665119 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665119",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "declare no competing interests. Ethical approval: This study is not applicable",
    "entities": []
  },
  {
    "text": "because it does not involve the use of animals or humans.",
    "entities": []
  },
  {
    "text": "46. J Ultrasound. 2025 Jul 16. doi: 10.1007/s40477-025-01037-4. Online ahead of",
    "entities": [
      {
        "text": "46",
        "label": "CARDINAL"
      },
      {
        "text": "J Ultrasound",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Accuracy of shear wave elastography in diagnosing axillary lymph node metastasis",
    "entities": []
  },
  {
    "text": "in patients with suspicious axillary lymph nodes: development of a predictive",
    "entities": []
  },
  {
    "text": "(1)Department of Diagnostic and Interventional Radiology, Chulabhorn Hospital,",
    "entities": [
      {
        "text": "Diagnostic",
        "label": "ORG"
      },
      {
        "text": "Interventional Radiology",
        "label": "ORG"
      },
      {
        "text": "Chulabhorn Hospital",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Chulabhorn Royal Academy, Bangkok, Thailand. wethaka.kri@cra.ac.th.",
    "entities": [
      {
        "text": "Chulabhorn Royal Academy",
        "label": "ORG"
      },
      {
        "text": "Bangkok",
        "label": "GPE"
      },
      {
        "text": "Thailand",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Radiology, Faculty of Medicine, Prince of Songkla University,",
    "entities": [
      {
        "text": "Radiology, Faculty of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Tanyawej Breast Center, Songklanagarind Hospital, Faculty of Medicine, Prince",
    "entities": [
      {
        "text": "Breast Center",
        "label": "ORG"
      },
      {
        "text": "Songklanagarind Hospital, Faculty of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Songkla University, Songkhla, Thailand.",
    "entities": [
      {
        "text": "Songkla University",
        "label": "ORG"
      },
      {
        "text": "Songkhla",
        "label": "GPE"
      },
      {
        "text": "Thailand",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "PURPOSE: This study aimed to evaluate shear wave elastography [SWE] for",
    "entities": [
      {
        "text": "PURPOSE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "predicting axillary lymph node metastasis in breast cancer patients.",
    "entities": []
  },
  {
    "text": "METHODS: Thirty-nine patients with suspicious axillary lymph nodes (BI-RADS \u2265 4",
    "entities": [
      {
        "text": "Thirty-nine",
        "label": "CARDINAL"
      },
      {
        "text": "BI-RADS",
        "label": "ORG"
      },
      {
        "text": "4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and abnormal B-mode ultrasound features) underwent B-mode ultrasound, strain",
    "entities": []
  },
  {
    "text": "elastography, and shear wave elastography (SWE) prior to ultrasound-guided core",
    "entities": []
  },
  {
    "text": "needle biopsy. Two experienced radiologists independently assessed lymph node",
    "entities": [
      {
        "text": "Two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "appearance, cortical thickness, vascularity, as well as shear wave and strain",
    "entities": []
  },
  {
    "text": "elastography using the Siemens ACUSON Sequoia system. Statistical analysis",
    "entities": [
      {
        "text": "the Siemens ACUSON Sequoia",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "compared imaging parameters between benign and malignant nodes using the",
    "entities": []
  },
  {
    "text": "Wilcoxon rank-sum test. Diagnostic performance was evaluated using receiver",
    "entities": [
      {
        "text": "Wilcoxon",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "operating characteristic (ROC) curves. A predictive nomogram incorporating",
    "entities": [
      {
        "text": "ROC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "B-mode, strain elastography, and SWE findings was developed to improve",
    "entities": [
      {
        "text": "SWE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: Malignant nodes showed significantly higher stiffness and velocity",
    "entities": []
  },
  {
    "text": "[p < 0.05]. Cut points for diagnostic accuracy were determined by using the",
    "entities": []
  },
  {
    "text": "Youden index. Combining B-Mode and elastography improved sensitivity and",
    "entities": [
      {
        "text": "Youden",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "specificity. A predictive nomogram incorporating SWE, strain elastography, and",
    "entities": []
  },
  {
    "text": "B-Mode appearance achieved high diagnostic efficacy [sensitivity = 0.96,",
    "entities": [
      {
        "text": "0.96",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "specificity = 0.77, PPV = 0.89, NPV = 0.91].",
    "entities": [
      {
        "text": "0.77",
        "label": "CARDINAL"
      },
      {
        "text": "PPV",
        "label": "ORG"
      },
      {
        "text": "0.89",
        "label": "CARDINAL"
      },
      {
        "text": "NPV",
        "label": "ORG"
      },
      {
        "text": "0.91",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: SWE demonstrates potential as a non-invasive tool for axillary",
    "entities": []
  },
  {
    "text": "nodal assessment in breast cancer patients. It effectively distinguishes between",
    "entities": []
  },
  {
    "text": "benign and malignant axillary lymph nodes, offering promise for optimizing",
    "entities": []
  },
  {
    "text": "management. The predictive nomogram, incorporating SWE, strain elastography, and",
    "entities": [
      {
        "text": "SWE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "B-Mode appearance, provides a practical tool for pre-operative decision-making,",
    "entities": []
  },
  {
    "text": "enhancing the diagnostic process and potentially improving the management of",
    "entities": []
  },
  {
    "text": "breast cancer patients.",
    "entities": []
  },
  {
    "text": "DOI: 10.1007/s40477-025-01037-4",
    "entities": [
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declarations. Funding: The authors received no",
    "entities": []
  },
  {
    "text": "funding for this work from any institutional or external sources. Conflict of",
    "entities": []
  },
  {
    "text": "interest: The authors declare that they have no conflict of interest. Research",
    "entities": []
  },
  {
    "text": "involving human participants and/or animals: This study was approved by Human",
    "entities": []
  },
  {
    "text": "Research Ethics Commitee, Prince of Songkla University, approval number",
    "entities": [
      {
        "text": "Research Ethics Commitee",
        "label": "ORG"
      },
      {
        "text": "Prince of Songkla University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "REC.64-032-7-4. Informed consent: All participants were informed and signed the",
    "entities": []
  },
  {
    "text": "consent document before enrolling in the study.",
    "entities": []
  },
  {
    "text": "Association of circulating immuno-oncology biomarkers with breast cancer risk:",
    "entities": []
  },
  {
    "text": "insights from two prospective cohorts.",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(1)Department of Epidemiology and Health Statistics, School of Public Health,",
    "entities": [
      {
        "text": "Epidemiology and Health Statistics, School of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Fujian Medical University, Fuzhou, China.",
    "entities": [
      {
        "text": "Fujian Medical University",
        "label": "ORG"
      },
      {
        "text": "Fuzhou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Epidemiology, School of Public Health, and the Key Laboratory",
    "entities": [
      {
        "text": "Epidemiology, School of Public Health",
        "label": "ORG"
      },
      {
        "text": "the Key Laboratory",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Public Health Safety of Ministry of Education, Fudan University, Shanghai,",
    "entities": [
      {
        "text": "Public Health Safety of Ministry of Education",
        "label": "ORG"
      },
      {
        "text": "Fudan University",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Fudan University Taizhou Institute of Health Sciences, Taizhou, Jiangsu,",
    "entities": [
      {
        "text": "3)Fudan University Taizhou Institute of Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Taizhou",
        "label": "GPE"
      },
      {
        "text": "Jiangsu",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Health Inspection and Quarantine, School of Public Health,",
    "entities": [
      {
        "text": "Health Inspection and Quarantine, School of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)State Key Laboratory of Genetic Engineering, Human Phenome Institute, and",
    "entities": [
      {
        "text": "Key Laboratory of Genetic Engineering",
        "label": "ORG"
      },
      {
        "text": "Human Phenome Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "School of Life Sciences, Fudan University, Shanghai, China.",
    "entities": [
      {
        "text": "School of Life Sciences",
        "label": "ORG"
      },
      {
        "text": "Fudan University",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Epidemiology and Health Statistics, School of Public Health,",
    "entities": [
      {
        "text": "Epidemiology and Health Statistics, School of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Fujian Medical University, Fuzhou, China. ywm@fjmu.edu.cn.",
    "entities": [
      {
        "text": "Fujian Medical University",
        "label": "ORG"
      },
      {
        "text": "Fuzhou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,",
    "entities": [
      {
        "text": "Medical Epidemiology and Biostatistics",
        "label": "ORG"
      },
      {
        "text": "Karolinska Institutet",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(8)Department of Epidemiology and Health Statistics, School of Public Health,",
    "entities": [
      {
        "text": "Epidemiology and Health Statistics, School of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Fujian Medical University, Fuzhou, China. haomin.yang@ki.se.",
    "entities": [
      {
        "text": "Fujian Medical University",
        "label": "ORG"
      },
      {
        "text": "Fuzhou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,",
    "entities": [
      {
        "text": "Medical Epidemiology and Biostatistics",
        "label": "ORG"
      },
      {
        "text": "Karolinska Institutet",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(10)Fudan University Taizhou Institute of Health Sciences, Taizhou, Jiangsu,",
    "entities": [
      {
        "text": "10)Fudan University Taizhou Institute of Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Taizhou",
        "label": "GPE"
      },
      {
        "text": "Jiangsu",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)State Key Laboratory of Genetic Engineering, Human Phenome Institute, and",
    "entities": [
      {
        "text": "11)State Key Laboratory of Genetic Engineering",
        "label": "ORG"
      },
      {
        "text": "Human Phenome Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Immuno-oncology biomarkers are promising tools for cancer risk assessment and",
    "entities": [
      {
        "text": "Immuno",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "early detection. To identify and validate their associations with breast cancer,",
    "entities": []
  },
  {
    "text": "nested case-control studies within the Taizhou Longitudinal Study (TZL) cohort",
    "entities": [
      {
        "text": "the Taizhou Longitudinal Study (",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and the UK biobank Pharma Proteomics Project (UKB-PPP) were conducted,",
    "entities": [
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "Pharma Proteomics Project",
        "label": "ORG"
      },
      {
        "text": "UKB-PPP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "comprising 195 and 881 incident breast cancer patients, together with their",
    "entities": [
      {
        "text": "195",
        "label": "CARDINAL"
      },
      {
        "text": "881",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "matched controls. Among the 92 plasma proteins tested by the Olink",
    "entities": [
      {
        "text": "92",
        "label": "CARDINAL"
      },
      {
        "text": "the Olink\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Immuno-oncology panel, 11 proteins were associated with breast cancer risk in",
    "entities": [
      {
        "text": "Immuno",
        "label": "ORG"
      },
      {
        "text": "11",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "the TZL cohort after multiple testing correction. Notably, hepatocyte growth",
    "entities": [
      {
        "text": "TZL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "factor (HGF) was validated in the UKB-PPP, particularly among postmenopausal",
    "entities": [
      {
        "text": "HGF",
        "label": "ORG"
      },
      {
        "text": "UKB-PPP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "women (OR = 1.13, 95% CI = 1.03-1.24). The association was stronger with",
    "entities": [
      {
        "text": "1.13",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.03-1.24",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Estrogen Receptor-negative breast cancer and confirmed by Mendelian",
    "entities": [
      {
        "text": "Estrogen Receptor-negative",
        "label": "ORG"
      },
      {
        "text": "Mendelian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Randomization analysis. Additionally, HGF mediated the effects of Healthy",
    "entities": [
      {
        "text": "HGF",
        "label": "ORG"
      },
      {
        "text": "Healthy\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Lifestyle Index (27.17%) and BMI (19.79%) on breast cancer risk. Therefore, HGF",
    "entities": [
      {
        "text": "Lifestyle Index",
        "label": "PERSON"
      },
      {
        "text": "27.17%",
        "label": "PERCENT"
      },
      {
        "text": "BMI",
        "label": "ORG"
      },
      {
        "text": "19.79%",
        "label": "PERCENT"
      },
      {
        "text": "HGF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "could be an intervention target by either medicines or lifestyle changes to",
    "entities": []
  },
  {
    "text": "improve the prevention and treatment of breast cancer.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Competing interests: The authors declare no",
    "entities": []
  },
  {
    "text": "competing interests.",
    "entities": []
  },
  {
    "text": "48. Nat Med. 2025 Jul 15. doi: 10.1038/s41591-025-03790-9. Online ahead of print.",
    "entities": [
      {
        "text": "48",
        "label": "CARDINAL"
      },
      {
        "text": "Nat Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Deep phenotyping of health-disease continuum in the Human Phenotype Project.",
    "entities": [
      {
        "text": "the Human Phenotype Project",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Y(12), Stossel C(12), Raitses-Gurevich M(12), Golan T(4)(12), Dhir R(13),",
    "entities": [
      {
        "text": "Stossel C(12",
        "label": "ORG"
      },
      {
        "text": "Raitses-Gurevich M(12",
        "label": "PERSON"
      },
      {
        "text": "Golan T(4)(12",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "(1)Department of Computer Science and Applied Mathematics, Weizmann Institute of",
    "entities": [
      {
        "text": "Computer Science",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Science, Rehovot, Israel.",
    "entities": [
      {
        "text": "Rehovot",
        "label": "GPE"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot,",
    "entities": [
      {
        "text": "Molecular Cell Biology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Lis Maternity and Women's Hospital, Tel Aviv Sourasky Medical Center, Tel",
    "entities": [
      {
        "text": "Tel Aviv Sourasky Medical Center",
        "label": "ORG"
      },
      {
        "text": "Tel\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(4)Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv,",
    "entities": [
      {
        "text": "4)Faculty of Medical and Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Tel Aviv University",
        "label": "ORG"
      },
      {
        "text": "Tel Aviv",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes,",
    "entities": [
      {
        "text": "Jesse Z",
        "label": "WORK_OF_ART"
      },
      {
        "text": "Sara Lea Shafer Institute for Endocrinology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "National Center for Childhood Diabetes, Schneider Children's Medical Center of",
    "entities": [
      {
        "text": "National Center for Childhood Diabetes",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Department of Internal Medicine A, Shamir Medical Center (Assaf Harofeh),",
    "entities": [
      {
        "text": "Internal Medicine A",
        "label": "ORG"
      },
      {
        "text": "Shamir Medical Center",
        "label": "ORG"
      },
      {
        "text": "Assaf Harofeh",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(7)Department of Cardiology, Rabin Medical Center, Petah-Tikva, Israel.",
    "entities": [
      {
        "text": "Cardiology",
        "label": "GPE"
      },
      {
        "text": "Rabin Medical Center",
        "label": "ORG"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Cancer Research Center, Sheba Medical Center, Ramat-Gan, Israel.",
    "entities": [
      {
        "text": "Research Center",
        "label": "ORG"
      },
      {
        "text": "Sheba Medical Center",
        "label": "ORG"
      },
      {
        "text": "Ramat-Gan",
        "label": "ORG"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Institute of Breast Oncology, the Jusidman Cancer Center, Sheba Medical",
    "entities": [
      {
        "text": "Breast Oncology",
        "label": "ORG"
      },
      {
        "text": "the Jusidman Cancer Center",
        "label": "ORG"
      },
      {
        "text": "Sheba Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(10)The Department of Gastroenterology and Liver Disease, Tel Aviv Medical",
    "entities": [
      {
        "text": "10)The Department of Gastroenterology and Liver Disease",
        "label": "ORG"
      },
      {
        "text": "Tel Aviv Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Center, affiliated to the Grey Faculty of Medicine and Health Sciences, Tel Aviv",
    "entities": [
      {
        "text": "the Grey Faculty of Medicine and Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Tel Aviv",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University, Tel Aviv, Israel.",
    "entities": [
      {
        "text": "Tel Aviv",
        "label": "GPE"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Department of Internal Medicine, SBS Shizuoka Health Promotion Center,",
    "entities": [
      {
        "text": "11)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Internal Medicine",
        "label": "ORG"
      },
      {
        "text": "SBS Shizuoka Health Promotion Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(12)The Jusidman Cancer Center, Sheba Medical Center, Tel Hashomer, Israel.",
    "entities": [
      {
        "text": "Jusidman Cancer Center",
        "label": "ORG"
      },
      {
        "text": "Sheba Medical Center",
        "label": "ORG"
      },
      {
        "text": "Tel Hashomer",
        "label": "PERSON"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(13)Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich,",
    "entities": [
      {
        "text": "13)Swiss Institute of Allergy and Asthma Research",
        "label": "ORG"
      },
      {
        "text": "University of Zurich",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(15)Mohamed bin Zayed University of Artificial Intelligence, Abu Dhabi, UAE.",
    "entities": [
      {
        "text": "15)Mohamed",
        "label": "CARDINAL"
      },
      {
        "text": "bin Zayed University of Artificial Intelligence",
        "label": "ORG"
      },
      {
        "text": "Abu Dhabi",
        "label": "GPE"
      },
      {
        "text": "UAE",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(17)Mohamed bin Zayed University of Artificial Intelligence, Abu Dhabi, UAE.",
    "entities": [
      {
        "text": "bin Zayed University of Artificial Intelligence",
        "label": "ORG"
      },
      {
        "text": "Abu Dhabi",
        "label": "GPE"
      },
      {
        "text": "UAE",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(18)Carnegie Mellon University Pittsburgh, Pittsburgh, PA, USA.",
    "entities": [
      {
        "text": "18)Carnegie",
        "label": "CARDINAL"
      },
      {
        "text": "Mellon University",
        "label": "ORG"
      },
      {
        "text": "Pittsburgh",
        "label": "GPE"
      },
      {
        "text": "Pittsburgh",
        "label": "GPE"
      },
      {
        "text": "PA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(19)Department of Computer Science and Applied Mathematics, Weizmann Institute",
    "entities": []
  },
  {
    "text": "of Science, Rehovot, Israel. eran.segal@weizmann.ac.il.",
    "entities": [
      {
        "text": "Science, Rehovot",
        "label": "GPE"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(20)Mohamed bin Zayed University of Artificial Intelligence, Abu Dhabi, UAE.",
    "entities": [
      {
        "text": "20)Mohamed",
        "label": "CARDINAL"
      },
      {
        "text": "University of Artificial Intelligence",
        "label": "ORG"
      },
      {
        "text": "Abu Dhabi",
        "label": "GPE"
      },
      {
        "text": "UAE",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "The Human Phenotype Project (HPP) is a large-scale deep-phenotype prospective",
    "entities": [
      {
        "text": "The Human Phenotype Project",
        "label": "ORG"
      },
      {
        "text": "HPP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cohort. To date, approximately 28,000 participants have enrolled, with more than",
    "entities": [
      {
        "text": "approximately 28,000",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "13,000 completing their initial visit. The project is aimed at identifying novel",
    "entities": [
      {
        "text": "13,000",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "molecular signatures with diagnostic, prognostic and therapeutic value, and at",
    "entities": []
  },
  {
    "text": "developing artificial intelligence (AI)-based predictive models for disease",
    "entities": []
  },
  {
    "text": "onset and progression. The HPP includes longitudinal profiling encompassing",
    "entities": [
      {
        "text": "HPP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "medical history, lifestyle and nutrition, anthropometrics, blood tests,",
    "entities": []
  },
  {
    "text": "continuous glucose and sleep monitoring, imaging and multi-omics data, including",
    "entities": [
      {
        "text": "continuous glucose",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "immune profiling. Analysis of these data highlights the variation of phenotypes",
    "entities": []
  },
  {
    "text": "with age and ethnicity and unravels molecular signatures of disease by",
    "entities": []
  },
  {
    "text": "comparison with matched healthy controls. Leveraging extensive dietary and",
    "entities": []
  },
  {
    "text": "lifestyle data, we identify associations between lifestyle factors and health",
    "entities": [
      {
        "text": "lifestyle data",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "outcomes. Finally, we present a multi-modal foundation AI model, trained using",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "self-supervised learning on diet and continuous-glucose-monitoring data, that",
    "entities": []
  },
  {
    "text": "outperforms existing methods in predicting disease onset. This framework can be",
    "entities": []
  },
  {
    "text": "extended to integrate other modalities and act as a personalized digital twin.",
    "entities": []
  },
  {
    "text": "In summary, we present a deeply phenotyped cohort that serves as a platform for",
    "entities": []
  },
  {
    "text": "advancing biomarker discovery, enabling the development of multi-modal AI models",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and personalized medicine approaches.",
    "entities": []
  },
  {
    "text": "\u00a9 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Springer Nature America, Inc.",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "DOI: 10.1038/s41591-025-03790-9",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Competing interests: Y.R., H.R. and Y.T.B are",
    "entities": [
      {
        "text": "Y.R.",
        "label": "GPE"
      },
      {
        "text": "H.R.",
        "label": "GPE"
      },
      {
        "text": "Y.T.B",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "employees at Pheno.AI. A.K., A.W. and E.S. are paid consultants of Pheno.AI.",
    "entities": [
      {
        "text": "Pheno",
        "label": "GPE"
      },
      {
        "text": "AI",
        "label": "ORG"
      },
      {
        "text": "A.K.",
        "label": "GPE"
      },
      {
        "text": "A.W.",
        "label": "GPE"
      },
      {
        "text": "E.S.",
        "label": "GPE"
      },
      {
        "text": "Pheno",
        "label": "GPE"
      },
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "N.M. has received speaking and consulting fees from Pfizer, Abbvie, Lilly,",
    "entities": [
      {
        "text": "N.M.",
        "label": "GPE"
      },
      {
        "text": "Pfizer, Abbvie, Lilly",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Takeda, Janssen, Ferring, BiomX, BMS, Nestle and Teva and grant support from",
    "entities": [
      {
        "text": "Ferring",
        "label": "GPE"
      },
      {
        "text": "BMS",
        "label": "ORG"
      },
      {
        "text": "Nestle",
        "label": "ORG"
      },
      {
        "text": "Teva",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the Helmsely Charitable Trust. The other authors declare no competing interests.",
    "entities": [
      {
        "text": "the Helmsely Charitable Trust",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "49. Strahlenther Onkol. 2025 Jul 15. doi: 10.1007/s00066-025-02441-9. Online",
    "entities": [
      {
        "text": "49",
        "label": "CARDINAL"
      },
      {
        "text": "Strahlenther Onkol",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Immune-sparing potential of isocentric lateral decubitus positioning in adjuvant",
    "entities": []
  },
  {
    "text": "whole-breast radiotherapy.",
    "entities": []
  },
  {
    "text": "(1)Proton Therapy Center (CPO), Institut Curie, Orsay, France.",
    "entities": [
      {
        "text": "Therapy Center",
        "label": "ORG"
      },
      {
        "text": "CPO",
        "label": "ORG"
      },
      {
        "text": "Institut Curie",
        "label": "PERSON"
      },
      {
        "text": "Orsay",
        "label": "GPE"
      },
      {
        "text": "France",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of radiation oncology, Institut Curie, Paris, France.",
    "entities": [
      {
        "text": "2)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Institut Curie",
        "label": "PERSON"
      },
      {
        "text": "Paris",
        "label": "GPE"
      },
      {
        "text": "France",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Proton Therapy Center (CPO), Institut Curie, Orsay, France.",
    "entities": [
      {
        "text": "Therapy Center",
        "label": "ORG"
      },
      {
        "text": "CPO",
        "label": "ORG"
      },
      {
        "text": "Institut Curie",
        "label": "PERSON"
      },
      {
        "text": "Orsay",
        "label": "GPE"
      },
      {
        "text": "France",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of radiation oncology, Institut Curie, Paris, France.",
    "entities": [
      {
        "text": "Institut Curie",
        "label": "PERSON"
      },
      {
        "text": "Paris",
        "label": "GPE"
      },
      {
        "text": "France",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Orsay, France. pierre.loap@gmail.com.",
    "entities": [
      {
        "text": "Orsay",
        "label": "GPE"
      },
      {
        "text": "France",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Lymphocytes are among the most radiosensitive cell types, and",
    "entities": []
  },
  {
    "text": "low-dose exposure during radiotherapy has been associated with measurable immune",
    "entities": []
  },
  {
    "text": "suppression. In breast cancer treatment, systemic immune exposure is partly",
    "entities": []
  },
  {
    "text": "driven by irradiation of highly vascularized organs such as the heart, lungs,",
    "entities": []
  },
  {
    "text": "and liver. The axillary lymph nodes also play a critical role in initiating",
    "entities": []
  },
  {
    "text": "antitumor immune responses. Isocentric lateral decubitus (ILD) positioning, by",
    "entities": [
      {
        "text": "antitumor immune responses",
        "label": "ORG"
      },
      {
        "text": "Isocentric",
        "label": "TIME"
      },
      {
        "text": "ILD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "modifying the beam orientation, may reduce incidental exposure to these",
    "entities": []
  },
  {
    "text": "immune-related structures. This study aimed to evaluate the potential of ILD to",
    "entities": [
      {
        "text": "ILD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "spare both circulating immune cells and axillary lymph nodes compared to",
    "entities": []
  },
  {
    "text": "standard supine positioning during whole-breast irradiation (WBI).",
    "entities": []
  },
  {
    "text": "METHODS: Eight patients with localized breast cancer treated with",
    "entities": [
      {
        "text": "Eight",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "breast-conserving surgery and adjuvant WBI (without nodal irradiation) were",
    "entities": []
  },
  {
    "text": "included in this retrospective dosimetric study. Each patient underwent CT",
    "entities": [
      {
        "text": "CT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "simulation and treatment planning in both supine and ILD positions. The",
    "entities": [
      {
        "text": "ILD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "estimated dose to circulating immune cells (EDIC) was calculated using a model",
    "entities": []
  },
  {
    "text": "based on mean doses to the lungs, heart, liver, and whole body. The level I",
    "entities": []
  },
  {
    "text": "axillary region was retrospectively contoured, and both the mean dose and D95",
    "entities": [
      {
        "text": "D95",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "were extracted. Dosimetric comparisons between positions were performed using",
    "entities": []
  },
  {
    "text": "paired Wilcoxon signed-rank tests.",
    "entities": [
      {
        "text": "Wilcoxon",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: Isocentric lateral decubitus positioning significantly reduced the EDIC",
    "entities": [
      {
        "text": "Isocentric",
        "label": "TIME"
      },
      {
        "text": "EDIC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "compared to the supine position (median 0.56 Gy vs. 1.12 Gy; p < 0.01). Lung,",
    "entities": [
      {
        "text": "0.56",
        "label": "CARDINAL"
      },
      {
        "text": "1.12",
        "label": "CARDINAL"
      },
      {
        "text": "Lung",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "heart, and liver doses were also significantly lower. The axillary dose was",
    "entities": []
  },
  {
    "text": "reduced, with the mean dose decreasing from 10.2 to 3.8 Gy (p = 0.016) and D95%",
    "entities": [
      {
        "text": "10.2",
        "label": "CARDINAL"
      },
      {
        "text": "3.8",
        "label": "CARDINAL"
      },
      {
        "text": "0.016",
        "label": "CARDINAL"
      },
      {
        "text": "D95%",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "from 0.82 to 0.35 Gy (p = 0.039).",
    "entities": [
      {
        "text": "0.82",
        "label": "CARDINAL"
      },
      {
        "text": "0.039",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSION: Isocentric lateral decubitus positioning significantly reduces both",
    "entities": [
      {
        "text": "Isocentric",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "systemic and regional immune irradiation during adjuvant WBI. These findings",
    "entities": []
  },
  {
    "text": "suggest that ILD may help to preserve immune function, particularly in",
    "entities": [
      {
        "text": "ILD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "immunogenic subtypes such as triple-negative breast cancer, and support its",
    "entities": []
  },
  {
    "text": "consideration in treatment planning when nodal irradiation is not indicated.",
    "entities": []
  },
  {
    "text": "\u00a9 2025. Springer-Verlag GmbH Germany, part of Springer Nature.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Springer-Verlag GmbH Germany",
        "label": "ORG"
      },
      {
        "text": "Springer Nature",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "DOI: 10.1007/s00066-025-02441-9",
    "entities": [
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Conflict of interest: C. Cheptea, Y. Kirova, and",
    "entities": [
      {
        "text": "C. Cheptea",
        "label": "PERSON"
      },
      {
        "text": "Y. Kirova",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "P. Loap declare that they have no competing interests.",
    "entities": [
      {
        "text": "P. Loap",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "50. Br J Cancer. 2025 Jul 15. doi: 10.1038/s41416-025-03116-z. Online ahead of",
    "entities": [
      {
        "text": "50",
        "label": "CARDINAL"
      },
      {
        "text": "Br J Cancer",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Fatigue in long-term cancer survivors: prevalence, associated factors, and",
    "entities": []
  },
  {
    "text": "mortality. A prospective population-based study.",
    "entities": []
  },
  {
    "text": "(1)Cancer Survivorship, Division of Clinical Epidemiology and Aging Research,",
    "entities": [
      {
        "text": "Survivorship, Division of Clinical Epidemiology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Cancer Survivorship, Division of Clinical Epidemiology and Aging Research,",
    "entities": [
      {
        "text": "Survivorship, Division of Clinical Epidemiology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "German Cancer Research Center (DKFZ), Heidelberg, Germany.",
    "entities": [
      {
        "text": "German Cancer Research Center",
        "label": "ORG"
      },
      {
        "text": "DKFZ",
        "label": "ORG"
      },
      {
        "text": "Heidelberg",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Division of Clinical Epidemiology and Aging Research, DKFZ, Heidelberg,",
    "entities": [
      {
        "text": "DKFZ",
        "label": "ORG"
      },
      {
        "text": "Heidelberg",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Germany.",
    "entities": [
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Cancer Registry of North Rhine-Westphalia, Bochum, Germany.",
    "entities": [
      {
        "text": "Bochum",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Bremen Cancer Registry, Leibniz Institute for Prevention Research and",
    "entities": [
      {
        "text": "Cancer Registry",
        "label": "ORG"
      },
      {
        "text": "Leibniz Institute for Prevention Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Epidemiology - BIPS, Bremen, Germany.",
    "entities": [
      {
        "text": "Bremen",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Hamburg Cancer Registry, Hamburg, Germany.",
    "entities": [
      {
        "text": "Cancer Registry",
        "label": "ORG"
      },
      {
        "text": "Hamburg",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Institute for Social Medicine and Epidemiology, University of L\u00fcbeck, L\u00fcbeck,",
    "entities": [
      {
        "text": "Social Medicine and Epidemiology",
        "label": "ORG"
      },
      {
        "text": "University of L\u00fcbeck",
        "label": "ORG"
      },
      {
        "text": "L\u00fcbeck",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Institute of Clinical Epidemiology and Biometry (ICE-B), Julius Maximilian",
    "entities": [
      {
        "text": "Clinical Epidemiology and Biometry",
        "label": "ORG"
      },
      {
        "text": "Julius Maximilian",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University of W\u00fcrzburg, W\u00fcrzburg, Germany.",
    "entities": [
      {
        "text": "University of W\u00fcrzburg",
        "label": "ORG"
      },
      {
        "text": "W\u00fcrzburg",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Cancer Registry of Rhineland-Palatinate, Mainz, Germany.",
    "entities": [
      {
        "text": "10)Cancer",
        "label": "CARDINAL"
      },
      {
        "text": "Registry of Rhineland-Palatinate",
        "label": "ORG"
      },
      {
        "text": "Mainz",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Department of Medical Psychology and Medical Sociology, University Hospital",
    "entities": [
      {
        "text": "12)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Medical Psychology and Medical Sociology",
        "label": "ORG"
      },
      {
        "text": "University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(13)Department of Psychosomatic Medicine and Psychotherapy, University Hospital",
    "entities": [
      {
        "text": "13)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Psychotherapy, University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.",
    "entities": [
      {
        "text": "Mainz",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(14)German Cancer Consortium (DKTK), DKFZ, Heidelberg, Germany.",
    "entities": [
      {
        "text": "14)German",
        "label": "CARDINAL"
      },
      {
        "text": "Cancer Consortium",
        "label": "ORG"
      },
      {
        "text": "DKFZ",
        "label": "ORG"
      },
      {
        "text": "Heidelberg",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: We compared fatigue severity in breast, prostate or colorectal",
    "entities": []
  },
  {
    "text": "cancer survivors 5-16 years post-diagnosis with cancer-free controls, and",
    "entities": [
      {
        "text": "5-16 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "examined factors associated with fatigue and its association with all-cause",
    "entities": []
  },
  {
    "text": "mortality in survivors.",
    "entities": []
  },
  {
    "text": "METHODS: Participants of the CAncEr Survivorship - A multi-Regional (CAESAR)",
    "entities": []
  },
  {
    "text": "study completed the Fatigue Assessment Questionnaire (FAQ) between 2009 and",
    "entities": [
      {
        "text": "the Fatigue Assessment Questionnaire",
        "label": "ORG"
      },
      {
        "text": "FAQ",
        "label": "ORG"
      },
      {
        "text": "between 2009",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "2011. The FAQ assesses affective, cognitive, and physical fatigue, and sleep",
    "entities": [
      {
        "text": "2011",
        "label": "DATE"
      },
      {
        "text": "FAQ",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "problems. We derived the odds of fatigue using logistic regression with the 75th",
    "entities": [
      {
        "text": "75th",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "percentile of population norms as the cut-off. All-cause mortality (up to end",
    "entities": []
  },
  {
    "text": "2021) was estimated using Cox regression models.",
    "entities": [
      {
        "text": "2021",
        "label": "DATE"
      },
      {
        "text": "Cox",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "RESULTS: The sample comprised 6057 survivors, of whom approximately one-third",
    "entities": [
      {
        "text": "6057",
        "label": "CARDINAL"
      },
      {
        "text": "approximately one-third",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "reported affective, cognitive, or physical fatigue. Demographic (age,",
    "entities": [
      {
        "text": "Demographic",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "relationship), clinical (chemotherapy), comorbidity (depression), lifestyle, and",
    "entities": []
  },
  {
    "text": "psychological factors were associated with higher odds of fatigue symptoms and",
    "entities": []
  },
  {
    "text": "total fatigue. Fatigue symptoms, predominantly physical fatigue, were strongly",
    "entities": []
  },
  {
    "text": "associated with mortality (unadjusted hazard ratios (HRs) ranged from 1.48 to",
    "entities": [
      {
        "text": "1.48",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "2.40). The HRs were attenuated after adjustment for comorbidities and depressive",
    "entities": [
      {
        "text": "2.40",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "symptoms, although affective and physical fatigue remained independent risk",
    "entities": []
  },
  {
    "text": "factors for mortality.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: Demographic, clinical, comorbidity, lifestyle, and psychological",
    "entities": [
      {
        "text": "Demographic",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "factors were associated with fatigue in long-term survivors. Fatigued survivors",
    "entities": []
  },
  {
    "text": "have a higher mortality risk. Lowering the burden of fatigue by a comprehensive",
    "entities": []
  },
  {
    "text": "approach might result in better survival.",
    "entities": []
  },
  {
    "text": "competing interests. Ethics approval and consent to participate: The ethics",
    "entities": []
  },
  {
    "text": "committee of the University of Heidelberg (S499/2012) and the responsible local",
    "entities": [
      {
        "text": "the University of Heidelberg",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "ethics committees of the participating cancer registries approved the CAESAR",
    "entities": [
      {
        "text": "CAESAR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "study. All participants provided written informed consent. All methods were",
    "entities": []
  },
  {
    "text": "performed in accordance with the relevant guidelines and regulations.",
    "entities": []
  },
  {
    "text": "The inner nuclear membrane protein, Banf1, has an essential role in triple",
    "entities": [
      {
        "text": "Banf1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "negative breast cancer cell proliferation and survival.",
    "entities": []
  },
  {
    "text": "Rose M(1), Burgess JT(1), Cheong CM(1), Richard I(1)(2), Suraweera A(1), Adams",
    "entities": [
      {
        "text": "Burgess JT(1",
        "label": "LOC"
      },
      {
        "text": "Cheong CM(1",
        "label": "PERSON"
      },
      {
        "text": "Richard I(1)(2",
        "label": "PERSON"
      },
      {
        "text": "Suraweera",
        "label": "ORG"
      },
      {
        "text": "Adams\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Cancer Genomics Program, Centre for Genomics and Personalised Health, School",
    "entities": [
      {
        "text": "Genomics Program",
        "label": "ORG"
      },
      {
        "text": "Centre for Genomics and Personalised Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Biomedical Sciences, Faculty of Health, Queensland University of Technology,",
    "entities": [
      {
        "text": "Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "Faculty of Health",
        "label": "ORG"
      },
      {
        "text": "University of Technology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Kelvin Grove, Brisbane, Australia.",
    "entities": [
      {
        "text": "Kelvin Grove",
        "label": "PERSON"
      },
      {
        "text": "Brisbane",
        "label": "GPE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Medical Research Council Laboratory of Molecular Biology (MRC LMB), Cambridge",
    "entities": [
      {
        "text": "Research Council Laboratory of Molecular Biology",
        "label": "ORG"
      },
      {
        "text": "Cambridge",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Biomedical Campus, Francis Crick Ave, Trumpington, Cambridge, CB2 0QH, UK.",
    "entities": [
      {
        "text": "Biomedical Campus",
        "label": "PERSON"
      },
      {
        "text": "Francis Crick",
        "label": "PERSON"
      },
      {
        "text": "Trumpington",
        "label": "GPE"
      },
      {
        "text": "Cambridge",
        "label": "GPE"
      },
      {
        "text": "0QH",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Queensland University of Technology (QUT), Translational Research Institute,",
    "entities": [
      {
        "text": "3)Queensland University of Technology",
        "label": "ORG"
      },
      {
        "text": "QUT",
        "label": "ORG"
      },
      {
        "text": "Translational Research Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Woolloongabba, Brisbane, Australia.",
    "entities": [
      {
        "text": "Woolloongabba",
        "label": "GPE"
      },
      {
        "text": "Brisbane",
        "label": "GPE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Centre for Cancer Biology, University of South Australia & SA Pathology,",
    "entities": [
      {
        "text": "4)Centre",
        "label": "CARDINAL"
      },
      {
        "text": "Cancer Biology,",
        "label": "ORG"
      },
      {
        "text": "University of South Australia & SA Pathology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Cancer Services, Princess Alexandra Hospital, Ipswich Road, Woolloongabba,",
    "entities": [
      {
        "text": "Alexandra Hospital",
        "label": "PERSON"
      },
      {
        "text": "Ipswich Road",
        "label": "ORG"
      },
      {
        "text": "Woolloongabba",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Brisbane, QLD, 4102, Australia.",
    "entities": [
      {
        "text": "Brisbane",
        "label": "GPE"
      },
      {
        "text": "QLD",
        "label": "ORG"
      },
      {
        "text": "4102",
        "label": "DATE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Cancer Genomics Program, Centre for Genomics and Personalised Health, School",
    "entities": [
      {
        "text": "Genomics Program",
        "label": "ORG"
      },
      {
        "text": "Centre for Genomics and Personalised Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Kelvin Grove, Brisbane, Australia. emma.bolderson@qut.edu.au.",
    "entities": [
      {
        "text": "Kelvin Grove",
        "label": "PERSON"
      },
      {
        "text": "Brisbane",
        "label": "GPE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      },
      {
        "text": "emma.bolderson@qut.edu.au",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Queensland University of Technology (QUT), Translational Research Institute,",
    "entities": [
      {
        "text": "University of Technology",
        "label": "ORG"
      },
      {
        "text": "QUT",
        "label": "ORG"
      },
      {
        "text": "Translational Research Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Woolloongabba, Brisbane, Australia. emma.bolderson@qut.edu.au.",
    "entities": [
      {
        "text": "Woolloongabba",
        "label": "GPE"
      },
      {
        "text": "Brisbane",
        "label": "GPE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      },
      {
        "text": "emma.bolderson@qut.edu.au",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(8)Queensland University of Technology, 60 Musk Avenue, Kelvin Grove, Brisbane,",
    "entities": [
      {
        "text": "University of Technology",
        "label": "ORG"
      },
      {
        "text": "60",
        "label": "CARDINAL"
      },
      {
        "text": "Kelvin Grove",
        "label": "GPE"
      },
      {
        "text": "Brisbane",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Triple negative breast cancers (TNBCs) are a heterogenous subcategory of breast",
    "entities": []
  },
  {
    "text": "cancers which have significantly worse survival outcomes compared to other",
    "entities": []
  },
  {
    "text": "breast cancer subtypes. However, limited advances have been made towards a",
    "entities": []
  },
  {
    "text": "targeted TNBC therapeutic and traditional chemotherapies remain the frontline",
    "entities": []
  },
  {
    "text": "therapy. Therefore, this study aimed to examine the therapeutic potential of a",
    "entities": []
  },
  {
    "text": "novel TNBC target, Barrier-to-Autointegration Factor 1 (Banf1), including",
    "entities": []
  },
  {
    "text": "determining Banf1 expression and cellular localisation in non-malignant breast",
    "entities": [
      {
        "text": "Banf1",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "cells and a panel of TNBC cell lines. Bioinformatic analysis of patient samples",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "demonstrated that Banf1 is overexpressed in all breast cancer stages and",
    "entities": [
      {
        "text": "Banf1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "subtypes. Banf1 depletion inhibited proliferation and induced mitotic arrest in",
    "entities": []
  },
  {
    "text": "TNBC cells via loss of nuclear envelope integrity and aberrant nuclear",
    "entities": []
  },
  {
    "text": "morphology, inducing TNBC tumour cell-specific cell death. These findings",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "highlight the significant overexpression and functional involvement of Banf1 in",
    "entities": [
      {
        "text": "Banf1",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "TNBC progression and suggests that it may have potential as a novel anti-cancer",
    "entities": []
  },
  {
    "text": "target, supporting further investigation.",
    "entities": []
  },
  {
    "text": "PMID: 40664994 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40664994",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "declare competing financial interests; EB, DR and KO are founders of Carpe Vitae",
    "entities": [
      {
        "text": "EB",
        "label": "GPE"
      },
      {
        "text": "DR",
        "label": "GPE"
      },
      {
        "text": "KO",
        "label": "PERSON"
      },
      {
        "text": "Carpe Vitae",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Pharmaceuticals. EB, JB, MA, KO, DR are inventors on provisional patent",
    "entities": [
      {
        "text": "EB",
        "label": "GPE"
      },
      {
        "text": "JB",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "KO",
        "label": "GPE"
      },
      {
        "text": "DR",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "applications filed by Queensland University of Technology. The remaining authors",
    "entities": [
      {
        "text": "Queensland University of Technology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "do not have any competing interest. Ethical approval: Experimental procedures",
    "entities": []
  },
  {
    "text": "were approved by the Queensland University of Technology, Human. 212 Research",
    "entities": [
      {
        "text": "the Queensland University of Technology, Human",
        "label": "ORG"
      },
      {
        "text": "212",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Ethics Committee (approval numbers 1700000940 and 1900000269).",
    "entities": [
      {
        "text": "Ethics Committee",
        "label": "ORG"
      },
      {
        "text": "1700000940",
        "label": "DATE"
      },
      {
        "text": "1900000269",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Efficacy of urolithin B-Loaded mesoporous silica nanoparticles modified with",
    "entities": []
  },
  {
    "text": "(1)Department of Biology, Ne.C., Islamic Azad University, Neyshabur, Iran.",
    "entities": [
      {
        "text": "Biology",
        "label": "GPE"
      },
      {
        "text": "Islamic Azad University",
        "label": "ORG"
      },
      {
        "text": "Neyshabur",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Biology, Ne.C., Islamic Azad University, Neyshabur, Iran.",
    "entities": [
      {
        "text": "Islamic Azad University",
        "label": "ORG"
      },
      {
        "text": "Neyshabur",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Biology, Ma.C., Islamic Azad University, Mashhad, Iran.",
    "entities": [
      {
        "text": "Islamic Azad University",
        "label": "ORG"
      },
      {
        "text": "Mashhad",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "This study investigated the anti-cancer effects of GQD@MSN-Uro-B nanoparticles",
    "entities": []
  },
  {
    "text": "(NPs) on the MCF7 cancer cell line, focusing on their antioxidant properties.",
    "entities": [
      {
        "text": "NPs",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "GQD@MSN-Uro-B was synthesized by first preparing graphene quantum dots (GQDs)",
    "entities": [
      {
        "text": "GQD@MSN-Uro-B",
        "label": "ORG"
      },
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "from graphene oxide (GO) through a hydrothermal method, followed by the sol-gel",
    "entities": []
  },
  {
    "text": "synthesis of mesoporous silica nanoparticles (MSNs). The GQDs were then",
    "entities": []
  },
  {
    "text": "covalently bonded to the MSNs, and Uro-B was loaded onto the resulting",
    "entities": []
  },
  {
    "text": "nanocarriers. Characterization using DLS revealed that GQD@MSN-Uro-B exhibited a",
    "entities": []
  },
  {
    "text": "Z-average particle size of 223.75 nm and a zeta potential of - 22.59 mV,",
    "entities": [
      {
        "text": "223.75",
        "label": "CARDINAL"
      },
      {
        "text": "22.59",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "indicating good stability compared to MSN-Uro-B@GQD, which had a larger",
    "entities": [
      {
        "text": "MSN-Uro-B@GQD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Z-average size of 241.02 nm and a zeta potential of - 14.99 mV. The NPs",
    "entities": [
      {
        "text": "241.02",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "demonstrated significant cytotoxicity with an IC50 of 10 \u00b5g/mL against MCF7",
    "entities": [
      {
        "text": "10",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "cells. At the same time, MSN-Uro-B@GQD had an IC50 of 83.19 \u00b5g/mL, effectively",
    "entities": [
      {
        "text": "MSN-Uro-B@GQD",
        "label": "ORG"
      },
      {
        "text": "83.19",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "inducing apoptosis in a dose-dependent manner, with early apoptosis rates",
    "entities": []
  },
  {
    "text": "increasing from 8.33% in untreated cells to 37.4% at 12 \u00b5g/mL. Gene expression",
    "entities": [
      {
        "text": "8.33%",
        "label": "PERCENT"
      },
      {
        "text": "37.4%",
        "label": "PERCENT"
      },
      {
        "text": "12",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "analysis revealed significant increases in TNF (from 0.92 \u00b1 0.008 to",
    "entities": [
      {
        "text": "TNF",
        "label": "ORG"
      },
      {
        "text": "0.92",
        "label": "CARDINAL"
      },
      {
        "text": "0.008",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "1.14 \u00b1 0.012), caspase-9 (from 0.85 \u00b1 0.008 to 3.3 \u00b1 0.012), and p21 (from",
    "entities": [
      {
        "text": "1.14",
        "label": "CARDINAL"
      },
      {
        "text": "0.012",
        "label": "CARDINAL"
      },
      {
        "text": "0.85",
        "label": "CARDINAL"
      },
      {
        "text": "0.008",
        "label": "CARDINAL"
      },
      {
        "text": "3.3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "0.87 \u00b1 0.008 to 1.32 \u00b1 0.012), indicating enhanced apoptotic activity.",
    "entities": [
      {
        "text": "0.87",
        "label": "CARDINAL"
      },
      {
        "text": "0.008",
        "label": "CARDINAL"
      },
      {
        "text": "0.012",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Additionally, the antioxidant capacity was validated by significant free radical",
    "entities": []
  },
  {
    "text": "scavenging, with 76% inhibition in the ABTS assay and 33.93% in the DPPH assay",
    "entities": [
      {
        "text": "76%",
        "label": "PERCENT"
      },
      {
        "text": "ABTS",
        "label": "ORG"
      },
      {
        "text": "33.93%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "at 2000 \u00b5g/mL. Overall, these findings highlight the potential of GQD@MSN-Uro-B",
    "entities": [
      {
        "text": "2000",
        "label": "DATE"
      },
      {
        "text": "mL. Overall",
        "label": "PERSON"
      },
      {
        "text": "GQD@MSN-Uro-B\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "nanoparticles as a promising candidate for targeted cancer therapy, combining",
    "entities": []
  },
  {
    "text": "effective cytotoxicity and antioxidant properties, warranting further",
    "entities": []
  },
  {
    "text": "investigation in clinical settings.",
    "entities": []
  },
  {
    "text": "DOI: 10.1038/s41598-025-10904-3",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40664936 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40664936",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Learning quality-guided multi-layer features for classifying visual types with",
    "entities": []
  },
  {
    "text": "ball sports application.",
    "entities": [
      {
        "text": "ball sports application",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Physical Education, Wuhan Institute of Technology, 430070,",
    "entities": [
      {
        "text": "Physical Education",
        "label": "ORG"
      },
      {
        "text": "Wuhan Institute of Technology",
        "label": "ORG"
      },
      {
        "text": "430070",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(2)Department of Physical Education, Wuhan Institute of Technology, 430070,",
    "entities": [
      {
        "text": "Physical Education",
        "label": "ORG"
      },
      {
        "text": "Wuhan Institute of Technology",
        "label": "ORG"
      },
      {
        "text": "430070",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(3)Intelligent Manufacturing College, Jinhua University of Vocational",
    "entities": [
      {
        "text": "Manufacturing College",
        "label": "ORG"
      },
      {
        "text": "Jinhua University of Vocational",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Technology, 321007, Jinhua, Zhejiang, China. yueyu1778@gmail.com.",
    "entities": [
      {
        "text": "321007",
        "label": "DATE"
      },
      {
        "text": "Jinhua",
        "label": "GPE"
      },
      {
        "text": "Zhejiang",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Nowadays, breast cancer is one of the leading causes of death among women. This",
    "entities": [
      {
        "text": "one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "highlights the need for precise X-ray image analysis in the medical and imaging",
    "entities": []
  },
  {
    "text": "fields. In this study, we present an advanced perceptual deep learning framework",
    "entities": []
  },
  {
    "text": "that extracts key features from large X-ray datasets, mimicking human visual",
    "entities": []
  },
  {
    "text": "perception. We begin by using a large dataset of breast cancer images and apply",
    "entities": []
  },
  {
    "text": "the BING objectness measure to identify relevant visual and semantic patches. To",
    "entities": [
      {
        "text": "BING",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "manage the large number of object-aware patches, we propose a new ranking",
    "entities": []
  },
  {
    "text": "technique in the weak annotation context. This technique identifies the patches",
    "entities": []
  },
  {
    "text": "that are most aligned with human visual judgment. These key patches are then",
    "entities": []
  },
  {
    "text": "aggregated to extract meaningful features from each image. We leverage these",
    "entities": []
  },
  {
    "text": "features to train a multi-class SVM classifier, which categorizes the images",
    "entities": [
      {
        "text": "SVM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "into various breast cancer stages. The effectiveness of our deep learning model",
    "entities": []
  },
  {
    "text": "is demonstrated through extensive comparative analysis and visual examples.",
    "entities": []
  },
  {
    "text": "DOI: 10.1038/s41598-025-10058-2",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40664935 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40664935",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "54. Eur Radiol. 2025 Jul 15. doi: 10.1007/s00330-025-11812-w. Online ahead of",
    "entities": [
      {
        "text": "54",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Enhancing breast positioning quality through real-time AI feedback.",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Radiology and Nuclear Medicine, Kantonsspital Baselland,",
    "entities": [
      {
        "text": "Radiology and Nuclear Medicine",
        "label": "ORG"
      },
      {
        "text": "Kantonsspital Baselland",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(2)Department of Radiology and Nuclear Medicine, University Hospital Basel,",
    "entities": [
      {
        "text": "Radiology and Nuclear Medicine",
        "label": "ORG"
      },
      {
        "text": "University Hospital Basel",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Radiology and Nuclear Medicine, University Hospital Basel,",
    "entities": [
      {
        "text": "Radiology and Nuclear Medicine",
        "label": "ORG"
      },
      {
        "text": "University Hospital Basel",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Institute of Radiology, Limmatthal Hospital, Schlieren, Switzerland.",
    "entities": [
      {
        "text": "Limmatthal Hospital",
        "label": "ORG"
      },
      {
        "text": "Schlieren",
        "label": "GPE"
      },
      {
        "text": "Switzerland",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "OBJECTIVES: Enhance mammography quality to increase cancer detection by",
    "entities": []
  },
  {
    "text": "implementing continuous AI-driven feedback mechanisms, ensuring reliable,",
    "entities": []
  },
  {
    "text": "consistent, and high-quality screening by the 'Perfect', 'Good', 'Moderate', and",
    "entities": []
  },
  {
    "text": "MATERIALS AND METHODS: To assess the impact of the AI software 'b-boxTM' on",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mammography quality, we conducted a comparative analysis of PGMI scores. We",
    "entities": [
      {
        "text": "PGMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "evaluated scores 50 days before (A) and after the software's implementation in",
    "entities": [
      {
        "text": "50 days",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "2021 (B), along with assessments made in the first week of August 2022 (C1) and",
    "entities": [
      {
        "text": "2021",
        "label": "DATE"
      },
      {
        "text": "the first week of August 2022",
        "label": "DATE"
      },
      {
        "text": "C1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "2023 (C2), comparing them to evaluations conducted by two readers. Except for",
    "entities": [
      {
        "text": "2023",
        "label": "DATE"
      },
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "postsurgical patients, we included all diagnostic and screening mammograms from",
    "entities": []
  },
  {
    "text": "one tertiary hospital.",
    "entities": [
      {
        "text": "one",
        "label": "CARDINAL"
      },
      {
        "text": "tertiary",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "RESULTS: A total of 4577 mammograms from 1220 women (mean age: 59, range: 21-94,",
    "entities": [
      {
        "text": "4577",
        "label": "CARDINAL"
      },
      {
        "text": "1220",
        "label": "DATE"
      },
      {
        "text": "59",
        "label": "CARDINAL"
      },
      {
        "text": "21-94",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "standard deviation: 11.18) were included. 1728 images were obtained before (A)",
    "entities": [
      {
        "text": "11.18",
        "label": "CARDINAL"
      },
      {
        "text": "1728",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and 2330 images after the 2021 software implementation (B), along with 269",
    "entities": [
      {
        "text": "2330",
        "label": "DATE"
      },
      {
        "text": "2021",
        "label": "DATE"
      },
      {
        "text": "269",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "images in 2022 (C1) and 250 images in 2023 (C2). The results indicated a",
    "entities": [
      {
        "text": "2022",
        "label": "DATE"
      },
      {
        "text": "C1",
        "label": "ORG"
      },
      {
        "text": "250",
        "label": "CARDINAL"
      },
      {
        "text": "2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "of 'Perfect' examinations rose from 22.34% to 32.27%, while 'Inadequate' images",
    "entities": [
      {
        "text": "22.34% to 32.27%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "decreased from 13.31% to 5.41% in 2021, continuing the positive trend with 4.46%",
    "entities": [
      {
        "text": "13.31% to 5.41%",
        "label": "PERCENT"
      },
      {
        "text": "2021",
        "label": "DATE"
      },
      {
        "text": "4.46%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "and 3.20% 'inadequate' images in 2022 and 2023, respectively (p < 0.01).",
    "entities": [
      {
        "text": "3.20%",
        "label": "PERCENT"
      },
      {
        "text": "2022",
        "label": "DATE"
      },
      {
        "text": "2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "CONCLUSION: Using a reliable software platform to perform AI-driven quality",
    "entities": []
  },
  {
    "text": "evaluation in real-time has the potential to make lasting improvements in image",
    "entities": []
  },
  {
    "text": "quality, support radiographers' professional growth, and elevate institutional",
    "entities": []
  },
  {
    "text": "quality standards and documentation simultaneously.",
    "entities": []
  },
  {
    "text": "KEY POINTS: Question How can AI-powered quality assessment reduce inadequate",
    "entities": []
  },
  {
    "text": "mammographic quality, which is known to impact sensitivity and increase the risk",
    "entities": []
  },
  {
    "text": "of interval cancers? Findings AI implementation decreased 'inadequate'",
    "entities": []
  },
  {
    "text": "mammograms from 13.31% to 3.20% and substantially improved parenchyma",
    "entities": [
      {
        "text": "13.31% to 3.20%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "visualization, with consistent subgroup trends. Clinical relevance By reducing",
    "entities": []
  },
  {
    "text": "'inadequate' mammograms and enhancing imaging quality, AI-driven tools improve",
    "entities": []
  },
  {
    "text": "diagnostic reliability and support better outcomes in breast cancer screening.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Compliance with ethical standards. Guarantor:",
    "entities": []
  },
  {
    "text": "The scientific guarantor of this publication is Noemi Schmidt. Conflict of",
    "entities": [
      {
        "text": "Noemi Schmidt",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "interest: Two of the authors (Karol Borkowski and Carlotta Ruppert) of this",
    "entities": [
      {
        "text": "Two",
        "label": "CARDINAL"
      },
      {
        "text": "Karol Borkowski",
        "label": "PERSON"
      },
      {
        "text": "Carlotta Ruppert",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "manuscript declare relationships with the following company: b-rayZ. Their",
    "entities": []
  },
  {
    "text": "involvement was restricted to providing software support and did not affect the",
    "entities": []
  },
  {
    "text": "research findings. The remaining authors declare no conflicts of interest.",
    "entities": []
  },
  {
    "text": "Statistics and biometry: One of the authors (Raphael Sexauer) has significant",
    "entities": [
      {
        "text": "One",
        "label": "CARDINAL"
      },
      {
        "text": "Raphael Sexauer",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "statistical expertise; however, no complex statistical methods were necessary",
    "entities": []
  },
  {
    "text": "for this paper. Informed consent: Written informed consent was waived by the",
    "entities": []
  },
  {
    "text": "Institutional Review Board (retrospective nature). Ethical approval:",
    "entities": [
      {
        "text": "Institutional Review Board",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institutional Review Board approval was obtained. Study subjects or cohorts",
    "entities": [
      {
        "text": "Institutional Review Board",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "overlap: No study subjects or cohorts have been previously reported.",
    "entities": []
  },
  {
    "text": "Methodology: Retrospective Observational study Performed at one institution",
    "entities": [
      {
        "text": "Retrospective Observational",
        "label": "ORG"
      },
      {
        "text": "one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "55. Nat Genet. 2025 Jul 15. doi: 10.1038/s41588-025-02250-x. Online ahead of",
    "entities": [
      {
        "text": "55",
        "label": "CARDINAL"
      },
      {
        "text": "Nat Genet",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Germline genetic variation impacts clonal hematopoiesis landscape and",
    "entities": []
  },
  {
    "text": "Liu J(1)(2), Tran D(2), Xue L(3), Wiley BJ(2), Vlasschaert C(4), Watson CJ(5),",
    "entities": [
      {
        "text": "Liu J(1)(2",
        "label": "PERSON"
      },
      {
        "text": "Tran D(2",
        "label": "PERSON"
      },
      {
        "text": "Xue L(3",
        "label": "PERSON"
      },
      {
        "text": "Wiley BJ(2",
        "label": "PERSON"
      },
      {
        "text": "Vlasschaert C(4",
        "label": "PERSON"
      },
      {
        "text": "Watson CJ(5",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "MacGregor HAJ(5)(6), Zong X(7), Chan ICC(2), Das I(2), Uddin MM(3), Niroula",
    "entities": [
      {
        "text": "MacGregor",
        "label": "ORG"
      },
      {
        "text": "Zong X(7",
        "label": "PERSON"
      },
      {
        "text": "Chan ICC(2",
        "label": "PERSON"
      },
      {
        "text": "Niroula",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Berger M(11), Zehir A(11), Ptashkin R(11), Levine RL(11), Papaemmanuil E(11),",
    "entities": [
      {
        "text": "Berger M(11",
        "label": "PERSON"
      },
      {
        "text": "Zehir A(11",
        "label": "PERSON"
      },
      {
        "text": "Ptashkin R(11",
        "label": "ORG"
      },
      {
        "text": "Levine RL(11",
        "label": "PERSON"
      },
      {
        "text": "Papaemmanuil E(11",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Cancer Biology Graduate Program, Washington University School of Medicine,",
    "entities": [
      {
        "text": "Biology Graduate Program",
        "label": "ORG"
      },
      {
        "text": "Washington University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Division of Oncology, Department of Medicine, Washington University School of",
    "entities": [
      {
        "text": "Oncology, Department of Medicine",
        "label": "ORG"
      },
      {
        "text": "Washington University School of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, St. Louis, MO, USA.",
    "entities": [
      {
        "text": "St. Louis",
        "label": "GPE"
      },
      {
        "text": "MO",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Program in Medical and Population Genetics and Cardiovascular Disease",
    "entities": []
  },
  {
    "text": "Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA.",
    "entities": [
      {
        "text": "Broad Institute of MIT",
        "label": "ORG"
      },
      {
        "text": "Harvard",
        "label": "ORG"
      },
      {
        "text": "Cambridge",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Medicine, Queen's University, Kingston, Ontario, Canada.",
    "entities": [
      {
        "text": "Medicine, Queen's University",
        "label": "ORG"
      },
      {
        "text": "Kingston",
        "label": "GPE"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Early Cancer Institute, University of Cambridge, Cambridge, UK.",
    "entities": [
      {
        "text": "5)Early",
        "label": "CARDINAL"
      },
      {
        "text": "Cancer Institute",
        "label": "ORG"
      },
      {
        "text": "University of Cambridge",
        "label": "ORG"
      },
      {
        "text": "Cambridge",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Centre for Cancer Genetic Epidemiology, Department of Public Health and",
    "entities": [
      {
        "text": "Cancer Genetic Epidemiology",
        "label": "ORG"
      },
      {
        "text": "Department of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Primary Care, University of Cambridge, Cambridge, UK.",
    "entities": [
      {
        "text": "Primary Care",
        "label": "ORG"
      },
      {
        "text": "University of Cambridge",
        "label": "ORG"
      },
      {
        "text": "Cambridge",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Division of Public Health Sciences, Department of Surgery, Washington",
    "entities": [
      {
        "text": "Public Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Department of Surgery",
        "label": "ORG"
      },
      {
        "text": "Washington",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University School of Medicine, St. Louis, MO, USA.",
    "entities": [
      {
        "text": "University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "St. Louis",
        "label": "GPE"
      },
      {
        "text": "MO",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Department of Medical Biochemistry and Cell Biology, Institute of",
    "entities": [
      {
        "text": "Medical Biochemistry and Cell Biology, Institute of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Biomedicine, University of Gothenburg, Gothenburg, Sweden.",
    "entities": [
      {
        "text": "University of Gothenburg",
        "label": "ORG"
      },
      {
        "text": "Gothenburg",
        "label": "GPE"
      },
      {
        "text": "Sweden",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)SciLifeLab, University of Gothenburg, Gothenburg, Sweden.",
    "entities": [
      {
        "text": "9)SciLifeLab, University of Gothenburg",
        "label": "ORG"
      },
      {
        "text": "Gothenburg",
        "label": "GPE"
      },
      {
        "text": "Sweden",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Division of Genetic Medicine, Department of Medicine, Vanderbilt University,",
    "entities": [
      {
        "text": "10)Division of Genetic Medicine, Department of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Nashville, TN, USA.",
    "entities": [
      {
        "text": "Nashville",
        "label": "GPE"
      },
      {
        "text": "TN",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Memorial Sloan-Kettering Cancer Center, New York, NY, USA.",
    "entities": [
      {
        "text": "11)Memorial",
        "label": "CARDINAL"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Department of Epidemiologic Methods and Etiologic Research, Leibniz",
    "entities": [
      {
        "text": "Epidemiologic Methods and Etiologic Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institute for Prevention Research and Epidemiology-BIPS and Faculty of Human and",
    "entities": [
      {
        "text": "Institute for Prevention Research and Epidemiology-BIPS and Faculty of Human",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Health Sciences, University of Bremen, Bremen, Germany.",
    "entities": [
      {
        "text": "Health Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Bremen, Bremen,",
        "label": "ORG"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(13)Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los",
    "entities": [
      {
        "text": "13)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Cedars-Sinai Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(14)Alvin J. Siteman Cancer Center, Washington University School of Medicine,",
    "entities": [
      {
        "text": "14)Alvin",
        "label": "CARDINAL"
      },
      {
        "text": "J. Siteman Cancer Center",
        "label": "ORG"
      },
      {
        "text": "Washington University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(15)Division of Gastroenterology, Department of Medicine, Washington University",
    "entities": [
      {
        "text": "Department of Medicine",
        "label": "ORG"
      },
      {
        "text": "Washington University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "School of Medicine, St. Louis, MO, USA.",
    "entities": [
      {
        "text": "School of Medicine",
        "label": "ORG"
      },
      {
        "text": "St. Louis",
        "label": "GPE"
      },
      {
        "text": "MO",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(16)Department of Biostatistics, Johns Hopkins Bloomberg School of Public",
    "entities": [
      {
        "text": "16)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Johns Hopkins Bloomberg School of Public",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Health, Baltimore, MD, USA.",
    "entities": [
      {
        "text": "Baltimore",
        "label": "GPE"
      },
      {
        "text": "MD",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(17)Division of Hematology/Oncology, Department of Medicine, and the Robert H.",
    "entities": [
      {
        "text": "Hematology/Oncology",
        "label": "ORG"
      },
      {
        "text": "Department of Medicine",
        "label": "ORG"
      },
      {
        "text": "Robert H.\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.",
    "entities": [
      {
        "text": "Lurie Comprehensive Cancer Center",
        "label": "ORG"
      },
      {
        "text": "Northwestern University",
        "label": "ORG"
      },
      {
        "text": "Chicago",
        "label": "GPE"
      },
      {
        "text": "IL",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(18)Division of Oncology, Department of Medicine, Washington University School",
    "entities": [
      {
        "text": "18)Division",
        "label": "CARDINAL"
      },
      {
        "text": "Department of Medicine",
        "label": "ORG"
      },
      {
        "text": "Washington University School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medicine, St. Louis, MO, USA. bolton@wustl.edu.",
    "entities": [
      {
        "text": "Medicine",
        "label": "GPE"
      },
      {
        "text": "St. Louis",
        "label": "GPE"
      },
      {
        "text": "MO",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "With age, clonal expansions occur pervasively across normal tissues yet only in",
    "entities": []
  },
  {
    "text": "rare instances lead to cancer, despite being driven by well-established cancer",
    "entities": []
  },
  {
    "text": "drivers. Characterization of the factors that influence clonal progression is",
    "entities": []
  },
  {
    "text": "needed to inform interventional approaches. Germline genetic variation",
    "entities": []
  },
  {
    "text": "influences cancer risk and shapes tumor mutational profile, but its influence on",
    "entities": []
  },
  {
    "text": "the mutational landscape of normal tissues is not well known. Here we studied",
    "entities": []
  },
  {
    "text": "the impact of germline genetic variation on clonal hematopoiesis (CH) in 731,835",
    "entities": [
      {
        "text": "731,835",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "individuals. We identified 22 new CH-predisposition genes, most of which",
    "entities": [
      {
        "text": "22",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "predispose to CH driven by specific mutational events. CH-predisposition genes",
    "entities": []
  },
  {
    "text": "contribute to unique somatic landscapes, reflecting the influence of germline",
    "entities": []
  },
  {
    "text": "genetic backdrop on gene-specific CH fitness. Correspondingly, somatic-germline",
    "entities": []
  },
  {
    "text": "interactions influence the risk of CH progression to hematologic malignancies.",
    "entities": []
  },
  {
    "text": "These results demonstrate that germline genetic variation influences somatic",
    "entities": []
  },
  {
    "text": "evolution in the blood, findings that likely extend to other tissues.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Competing interests: K.L.B. reports research",
    "entities": [
      {
        "text": "K.L.B.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "grants and personal fees from Servier. E.P. is the co-founder of and holds a",
    "entities": [
      {
        "text": "Servier",
        "label": "PERSON"
      },
      {
        "text": "E.P.",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "fiduciary role in Isabl Inc. P.N. reports research grants from Allelica, Amgen,",
    "entities": [
      {
        "text": "Isabl Inc.",
        "label": "ORG"
      },
      {
        "text": "P.N.",
        "label": "ORG"
      },
      {
        "text": "Allelica",
        "label": "GPE"
      },
      {
        "text": "Amgen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Apple, Boston Scientific, Genentech or Roche and Novartis; personal fees from",
    "entities": [
      {
        "text": "Apple",
        "label": "ORG"
      },
      {
        "text": "Boston Scientific",
        "label": "ORG"
      },
      {
        "text": "Genentech",
        "label": "ORG"
      },
      {
        "text": "Roche",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Bristol Myers Squibb,",
    "entities": [
      {
        "text": "Allelica",
        "label": "GPE"
      },
      {
        "text": "Apple",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Blackstone Life Sciences",
        "label": "ORG"
      },
      {
        "text": "Bristol Myers Squibb",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion",
    "entities": [
      {
        "text": "CRISPR Therapeutics",
        "label": "PERSON"
      },
      {
        "text": "Eli Lilly & Co",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Therapeutics, Foresite Capital, Foresite Labs, Genentech or Roche, GV,",
    "entities": [
      {
        "text": "Foresite Capital",
        "label": "ORG"
      },
      {
        "text": "Foresite Labs",
        "label": "PERSON"
      },
      {
        "text": "Genentech",
        "label": "ORG"
      },
      {
        "text": "Roche",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "HeartFlow, Magnet Biomedicine, Merck, Novartis, Novo Nordisk, TenSixteen Bio and",
    "entities": [
      {
        "text": "HeartFlow",
        "label": "ORG"
      },
      {
        "text": "Magnet Biomedicine",
        "label": "PERSON"
      },
      {
        "text": "Merck",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "GPE"
      },
      {
        "text": "Novo Nordisk",
        "label": "PERSON"
      },
      {
        "text": "TenSixteen Bio",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Tourmaline Bio; equity in Bolt, Candela, Mercury, MyOme, Parameter Health,",
    "entities": [
      {
        "text": "Tourmaline Bio",
        "label": "PERSON"
      },
      {
        "text": "Bolt",
        "label": "GPE"
      },
      {
        "text": "Candela",
        "label": "GPE"
      },
      {
        "text": "Mercury",
        "label": "ORG"
      },
      {
        "text": "MyOme, Parameter Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Preciseli and TenSixteen Bio; and spousal employment at Vertex Pharmaceuticals,",
    "entities": [
      {
        "text": "TenSixteen Bio",
        "label": "ORG"
      },
      {
        "text": "Vertex Pharmaceuticals",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "all unrelated to the present work. R.L.L. is on the Supervisory Board of QIAGEN",
    "entities": [
      {
        "text": "R.L.L.",
        "label": "ORG"
      },
      {
        "text": "the Supervisory Board",
        "label": "ORG"
      },
      {
        "text": "QIAGEN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(compensation or equity), a co-founder of or board member at Ajax (equity) and a",
    "entities": [
      {
        "text": "Ajax",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "scientific advisor to Mission Bio, Kurome, Anovia, Bakx, Syndax, Scorpion,",
    "entities": [
      {
        "text": "Mission Bio",
        "label": "PERSON"
      },
      {
        "text": "Kurome",
        "label": "GPE"
      },
      {
        "text": "Anovia",
        "label": "GPE"
      },
      {
        "text": "Bakx",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Zentalis, Auron, Prelude and C4 Therapeutics; for each of these entities he",
    "entities": [
      {
        "text": "Zentalis",
        "label": "GPE"
      },
      {
        "text": "Auron",
        "label": "PERSON"
      },
      {
        "text": "Prelude",
        "label": "PRODUCT"
      },
      {
        "text": "C4 Therapeutics",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "receives equity or compensation. He has received research support from the Cure",
    "entities": []
  },
  {
    "text": "Breast Cancer Foundation, Calico, Zentalis and Ajax, and has consulted for",
    "entities": [
      {
        "text": "Breast Cancer Foundation",
        "label": "ORG"
      },
      {
        "text": "Calico",
        "label": "GPE"
      },
      {
        "text": "Zentalis",
        "label": "GPE"
      },
      {
        "text": "Ajax",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Jubilant, Goldman Sachs, Incyte, AstraZeneca and Janssen. A.G.B. reports",
    "entities": [
      {
        "text": "Jubilant",
        "label": "PERSON"
      },
      {
        "text": "Goldman Sachs",
        "label": "ORG"
      },
      {
        "text": "Incyte",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "NORP"
      },
      {
        "text": "Janssen",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "personal fees and equity in TenSixteen Bio, all unrelated to this work. The",
    "entities": [
      {
        "text": "TenSixteen Bio",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "other authors declare no competing interests.",
    "entities": []
  },
  {
    "text": "AI-powered prediction model for neoadjuvant chemotherapy efficacy: comprehensive",
    "entities": []
  },
  {
    "text": "analysis of breast cancer histological images.",
    "entities": []
  },
  {
    "text": "(1)Department of Pathology, West China Hospital, Sichuan University, Chengdu,",
    "entities": [
      {
        "text": "Pathology",
        "label": "GPE"
      },
      {
        "text": "West China Hospital",
        "label": "ORG"
      },
      {
        "text": "Sichuan University",
        "label": "ORG"
      },
      {
        "text": "Chengdu",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Institute of Clinical Pathology, West China Hospital, Sichuan University,",
    "entities": [
      {
        "text": "2)Institute",
        "label": "CARDINAL"
      },
      {
        "text": "Clinical Pathology",
        "label": "ORG"
      },
      {
        "text": "West China Hospital",
        "label": "ORG"
      },
      {
        "text": "Sichuan University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chengdu, China.",
    "entities": [
      {
        "text": "Chengdu",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Pathology, The First Affiliated Hospital, Sun Yat-sen",
    "entities": [
      {
        "text": "Pathology",
        "label": "ORG"
      },
      {
        "text": "The First Affiliated Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Guangzhou, China.",
    "entities": [
      {
        "text": "Guangzhou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Pathology, Shanxi Province Cancer Hospital/Shanxi Hospital",
    "entities": [
      {
        "text": "Pathology",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer",
    "entities": [
      {
        "text": "Cancer Hospital",
        "label": "ORG"
      },
      {
        "text": "Chinese Academy of Medical Sciences/Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hospital Affiliated to Shanxi Medical University, Taiyuan, China.",
    "entities": [
      {
        "text": "Hospital Affiliated",
        "label": "FAC"
      },
      {
        "text": "Shanxi Medical University",
        "label": "ORG"
      },
      {
        "text": "Taiyuan",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Pathology, Sichuan Provincial People's Hospital, Chengdu,",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Pathology",
        "label": "GPE"
      },
      {
        "text": "Sichuan Provincial People's Hospital",
        "label": "ORG"
      },
      {
        "text": "Chengdu",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Pathology, The Affiliated Hospital of Southwest Medical",
    "entities": [
      {
        "text": "Pathology",
        "label": "ORG"
      },
      {
        "text": "The Affiliated Hospital of Southwest Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Luzhou, China.",
    "entities": [
      {
        "text": "Luzhou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Institute of Clinical Pathology, West China Hospital, Sichuan University,",
    "entities": [
      {
        "text": "Clinical Pathology",
        "label": "ORG"
      },
      {
        "text": "West China Hospital",
        "label": "ORG"
      },
      {
        "text": "Sichuan University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chengdu, China. yuhaoyi@scu.edu.cn.",
    "entities": [
      {
        "text": "Chengdu",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "yuhaoyi@scu.edu.cn",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(8)Institute of Clinical Pathology, West China Hospital, Sichuan University,",
    "entities": [
      {
        "text": "Clinical Pathology",
        "label": "ORG"
      },
      {
        "text": "West China Hospital",
        "label": "ORG"
      },
      {
        "text": "Sichuan University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chengdu, China. remy_yang@foxmail.com.",
    "entities": [
      {
        "text": "Chengdu",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Breast cancer patients exhibit variable responses to neoadjuvant therapy (NAT),",
    "entities": [
      {
        "text": "NAT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "necessitating robust predictive biomarkers. We developed an artificial",
    "entities": []
  },
  {
    "text": "intelligence (AI)-driven integrated predictive model (IPM) combining",
    "entities": []
  },
  {
    "text": "histopathological, clinical, and immune features to address this challenge.",
    "entities": []
  },
  {
    "text": "Using whole-slide images from 1035 patients across four centers, we compared",
    "entities": [
      {
        "text": "1035",
        "label": "DATE"
      },
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "tumor epithelium (TE-score), stroma (TS-score), and whole-tumor (TR-score) deep",
    "entities": [
      {
        "text": "stroma",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "learning biomarkers, identifying TR-score as optimal (AUC = 0.729 vs.",
    "entities": [
      {
        "text": "0.729",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "0.686/0.719 for TE/TS-scores). The IPM, incorporating TR-score and clinical",
    "entities": [
      {
        "text": "TE/TS-scores",
        "label": "ORG"
      },
      {
        "text": "IPM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "variables, demonstrated superior NAT response prediction versus",
    "entities": [
      {
        "text": "NAT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "clinicopathological models (validation AUC = 0.780 vs. 0.706, p < 0.001), with",
    "entities": [
      {
        "text": "0.780",
        "label": "CARDINAL"
      },
      {
        "text": "0.706",
        "label": "CARDINAL"
      },
      {
        "text": "p < 0.001",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "10% higher accuracy. Immune profiling further enhanced performance (AUC = 0.831",
    "entities": [
      {
        "text": "10%",
        "label": "PERCENT"
      },
      {
        "text": "0.831",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "vs. 0.822, p = 0.183). These results establish the biological and clinical",
    "entities": [
      {
        "text": "0.822",
        "label": "CARDINAL"
      },
      {
        "text": "0.183",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "validity of TR-score for characterizing tumor-stroma interactions, with IPM",
    "entities": [
      {
        "text": "IPM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "providing a generalizable framework for precision oncology. The model's",
    "entities": []
  },
  {
    "text": "stability across multicenter cohorts (AUCs 0.781-0.816) and incremental value of",
    "entities": [
      {
        "text": "0.781-0.816",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "immune data suggest its utility in guiding NAT decision-making and trial",
    "entities": [
      {
        "text": "NAT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Green synthesis of silver nanoparticles from plant Astragalus fasciculifolius",
    "entities": [
      {
        "text": "Astragalus",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Bioss and evaluating cytotoxic effects on MCF7 human breast cancer cells.",
    "entities": []
  },
  {
    "text": "(1)Department of Plant Breeding and Biotechnology, Faculty of Agriculture,",
    "entities": [
      {
        "text": "Plant Breeding and Biotechnology, Faculty of Agriculture",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Zabol, Zabol, Iran.",
    "entities": [
      {
        "text": "University of Zabol",
        "label": "ORG"
      },
      {
        "text": "Zabol",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Plant Breeding and Biotechnology, Faculty of Agriculture,",
    "entities": [
      {
        "text": "Plant Breeding and Biotechnology, Faculty of Agriculture",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Zabol, Zabol, Iran. Fakheri@uoz.ac.ir.",
    "entities": [
      {
        "text": "University of Zabol",
        "label": "ORG"
      },
      {
        "text": "Zabol",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Pharmacology Research Center, Zahedan University of Medical Sciences,",
    "entities": [
      {
        "text": "3)Pharmacology Research Center",
        "label": "ORG"
      },
      {
        "text": "Zahedan University of Medical Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Agronomy and Plant Breeding, Agriculture Institute, Research",
    "entities": [
      {
        "text": "Agronomy and Plant Breeding",
        "label": "ORG"
      },
      {
        "text": "Agriculture Institute, Research\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institute of Zabol, Zabol, Iran. bfazelinasab@gmail.com.",
    "entities": [
      {
        "text": "Institute of Zabol",
        "label": "ORG"
      },
      {
        "text": "Zabol",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Astragalus fasciculifolius Bioss, commonly known as Anzaroot, is a medicinal",
    "entities": [
      {
        "text": "Astragalus fasciculifolius Bioss",
        "label": "PERSON"
      },
      {
        "text": "Anzaroot",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "plant from the Fabaceae family, recognized for its therapeutic properties due to",
    "entities": [
      {
        "text": "Fabaceae",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "its rich composition of saponins, flavonoids, and polysaccharides. These",
    "entities": []
  },
  {
    "text": "compounds have been shown to effectively treat heart diseases and inhibit cancer",
    "entities": []
  },
  {
    "text": "cell growth while also alleviating chemotherapy side effects. Recent research",
    "entities": []
  },
  {
    "text": "has focused on the green synthesis of silver nanoparticles (AgNPs) from",
    "entities": [
      {
        "text": "AgNPs",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Anzaroot, exploring their potential cytotoxic effects against MCF-7 human breast",
    "entities": [
      {
        "text": "Anzaroot",
        "label": "GPE"
      },
      {
        "text": "MCF-7",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "cancer cells. This study aims to bridge traditional herbal medicine and modern",
    "entities": []
  },
  {
    "text": "nanotechnology by evaluating the anticancer properties of AgNPs derived from",
    "entities": [
      {
        "text": "AgNPs",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "this lesser-explored plant. This study was aimed to assess the cytotoxic effect",
    "entities": []
  },
  {
    "text": "of Anzaroot and green synthesized AgNPs using aqueous extract of Anzaroot on the",
    "entities": [
      {
        "text": "Anzaroot",
        "label": "GPE"
      },
      {
        "text": "AgNPs",
        "label": "GPE"
      },
      {
        "text": "Anzaroot",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "MCF-7 cell line. To optimization of AgNPs synthesis, different parameters were",
    "entities": [
      {
        "text": "MCF-7",
        "label": "CARDINAL"
      },
      {
        "text": "AgNPs",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "evaluated including Anzaroot aqueous extract volumes (1, 2, 3 and 4 ml), silver",
    "entities": [
      {
        "text": "Anzaroot",
        "label": "GPE"
      },
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "2",
        "label": "DATE"
      },
      {
        "text": "3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "nitrate solution (AgNO3) concentrations (1, 5 and 10 mM), reaction time (30, 60",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "5",
        "label": "DATE"
      },
      {
        "text": "10",
        "label": "CARDINAL"
      },
      {
        "text": "30",
        "label": "CARDINAL"
      },
      {
        "text": "60",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and 300 min) and reaction solution pH (2, 4, 6, 8 and 10) at room temperature.",
    "entities": [
      {
        "text": "300",
        "label": "CARDINAL"
      },
      {
        "text": "2, 4",
        "label": "DATE"
      },
      {
        "text": "6",
        "label": "DATE"
      },
      {
        "text": "8",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Transmission electron microscopy (TEM), Fourier transform infrared (FTIR)",
    "entities": [
      {
        "text": "TEM",
        "label": "ORG"
      },
      {
        "text": "Fourier",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "spectroscopy, ultraviolet-visible (UV-Vis) spectroscopy, and X-ray diffraction",
    "entities": []
  },
  {
    "text": "analysis (XRD) were used to characterization of the AgNPs using aqueous extract",
    "entities": [
      {
        "text": "XRD",
        "label": "ORG"
      },
      {
        "text": "AgNPs",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "of Anzaroot-silver nanoparticles (Anz@AgNPs). The obtained Anz@AgNPs exhibited",
    "entities": [
      {
        "text": "Anzaroot",
        "label": "GPE"
      },
      {
        "text": "Anz@AgNPs",
        "label": "GPE"
      },
      {
        "text": "Anz@AgNPs",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Surface Plasmon Resonance (SPR) centered at 443 nm, with an average particle",
    "entities": [
      {
        "text": "Surface Plasmon Resonance",
        "label": "PERSON"
      },
      {
        "text": "SPR",
        "label": "ORG"
      },
      {
        "text": "443",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "size calculated to be about 16 nm. The XRD spectrum of Anz@AgNPs showed a",
    "entities": [
      {
        "text": "about 16",
        "label": "CARDINAL"
      },
      {
        "text": "XRD",
        "label": "ORG"
      },
      {
        "text": "Anz@AgNPs",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "face-centred cubic (FCC) crystalline nature. The optimized parameters for",
    "entities": [
      {
        "text": "FCC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "successfully AgNPs synthesis were optained as follow: 4 ml aqueous extract",
    "entities": [
      {
        "text": "AgNPs",
        "label": "GPE"
      },
      {
        "text": "4 ml",
        "label": "QUANTITY"
      }
    ]
  },
  {
    "text": "volume, 1 and 5 mM AgNO3, reaction time of 300 min, and pH 8. MTT assay",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "5 mM AgNO3",
        "label": "QUANTITY"
      },
      {
        "text": "300",
        "label": "CARDINAL"
      },
      {
        "text": "MTT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "demonstrated the remarkable dependent dosage anticancer effect of the Anz@AgNPs",
    "entities": [
      {
        "text": "Anz@AgNPs",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "against MCF-7 cell line. The IC50 value exposed that The lowest and the highest",
    "entities": [
      {
        "text": "MCF-7",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "IC50 values was demonstrated for the Anz@AgNPs synthesized through the root",
    "entities": [
      {
        "text": "Anz@AgNPs",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "extract (21.73 \u03bcg/Ml) and the aqueous root extract (348.21 \u03bcg/Ml) treatment.",
    "entities": [
      {
        "text": "21.73",
        "label": "CARDINAL"
      },
      {
        "text": "348.21",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Based on the MTT assay, the Anz@AgNPs showed the inhibition of cell",
    "entities": [
      {
        "text": "MTT",
        "label": "ORG"
      },
      {
        "text": "Anz@AgNPs",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "proliferation potential more than the aqueous extract of this plant. The plant",
    "entities": []
  },
  {
    "text": "organs used in Anz@AgNPs synthesis, root and gum, influenced their anticancer",
    "entities": [
      {
        "text": "Anz@AgNPs",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "activity; nanoparticles synthesized from root extract demonstrated a stronger",
    "entities": []
  },
  {
    "text": "growth inhibitory effect than those from gum extract. The results demonstrated",
    "entities": []
  },
  {
    "text": "that anzroot plant can be effectively used as a reducing agent for AgNPs",
    "entities": [
      {
        "text": "AgNPs",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "synthesis, and AgNPs have the potential to be used effectively in cancer therapy",
    "entities": [
      {
        "text": "AgNPs",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "methods and to inhibit the growth of cancer cells.",
    "entities": []
  },
  {
    "text": "PMID: 40664749 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40664749",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "declare no competing interests. Ethics approval and consent to participate: No",
    "entities": []
  },
  {
    "text": "human or animals were used in the present research. Ethical issues: Ethical",
    "entities": []
  },
  {
    "text": "issues (including plagiarism, data fabrication, double publication) have been",
    "entities": []
  },
  {
    "text": "completely observed by the authors. The authors have adhered to ethical",
    "entities": []
  },
  {
    "text": "standards, including avoiding plagiarism, data fabrication, and double",
    "entities": []
  },
  {
    "text": "publication. Consent for publication: All authors read and approved the final",
    "entities": []
  },
  {
    "text": "manuscript for publication. Informed consent: The authors declare not used any",
    "entities": []
  },
  {
    "text": "patients in this research.",
    "entities": []
  },
  {
    "text": "Decision level scheme for fusing multiomics and histology slide images using",
    "entities": []
  },
  {
    "text": "deep neural network for tumor prognosis prediction.",
    "entities": []
  },
  {
    "text": "(1)Center for Biomedical Informatics, Shanghai Engineering Research Center for",
    "entities": [
      {
        "text": "1)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Biomedical Informatics",
        "label": "ORG"
      },
      {
        "text": "Shanghai Engineering Research Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Big Data in Pediatric Precision Medicine, Shanghai Children's Hospital,",
    "entities": [
      {
        "text": "Big Data",
        "label": "ORG"
      },
      {
        "text": "Shanghai Children's Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)SJTU-Yale Joint Center for Biostatistics and Data Science, Institute of",
    "entities": [
      {
        "text": "2)SJTU-Yale Joint Center for Biostatistics and Data Science, Institute of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.",
    "entities": [
      {
        "text": "Translational Medicine",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      },
      {
        "text": "Tong University",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Institute of Bioinformatics, Shanghai Academy of Experimental Medicine,",
    "entities": [
      {
        "text": "Bioinformatics",
        "label": "GPE"
      },
      {
        "text": "Shanghai Academy of Experimental Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)State Key Laboratory of Microbial Metabolism, Department of Bioinformatics",
    "entities": [
      {
        "text": "Key Laboratory",
        "label": "ORG"
      },
      {
        "text": "Microbial Metabolism,",
        "label": "ORG"
      },
      {
        "text": "Department of Bioinformatics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong",
    "entities": [
      {
        "text": "Biostatistics, School of Life Sciences and Biotechnology",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      },
      {
        "text": "Jiao Tong",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University, Shanghai, China.",
    "entities": [
      {
        "text": "University",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Center for Biomedical Informatics, Shanghai Engineering Research Center for",
    "entities": [
      {
        "text": "Biomedical Informatics",
        "label": "ORG"
      },
      {
        "text": "Shanghai Engineering Research Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)SJTU-Yale Joint Center for Biostatistics and Data Science, Institute of",
    "entities": [
      {
        "text": "6)SJTU",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Molecular biostatistical workflows in oncology often rely on predictive models",
    "entities": []
  },
  {
    "text": "that use multimodal data. Advances in deep learning and artificial intelligence",
    "entities": []
  },
  {
    "text": "technologies have enabled the multimodal fusion of large volumes of multimodal",
    "entities": []
  },
  {
    "text": "data. Here, we presented a decision level multimodal data fusion framework for",
    "entities": []
  },
  {
    "text": "integrating multiomics and pathological tissue slide images for prognosis",
    "entities": []
  },
  {
    "text": "prediction. Our approach established the spatial map of instances by connecting",
    "entities": []
  },
  {
    "text": "the neighboring nuclei in space and calculated the characteristic tensor via",
    "entities": []
  },
  {
    "text": "graph convolution layers for the input pathological tissue slide images. Global",
    "entities": []
  },
  {
    "text": "Average Pooling was applied to align and normalize the feature tensors from",
    "entities": [
      {
        "text": "Pooling",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "pathological images and the multiomics data, enabling seamless integration. We",
    "entities": []
  },
  {
    "text": "tested our proposed approach using Breast Invasive Carcinoma data and Non-Small",
    "entities": [
      {
        "text": "Breast Invasive Carcinoma",
        "label": "ORG"
      },
      {
        "text": "Non-Small",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cell Lung Cancer data from the Cancer Genome Atlas, which contains paired",
    "entities": [
      {
        "text": "Lung Cancer",
        "label": "PERSON"
      },
      {
        "text": "the Cancer Genome Atlas",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "whole-slide images, transcriptome data, genotype, epienetic, and survival",
    "entities": []
  },
  {
    "text": "information. In a 10-fold cross-validation, the comparison results demonstrated",
    "entities": [
      {
        "text": "10-fold",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "that the multimodal fusion paradigm improves outcome predictions from single",
    "entities": []
  },
  {
    "text": "modal data alone with the average C-index increasing from 0.61 to 0.52 to 0.75",
    "entities": [
      {
        "text": "0.61",
        "label": "CARDINAL"
      },
      {
        "text": "0.52 to 0.75",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and 0.67 for breast cancer and non-small cell lung cancer cohort, respectively.",
    "entities": [
      {
        "text": "0.67",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "The proposed decision level multimodal data fusion framework is expected to",
    "entities": []
  },
  {
    "text": "provide insights and technical methodologies for the follow-up studies.",
    "entities": []
  },
  {
    "text": "DOI: 10.1038/s41598-025-09869-0",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40664732 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "Author Correction: Palbociclib and dsRNA sensor co-operate to enhance",
    "entities": []
  },
  {
    "text": "anti-cancer effects through ER stress and modulation of immune evasion.",
    "entities": [
      {
        "text": "ER",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Roulstone V(#)(1), Kyula-Currie J(#)(2), Wright J(2), Patin EC(2), Dean I(2), Yu",
    "entities": [
      {
        "text": "Kyula-Currie",
        "label": "ORG"
      },
      {
        "text": "Wright",
        "label": "PERSON"
      },
      {
        "text": "Patin EC(2",
        "label": "PERSON"
      },
      {
        "text": "Dean",
        "label": "PERSON"
      },
      {
        "text": "Yu\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "L(2), Barreiro-Alonso A(2), Melake M(2), Choudhary J(2), Elliott R(3), Lord",
    "entities": [
      {
        "text": "Barreiro-Alonso",
        "label": "PERSON"
      },
      {
        "text": "M(2",
        "label": "CARDINAL"
      },
      {
        "text": "Elliott",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "CJ(3), Mansfield D(2), Matthews N(2), Chauhan R(2), Jennings V(2), Chan Wah Hak",
    "entities": [
      {
        "text": "Mansfield D(2",
        "label": "PERSON"
      },
      {
        "text": "Matthews",
        "label": "ORG"
      },
      {
        "text": "Chauhan",
        "label": "GPE"
      },
      {
        "text": "Jennings",
        "label": "PERSON"
      },
      {
        "text": "Chan Wah Hak",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "C(2), Baldock H(2), Butera F(2), Appleton E(2), Nenclares P(2), Pedersen M(2),",
    "entities": [
      {
        "text": "C(2",
        "label": "ORG"
      },
      {
        "text": "Butera",
        "label": "PERSON"
      },
      {
        "text": "Appleton",
        "label": "GPE"
      },
      {
        "text": "Nenclares",
        "label": "PERSON"
      },
      {
        "text": "Pedersen",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)The Institute of Cancer Research, London, UK. Victoria.Roulstone@icr.ac.uk.",
    "entities": [
      {
        "text": "1)The Institute of Cancer Research",
        "label": "ORG"
      },
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)The Institute of Cancer Research, London, UK.",
    "entities": [
      {
        "text": "2)The Institute of Cancer Research",
        "label": "ORG"
      },
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research",
    "entities": [
      {
        "text": "CRUK Gene Function Laboratory",
        "label": "ORG"
      },
      {
        "text": "Breast Cancer",
        "label": "PERSON"
      },
      {
        "text": "Toby Robins Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Centre, The Institute of Cancer Research, London, UK.",
    "entities": [
      {
        "text": "The Institute of Cancer Research",
        "label": "ORG"
      },
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Mayo Clinic, Rochester, MN, USA.",
    "entities": [
      {
        "text": "4)Mayo Clinic",
        "label": "ORG"
      },
      {
        "text": "Rochester",
        "label": "GPE"
      },
      {
        "text": "MN,",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)University of Surrey, Guildford, UK.",
    "entities": [
      {
        "text": "Surrey, Guildford",
        "label": "PERSON"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Nat Commun. 2025 May 25;16(1):4855. doi: 10.1038/s41467-025-60133-5.",
    "entities": [
      {
        "text": "Nat Commun",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "DOI: 10.1038/s41467-025-61212-3",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Unlocking tumor barrier: annexin A2-mediated transcytosis boosts drug delivery",
    "entities": [
      {
        "text": "A2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "in pancreatic and breast tumors.",
    "entities": []
  },
  {
    "text": "(1)CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety,",
    "entities": [
      {
        "text": "1)CAS",
        "label": "CARDINAL"
      },
      {
        "text": "Key Laboratory for Biomedical Effects of Nanomaterials",
        "label": "ORG"
      },
      {
        "text": "Nanosafety",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "National Center for Nanoscience and Technology, Beijing, China.",
    "entities": [
      {
        "text": "National Center for Nanoscience and Technology",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)University of Chinese Academy of Sciences, Beijing, China.",
    "entities": [
      {
        "text": "2)University",
        "label": "CARDINAL"
      },
      {
        "text": "Chinese Academy of Sciences",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese",
    "entities": [
      {
        "text": "Cancer Hospital",
        "label": "ORG"
      },
      {
        "text": "Hangzhou Institute of Medicine",
        "label": "ORG"
      },
      {
        "text": "Chinese",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Academy of Sciences, Hangzhou, China.",
    "entities": [
      {
        "text": "Academy of Sciences",
        "label": "ORG"
      },
      {
        "text": "Hangzhou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)National Institute of Metrology of China, Beijing, China.",
    "entities": [
      {
        "text": "Institute of Metrology of China",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)The University of New Mexico, Center for Micro-Engineering Materials,",
    "entities": [
      {
        "text": "5)The University of New Mexico",
        "label": "ORG"
      },
      {
        "text": "Center for Micro-Engineering Materials",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)College of Chemistry and Materials Science, and Institute of Nanotechnology",
    "entities": [
      {
        "text": "Chemistry and Materials Science",
        "label": "ORG"
      },
      {
        "text": "Institute of Nanotechnology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Intelligence (INAI), Jinan University, Guangzhou, China.",
    "entities": [
      {
        "text": "Intelligence (INAI)",
        "label": "ORG"
      },
      {
        "text": "Jinan University",
        "label": "ORG"
      },
      {
        "text": "Guangzhou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety,",
    "entities": [
      {
        "text": "Key Laboratory for Biomedical Effects of",
        "label": "ORG"
      },
      {
        "text": "Nanomaterials",
        "label": "GPE"
      },
      {
        "text": "Nanosafety",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "The efficacy of many cancer nanocarriers has traditionally been attributed to",
    "entities": []
  },
  {
    "text": "enlarged tumor vasculature fenestrations, giving rise to the concept of the",
    "entities": []
  },
  {
    "text": "enhanced permeability and retention (EPR) effect. However, emerging evidence",
    "entities": [
      {
        "text": "EPR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "suggests that active biological processes, such as transcytosis, may play a",
    "entities": []
  },
  {
    "text": "central (and sometimes dominant) role in nanoparticle transport across tumor",
    "entities": []
  },
  {
    "text": "vasculature. In this study, we develop lipid-coated mesoporous silica",
    "entities": []
  },
  {
    "text": "nanoparticles (LC-MSNP) as a model platform to investigate the contribution of",
    "entities": []
  },
  {
    "text": "surface-bound proteins to transcytosis-mediated tumor delivery. Through",
    "entities": []
  },
  {
    "text": "comparative analysis, we identify Annexin A2 (A2) as a key endogenous protein",
    "entities": [
      {
        "text": "Annexin A2",
        "label": "PERSON"
      },
      {
        "text": "A2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "that facilitates this process. Pre-coating LC-MSNP with A2 significantly",
    "entities": [
      {
        "text": "A2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "enhances the delivery of irinotecan and doxorubicin to breast and pancreatic",
    "entities": [
      {
        "text": "irinotecan",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "tumors in vivo. This strategy is successfully extended to both an in-house",
    "entities": []
  },
  {
    "text": "liposome formulation and a commercial doxorubicin liposome, leading to improved",
    "entities": []
  },
  {
    "text": "therapeutic efficacy, including long-term survival in a subset of treated mice.",
    "entities": []
  },
  {
    "text": "Mechanistic studies reveal that this enhancement is governed by a specific",
    "entities": []
  },
  {
    "text": "nanosurface-A2-\u03b15\u03b21 integrin interaction. In both murine and patient-derived",
    "entities": [
      {
        "text": "nanosurface-A2-\u03b15\u03b21",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "xenograft models, therapeutic benefit correlates with \u03b15\u03b21 integrin expression",
    "entities": [
      {
        "text": "xenograft",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "on tumor vasculature. These findings establish a mechanistic basis for",
    "entities": []
  },
  {
    "text": "protein-mediated transcytosis and provide a translational strategy to improve",
    "entities": []
  },
  {
    "text": "the performance of clinically approved nanomedicines.",
    "entities": []
  },
  {
    "text": "PMID: 40664649 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40664649",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "competing interests.61. Cell Prolif. 2025 Jul 15:e70100. doi: 10.1111/cpr.70100. Online ahead of",
    "entities": [
      {
        "text": "Cell Prolif",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1111",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Endocrine Resistance Score Based on Three Key Genes Predicts Prognosis and",
    "entities": []
  },
  {
    "text": "Reveals Potential Therapeutic Targets for ER+HER2- Breast Cancer.",
    "entities": [
      {
        "text": "Reveals Potential Therapeutic Targets",
        "label": "ORG"
      },
      {
        "text": "Breast Cancer",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Hematology, The First Affiliated Hospital of Guangzhou",
    "entities": [
      {
        "text": "Hematology",
        "label": "ORG"
      },
      {
        "text": "The First Affiliated Hospital",
        "label": "ORG"
      },
      {
        "text": "Guangzhou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University of Traditional Chinese Medicine, Guangzhou, China.",
    "entities": [
      {
        "text": "University of Traditional Chinese Medicine",
        "label": "ORG"
      },
      {
        "text": "Guangzhou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)The First People's Hospital of Foshan (The Affiliated Foshan Hospital of",
    "entities": [
      {
        "text": "First People's Hospital of Foshan",
        "label": "ORG"
      },
      {
        "text": "The Affiliated Foshan Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Southern University of Science and Technology), School of Medicine, Southern",
    "entities": [
      {
        "text": "Southern University of Science and Technology",
        "label": "ORG"
      },
      {
        "text": "School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Southern",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "University of Science and Technology, Foshan, China.",
    "entities": [
      {
        "text": "University of Science and Technology",
        "label": "ORG"
      },
      {
        "text": "Foshan",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)The First Affiliated Hospital, Hengyang Medical School, University of South",
    "entities": [
      {
        "text": "First Affiliated Hospital",
        "label": "ORG"
      },
      {
        "text": "Hengyang Medical School",
        "label": "ORG"
      },
      {
        "text": "University of South",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in",
    "entities": [
      {
        "text": "Yat-sen University Cancer Center",
        "label": "ORG"
      },
      {
        "text": "State Key Laboratory of Oncology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "South China, Collaborative Innovation Center for Cancer Medicine, Guangdong",
    "entities": [
      {
        "text": "South China",
        "label": "LOC"
      },
      {
        "text": "Collaborative Innovation Center for Cancer Medicine",
        "label": "ORG"
      },
      {
        "text": "Guangdong",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China.",
    "entities": [
      {
        "text": "Provincial Clinical Research Center for Cancer",
        "label": "ORG"
      },
      {
        "text": "Guangzhou",
        "label": "GPE"
      },
      {
        "text": "Guangdong",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Endocrine resistance is a leading cause of mortality in oestrogen",
    "entities": []
  },
  {
    "text": "receptor-positive and human epidermal growth factor receptor 2-negative",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(ER+HER2-) breast cancer (BC), highlighting the urgent need to understand its",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "underlying molecular mechanisms and identify potentially resistant patients for",
    "entities": []
  },
  {
    "text": "effective management. In this study, we constructed endocrine-resistant cell",
    "entities": []
  },
  {
    "text": "lines through long-term oestrogen deprivation and identified differentially",
    "entities": []
  },
  {
    "text": "expressed genes (DEGs) via transcriptome analysis. Key endocrine-resistant genes",
    "entities": []
  },
  {
    "text": "were defined through Cox regression analysis. Our findings revealed that the",
    "entities": [
      {
        "text": "Cox",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "genes CLEC3A, PCDH10, and ST3GAL1 were significantly upregulated in",
    "entities": [
      {
        "text": "CLEC3A",
        "label": "PERSON"
      },
      {
        "text": "PCDH10",
        "label": "PERSON"
      },
      {
        "text": "ST3GAL1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "endocrine-resistant cells and serve as independent prognostic factors for",
    "entities": []
  },
  {
    "text": "ER+HER2- BC patients. We developed an endocrine resistance score (ERS), and a",
    "entities": [
      {
        "text": "ER+HER2- BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "nomogram model incorporating ERS demonstrated robust predictive capabilities for",
    "entities": [
      {
        "text": "ERS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "patient prognosis. Single-cell RNA sequencing analysis demonstrated that the ERS",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      },
      {
        "text": "ERS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and the three core genes constituting the ERS were significantly upregulated in",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      },
      {
        "text": "ERS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "tissue specimens from patients with resistance to endocrine neoadjuvant therapy.",
    "entities": []
  },
  {
    "text": "Additionally, knocking down CLEC3A, PCDH10, and ST3GAL1 led to reduced",
    "entities": [
      {
        "text": "CLEC3A",
        "label": "PERSON"
      },
      {
        "text": "PCDH10",
        "label": "PERSON"
      },
      {
        "text": "ST3GAL1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "malignancy progression in endocrine-resistant BC cells. Mechanistic studies",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "revealed that CLEC3A promotes endocrine resistance by upregulating the PI3K-AKT",
    "entities": [
      {
        "text": "CLEC3A promotes",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "pathway. This study suggests that CLEC3A, PCDH10, and ST3GAL1 are associated",
    "entities": [
      {
        "text": "CLEC3A",
        "label": "PERSON"
      },
      {
        "text": "PCDH10",
        "label": "PERSON"
      },
      {
        "text": "ST3GAL1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "with endocrine resistance and can reflect the prognosis of ER+HER2- BC patients",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "receiving endocrine therapy, providing potential therapeutic targets and a",
    "entities": []
  },
  {
    "text": "\u00a9 2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Beijing Institute for Stem\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cell and Regenerative Medicine and John Wiley & Sons Ltd.",
    "entities": [
      {
        "text": "John Wiley & Sons Ltd.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "10.2967/jnmt.124.268823. Online ahead of print.",
    "entities": [
      {
        "text": "10.2967",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Bone SPECT/CT of an Intervertebral Disk Calcification.",
    "entities": [
      {
        "text": "SPECT/CT of an Intervertebral Disk Calcification",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Khan MA(1), Bashir H(2), Williams A(2).",
    "entities": [
      {
        "text": "Khan MA(1",
        "label": "PERSON"
      },
      {
        "text": "Bashir",
        "label": "PERSON"
      },
      {
        "text": "Williams A(2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Radiology, East Kent Hospitals University NHS Foundation Trust,",
    "entities": [
      {
        "text": "Radiology, East Kent Hospitals University NHS Foundation Trust",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Willesborough, United Kingdom; and muhammad.khan122@nhs.net.",
    "entities": [
      {
        "text": "United Kingdom",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Nuclear Medicine, East Kent Hospitals University NHS Foundation",
    "entities": [
      {
        "text": "East Kent Hospitals University NHS Foundation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Trust, Willesborough, United Kingdom.",
    "entities": [
      {
        "text": "Willesborough",
        "label": "GPE"
      },
      {
        "text": "United Kingdom",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Calcific diskitis (CD) is a rare condition characterized by inflammation and",
    "entities": []
  },
  {
    "text": "calcification of an intervertebral disk, typically causing localized back pain.",
    "entities": []
  },
  {
    "text": "We present the case of a 65-y-old woman with a history of breast cancer and",
    "entities": [
      {
        "text": "65-y-old",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "persistent back pain. SPECT/CT identified focal uptake at the T10-T11 vertebrae,",
    "entities": [
      {
        "text": "SPECT/CT",
        "label": "ORG"
      },
      {
        "text": "T10-T11",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "localized to the intervertebral disk. Retrospective review of MR images from",
    "entities": []
  },
  {
    "text": "2016 demonstrated a hypointense signal within the same disk on both T1- and",
    "entities": [
      {
        "text": "2016",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "T2-weighted images, consistent with disk calcification. This case highlights the",
    "entities": [
      {
        "text": "T2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "utility of SPECT/CT in identifying CD and distinguishing it from other",
    "entities": [
      {
        "text": "SPECT/CT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "pathologies, including metastatic or degenerative spinal disease. CD should be",
    "entities": []
  },
  {
    "text": "considered in the differential diagnoses of backache.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 by the Society of Nuclear Medicine and Molecular Imaging.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "the Society of Nuclear Medicine and Molecular Imaging",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Alternative splicing generates HER2 isoform diversity underlying antibody-drug",
    "entities": []
  },
  {
    "text": "conjugate resistance in breast cancer.",
    "entities": []
  },
  {
    "text": "(2)University of Manitoba.",
    "entities": [
      {
        "text": "2)University",
        "label": "CARDINAL"
      },
      {
        "text": "Manitoba",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)University of Wisconsin-Madison.",
    "entities": [
      {
        "text": "Wisconsin",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Breast cancer (BC) is a heterogeneous disease that can be molecularly classified",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "based on the expression of the ERBB2 receptor (also known as HER2) and hormone",
    "entities": [
      {
        "text": "ERBB2",
        "label": "ORG"
      },
      {
        "text": "HER2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "receptors. Targeted therapies for HER2-positive BC, such as trastuzumab,",
    "entities": [
      {
        "text": "HER2",
        "label": "GPE"
      },
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors, have improved",
    "entities": []
  },
  {
    "text": "patient outcomes but primary/acquired resistance still pose challenges that can",
    "entities": []
  },
  {
    "text": "limit treatments' long-term efficacy. Addressing these obstacles is vital for",
    "entities": []
  },
  {
    "text": "enhancing therapeutic strategies and patient care. Alternative splicing, a",
    "entities": []
  },
  {
    "text": "post-transcriptional mechanism that enhances transcript diversity (isoforms),",
    "entities": []
  },
  {
    "text": "can produce proteins with varied functions, cellular localizations, or binding",
    "entities": []
  },
  {
    "text": "properties. Here, we comprehensively characterized the HER2 alternative splicing",
    "entities": [
      {
        "text": "HER2",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "isoforms, assessed their expression in primary BC patients and cell lines, and",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "explored their role in resistance to anti-HER2 therapies. We expanded the",
    "entities": []
  },
  {
    "text": "catalog of known HER2 protein-coding isoforms from 13 to 90, revealing distinct",
    "entities": [
      {
        "text": "HER2",
        "label": "PERSON"
      },
      {
        "text": "13",
        "label": "CARDINAL"
      },
      {
        "text": "90",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "patterns of protein domains, cellular localizations, and protein structures,",
    "entities": []
  },
  {
    "text": "along with their antibody-binding sites. By profiling expression in 561 primary",
    "entities": [
      {
        "text": "561",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "BC samples and mass spectrometry data, we discovered a complex landscape of HER2",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      },
      {
        "text": "HER2",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "isoform, revealing novel transcripts that were previously unrecognized and are",
    "entities": []
  },
  {
    "text": "not assessed in routine clinical practice. Finally, the assessment of HER2",
    "entities": [
      {
        "text": "HER2",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "isoform expression in BC cell cultures sensitive or resistant to trastuzumab and",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "ADCs revealed that drug-resistant cells shifted their expression toward isoforms",
    "entities": []
  },
  {
    "text": "lacking antibody-binding domains. Our results broaden the understanding of HER2",
    "entities": [
      {
        "text": "HER2",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "isoforms, revealing distinct mechanisms of potential resistance to anti-HER2",
    "entities": [
      {
        "text": "anti-HER2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "therapies, particularly ADCs. This expanded landscape of HER2 isoforms",
    "entities": []
  },
  {
    "text": "emphasizes the crucial role of alternative splicing investigations in advancing",
    "entities": []
  },
  {
    "text": "precision-targeted cancer therapies.",
    "entities": []
  },
  {
    "text": "Published by Cold Spring Harbor Laboratory Press.",
    "entities": [
      {
        "text": "Cold Spring Harbor Laboratory Press",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CX-5461 inhibits cell proliferation and induces ferroptosis of colorectal cancer",
    "entities": []
  },
  {
    "text": "cells by inactivating Nrf2 pathway.",
    "entities": [
      {
        "text": "Nrf2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Central Laboratory, The Affiliated Hospital of Yanbian University, Yanji,",
    "entities": [
      {
        "text": "The Affiliated Hospital of Yanbian University",
        "label": "ORG"
      },
      {
        "text": "Yanji",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "China; Key Laboratory of Pathobiology (Yanbian University), State Ethnic Affairs",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "Key Laboratory of Pathobiology",
        "label": "ORG"
      },
      {
        "text": "State Ethnic Affairs",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Key Laboratory of Pathobiology (Yanbian University), State Ethnic Affairs",
    "entities": [
      {
        "text": "2)Key Laboratory of Pathobiology (Yanbian University",
        "label": "ORG"
      },
      {
        "text": "State Ethnic Affairs",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Central Laboratory, The Affiliated Hospital of Yanbian University, Yanji,",
    "entities": [
      {
        "text": "The Affiliated Hospital of Yanbian University",
        "label": "ORG"
      },
      {
        "text": "Yanji",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "China; Department of ophthalmology, Affiliated Hospital of Yanbian University,",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "Affiliated Hospital of Yanbian University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Central Laboratory, The Affiliated Hospital of Yanbian University, Yanji,",
    "entities": [
      {
        "text": "The Affiliated Hospital of Yanbian University",
        "label": "ORG"
      },
      {
        "text": "Yanji",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Ferroptosis is a newly identified type of cell death, characterized by iron",
    "entities": []
  },
  {
    "text": "dependent lipid peroxidation. Triggering ferroptosis is considered a promising",
    "entities": []
  },
  {
    "text": "target, and efforts have been made to identify ferroptosis inducers in cancer.",
    "entities": []
  },
  {
    "text": "CX-5461 is a RNA polymerase I inhibitors that has been approved by FDA to treat",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      },
      {
        "text": "FDA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "breast and ovarian cancer patients with BRCA1/2 mutations. In our previous",
    "entities": []
  },
  {
    "text": "study, we found that CX-5461 inhibited GSH synthesis and promote lipid",
    "entities": []
  },
  {
    "text": "peroxidation in colorectal cancer (CRC) cells, suggesting that CX-5461 could",
    "entities": [
      {
        "text": "CRC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "induce ferroptosis. Therefore, we aim to elucidate the anti-cancer activity of",
    "entities": []
  },
  {
    "text": "CX-5461 in CRC,and the mechanisms of CX-5461-mediated ferroptosis. As a result,",
    "entities": [
      {
        "text": "CRC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "we found that CX-5461 inhibited the proliferation of CRC cells, determined by",
    "entities": [
      {
        "text": "CRC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CCK-8, EdU and colony formation assay. RNA-seq analysis suggested that",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "differentially expressed genes (DEGs) were related to cell adhesion molecular,",
    "entities": []
  },
  {
    "text": "focal adhesion, and cell cycle, etc. Consistently, we observed that CX-5461",
    "entities": []
  },
  {
    "text": "induced cell cycle arrest, and inhibited migration, invasion and EMT progression",
    "entities": [
      {
        "text": "EMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "in CRC cells. Of note, the GSH, SLC7A11 and GPX4 were decreased in CX-5462",
    "entities": [
      {
        "text": "CRC",
        "label": "ORG"
      },
      {
        "text": "GSH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "treated CRC cells, meanwhile ROS, MDA, and lipid ROS were increased.",
    "entities": [
      {
        "text": "CRC",
        "label": "ORG"
      },
      {
        "text": "ROS",
        "label": "ORG"
      },
      {
        "text": "MDA",
        "label": "ORG"
      },
      {
        "text": "ROS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Furthermore, CX-5461 down-regulated Nrf2. Nrf2 activator THBQ successfully",
    "entities": [
      {
        "text": "Nrf2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "reversed the effect of CX-5461 on cell proliferation and ferroptosis.",
    "entities": []
  },
  {
    "text": "Mechanically, CX-5461 induces ubiquitinization of Nrf2. The decreased Nrf2",
    "entities": [
      {
        "text": "Nrf2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "subsequently down-regulates SLC7A11 and GPX4. In conclusion, these results",
    "entities": []
  },
  {
    "text": "demonstrated that CX-5461 induced ferroptosis through inhibiting SLC7A11/GPX4",
    "entities": []
  },
  {
    "text": "axis by promoting ubiquitinization of Nrf2 in CRC cells, suggesting that CX-5461",
    "entities": [
      {
        "text": "Nrf2",
        "label": "ORG"
      },
      {
        "text": "CRC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "may be a valuable candidate for anti-cancer agent in CRC.",
    "entities": [
      {
        "text": "CRC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Copyright \u00a9 2025. Published by Elsevier Inc.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Elsevier Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declaration of competing interest The authors",
    "entities": []
  },
  {
    "text": "declare the following financial interests/personal relationships which may be",
    "entities": []
  },
  {
    "text": "considered as potential competing interests:",
    "entities": []
  },
  {
    "text": "The association between perinatal maternal mental health during the COVID-19",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "pandemic and offspring neurodevelopment at 24 months of age.",
    "entities": [
      {
        "text": "24 months of age",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Huddleston R(6), Julian-Kwong M(7), Corley J(8), Hoskin E(9), Lindquist KJ(10).",
    "entities": [
      {
        "text": "Huddleston",
        "label": "ORG"
      },
      {
        "text": "Julian-Kwong",
        "label": "NORP"
      },
      {
        "text": "Corley J(8",
        "label": "PERSON"
      },
      {
        "text": "Lindquist",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Center for Reproductive Health, 499 Illinois Street, 6th Floor, University of",
    "entities": [
      {
        "text": "Reproductive Health",
        "label": "ORG"
      },
      {
        "text": "499",
        "label": "CARDINAL"
      },
      {
        "text": "Illinois Street",
        "label": "ORG"
      },
      {
        "text": "6th Floor, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)School of Public Health, 2121 Berkeley Way, University of California,",
    "entities": [
      {
        "text": "2121",
        "label": "DATE"
      },
      {
        "text": "Berkeley Way",
        "label": "ORG"
      },
      {
        "text": "University of California",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Berkeley, Berkeley, CA 94704, USA. Electronic address: kgeisler@berkeley.edu.",
    "entities": [
      {
        "text": "Berkeley",
        "label": "GPE"
      },
      {
        "text": "Berkeley",
        "label": "GPE"
      },
      {
        "text": "CA 94704",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Center for Reproductive Health, 499 Illinois Street, 6th Floor, University of",
    "entities": [
      {
        "text": "Reproductive Health",
        "label": "ORG"
      },
      {
        "text": "499",
        "label": "CARDINAL"
      },
      {
        "text": "Illinois Street",
        "label": "ORG"
      },
      {
        "text": "6th Floor, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Center for Reproductive Health, 499 Illinois Street, 6th Floor, University of",
    "entities": [
      {
        "text": "Reproductive Health",
        "label": "ORG"
      },
      {
        "text": "499",
        "label": "CARDINAL"
      },
      {
        "text": "Illinois Street",
        "label": "ORG"
      },
      {
        "text": "6th Floor, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Center for Reproductive Health, 499 Illinois Street, 6th Floor, University of",
    "entities": [
      {
        "text": "Reproductive Health",
        "label": "ORG"
      },
      {
        "text": "499",
        "label": "CARDINAL"
      },
      {
        "text": "Illinois Street",
        "label": "ORG"
      },
      {
        "text": "6th Floor, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Depertment of Integrative Biology, 45 Noland Hall, 250 N Mills St, University",
    "entities": [
      {
        "text": "Integrative Biology",
        "label": "ORG"
      },
      {
        "text": "45",
        "label": "DATE"
      },
      {
        "text": "Noland Hall",
        "label": "PERSON"
      },
      {
        "text": "250",
        "label": "CARDINAL"
      },
      {
        "text": "N Mills St",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Wisconsin-Madison, Madison, WI 53706, USA. Electronic address:",
    "entities": [
      {
        "text": "Wisconsin",
        "label": "GPE"
      },
      {
        "text": "Madison",
        "label": "PERSON"
      },
      {
        "text": "WI 53706",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Department of Neuroscience, Box G-LN, Brown University, Providence, RI 02912,",
    "entities": [
      {
        "text": "Neuroscience",
        "label": "ORG"
      },
      {
        "text": "Box G-LN",
        "label": "PERSON"
      },
      {
        "text": "Brown University",
        "label": "ORG"
      },
      {
        "text": "Providence",
        "label": "GPE"
      },
      {
        "text": "RI 02912",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(8)Center for Reproductive Health, 499 Illinois Street, 6th Floor, University of",
    "entities": [
      {
        "text": "8)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Reproductive Health",
        "label": "ORG"
      },
      {
        "text": "499",
        "label": "CARDINAL"
      },
      {
        "text": "Illinois Street",
        "label": "ORG"
      },
      {
        "text": "6th Floor, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(9)Center for Reproductive Health, 499 Illinois Street, 6th Floor, University of",
    "entities": [
      {
        "text": "Reproductive Health",
        "label": "ORG"
      },
      {
        "text": "499",
        "label": "CARDINAL"
      },
      {
        "text": "Illinois Street",
        "label": "ORG"
      },
      {
        "text": "6th Floor, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(10)Center for Reproductive Health, 499 Illinois Street, 6th Floor, University",
    "entities": [
      {
        "text": "10)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Reproductive Health",
        "label": "ORG"
      },
      {
        "text": "499",
        "label": "CARDINAL"
      },
      {
        "text": "Illinois Street",
        "label": "ORG"
      },
      {
        "text": "6th Floor, University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:",
    "entities": [
      {
        "text": "California",
        "label": "GPE"
      },
      {
        "text": "San Francisco",
        "label": "GPE"
      },
      {
        "text": "San Francisco",
        "label": "GPE"
      },
      {
        "text": "CA 94158",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Prenatal anxiety and depression have been linked to adverse",
    "entities": []
  },
  {
    "text": "childhood neurodevelopment, potentially through cortisol-induced epigenetic",
    "entities": []
  },
  {
    "text": "changes. Postpartum depression is also associated with neurodevelopmental",
    "entities": []
  },
  {
    "text": "mental health may be correlated, their relative and independent impacts on",
    "entities": []
  },
  {
    "text": "offspring neurodevelopment remain unclear. This study examines the effects of",
    "entities": []
  },
  {
    "text": "prenatal and postpartum anxiety and/or depression on neurodevelopmental delay at",
    "entities": []
  },
  {
    "text": "24 months.",
    "entities": [
      {
        "text": "24 months",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "METHODS: In a nationwide prospective cohort from the \"Assessing the Safety of",
    "entities": [
      {
        "text": "Assessing the Safety of\n",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "Pregnancy in the Coronavirus Pandemic\" study, prenatal anxiety (GAD-7), prenatal",
    "entities": [
      {
        "text": "GAD-7",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "depression (PHQ-9), and six-week postpartum depression (EPDS) were assessed.",
    "entities": [
      {
        "text": "six-week",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Childhood neurodevelopment was measured using the Ages and Stages Questionnaire,",
    "entities": [
      {
        "text": "Childhood",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "3rd edition (ASQ-3). Logistic regression tested associations between",
    "entities": [
      {
        "text": "3rd",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "moderate-to-severe maternal anxiety/depression and neurodevelopmental delay,",
    "entities": []
  },
  {
    "text": "adjusting for participant age, education, household income, and residential",
    "entities": []
  },
  {
    "text": "density. Alcohol, nicotine, anxiety/depression medication use during pregnancy,",
    "entities": []
  },
  {
    "text": "and preterm birth were considered as moderators/mediators.",
    "entities": []
  },
  {
    "text": "RESULTS: Offspring of participants experiencing both prenatal and postpartum",
    "entities": []
  },
  {
    "text": "moderate-to-severe anxiety or depression (N = 62) had a higher risk of",
    "entities": [
      {
        "text": "62",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "neurodevelopmental delay at 24 months compared to those who experienced neither",
    "entities": [
      {
        "text": "24 months",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(N = 1060) with an adjusted risk ratio of 1.88 (p < 0.001). While delay risk was",
    "entities": [
      {
        "text": "1060",
        "label": "DATE"
      },
      {
        "text": "1.88",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "higher in offspring of those with only prenatal (N = 218) or postpartum (N = 45)",
    "entities": [
      {
        "text": "218",
        "label": "CARDINAL"
      },
      {
        "text": "45",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "anxiety/depression, these were not statistically significant.",
    "entities": []
  },
  {
    "text": "CONCLUSION: Having both moderate-to-severe prenatal and postpartum anxiety or",
    "entities": []
  },
  {
    "text": "depression independently increased the risk of developmental delay at 24 months,",
    "entities": [
      {
        "text": "24 months",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "even after adjusting for confounders. Further research is needed to explore",
    "entities": []
  },
  {
    "text": "underlying mechanisms linking maternal mental health and fetal neurodevelopment.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025. Published by Elsevier B.V.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Elsevier B.V.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "considered as potential competing interests: Marcelle I. Cedars reports",
    "entities": [
      {
        "text": "Marcelle I. Cedars",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "financial support was provided by Start Smal Foundation. Marcelle I. Cedars",
    "entities": [
      {
        "text": "Start Smal Foundation",
        "label": "ORG"
      },
      {
        "text": "Marcelle I. Cedars",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "reports financial support was provided by California Breast Cancer Research",
    "entities": [
      {
        "text": "California Breast Cancer Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Program. Marcelle I. Cedars reports financial support was provided by COVID",
    "entities": [
      {
        "text": "Marcelle I. Cedars",
        "label": "PERSON"
      },
      {
        "text": "COVID",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Catalyst Award. Marcelle I. Cedars reports financial support was provided by",
    "entities": [
      {
        "text": "Marcelle I. Cedars",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "AbbVie Inc. Marcelle I. Cedars reports financial support was provided by Ferring",
    "entities": [
      {
        "text": "AbbVie Inc.",
        "label": "ORG"
      },
      {
        "text": "Marcelle I. Cedars",
        "label": "PERSON"
      },
      {
        "text": "Ferring\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Pharmaceuticals. Marcelle I. Cedars reports administrative support was provided",
    "entities": [
      {
        "text": "Marcelle I. Cedars",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "by The Society for Assisted Reproductive Technology. Heather G. Huddleston",
    "entities": [
      {
        "text": "The Society for Assisted Reproductive Technology",
        "label": "ORG"
      },
      {
        "text": "G. Huddleston",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "reports a relationship with Allara Health that includes: consulting or advisory.",
    "entities": [
      {
        "text": "Allara Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Heather G. Huddleston reports a relationship with May Health that includes:",
    "entities": [
      {
        "text": "G. Huddleston",
        "label": "PERSON"
      },
      {
        "text": "May Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "funding grants. Heather G. Huddleston reports a relationship with Rejoni that",
    "entities": [
      {
        "text": "G. Huddleston",
        "label": "PERSON"
      },
      {
        "text": "Rejoni",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "includes: funding grants. Marcelle I. Cedars reports a relationship with",
    "entities": [
      {
        "text": "Marcelle I. Cedars",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "American Society for Reproductive Medicine that includes: board membership.",
    "entities": [
      {
        "text": "American Society for Reproductive Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Marcelle I. Cedars reports a relationship with American Gynecological &",
    "entities": [
      {
        "text": "Marcelle I. Cedars",
        "label": "PERSON"
      },
      {
        "text": "American Gynecological &\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Obstetrical Society that includes: board membership. Marcelle I. Cedars reports",
    "entities": [
      {
        "text": "Marcelle I. Cedars",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "a relationship with UptoDate Inc. that includes: consulting or advisory. Eleni",
    "entities": [
      {
        "text": "UptoDate Inc.",
        "label": "ORG"
      },
      {
        "text": "Eleni\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "G. Jaswa reports a relationship with Oura Health that includes: consulting or",
    "entities": [
      {
        "text": "G. Jaswa",
        "label": "PERSON"
      },
      {
        "text": "Oura Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "advisory. If there are other authors, they declare that they have no known",
    "entities": []
  },
  {
    "text": "competing financial interests or personal relationships that could have appeared",
    "entities": []
  },
  {
    "text": "to influence the work reported in this paper.",
    "entities": []
  },
  {
    "text": "One-pot multi-component synthesis and biological evaluation of spirooxindole",
    "entities": [
      {
        "text": "One",
        "label": "CARDINAL"
      },
      {
        "text": "spirooxindole",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "carbamate derivatives of major flavonoids isolated from oroxylum indicum:",
    "entities": []
  },
  {
    "text": "Identification of potent anti-proliferative leads active against hepatocellular",
    "entities": []
  },
  {
    "text": "(1)Division of Natural Products and Medicinal Chemistry, CSIR-Indian Institute",
    "entities": []
  },
  {
    "text": "of Chemical Technology, Hyderabad 500 007, India; Academy of Scientific and",
    "entities": [
      {
        "text": "Chemical Technology",
        "label": "ORG"
      },
      {
        "text": "500 007",
        "label": "CARDINAL"
      },
      {
        "text": "India",
        "label": "GPE"
      },
      {
        "text": "Academy of Scientific",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Innovative Research (AcSIR), Ghaziabad 201002, India.",
    "entities": [
      {
        "text": "Innovative Research (AcSIR",
        "label": "ORG"
      },
      {
        "text": "Ghaziabad",
        "label": "GPE"
      },
      {
        "text": "201002",
        "label": "DATE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Division of Natural Products and Medicinal Chemistry, CSIR-Indian Institute",
    "entities": [
      {
        "text": "Natural Products",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Chemical Technology, Hyderabad 500 007, India.",
    "entities": [
      {
        "text": "Chemical Technology",
        "label": "ORG"
      },
      {
        "text": "500 007",
        "label": "CARDINAL"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002,",
    "entities": [
      {
        "text": "3)Academy",
        "label": "CARDINAL"
      },
      {
        "text": "Scientific and Innovative Research",
        "label": "ORG"
      },
      {
        "text": "Ghaziabad",
        "label": "GPE"
      },
      {
        "text": "201002",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "India; Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad",
    "entities": [
      {
        "text": "India",
        "label": "GPE"
      },
      {
        "text": "Applied Biology",
        "label": "ORG"
      },
      {
        "text": "Institute of Chemical Technology",
        "label": "ORG"
      },
      {
        "text": "Hyderabad",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002,",
    "entities": [
      {
        "text": "Scientific and Innovative Research",
        "label": "ORG"
      },
      {
        "text": "Ghaziabad",
        "label": "GPE"
      },
      {
        "text": "201002",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "India; Center for X-ray Crystallography, Department of Analytical and Structural",
    "entities": [
      {
        "text": "India",
        "label": "GPE"
      },
      {
        "text": "Crystallography, Department of Analytical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad 500 007,",
    "entities": [
      {
        "text": "Institute of Chemical Technology",
        "label": "ORG"
      },
      {
        "text": "500 007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(5)Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002,",
    "entities": [
      {
        "text": "5)Academy",
        "label": "CARDINAL"
      },
      {
        "text": "Scientific and Innovative Research",
        "label": "ORG"
      },
      {
        "text": "Ghaziabad",
        "label": "GPE"
      },
      {
        "text": "201002",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(6)Division of Natural Products and Medicinal Chemistry, CSIR-Indian Institute",
    "entities": []
  },
  {
    "text": "Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address:",
    "entities": [
      {
        "text": "Innovative Research (AcSIR",
        "label": "ORG"
      },
      {
        "text": "Ghaziabad",
        "label": "GPE"
      },
      {
        "text": "201002",
        "label": "DATE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "A series of 30 novel spirooxindole carbamate derivatives of flavonoids (chrysin,",
    "entities": [
      {
        "text": "30",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "oroxylin A and baicailein) were synthesized in a one-pot three-component",
    "entities": [
      {
        "text": "one",
        "label": "CARDINAL"
      },
      {
        "text": "three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "reaction via a sequence of Knoevenagel condensation, cyclization reactions in a",
    "entities": [
      {
        "text": "Knoevenagel",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "highly efficient and selective manner. The structures of all the derivatives",
    "entities": []
  },
  {
    "text": "(6a-6 l, 7a-7 l and 8a-8f) were characterized by interpretation of NMR (1H NMR,",
    "entities": [
      {
        "text": "6a-6",
        "label": "CARDINAL"
      },
      {
        "text": "NMR",
        "label": "ORG"
      },
      {
        "text": "1H",
        "label": "CARDINAL"
      },
      {
        "text": "NMR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "13C NMR) and mass spectral data. The structures of the compounds 6d and 7f were",
    "entities": [
      {
        "text": "13C",
        "label": "CARDINAL"
      },
      {
        "text": "NMR",
        "label": "ORG"
      },
      {
        "text": "6d",
        "label": "CARDINAL"
      },
      {
        "text": "7f",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "further confirmed by single-crystal X-ray diffraction for the first time. The",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "anti-proliferative potential of these derivatives was assessed against various",
    "entities": []
  },
  {
    "text": "cancer cells such as A549 (lung), MDA-MB-231 (breast), HeLa (cervical), HepG2",
    "entities": [
      {
        "text": "A549",
        "label": "PRODUCT"
      },
      {
        "text": "HeLa",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(liver), and HEK 293 (normal kidney) cell lines using the Sulforhodamine-B",
    "entities": []
  },
  {
    "text": "assay. Among all tested compounds, 6d exhibited the most potent",
    "entities": [
      {
        "text": "6d",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "anti-proliferative activity, with an IC\u2085\u2080 of 2.50 \u00b1 0.25 \u03bcM against the HepG2",
    "entities": [
      {
        "text": "2.50",
        "label": "CARDINAL"
      },
      {
        "text": "0.25",
        "label": "CARDINAL"
      },
      {
        "text": "HepG2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cell line. Compound 6d significantly enhanced early apoptosis in comparison to",
    "entities": [
      {
        "text": "6d",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "control cells and markedly (p < 0.001) reduced the population of CD133+ cancer",
    "entities": [
      {
        "text": "CD133",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "stem-like cells, which are critical mediators of metastasis and drug resistance.",
    "entities": []
  },
  {
    "text": "Molecular docking studies revealed a strong interactions between compound 6d and",
    "entities": [
      {
        "text": "6d",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "critical residues of CD133, including Phe787, Val794, Phe62, Lys791, and Leu5,",
    "entities": [
      {
        "text": "CD133",
        "label": "PRODUCT"
      },
      {
        "text": "Phe787",
        "label": "GPE"
      },
      {
        "text": "Val794",
        "label": "GPE"
      },
      {
        "text": "Lys791",
        "label": "GPE"
      },
      {
        "text": "Leu5",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "with a binding affinity of -10.2 kcal/mol. Furthermore, compound 6d treatment",
    "entities": [
      {
        "text": "6d",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "reduced sphere formation in a dose-dependent manner in HepG2 cells. In vivo",
    "entities": []
  },
  {
    "text": "studies using a xenograft model demonstrated that compound 6d significantly",
    "entities": [
      {
        "text": "6d",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "suppressed tumor growth and reduced tumor weight, indicating its potential as a",
    "entities": []
  },
  {
    "text": "promising therapeutic candidate for hepatocellular carcinoma.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Elsevier Inc. All rights reserved.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "declare that they have no known competing financial interests or personal",
    "entities": []
  },
  {
    "text": "relationships that could have appeared to influence the work reported in this",
    "entities": []
  },
  {
    "text": "10.1016/j.compbiomed.2025.110771. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Therapeutic targeting of triple-negative breast cancer: A multi-model evaluation",
    "entities": []
  },
  {
    "text": "of LNA-anti-miR-19b-3p and small molecule inhibitors.",
    "entities": []
  },
  {
    "text": "(1)Cellular and Molecular Biology Research Center, Health Research Institute,",
    "entities": [
      {
        "text": "Molecular Biology Research Center",
        "label": "ORG"
      },
      {
        "text": "Health Research Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Babol University of Medical Sciences, Babol, Iran; Department of Medical",
    "entities": [
      {
        "text": "Babol University of Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Babol",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      },
      {
        "text": "Department of Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Genetics, School of Medicine, Babol University of Medical Sciences, Babol, Iran.",
    "entities": [
      {
        "text": "Genetics, School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Babol University of Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Babol",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Student Research Committee, Babol University of Medical Sciences, Babol,",
    "entities": [
      {
        "text": "Research Committee",
        "label": "ORG"
      },
      {
        "text": "Babol University of Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Babol",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(3)Department of Medical Genetics, School of Medicine, Babol University of",
    "entities": [
      {
        "text": "Medical Genetics, School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Babol University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Deputy of Research and Technology, Babol University of Medical Sciences,",
    "entities": [
      {
        "text": "Research and Technology",
        "label": "ORG"
      },
      {
        "text": "Babol University of Medical Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Cell & Molecular Biology, Faculty of Biological Sciences,",
    "entities": [
      {
        "text": "Cell & Molecular Biology, Faculty of Biological Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Kharazmi University, Tehran, Iran.",
    "entities": [
      {
        "text": "Kharazmi University",
        "label": "ORG"
      },
      {
        "text": "Tehran",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Cellular and Molecular Biology Research Center, Health Research Institute,",
    "entities": [
      {
        "text": "Molecular Biology Research Center",
        "label": "ORG"
      },
      {
        "text": "Health Research Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The potential of inhibiting hsa-miR-19b-3p as a therapeutic approach for",
    "entities": []
  },
  {
    "text": "triple-negative breast cancer (TNBC) was investigated. To explore this, we",
    "entities": []
  },
  {
    "text": "studied the function of hsa-miR-19b-3p in TNBC cells, specifically the",
    "entities": []
  },
  {
    "text": "MDA-MB-231 cell line. We transfected these cells with LNA-anti-miR to inhibit",
    "entities": [
      {
        "text": "LNA-anti-miR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the miRNA and then used qRT-PCR to measure the level of inhibition.",
    "entities": []
  },
  {
    "text": "Interestingly, we observed over 95 % inhibition at 24 h, and even at 48 h, the",
    "entities": [
      {
        "text": "95 %",
        "label": "PERCENT"
      },
      {
        "text": "24",
        "label": "CARDINAL"
      },
      {
        "text": "48",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "inhibition remained high at over 75 %. Upon closer examination, we determined",
    "entities": [
      {
        "text": "over 75 %",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "the impact of this inhibition on cell viability using MTT assays, which showed a",
    "entities": [
      {
        "text": "MTT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "significant decrease in cell numbers following treatment with",
    "entities": []
  },
  {
    "text": "LNA-anti-miR-19b-3p. Furthermore, our apoptosis analysis, using Annexin",
    "entities": [
      {
        "text": "Annexin",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "V/Propidium iodide staining, revealed an increased apoptosis rate in the",
    "entities": []
  },
  {
    "text": "transfected cells compared to the controls. Alongside these experimental",
    "entities": []
  },
  {
    "text": "studies, we employed computational methods to investigate hsa-miR-19b-3p in",
    "entities": []
  },
  {
    "text": "greater detail, including RNA-Seq analysis of TCGA data, which identified 2585",
    "entities": [
      {
        "text": "RNA-Seq",
        "label": "ORG"
      },
      {
        "text": "TCGA",
        "label": "ORG"
      },
      {
        "text": "2585",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "upregulated and 4251 downregulated genes. Cross-referencing downregulated genes",
    "entities": [
      {
        "text": "4251",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "with target genes from miRTarBase, RNAInter, and miRWalk led to the",
    "entities": [
      {
        "text": "RNAInter",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "identification of four potential hsa-miR-19b-3p targets: TMTC1, MBNL3, FAT3, and",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      },
      {
        "text": "TMTC1",
        "label": "ORG"
      },
      {
        "text": "MBNL3",
        "label": "GPE"
      },
      {
        "text": "FAT3",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GFOD1, with TMTC1 and MBNL3 showing statistically significant downregulation.",
    "entities": [
      {
        "text": "GFOD1",
        "label": "PRODUCT"
      },
      {
        "text": "TMTC1",
        "label": "ORG"
      },
      {
        "text": "MBNL3",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "Additionally, we screened for potential small molecule inhibitors, identifying",
    "entities": []
  },
  {
    "text": "four promising candidates, including Dovitinib, S-Adenosylmethionine,",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      },
      {
        "text": "Dovitinib",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "Guanosine-5',3'-tetraphosphate, and Neomycin, which exhibited favorable",
    "entities": [
      {
        "text": "Neomycin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "drug-like characteristics. In conclusion, our multifaceted approach demonstrates",
    "entities": []
  },
  {
    "text": "the significant potential of LNA-anti-miR-19b-3p as a therapeutic option for",
    "entities": []
  },
  {
    "text": "TNBC patients, and the small molecule inhibitors we've uncovered could open new",
    "entities": []
  },
  {
    "text": "avenues for treating this aggressive form of breast cancer.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Elsevier Ltd. All rights reserved.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "DOI: 10.1016/j.compbiomed.2025.110771",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Online ahead of print.",
    "entities": []
  },
  {
    "text": "Characterization and functional analysis of BRCA1 and BRCA2 variants in a cohort",
    "entities": [
      {
        "text": "BRCA1",
        "label": "GPE"
      },
      {
        "text": "BRCA2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "of 100 unselected patients undergoing germline screening.",
    "entities": [
      {
        "text": "100",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(1)Department of Laboratory Medicine, the Third Affiliated Hospital of Zhengzhou",
    "entities": [
      {
        "text": "Laboratory Medicine",
        "label": "ORG"
      },
      {
        "text": "the Third Affiliated Hospital",
        "label": "ORG"
      },
      {
        "text": "Zhengzhou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University, Zhengzhou, Henan, , 450052, China; Zhengzhou Key Laboratory for In",
    "entities": [
      {
        "text": "Zhengzhou",
        "label": "GPE"
      },
      {
        "text": "Henan",
        "label": "GPE"
      },
      {
        "text": "450052",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "Zhengzhou Key Laboratory",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Vitro Diagnosis of Hypertensive Disorders of Pregnancy, Zhengzhou, Henan,",
    "entities": [
      {
        "text": "Zhengzhou",
        "label": "GPE"
      },
      {
        "text": "Henan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "450052, China; Tianjian Laboratory of Advanced Biomedical Sciences, Institute of",
    "entities": [
      {
        "text": "450052",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "Tianjian Laboratory of Advanced Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "Institute of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, Henan, , 450000,",
    "entities": [
      {
        "text": "Advanced Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "Zhengzhou University",
        "label": "ORG"
      },
      {
        "text": "Zhengzhou",
        "label": "GPE"
      },
      {
        "text": "Henan",
        "label": "GPE"
      },
      {
        "text": "450000",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "China. Electronic address: qianqianshi@zzu.edu.cn.",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Laboratory Medicine, the Third Affiliated Hospital of Zhengzhou",
    "entities": [
      {
        "text": "Laboratory Medicine",
        "label": "ORG"
      },
      {
        "text": "the Third Affiliated Hospital",
        "label": "ORG"
      },
      {
        "text": "Zhengzhou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Breast Surgery, the Third Affiliated Hospital of Zhengzhou",
    "entities": [
      {
        "text": "Breast Surgery",
        "label": "PERSON"
      },
      {
        "text": "the Third Affiliated Hospital",
        "label": "ORG"
      },
      {
        "text": "Zhengzhou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University, Zhengzhou, Henan, 450052, China.",
    "entities": [
      {
        "text": "Zhengzhou",
        "label": "GPE"
      },
      {
        "text": "Henan",
        "label": "GPE"
      },
      {
        "text": "450052",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Laboratory Medicine, the Third Affiliated Hospital of Zhengzhou",
    "entities": [
      {
        "text": "Laboratory Medicine",
        "label": "ORG"
      },
      {
        "text": "the Third Affiliated Hospital",
        "label": "ORG"
      },
      {
        "text": "Zhengzhou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Tianjian Laboratory of Advanced Biomedical Sciences, Institute of Advanced",
    "entities": [
      {
        "text": "5)Tianjian Laboratory of Advanced Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "Institute of Advanced",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Biomedical Sciences, Zhengzhou University, Zhengzhou, Henan, , 450000, China;",
    "entities": [
      {
        "text": "Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "Zhengzhou University",
        "label": "ORG"
      },
      {
        "text": "Zhengzhou",
        "label": "GPE"
      },
      {
        "text": "Henan",
        "label": "GPE"
      },
      {
        "text": "450000",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Department of Breast Surgery, the Third Affiliated Hospital of Zhengzhou",
    "entities": [
      {
        "text": "the Third Affiliated Hospital",
        "label": "ORG"
      },
      {
        "text": "Zhengzhou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University, Zhengzhou, Henan, 450052, China. Electronic address:",
    "entities": [
      {
        "text": "Zhengzhou",
        "label": "GPE"
      },
      {
        "text": "Henan",
        "label": "GPE"
      },
      {
        "text": "450052",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Tianjian Laboratory of Advanced Biomedical Sciences, Institute of Advanced",
    "entities": [
      {
        "text": "6)Tianjian",
        "label": "CARDINAL"
      },
      {
        "text": "Laboratory of Advanced Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "Institute of Advanced",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Biomedical Sciences, Zhengzhou University, Zhengzhou, Henan, , 450000, China.",
    "entities": [
      {
        "text": "Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "Zhengzhou University",
        "label": "ORG"
      },
      {
        "text": "Zhengzhou",
        "label": "GPE"
      },
      {
        "text": "Henan",
        "label": "GPE"
      },
      {
        "text": "450000",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Department of Laboratory Medicine, the Third Affiliated Hospital of Zhengzhou",
    "entities": [
      {
        "text": "Laboratory Medicine",
        "label": "ORG"
      },
      {
        "text": "the Third Affiliated Hospital",
        "label": "ORG"
      },
      {
        "text": "Zhengzhou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "China. Electronic address: zll7376@zzu.edu.cn.",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Germline loss-of-function mutations in BRCA1 and BRCA2 (BRCA) genes are",
    "entities": [
      {
        "text": "Germline",
        "label": "ORG"
      },
      {
        "text": "BRCA1",
        "label": "GPE"
      },
      {
        "text": "BRCA2",
        "label": "PERSON"
      },
      {
        "text": "BRCA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "well-established as causative factors for hereditary breast and ovarian cancer",
    "entities": []
  },
  {
    "text": "(HBOC), conferring an approximately tenfold increased lifetime risk. The",
    "entities": []
  },
  {
    "text": "identification of BRCA mutations is essential for risk assessment and management",
    "entities": [
      {
        "text": "BRCA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "in high-risk individuals and cancer patients. In this study, we utilized",
    "entities": []
  },
  {
    "text": "next-generation sequencing (NGS) to comprehensively analyze the entire coding",
    "entities": [
      {
        "text": "NGS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "regions of BRCA genes in a cohort of 100 unselected patients undergoing germline",
    "entities": [
      {
        "text": "BRCA",
        "label": "ORG"
      },
      {
        "text": "100",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "screening (average age \u226445 years and/or family history of related cancers). A",
    "entities": []
  },
  {
    "text": "total of twenty-two variants were identified, including thirteen pathogenic or",
    "entities": [
      {
        "text": "twenty-two",
        "label": "CARDINAL"
      },
      {
        "text": "thirteen",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "likely pathogenic variants (PVs/LPVs) and nine variants of uncertain",
    "entities": [
      {
        "text": "nine",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "significance (VUSs). Notably, six novel variants (two in BRCA1 and four in",
    "entities": [
      {
        "text": "six",
        "label": "CARDINAL"
      },
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "BRCA1",
        "label": "GPE"
      },
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "BRCA2) were discovered. Molecular subtyping revealed that breast cancer (BC)",
    "entities": [
      {
        "text": "BRCA2",
        "label": "ORG"
      },
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "patients with BRCA variants were predominantly human epidermal growth factor",
    "entities": [
      {
        "text": "BRCA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "receptor-2 (HER2)-negative. Using in silico prediction tools, nine VUSs were",
    "entities": [
      {
        "text": "nine",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "reclassified, with functional impairment confirmed for the BRCA2 p.W2619C and",
    "entities": [
      {
        "text": "BRCA2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "BRCA2 p.N1023_I1024del variants. Functional assays demonstrated that the BRCA2",
    "entities": [
      {
        "text": "BRCA2",
        "label": "ORG"
      },
      {
        "text": "N1023_I1024del",
        "label": "ORG"
      },
      {
        "text": "BRCA2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "p.W2619C variant significantly enhanced cell proliferation, migration, and",
    "entities": [
      {
        "text": "p.W2619C",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "invasion. Moreover, cells harboring the BRCA2 p.W2619C mutation exhibited",
    "entities": [
      {
        "text": "BRCA2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "increased sensitivity to Olaparib, suggesting potential therapeutic benefit from",
    "entities": [
      {
        "text": "Olaparib",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "PARP inhibitors for patients with this variant. Our study identified six novel",
    "entities": [
      {
        "text": "six",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "BRCA mutations and functionally validated the pathogenicity of the BRCA2",
    "entities": [
      {
        "text": "BRCA",
        "label": "ORG"
      },
      {
        "text": "BRCA2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "p.W2619C variant, thereby advancing the understanding of BRCA-related cancer",
    "entities": [
      {
        "text": "p.W2619C variant",
        "label": "PERSON"
      },
      {
        "text": "BRCA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "risk and supporting enhanced genetic counseling and testing strategies for",
    "entities": []
  },
  {
    "text": "at-risk populations.",
    "entities": []
  },
  {
    "text": "69. Eur J Med Chem. 2025 Jul 7;297:117936. doi: 10.1016/j.ejmech.2025.117936.",
    "entities": [
      {
        "text": "69",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Targeting voltage-gated proton channel H(V)1: Optimised",
    "entities": []
  },
  {
    "text": "5-phenyl-2-aminoimidazoles with anticancer potential.",
    "entities": [
      {
        "text": "5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(2)Faculty of Medicine, Department of Biophysics and Cell Biology, University of",
    "entities": [
      {
        "text": "Medicine, Department of Biophysics and Cell Biology, University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The voltage-gated proton channel (HV1) has been linked to the development of",
    "entities": [
      {
        "text": "HV1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "tumours, neuroinflammatory diseases, immune disorders and infertility, making",
    "entities": []
  },
  {
    "text": "HV1 inhibitors promising candidates for therapeutic development. In this study,",
    "entities": [
      {
        "text": "HV1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "we designed and synthesized an optimised series of",
    "entities": []
  },
  {
    "text": "5-phenyl-2-aminoimidazole-based HV1 inhibitors, with the most potent compounds",
    "entities": [
      {
        "text": "5",
        "label": "CARDINAL"
      },
      {
        "text": "HV1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "exhibiting low micromolar IC50 values. Structural analysis highlighted the",
    "entities": []
  },
  {
    "text": "importance of an unsubstituted 2-aminoimidazole core and flexible linkers for",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "interactions. Antiproliferative assays showed that the most potent HV1",
    "entities": [
      {
        "text": "HV1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "inhibitors had IC50 values in the low micromolar range, with greater efficacy",
    "entities": []
  },
  {
    "text": "against THP-1 cells (human monocytic leukaemia), which express HV1 at high",
    "entities": [
      {
        "text": "THP-1",
        "label": "ORG"
      },
      {
        "text": "HV1",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "levels, compared to MCF-7 cells (human breast cancer) with lower HV1 expression.",
    "entities": [
      {
        "text": "MCF-7",
        "label": "CARDINAL"
      },
      {
        "text": "HV1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The type II compounds exhibited superior drug-like properties, including",
    "entities": []
  },
  {
    "text": "improved solubility, plasma protein binding and permeability compared to",
    "entities": []
  },
  {
    "text": "previous 5-phenyl-2-aminoimidazole-based HV1 inhibitors, as well as robust",
    "entities": [
      {
        "text": "5",
        "label": "CARDINAL"
      },
      {
        "text": "HV1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "metabolic stability. However, selectivity over the KV1.3 and NaV1.5 channels",
    "entities": []
  },
  {
    "text": "remained limited. This work advances the development of HV1 inhibitors. It",
    "entities": [
      {
        "text": "HV1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "provides valuable chemical tools to study the role of HV1 in disease",
    "entities": [
      {
        "text": "HV1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "pathogenesis and lays the foundation for new therapeutic strategies targeting",
    "entities": []
  },
  {
    "text": "HV1-mediated signalling pathways.",
    "entities": [
      {
        "text": "HV1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Copyright \u00a9 2025 The Author(s). Published by Elsevier Masson SAS.. All rights",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Masson SAS",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "considered as potential competing interests: Nace Zidar reports financial",
    "entities": [
      {
        "text": "Nace Zidar",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "support was provided by Slovenian Research and Innovation Agency. Zoltan Varga,",
    "entities": [
      {
        "text": "Slovenian Research and Innovation Agency",
        "label": "ORG"
      },
      {
        "text": "Zoltan Varga",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Florina Zakany, Tamas Kovacs, Adam Feher reports financial support was provided",
    "entities": [
      {
        "text": "Florina Zakany",
        "label": "ORG"
      },
      {
        "text": "Tamas Kovacs",
        "label": "PERSON"
      },
      {
        "text": "Adam Feher",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "by National Research Development and Innovation Office. If there are other",
    "entities": [
      {
        "text": "National Research Development and Innovation Office",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "authors, they declare that they have no known competing financial interests or",
    "entities": []
  },
  {
    "text": "personal relationships that could have appeared to influence the work reported",
    "entities": []
  },
  {
    "text": "in this paper.",
    "entities": []
  },
  {
    "text": "Neutrophil-to-lymphocyte ratio, a predictor for mortality and unplanned hospital",
    "entities": []
  },
  {
    "text": "readmissions in patients aged 75 years and older with cancer.",
    "entities": [
      {
        "text": "aged 75 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(1)Department of Geriatrics, University Hospital of Poitiers, 2 rue de la",
    "entities": [
      {
        "text": "Geriatrics, University Hospital of Poitiers",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "rue de la\n",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "(2)Department of Geriatrics, University Hospital of Poitiers, 2 rue de la",
    "entities": [
      {
        "text": "2)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Geriatrics, University Hospital of Poitiers",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "rue de la\n",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "(3)Department of Medical Oncology, University Hospital of Poitiers, 2 rue de la",
    "entities": [
      {
        "text": "Medical Oncology",
        "label": "ORG"
      },
      {
        "text": "University Hospital of Poitiers",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "rue de la\n",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "(4)Department of Geriatrics, University Hospital of Poitiers, 2 rue de la",
    "entities": [
      {
        "text": "Geriatrics, University Hospital of Poitiers",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "rue de la\n",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "(5)Department of Geriatrics, University Hospital of Poitiers, 2 rue de la",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Geriatrics, University Hospital of Poitiers",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "rue de la\n",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "INTRODUCTION: Assessing the prognosis of older patients with cancer is essential",
    "entities": []
  },
  {
    "text": "to determine the best strategy for oncological care, given the heterogeneous",
    "entities": []
  },
  {
    "text": "profiles of this population. Evaluation should consider frailty, comorbidities,",
    "entities": []
  },
  {
    "text": "geriatric parameters, and oncological parameters. Finding early prognostic",
    "entities": []
  },
  {
    "text": "indicators would be helpful to optimize care. We aimed to investigate the",
    "entities": []
  },
  {
    "text": "prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in patients aged 75",
    "entities": [
      {
        "text": "NLR",
        "label": "ORG"
      },
      {
        "text": "75",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and above with solid cancers.",
    "entities": []
  },
  {
    "text": "MATERIALS AND METHODS: Retrospective review of the ANCRAGE (ANalyse CanceR et",
    "entities": []
  },
  {
    "text": "sujet AGE) cohort that included all patients \u226575 years of age with solid cancer",
    "entities": [
      {
        "text": "years of age",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "who were consecutively assessed in the geriatric oncology clinic of the",
    "entities": []
  },
  {
    "text": "University Hospital of Poitiers (France) between January 1, 2016 and August 31,",
    "entities": [
      {
        "text": "University Hospital of Poitiers",
        "label": "ORG"
      },
      {
        "text": "France",
        "label": "GPE"
      },
      {
        "text": "between January 1, 2016",
        "label": "DATE"
      },
      {
        "text": "August 31",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "2023. Pretreatment assessment included socio-demographic data, oncological,",
    "entities": [
      {
        "text": "2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "clinical frailty scale (CFS) and geriatric assessment (GA). Geriatric domains",
    "entities": [
      {
        "text": "CFS",
        "label": "ORG"
      },
      {
        "text": "Geriatric",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "assessed were level of dependence, risk of falls, nutrition, mood, and",
    "entities": []
  },
  {
    "text": "cognition. We defined frailty as the presence of at least one impairment in any",
    "entities": [
      {
        "text": "at least one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "of the geriatric domains. The NLR was determined within seven days before or",
    "entities": [
      {
        "text": "NLR",
        "label": "ORG"
      },
      {
        "text": "seven days",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "after the GA and before any specific cancer treatment. Survival curves and Cox",
    "entities": [
      {
        "text": "GA",
        "label": "ORG"
      },
      {
        "text": "Cox\n",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "regression analyses were performed to assess the prognostic values in terms of",
    "entities": []
  },
  {
    "text": "overall survival (OS) and unplanned hospital readmissions (UHR).",
    "entities": []
  },
  {
    "text": "RESULTS: Overall, 1446 patients were included. Mean age was 86.6 years (\u00b1",
    "entities": [
      {
        "text": "1446",
        "label": "DATE"
      },
      {
        "text": "86.6 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "5.2 years), with a male predominance (59 %). Most prevalent cancer sites were",
    "entities": [
      {
        "text": "5.2 years",
        "label": "DATE"
      },
      {
        "text": "59 %",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "skin (9 %, n = 134), and lung (7 %, n = 103), with metastatic status in over",
    "entities": [
      {
        "text": "9 %",
        "label": "PERCENT"
      },
      {
        "text": "134",
        "label": "CARDINAL"
      },
      {
        "text": "7 %",
        "label": "PERCENT"
      },
      {
        "text": "103",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "one-third of cases. The pretreatment GA identified frailty in 70 % of cases",
    "entities": [
      {
        "text": "one-third",
        "label": "CARDINAL"
      },
      {
        "text": "GA",
        "label": "ORG"
      },
      {
        "text": "70 %",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "(n = 1012), with malnutrition (54 %, n = 774) and risk of falls (37 %, n = 538)",
    "entities": [
      {
        "text": "1012",
        "label": "DATE"
      },
      {
        "text": "54 %",
        "label": "PERCENT"
      },
      {
        "text": "774",
        "label": "CARDINAL"
      },
      {
        "text": "37 %",
        "label": "PERCENT"
      },
      {
        "text": "538",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "being the main contributing factors. Median NLR was 3.50 [2.34-5.31]. There was",
    "entities": [
      {
        "text": "NLR",
        "label": "ORG"
      },
      {
        "text": "3.50",
        "label": "CARDINAL"
      },
      {
        "text": "2.34",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "a significant association between NLR and frailty using the CFS score",
    "entities": [
      {
        "text": "NLR",
        "label": "ORG"
      },
      {
        "text": "CFS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(p < 0.001). The median follow-up time for OS analysis was 487 days [186-957].",
    "entities": [
      {
        "text": "487 days",
        "label": "DATE"
      },
      {
        "text": "186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "The results of the multivariate analysis indicated that pretreatment NLR was an",
    "entities": [
      {
        "text": "NLR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "independent predictor of OS (hazard ratio [HR] 1.010, 95 % CI: 1.005-1.015,",
    "entities": [
      {
        "text": "1.010",
        "label": "CARDINAL"
      },
      {
        "text": "95 %",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.005-1.015",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "p < 0.001) and of UHR (HR 1.057, 95 % CI: 1.014-1.101, p = 0.008). Cut-off value",
    "entities": [
      {
        "text": "p < 0.001",
        "label": "ORG"
      },
      {
        "text": "UHR",
        "label": "ORG"
      },
      {
        "text": "1.057",
        "label": "CARDINAL"
      },
      {
        "text": "95 %",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.014-1.101",
        "label": "CARDINAL"
      },
      {
        "text": "0.008",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": ">3.5 was associated with lower OS (p < 0.001).",
    "entities": [
      {
        "text": "3.5",
        "label": "CARDINAL"
      },
      {
        "text": "OS (p < 0.001",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DISCUSSION: In our study, NLR was independently associated with higher mortality",
    "entities": [
      {
        "text": "NLR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and high risk of unplanned hospital readmissions within one year of GA in older",
    "entities": [
      {
        "text": "one year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "patients with solid tumors.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Elsevier Ltd",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declaration of Competing Interest The authors",
    "entities": []
  },
  {
    "text": "Overdiagnosis of catheter-related thrombosis: When intensive screening detects",
    "entities": []
  },
  {
    "text": "clinically irrelevant findings.",
    "entities": []
  },
  {
    "text": "(1)Department of Urology, Liaoning Provincial Cancer Hospital, Shenyang 110042,",
    "entities": [
      {
        "text": "Urology, Liaoning Provincial Cancer Hospital",
        "label": "ORG"
      },
      {
        "text": "110042",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(2)Department of Breast Surgery, Liaoning Provincial Cancer Hospital, Shenyang",
    "entities": [
      {
        "text": "Breast Surgery",
        "label": "GPE"
      },
      {
        "text": "Liaoning Provincial Cancer Hospital",
        "label": "ORG"
      },
      {
        "text": "Shenyang",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Intravenous Cannula Maintenance Clinic, Liaoning Provincial",
    "entities": [
      {
        "text": "Intravenous Cannula Maintenance Clinic",
        "label": "ORG"
      },
      {
        "text": "Liaoning Provincial",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cancer Hospital, Shenyang 110042, Liaoning, China. Electronic address:",
    "entities": [
      {
        "text": "Cancer Hospital",
        "label": "ORG"
      },
      {
        "text": "110042",
        "label": "DATE"
      },
      {
        "text": "Liaoning",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "declare that they have no competing interests.",
    "entities": []
  },
  {
    "text": "Mastectomy skin flap necrosis after implant-based breast reconstruction:",
    "entities": []
  },
  {
    "text": "Intraoperative predictors and indocyanine green angiography.",
    "entities": []
  },
  {
    "text": "(1)Department of Breast Surgery, Chris O'Brien Lifehouse 119-143 Missenden Rd,",
    "entities": [
      {
        "text": "Breast Surgery",
        "label": "PERSON"
      },
      {
        "text": "Chris O'Brien Lifehouse",
        "label": "PERSON"
      },
      {
        "text": "119",
        "label": "CARDINAL"
      },
      {
        "text": "Missenden Rd",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Camperdown NSW 2050, Australia.",
    "entities": [
      {
        "text": "2050",
        "label": "DATE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Surgery, Royal Prince Alfred Hospital 50 Missenden Rd,",
    "entities": [
      {
        "text": "Surgery",
        "label": "ORG"
      },
      {
        "text": "Royal Prince Alfred Hospital",
        "label": "ORG"
      },
      {
        "text": "Missenden Rd",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(3)Department of Surgery, The University of Sydney Camperdown NSW 2050,",
    "entities": [
      {
        "text": "Surgery,",
        "label": "ORG"
      },
      {
        "text": "The University of Sydney Camperdown NSW",
        "label": "ORG"
      },
      {
        "text": "2050",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Nipple-sparing mastectomy (NSM) carries significant risk of",
    "entities": [
      {
        "text": "NSM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mastectomy skin flap necrosis (MSFN) which can compromise oncological, surgical,",
    "entities": [
      {
        "text": "MSFN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and quality-of-life outcomes. Prospective data on intraoperative predictors of",
    "entities": []
  },
  {
    "text": "MSFN could help with mitigating this risk.",
    "entities": [
      {
        "text": "MSFN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: Single institution prospective trial of patients undergoing NSM",
    "entities": [
      {
        "text": "NSM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "implant-based reconstruction for breast cancer or prophylaxis (2021-2024). Flap",
    "entities": [
      {
        "text": "2021-2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "perfusion was evaluated using clinical assessment, and indocyanine green (ICG)",
    "entities": []
  },
  {
    "text": "angiography perfusion values and angiogram patterns. Ischemic complications up",
    "entities": []
  },
  {
    "text": "to 90 days postoperative were documented. Patient, operative factors, and",
    "entities": [
      {
        "text": "90 days",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "perfusion analyses, evaluated with univariate and multivariate analysis. Trial",
    "entities": []
  },
  {
    "text": "RESULTS: One hundred eighty-eight patients underwent 274 NSMs. Eight percent of",
    "entities": [
      {
        "text": "One hundred eighty-eight",
        "label": "CARDINAL"
      },
      {
        "text": "274",
        "label": "CARDINAL"
      },
      {
        "text": "Eight percent",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "breasts (22 of 274) developed nipple or skin flap necrosis. Among these, 27.3%",
    "entities": [
      {
        "text": "22",
        "label": "CARDINAL"
      },
      {
        "text": "274",
        "label": "CARDINAL"
      },
      {
        "text": "27.3%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "had superficial, 31.8% had partial-thickness, and 40.9% had full-thickness",
    "entities": [
      {
        "text": "31.8%",
        "label": "PERCENT"
      },
      {
        "text": "40.9%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "necrosis. Multivariate analysis identified previous radiotherapy, ICG",
    "entities": []
  },
  {
    "text": "angiography absolute perfusion value <14units, ICG angiography relative",
    "entities": []
  },
  {
    "text": "perfusion value <30%, and absence of a second intercostal perforator vessel as",
    "entities": [
      {
        "text": "30%",
        "label": "PERCENT"
      },
      {
        "text": "second",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "independent factors associated with necrosis (HR 2.17, 95% CI 0.92-4.11,",
    "entities": [
      {
        "text": "2.17",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.92-4.11",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "2.81, 95% CI 1.13-3.44, p=0.046, respectively). Mastectomy incision type,",
    "entities": [
      {
        "text": "2.81",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.13-3.44",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "clinical assessment of flap perfusion, mastectomy weight, and initial tissue",
    "entities": []
  },
  {
    "text": "expander fill ratio were not found to be independent factors associated with",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: Preservation of the second intercostal perforator vessel was",
    "entities": [
      {
        "text": "second",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "identified as a modifiable intraoperative factor that may decrease the risk of",
    "entities": []
  },
  {
    "text": "necrosis after NSM. Poor intraoperative perfusion, as detected by ICG",
    "entities": [
      {
        "text": "NSM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "angiography, was associated with a greater likelihood of necrosis.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 by the American Society of Plastic Surgeons.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "the American Society of Plastic Surgeons",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Financial Disclosures, Conflicts of Interest,",
    "entities": [
      {
        "text": "Financial Disclosures",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Products: None to disclose.",
    "entities": []
  },
  {
    "text": "73. Anesthesiology. 2025 Jul 14. doi: 10.1097/ALN.0000000000005649. Online ahead",
    "entities": [
      {
        "text": "73",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1097",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "A Randomized Controlled Trial of Intraoperative Ketamine for Acute Postsurgical",
    "entities": []
  },
  {
    "text": "Pain after Breast Cancer Surgery: The Moderating Effect of Baseline Temporal",
    "entities": [
      {
        "text": "Breast Cancer",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Summation of Pain.",
    "entities": []
  },
  {
    "text": "(1)Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and",
    "entities": [
      {
        "text": "Anesthesiology, Perioperative",
        "label": "ORG"
      },
      {
        "text": "Pain Medicine",
        "label": "ORG"
      },
      {
        "text": "Brigham",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "Women's Hospital and Harvard Medical School, Boston, MA, USA.",
    "entities": [
      {
        "text": "Women's Hospital",
        "label": "ORG"
      },
      {
        "text": "Harvard Medical School",
        "label": "ORG"
      },
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Activation of nociceptive pathways by surgical trauma can induce",
    "entities": []
  },
  {
    "text": "central sensitization, which is associated with greater pain severity and",
    "entities": []
  },
  {
    "text": "persistence. The NMDA-receptor antagonist ketamine blocks central sensitization,",
    "entities": [
      {
        "text": "NMDA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "but has a variable track-record for preventing postsurgical pain. Patient-level",
    "entities": []
  },
  {
    "text": "factors contribute to variability in pain and may serve as markers of",
    "entities": []
  },
  {
    "text": "differential efficacy of preventive effect.",
    "entities": []
  },
  {
    "text": "METHODS: This prospective, longitudinal randomized controlled trial investigated",
    "entities": []
  },
  {
    "text": "the effectiveness of intraoperatively administered ketamine to decrease",
    "entities": []
  },
  {
    "text": "postoperative pain after breast surgery. Before surgery, patients reported",
    "entities": []
  },
  {
    "text": "demographic and medical information and completed validated pain and",
    "entities": []
  },
  {
    "text": "sensory testing to assess baseline temporal summation of pain (central",
    "entities": []
  },
  {
    "text": "sensitization tendency). Analyses of Covariance, controlling for relevant pre-",
    "entities": [
      {
        "text": "Covariance",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and peri-operative factors, examined treatment group (ketamine vs. saline)",
    "entities": [
      {
        "text": "ketamine",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "differences in 2-week postoperative pain outcomes. Exploratory moderation",
    "entities": [
      {
        "text": "2-week",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "analysis explored whether the efficacy of ketamine differed based on patients'",
    "entities": []
  },
  {
    "text": "baseline temporal summation of pain.",
    "entities": []
  },
  {
    "text": "RESULTS: Of the sample of 225 patients, 113 received ketamine and 112 received",
    "entities": [
      {
        "text": "225",
        "label": "CARDINAL"
      },
      {
        "text": "113",
        "label": "CARDINAL"
      },
      {
        "text": "112",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "placebo. The majority of patients underwent lumpectomy (53%), with 16%",
    "entities": [
      {
        "text": "53%",
        "label": "PERCENT"
      },
      {
        "text": "16%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "undergoing mastectomy and 30% mastectomy with reconstruction. There were no",
    "entities": [
      {
        "text": "30%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "significant treatment group differences in pain severity or impact reported two",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "weeks after surgery. However, moderation analysis revealed that among patients",
    "entities": [
      {
        "text": "weeks",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "with higher baseline temporal summation of pain, ketamine was associated with",
    "entities": []
  },
  {
    "text": "lower pain severity and impact scores.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: Ketamine was not associated with an analgesic benefit over placebo",
    "entities": [
      {
        "text": "Ketamine",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "in the acute postoperative period, as measured using a variety of pain",
    "entities": []
  },
  {
    "text": "assessments. However, exploratory moderation analysis suggested that patients",
    "entities": []
  },
  {
    "text": "with evidence of a greater central sensitization at baseline may derive an",
    "entities": []
  },
  {
    "text": "analgesic effect of ketamine. These findings support future collection of",
    "entities": []
  },
  {
    "text": "baseline phenotypic patient characteristics related to relevant mechanisms in",
    "entities": []
  },
  {
    "text": "trials, to identify which patients may derive a larger benefit from analgesic",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 American Society of Anesthesiologists. All Rights Reserved.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Conflicts of interest: The authors declare no",
    "entities": []
  },
  {
    "text": "74. JCI Insight. 2025 Jul 15:e193091. doi: 10.1172/jci.insight.193091. Online",
    "entities": [
      {
        "text": "74",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1172",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Elevated tumor NOS2/COX2 promotes immunosuppressive phenotypes associated with",
    "entities": []
  },
  {
    "text": "poor survival in ER- breast cancer patients.",
    "entities": [
      {
        "text": "ER-",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "EL(1), Moffat RL(4), Wink AL(2), Imtiaz F(2), Coutinho LL(1), Butcher D(5),",
    "entities": [
      {
        "text": "Moffat",
        "label": "PERSON"
      },
      {
        "text": "Wink AL(2",
        "label": "PERSON"
      },
      {
        "text": "Imtiaz",
        "label": "GPE"
      },
      {
        "text": "Coutinho LL(1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "MP(10), McVicar DW(1), Li X(11), Anderson SK(1), Paolocci N(12), Hewitt SM(13),",
    "entities": [
      {
        "text": "McVicar",
        "label": "PERSON"
      },
      {
        "text": "Li X(11",
        "label": "PERSON"
      },
      {
        "text": "Anderson SK(1",
        "label": "PERSON"
      },
      {
        "text": "Paolocci N(12",
        "label": "PERSON"
      },
      {
        "text": "Hewitt",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Ambs S(14), Billiar TR(15), Chang JC(7), Lockett SJ(2), Wink DA(1).",
    "entities": [
      {
        "text": "Billiar TR(15",
        "label": "PERSON"
      },
      {
        "text": "Chang JC(7",
        "label": "PERSON"
      },
      {
        "text": "Lockett",
        "label": "PERSON"
      },
      {
        "text": "Wink DA(1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Cancer Innovation Laboratory, Center for Cancer Research, National Cancer",
    "entities": [
      {
        "text": "Innovation Laboratory",
        "label": "ORG"
      },
      {
        "text": "Center for Cancer Research",
        "label": "ORG"
      },
      {
        "text": "National Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institute, NIH, Frederick, United States of America.",
    "entities": [
      {
        "text": "Institute",
        "label": "ORG"
      },
      {
        "text": "NIH",
        "label": "ORG"
      },
      {
        "text": "Frederick",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Optical Microscopy and Analysis Laboratory, Cancer Research Technology Prog,",
    "entities": [
      {
        "text": "Microscopy and Analysis Laboratory",
        "label": "ORG"
      },
      {
        "text": "Cancer Research Technology Prog",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Frederick National Laboratory for Cancer Research, National Cancer Institute,",
    "entities": [
      {
        "text": "Frederick National Laboratory for Cancer Research",
        "label": "ORG"
      },
      {
        "text": "National Cancer Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "NIH, Frederick, United States of America.",
    "entities": [
      {
        "text": "NIH",
        "label": "ORG"
      },
      {
        "text": "Frederick",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Imaging Mass Cytometry Laboratory, Frederick National Laboratory for Cancer",
    "entities": [
      {
        "text": "Mass Cytometry Laboratory",
        "label": "ORG"
      },
      {
        "text": "Frederick National Laboratory for Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Research, National Cancer Institute, NIH, Frederick, United States of America.",
    "entities": [
      {
        "text": "National Cancer Institute",
        "label": "ORG"
      },
      {
        "text": "NIH",
        "label": "ORG"
      },
      {
        "text": "Frederick",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Optical Microscopy and Analysis Laboratory, Office of Science and Technolog,",
    "entities": [
      {
        "text": "Microscopy and Analysis Laboratory",
        "label": "ORG"
      },
      {
        "text": "Office of Science and Technolog",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Center for Cancer Research, National Cancer Institute, NIH, Frederick, United",
    "entities": [
      {
        "text": "Center for Cancer Research",
        "label": "ORG"
      },
      {
        "text": "National Cancer Institute",
        "label": "ORG"
      },
      {
        "text": "NIH",
        "label": "ORG"
      },
      {
        "text": "Frederick",
        "label": "GPE"
      },
      {
        "text": "United",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "States of America.",
    "entities": []
  },
  {
    "text": "(5)Molecular Histopathology Laboratory, Frederick National Laboratory for Cancer",
    "entities": [
      {
        "text": "5)Molecular Histopathology Laboratory",
        "label": "ORG"
      },
      {
        "text": "Frederick National Laboratory for Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Center for Translational Research in Oncology, ICESP/HC, Faculdade de",
    "entities": [
      {
        "text": "6)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Translational Research in Oncology",
        "label": "ORG"
      },
      {
        "text": "Faculdade de\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(7)Department of Systems Medicine and Bioengineering, Houston Methodist",
    "entities": [
      {
        "text": "Systems Medicine and Bioengineering",
        "label": "ORG"
      },
      {
        "text": "Houston Methodist",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Hospital, Houston, United States of America.",
    "entities": [
      {
        "text": "Houston",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Women's Malignancies Branch, Center for Cancer Research, National Cancer",
    "entities": [
      {
        "text": "Malignancies Branch",
        "label": "ORG"
      },
      {
        "text": "Center for Cancer Research",
        "label": "ORG"
      },
      {
        "text": "National Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institute, NIH, Bethesda, United States of America.",
    "entities": [
      {
        "text": "Institute",
        "label": "ORG"
      },
      {
        "text": "NIH",
        "label": "ORG"
      },
      {
        "text": "Bethesda",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Discipline of Pathology, Lambe Institute for Translational Research, School",
    "entities": [
      {
        "text": "Pathology, Lambe Institute for Translational Research, School\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medicine, University of Galway, Galway, Ireland.",
    "entities": [
      {
        "text": "Medicine, University of Galway",
        "label": "ORG"
      },
      {
        "text": "Galway",
        "label": "GPE"
      },
      {
        "text": "Ireland",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Department of Neurology, School of Medicine, Duke University, Durham, United",
    "entities": [
      {
        "text": "10)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Neurology, School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Duke University",
        "label": "ORG"
      },
      {
        "text": "Durham",
        "label": "GPE"
      },
      {
        "text": "United",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Department of Pathology and Laboratory Medicine, Emory University School of",
    "entities": [
      {
        "text": "11)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Pathology and Laboratory Medicine",
        "label": "ORG"
      },
      {
        "text": "Emory University School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Atlanta, United States of America.",
    "entities": [
      {
        "text": "Atlanta",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Division of Cardiology, Department of Medicine, Johns Hopkins University",
    "entities": [
      {
        "text": "12)Division",
        "label": "CARDINAL"
      },
      {
        "text": "Cardiology, Department of Medicine",
        "label": "ORG"
      },
      {
        "text": "Johns Hopkins University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "School of Medicine, Baltimore, United States of America.",
    "entities": [
      {
        "text": "School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Baltimore",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(13)Laboratory of Pathology, Center for Cancer Research, National Cancer",
    "entities": [
      {
        "text": "13)Laboratory",
        "label": "CARDINAL"
      },
      {
        "text": "Pathology, Center for Cancer Research",
        "label": "ORG"
      },
      {
        "text": "National Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(14)Laboratory of Human Carcinogenesis, Center for Cancer Research, National",
    "entities": [
      {
        "text": "14)Laboratory",
        "label": "CARDINAL"
      },
      {
        "text": "Center for Cancer Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cancer Institute, NIH, Bethesda, United States of America.",
    "entities": [
      {
        "text": "Cancer Institute",
        "label": "ORG"
      },
      {
        "text": "NIH",
        "label": "ORG"
      },
      {
        "text": "Bethesda",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(15)Department of Surgery, University of Pittsburgh School of Medicine,",
    "entities": [
      {
        "text": "15)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Surgery, University of Pittsburgh School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pittsburgh, United States of America.",
    "entities": [
      {
        "text": "Pittsburgh",
        "label": "GPE"
      },
      {
        "text": "United States of America",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Tumor immunosuppression impacts survival and treatment efficacy. Tumor NOS2/COX2",
    "entities": []
  },
  {
    "text": "coexpression strongly predicts poor outcome in ER- breast cancer by promoting",
    "entities": []
  },
  {
    "text": "metastasis, drug resistance, cancer stemness, and immune suppression. Herein, a",
    "entities": []
  },
  {
    "text": "spatially distinct NOS2/COX2 and CD3+CD8+PD1- T effector (TEff) cell landscape",
    "entities": []
  },
  {
    "text": "correlated with poor survival in ER- tumors. NOS2 was primarily expressed at the",
    "entities": [
      {
        "text": "ER-",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "tumor margin, whereas COX2 together with B7H4 was associated with immune desert",
    "entities": []
  },
  {
    "text": "regions lacking TEff cells, where a higher ratio of tumor NOS2 or COX2 to TEff",
    "entities": []
  },
  {
    "text": "cells predicted poor survival. Also, PDL1/PD1, regulatory T cells (TReg) and",
    "entities": []
  },
  {
    "text": "IDO1 were primarily associated with stroma restricted TEff cells. Regardless of",
    "entities": [
      {
        "text": "stroma",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "the survival outcome, CD4+ T cells and macrophages were primarily in stromal",
    "entities": []
  },
  {
    "text": "lymphoid aggregates. Finally, in a 4T1 model, COX2 inhibition led to increased",
    "entities": [
      {
        "text": "4T1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CD8+ TEff/CD4+ TReg ratio and CD8+ TEff infiltration while Nos2 deficiency had",
    "entities": []
  },
  {
    "text": "no significant effect, thus reinforcing our observations that COX2 is an",
    "entities": []
  },
  {
    "text": "essential component of immunosuppression through CD8+ TEff cell exclusion from",
    "entities": []
  },
  {
    "text": "the tumor. Our study indicates that tumor NOS2/COX2 expression plays a central",
    "entities": []
  },
  {
    "text": "role in tumor immune evasion, suggesting that strategies combining clinically",
    "entities": []
  },
  {
    "text": "available NOS2/COX2 inhibitors with immune therapy could provide effective",
    "entities": []
  },
  {
    "text": "options for the treatment of aggressive and drug-resistant ER- breast tumors.",
    "entities": []
  },
  {
    "text": "DOI: 10.1172/jci.insight.193091",
    "entities": [
      {
        "text": "10.1172",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "75. Breast Cancer Res Treat. 2025 Jul 15. doi: 10.1007/s10549-025-07780-w. Online",
    "entities": [
      {
        "text": "75",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Time and location of specialty palliative care for women dying with metastatic",
    "entities": []
  },
  {
    "text": "breast cancer.",
    "entities": []
  },
  {
    "text": "(1)Department of Internal Medicine, University of Texas Southwestern Medical",
    "entities": [
      {
        "text": "Internal Medicine, University of Texas Southwestern Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.",
    "entities": [
      {
        "text": "5323",
        "label": "DATE"
      },
      {
        "text": "Harry Hines Blvd",
        "label": "PERSON"
      },
      {
        "text": "Dallas",
        "label": "GPE"
      },
      {
        "text": "TX",
        "label": "ORG"
      },
      {
        "text": "75390",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Health Economics, Systems, and Policy, Peter O'Donnell Jr.",
    "entities": [
      {
        "text": "Health Economics, Systems",
        "label": "ORG"
      },
      {
        "text": "Policy",
        "label": "PERSON"
      },
      {
        "text": "Peter O'Donnell Jr.",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "School of Public Health, University of Texas Southwestern Medical Center,",
    "entities": [
      {
        "text": "School of Public Health",
        "label": "ORG"
      },
      {
        "text": "University of Texas Southwestern Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Dallas, TX, USA.",
    "entities": [
      {
        "text": "Dallas",
        "label": "GPE"
      },
      {
        "text": "TX",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical",
    "entities": []
  },
  {
    "text": "Center, Dallas, TX, USA.",
    "entities": [
      {
        "text": "Dallas",
        "label": "GPE"
      },
      {
        "text": "TX",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Medicine, Geisel School of Medicine, Lebanon, NH, USA.",
    "entities": [
      {
        "text": "Medicine, Geisel School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Lebanon",
        "label": "GPE"
      },
      {
        "text": "NH",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Dartmouth Cancer Center, Lebanon, NH, USA.",
    "entities": [
      {
        "text": "Cancer Center",
        "label": "FAC"
      },
      {
        "text": "Lebanon",
        "label": "GPE"
      },
      {
        "text": "NH",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Health Data Science & Biostatistics, Peter O'Donnell Jr. School",
    "entities": [
      {
        "text": "Health Data Science & Biostatistics",
        "label": "ORG"
      },
      {
        "text": "Peter O'Donnell Jr.",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "of Public, Health University of Texas Southwestern Medical Center, Dallas, TX,",
    "entities": [
      {
        "text": "Public, Health University of Texas Southwestern Medical Center",
        "label": "ORG"
      },
      {
        "text": "Dallas",
        "label": "GPE"
      },
      {
        "text": "TX",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Department of Social & Behavioral Sciences, Peter O'Donnell Jr. School of",
    "entities": [
      {
        "text": "Social & Behavioral Sciences",
        "label": "ORG"
      },
      {
        "text": "Peter O'Donnell Jr.",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Public, Health University of Texas Southwestern Medical Center, Dallas, TX, USA.",
    "entities": [
      {
        "text": "Health University of Texas Southwestern Medical Center",
        "label": "ORG"
      },
      {
        "text": "Dallas",
        "label": "GPE"
      },
      {
        "text": "TX",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Parkland Health, Dallas, TX, USA.",
    "entities": [
      {
        "text": "Dallas",
        "label": "GPE"
      },
      {
        "text": "TX",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Department of Immunology, University of Texas Southwestern Medical Center,",
    "entities": [
      {
        "text": "Immunology, University of Texas Southwestern Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(10)Center for Health Optimization and Implementation Research (CHOIR), VA",
    "entities": [
      {
        "text": "10)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Health Optimization and Implementation Research",
        "label": "ORG"
      },
      {
        "text": "VA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Bedford Healthcare System, Bedford, MA, USA.",
    "entities": [
      {
        "text": "Bedford Healthcare System",
        "label": "ORG"
      },
      {
        "text": "Bedford",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.",
    "entities": [
      {
        "text": "11)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Internal Medicine, University of Michigan",
        "label": "ORG"
      },
      {
        "text": "Ann Arbor",
        "label": "GPE"
      },
      {
        "text": "MI",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Department of Internal Medicine, University of Texas Southwestern Medical",
    "entities": [
      {
        "text": "12)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Internal Medicine, University of Texas Southwestern Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(13)Department of Health Economics, Systems, and Policy, Peter O'Donnell Jr.",
    "entities": [
      {
        "text": "13)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Health Economics, Systems",
        "label": "ORG"
      },
      {
        "text": "Policy",
        "label": "PERSON"
      },
      {
        "text": "Peter O'Donnell Jr.",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Dallas, TX, USA. megan.mullins@utsouthwestern.edu.",
    "entities": [
      {
        "text": "Dallas",
        "label": "GPE"
      },
      {
        "text": "TX",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(14)Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical",
    "entities": [
      {
        "text": "14)Harold C. Simmons",
        "label": "MONEY"
      }
    ]
  },
  {
    "text": "Center, Dallas, TX, USA. megan.mullins@utsouthwestern.edu.",
    "entities": [
      {
        "text": "Dallas",
        "label": "GPE"
      },
      {
        "text": "TX",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Despite guideline recommendations, evidence suggests many women with",
    "entities": []
  },
  {
    "text": "metastatic breast cancer (mBC) do not receive specialty palliative care services",
    "entities": []
  },
  {
    "text": "despite high morbidity burden. Given the varied prognoses and disease",
    "entities": []
  },
  {
    "text": "trajectories of women with mBC, relatively little is known about palliative care",
    "entities": []
  },
  {
    "text": "delivery in this growing population, including timing and frequency of visits,",
    "entities": []
  },
  {
    "text": "location (inpatient vs. outpatient), and reasons for referral.",
    "entities": []
  },
  {
    "text": "METHODS: Using electronic health record and tumor registry data from a North",
    "entities": [
      {
        "text": "North",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "Texas Comprehensive Cancer Center (2010-2023), we identified women who died with",
    "entities": [
      {
        "text": "Texas Comprehensive Cancer Center",
        "label": "ORG"
      },
      {
        "text": "2010-2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "de novo or recurrent mBC. We examined receipt of palliative care (inpatient and",
    "entities": []
  },
  {
    "text": "outpatient), reasons for referral, and timing of palliative care encounters by",
    "entities": []
  },
  {
    "text": "duration of patient survival. We used multivariable logistic regression to",
    "entities": []
  },
  {
    "text": "assess associations between receipt of specialty palliative care and",
    "entities": []
  },
  {
    "text": "demographic, clinical, and survival characteristics.",
    "entities": []
  },
  {
    "text": "RESULTS: Among 265 women with mBC, 55.5% received no palliative care. Only women",
    "entities": [
      {
        "text": "265",
        "label": "CARDINAL"
      },
      {
        "text": "55.5%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "with short survival (< 18 months) received palliative care within 8 weeks of",
    "entities": [
      {
        "text": "18 months",
        "label": "DATE"
      },
      {
        "text": "8 weeks",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "diagnosis. Most palliative care encounters were inpatient and occurred",
    "entities": []
  },
  {
    "text": "within ~ 1 month of death. In adjusted models, comorbidities and younger age",
    "entities": [
      {
        "text": "1 month",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "were strongly associated with receiving outpatient palliative care. Most women",
    "entities": []
  },
  {
    "text": "were referred to palliative care for multiple reasons, with long-term survivors",
    "entities": []
  },
  {
    "text": "more likely to be referred for goals of care discussions alone.",
    "entities": []
  },
  {
    "text": "CONCLUSION: Palliative care for women with mBC is infrequent and often late,",
    "entities": []
  },
  {
    "text": "with referrals seemingly driven by the imminence of death rather than metastatic",
    "entities": []
  },
  {
    "text": "diagnosis. Strategies to better identify and triage specialty palliative care",
    "entities": []
  },
  {
    "text": "needs and make timely referrals are needed.",
    "entities": []
  },
  {
    "text": "\u00a9 2025. The Author(s), under exclusive licence to Springer Science+Business",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Springer Science+Business\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Media, LLC, part of Springer Nature.",
    "entities": [
      {
        "text": "LLC",
        "label": "ORG"
      },
      {
        "text": "Springer Nature",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "Loss of IL13RA2 promotes metastatic tumor growth in triple-negative breast",
    "entities": [
      {
        "text": "IL13RA2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cancer via increased AKT and NF-\u03baB signaling.",
    "entities": [
      {
        "text": "AKT",
        "label": "ORG"
      },
      {
        "text": "NF-\u03baB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Bindeman WE(1), Corn KC(2), Rafat M(1)(2)(3)(4), Fingleton B(5)(6).",
    "entities": [
      {
        "text": "Bindeman WE(1",
        "label": "PERSON"
      },
      {
        "text": "Corn KC(2",
        "label": "PERSON"
      },
      {
        "text": "Rafat M(1)(2)(3)(4",
        "label": "PERSON"
      },
      {
        "text": "Fingleton",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA.",
    "entities": [
      {
        "text": "Cancer Biology",
        "label": "ORG"
      },
      {
        "text": "Nashville",
        "label": "GPE"
      },
      {
        "text": "TN",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Chemical and Biomolecular Engineering, Vanderbilt University,",
    "entities": [
      {
        "text": "Chemical and Biomolecular Engineering",
        "label": "ORG"
      },
      {
        "text": "Vanderbilt University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Biomedical Engineering, Vanderbilt University, Nashville, TN,",
    "entities": [
      {
        "text": "Biomedical Engineering",
        "label": "ORG"
      },
      {
        "text": "Vanderbilt University",
        "label": "ORG"
      },
      {
        "text": "Nashville",
        "label": "GPE"
      },
      {
        "text": "TN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Radiation Oncology, Vanderbilt University, Nashville, TN, USA.",
    "entities": [
      {
        "text": "Radiation Oncology",
        "label": "ORG"
      },
      {
        "text": "Vanderbilt University",
        "label": "ORG"
      },
      {
        "text": "Nashville",
        "label": "GPE"
      },
      {
        "text": "TN",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA.",
    "entities": [
      {
        "text": "Cancer Biology",
        "label": "ORG"
      },
      {
        "text": "Nashville",
        "label": "GPE"
      },
      {
        "text": "TN",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Pharmacology, Vanderbilt University, 2220 Pierce Ave, 771 PRB,",
    "entities": [
      {
        "text": "Pharmacology, Vanderbilt University",
        "label": "ORG"
      },
      {
        "text": "2220",
        "label": "DATE"
      },
      {
        "text": "Pierce Ave",
        "label": "PERSON"
      },
      {
        "text": "771",
        "label": "CARDINAL"
      },
      {
        "text": "PRB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Triple-negative breast cancer is associated with poor patient prognosis and high",
    "entities": []
  },
  {
    "text": "rates of distant metastasis. These patients are at elevated risk of brain",
    "entities": []
  },
  {
    "text": "metastasis, which remains a major therapeutic challenge. IL13RA2, a",
    "entities": [
      {
        "text": "IL13RA2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "high-affinity receptor for IL13, is highly expressed in primary brain cancers,",
    "entities": []
  },
  {
    "text": "many extracranial solid tumors, and in lung- and brain-seeking metastatic",
    "entities": []
  },
  {
    "text": "variant cell lines. However, the relationship between IL13RA2 and patient",
    "entities": [
      {
        "text": "IL13RA2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "prognosis is variable, and the biological function of this receptor in cancer",
    "entities": []
  },
  {
    "text": "remains controversial. We sought to define the role of IL13RA2 in",
    "entities": [
      {
        "text": "IL13RA2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "triple-negative breast cancer growth and metastasis, with an emphasis on",
    "entities": []
  },
  {
    "text": "breast-to-brain metastasis. We generated IL13RA2-CRISPR knockout derivatives of",
    "entities": [
      {
        "text": "IL13RA2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the human brain-seeking breast cancer cell line MDA231BrM2, as well as murine",
    "entities": [
      {
        "text": "MDA231BrM2",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "4T1 cells, and evaluated changes in gene expression, proliferation, survival,",
    "entities": [
      {
        "text": "4T1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and metastatic growth in vivo. Both IL13RA2-deficient models demonstrate",
    "entities": [
      {
        "text": "IL13RA2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "enhanced cell survival in vitro, as well as augmented metastatic tumor growth",
    "entities": []
  },
  {
    "text": "and worsened animal survival in intracardiac models of brain metastasis.",
    "entities": []
  },
  {
    "text": "Concordantly, elevated IL13RA2 mRNA expression is positively correlated with",
    "entities": [
      {
        "text": "IL13RA2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "overall survival in patients with basal-like breast cancer. Mechanistically,",
    "entities": []
  },
  {
    "text": "IL13RA2-deficient cells exhibit increased AKT and NF-\u03baB signaling. These cells",
    "entities": [
      {
        "text": "IL13RA2",
        "label": "ORG"
      },
      {
        "text": "AKT",
        "label": "ORG"
      },
      {
        "text": "NF-\u03baB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "are sensitive to inhibition of either pathway, but especially AKT, which may",
    "entities": [
      {
        "text": "AKT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "represent a clinically useful vulnerability for patients with IL13RA2-low",
    "entities": [
      {
        "text": "IL13RA2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "tumors. Our data suggest that inhibition of IL13RA2, though promising in other",
    "entities": [
      {
        "text": "IL13RA2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "tumor contexts, may be deleterious in metastatic triple-negative breast cancer.",
    "entities": []
  },
  {
    "text": "PMID: 40663259 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Declarations. Ethics approval: All animal",
    "entities": []
  },
  {
    "text": "studies were approved by Vanderbilt\u2019s Institutional Animal Care and Use",
    "entities": [
      {
        "text": "Vanderbilt",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Committee (protocol M2300038-00). Competing interests: Barbara Fingleton is a",
    "entities": [
      {
        "text": "Barbara Fingleton",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "member of the editorial board for Clinical and Experimental Metastasis.",
    "entities": []
  },
  {
    "text": "History of family member incarceration during childhood and receipt of cancer",
    "entities": []
  },
  {
    "text": "screenings during adulthood in the United States.",
    "entities": [
      {
        "text": "the United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(1)Surveillance and Health Equity Science, American Cancer Society, 270",
    "entities": [
      {
        "text": "Health Equity Science",
        "label": "ORG"
      },
      {
        "text": "270",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Peachtree Street NW, Atlanta, GA, 30303, USA. Jingxuan.zhao@cancer.org.",
    "entities": [
      {
        "text": "Atlanta",
        "label": "GPE"
      },
      {
        "text": "GA",
        "label": "ORG"
      },
      {
        "text": "30303",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      },
      {
        "text": "Jingxuan.zhao@cancer.org",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Rollins School of Public Health, Emory University, Atlanta, GA, USA.",
    "entities": [
      {
        "text": "2)Rollins",
        "label": "CARDINAL"
      },
      {
        "text": "School of Public Health",
        "label": "ORG"
      },
      {
        "text": "Emory University",
        "label": "ORG"
      },
      {
        "text": "Atlanta",
        "label": "GPE"
      },
      {
        "text": "GA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Surveillance and Health Equity Science, American Cancer Society, 270",
    "entities": [
      {
        "text": "Health Equity Science",
        "label": "ORG"
      },
      {
        "text": "270",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Peachtree Street NW, Atlanta, GA, 30303, USA.",
    "entities": [
      {
        "text": "Atlanta",
        "label": "GPE"
      },
      {
        "text": "GA",
        "label": "ORG"
      },
      {
        "text": "30303",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Rollins School of Public Health, Emory University, Atlanta, GA, USA.",
    "entities": [
      {
        "text": "School of Public Health",
        "label": "ORG"
      },
      {
        "text": "Emory University",
        "label": "ORG"
      },
      {
        "text": "Atlanta",
        "label": "GPE"
      },
      {
        "text": "GA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "PURPOSE: To examine the association between family member incarceration (FMI)",
    "entities": [
      {
        "text": "PURPOSE",
        "label": "ORG"
      },
      {
        "text": "FMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "during childhood and receipt of breast, colorectal, cervical, and lung cancer",
    "entities": []
  },
  {
    "text": "METHODS: Adults with and without FMI during childhood were identified from the",
    "entities": [
      {
        "text": "FMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "2020 and/or 2022 Behavioral Risk Factor Surveillance System surveys. Using",
    "entities": [
      {
        "text": "2020",
        "label": "CARDINAL"
      },
      {
        "text": "Behavioral Risk Factor Surveillance System",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "multivariate logistic regression, we examined the associations of FMI and",
    "entities": [
      {
        "text": "FMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "receipt of past year and guideline-concordant cancer screening, adjusting for",
    "entities": [
      {
        "text": "past year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "age, sex, marital status, number of health conditions, state of residence,",
    "entities": []
  },
  {
    "text": "number of other adverse childhood experiences, and survey year with sequential",
    "entities": []
  },
  {
    "text": "adjustment for socioeconomic factors (educational attainment, home ownership,",
    "entities": []
  },
  {
    "text": "and health insurance coverage).",
    "entities": []
  },
  {
    "text": "cervical (n = 31789), and lung (n = 3646) cancer screenings were included.",
    "entities": [
      {
        "text": "cervical (n = 31789",
        "label": "ORG"
      },
      {
        "text": "3646",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Having FMI was associated with lower likelihood of receiving past year and",
    "entities": [
      {
        "text": "FMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "guideline-concordant breast cancer screening [odds ratio: 0.81(0.67-0.99);",
    "entities": []
  },
  {
    "text": "0.77(0.61-0.96)] and guideline-concordant lung cancer screening",
    "entities": []
  },
  {
    "text": "[0.44(0.24-0.80)]. The associations were attenuated with additional adjustment",
    "entities": [
      {
        "text": "0.80",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "for socioeconomic factors [past year and guideline-concordant breast cancer",
    "entities": [
      {
        "text": "past year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "screening: 0.83(0.68-1.01) and 0.81(0.65-1.02); lung cancer screening:",
    "entities": [
      {
        "text": "0.81(0.65-1.02",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSION: Having FMI during childhood was associated with a lower likelihood",
    "entities": []
  },
  {
    "text": "of receiving breast and lung cancer screenings in adulthood. Programs to improve",
    "entities": []
  },
  {
    "text": "receipt of cancer screenings among people with FMI are warranted.",
    "entities": [
      {
        "text": "FMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "\u00a9 2025. The Author(s), under exclusive licence to Springer Nature Switzerland",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Springer Nature",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "DOI: 10.1007/s10552-025-02031-1",
    "entities": [
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "declare no conflict of interest.",
    "entities": []
  },
  {
    "text": "Where are we now and where do we go from here? A structured literature review",
    "entities": []
  },
  {
    "text": "analyzing the current state of breast density research trends and discussions.",
    "entities": []
  },
  {
    "text": "(1)George Washington University School of Nursing, 1919 Pennsylvania Avenue,",
    "entities": [
      {
        "text": "1)George",
        "label": "CARDINAL"
      },
      {
        "text": "Washington University School of Nursing",
        "label": "ORG"
      },
      {
        "text": "1919",
        "label": "DATE"
      },
      {
        "text": "Pennsylvania Avenue",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Suite 500, Washington DC, 20006, USA.",
    "entities": [
      {
        "text": "500",
        "label": "CARDINAL"
      },
      {
        "text": "Washington DC",
        "label": "GPE"
      },
      {
        "text": "20006",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)George Washington University School of Nursing, 1919 Pennsylvania Avenue,",
    "entities": [
      {
        "text": "2)George",
        "label": "CARDINAL"
      },
      {
        "text": "Washington University School of Nursing",
        "label": "ORG"
      },
      {
        "text": "1919",
        "label": "DATE"
      },
      {
        "text": "Pennsylvania Avenue",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Suite 500, Washington DC, 20006, USA. sflyntwalling31@gwu.edu.",
    "entities": [
      {
        "text": "500",
        "label": "CARDINAL"
      },
      {
        "text": "Washington DC",
        "label": "GPE"
      },
      {
        "text": "20006",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)George Washington Milken Institutes School of Public Health, Washington DC,",
    "entities": [
      {
        "text": "3)George",
        "label": "CARDINAL"
      },
      {
        "text": "Washington Milken Institutes School of Public Health",
        "label": "ORG"
      },
      {
        "text": "Washington DC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)George Washington Cancer Center, Washington DC, USA. sflyntwalling31@gwu.edu.",
    "entities": [
      {
        "text": "4)George",
        "label": "CARDINAL"
      },
      {
        "text": "Washington Cancer Center",
        "label": "ORG"
      },
      {
        "text": "Washington DC",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)George Washington Medical Faculty Associates, Washington DC, USA.",
    "entities": [
      {
        "text": "Washington Medical Faculty Associates",
        "label": "ORG"
      },
      {
        "text": "Washington DC",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "PURPOSE: This structured literature review has been conducted to identify and",
    "entities": [
      {
        "text": "PURPOSE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "map existing research on patient understanding of breast density, its",
    "entities": []
  },
  {
    "text": "implications for breast cancer risk, and the effects of breast density",
    "entities": []
  },
  {
    "text": "notification laws on supplemental screening and patient-provider communication.",
    "entities": []
  },
  {
    "text": "The study aimed to synthesize key research themes and identify gaps in the",
    "entities": []
  },
  {
    "text": "literature related to breast density awareness, communication, and policy",
    "entities": []
  },
  {
    "text": "METHODS: The public health and medical literature were searched in the National",
    "entities": []
  },
  {
    "text": "Library of Medicine's online database, PubMed. Articles were limited to",
    "entities": [
      {
        "text": "PubMed",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "U.S.-based research projects, and specifically excluded other literature",
    "entities": []
  },
  {
    "text": "reviews.",
    "entities": []
  },
  {
    "text": "RESULTS: This examination resulted in a review of 69 articles and themes that",
    "entities": [
      {
        "text": "69",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "included breast density risk, racial differences and disparities, the impact of",
    "entities": []
  },
  {
    "text": "the notification laws on knowledge and reactions regarding notification, how",
    "entities": []
  },
  {
    "text": "notification laws impacted supplemental screening, the impacts within vulnerable",
    "entities": []
  },
  {
    "text": "populations, provider knowledge, patient's understanding and perceptions, and",
    "entities": []
  },
  {
    "text": "effectiveness and comprehension of potential educational and decision aid",
    "entities": []
  },
  {
    "text": "materials used.",
    "entities": []
  },
  {
    "text": "CONCLUSION: Based on the review, recommendations for future research and",
    "entities": []
  },
  {
    "text": "improved communications-both patient notifications and provider training-are",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Declarations. Competing interest: The authors",
    "entities": []
  },
  {
    "text": "have no relevant financial or non-financial interests to disclose and have no",
    "entities": []
  },
  {
    "text": "competing interests to declare that are relevant to the content of this article.",
    "entities": []
  },
  {
    "text": "Consent to participate: As a literature review study, there were no human",
    "entities": []
  },
  {
    "text": "subjects. As such, the Institutional Review Board did not require an informed",
    "entities": [
      {
        "text": "the Institutional Review Board",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "79. Invest New Drugs. 2025 Jul 15. doi: 10.1007/s10637-025-01552-5. Online ahead",
    "entities": [
      {
        "text": "79",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Safety and pharmacokinetics of FCN-437c, a novel cyclin-dependent kinase 4/6",
    "entities": [
      {
        "text": "4/6",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "inhibitor, in Chinese patients with hepatic impairment.",
    "entities": [
      {
        "text": "Chinese",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "(1)Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun,",
    "entities": [
      {
        "text": "First Hospital",
        "label": "ORG"
      },
      {
        "text": "Jilin University",
        "label": "ORG"
      },
      {
        "text": "Changchun",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun,",
    "entities": [
      {
        "text": "First Hospital",
        "label": "ORG"
      },
      {
        "text": "Jilin University",
        "label": "ORG"
      },
      {
        "text": "Changchun",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)AVANC PHARMACEUTICAL CO., LTD, Dongzhou Road, Bixi Street, 215513, Changshu",
    "entities": [
      {
        "text": "3)AVANC PHARMACEUTICAL CO.",
        "label": "ORG"
      },
      {
        "text": "LTD",
        "label": "GPE"
      },
      {
        "text": "Dongzhou Road",
        "label": "FAC"
      },
      {
        "text": "Bixi Street",
        "label": "FAC"
      },
      {
        "text": "215513",
        "label": "DATE"
      },
      {
        "text": "Changshu",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)AVANC PHARMACEUTICAL CO., LTD, Dongzhou Road, Bixi Street, 215513, Changshu",
    "entities": [
      {
        "text": "4)AVANC PHARMACEUTICAL CO.",
        "label": "ORG"
      },
      {
        "text": "LTD",
        "label": "GPE"
      },
      {
        "text": "Dongzhou Road",
        "label": "FAC"
      },
      {
        "text": "Bixi Street",
        "label": "FAC"
      },
      {
        "text": "215513",
        "label": "DATE"
      },
      {
        "text": "Changshu",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "City, Jiangsu, China.",
    "entities": [
      {
        "text": "Jiangsu",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Shanghai Fosun Pharmaceutical Group Co Ltd, Building A, No. 1289 Yishan Road,",
    "entities": [
      {
        "text": "Fosun Pharmaceutical Group Co Ltd",
        "label": "ORG"
      },
      {
        "text": "1289",
        "label": "DATE"
      },
      {
        "text": "Yishan Road",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "This study explored the impact of hepatic impairment on the safety and",
    "entities": []
  },
  {
    "text": "pharmacokinetics (PK) of FCN-437c, a novel dual CDK4/6 inhibitor for potential",
    "entities": [
      {
        "text": "CDK4/6",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "breast cancer treatment. In an open-label trial, 25 subjects (8 with mild",
    "entities": [
      {
        "text": "25",
        "label": "CARDINAL"
      },
      {
        "text": "8",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "hepatic impairment, 8 with moderate hepatic impairment, and 8 healthy controls",
    "entities": [
      {
        "text": "8",
        "label": "CARDINAL"
      },
      {
        "text": "8",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "matched for age, sex, and body weight) received a single 200-mg dose of",
    "entities": [
      {
        "text": "200",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "FCN-437c. Results showed that FCN-437c was generally well-tolerated, with no",
    "entities": []
  },
  {
    "text": "serious adverse events. In mild hepatic impairment group, total FCN-437c Cmax",
    "entities": [
      {
        "text": "Cmax\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "increased by 9.5%, while AUC0-t and AUC0-\u221e decreased by 4.8%. Free drug exposure",
    "entities": [
      {
        "text": "9.5%",
        "label": "PERCENT"
      },
      {
        "text": "4.8%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "increased by 24.7%, 8.4%, and 8.4%. In moderate hepatic impairment group, total",
    "entities": [
      {
        "text": "24.7%",
        "label": "PERCENT"
      },
      {
        "text": "8.4%",
        "label": "PERCENT"
      },
      {
        "text": "8.4%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "FCN-437c Cmax, AUC0-t, and AUC0-\u221e decreased by 16.7%, 17.1%, and 15.7%, and free",
    "entities": [
      {
        "text": "Cmax",
        "label": "PERSON"
      },
      {
        "text": "16.7%",
        "label": "PERCENT"
      },
      {
        "text": "17.1%",
        "label": "PERCENT"
      },
      {
        "text": "15.7%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "drug exposure increased by 47.8%, 47.0%, and 49.6%. Overall, no clinically",
    "entities": [
      {
        "text": "47.8%",
        "label": "PERCENT"
      },
      {
        "text": "47.0%",
        "label": "PERCENT"
      },
      {
        "text": "49.6%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "relevant differences in FCN-437c exposure were found between subjects with mild",
    "entities": []
  },
  {
    "text": "or moderate hepatic impairment and normal controls, but moderate hepatic",
    "entities": []
  },
  {
    "text": "impairment increased free drug exposure. Thus, no dose adjustment is needed for",
    "entities": []
  },
  {
    "text": "patients with mild hepatic impairment, but a reduced dose may be necessary for",
    "entities": []
  },
  {
    "text": "those with moderate hepatic impairment. Trial Registration:",
    "entities": []
  },
  {
    "text": "www.clinicaltrials.gov identifier NCT06620731 (retrospectively registered).",
    "entities": [
      {
        "text": "NCT06620731",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "DOI: 10.1007/s10637-025-01552-5",
    "entities": [
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declarations. Conflicts of interest: The authors",
    "entities": []
  },
  {
    "text": "E2F7 transcriptionally upregulates SPC24 to mediate aerobic Glycolysis and",
    "entities": [
      {
        "text": "Glycolysis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "facilitate stemness of breast cancer.",
    "entities": []
  },
  {
    "text": "(1)Department of General Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of",
    "entities": [
      {
        "text": "Surgery",
        "label": "PERSON"
      },
      {
        "text": "Cancer Hospital & Jiangsu Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University,",
    "entities": [
      {
        "text": "Cancer Research &",
        "label": "ORG"
      },
      {
        "text": "The Affiliated Cancer Hospital",
        "label": "ORG"
      },
      {
        "text": "Nanjing Medical University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer",
    "entities": [
      {
        "text": "Jiangsu Cancer Hospital & Jiangsu Institute of Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Research & The Affiliated Cancer Hospital of Nanjing Medical University, No. 42",
    "entities": [
      {
        "text": "Research &",
        "label": "ORG"
      },
      {
        "text": "The Affiliated Cancer Hospital",
        "label": "ORG"
      },
      {
        "text": "Nanjing Medical University",
        "label": "ORG"
      },
      {
        "text": "42",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Metabolic reprogramming characterized by aerobic glycolysis is observed in",
    "entities": [
      {
        "text": "Metabolic",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "various cancers, including breast cancer (BC), exerting essential influence on",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "maintaining cancer stemness. The abnormal expression of SPC24 is linked to the",
    "entities": []
  },
  {
    "text": "occurrence and development of various cancers, but its role in BC remains",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "unelucidated. Bioinformatics analysis was undertaken to determine the levels of",
    "entities": []
  },
  {
    "text": "SPC24 and E2F7 in BC, and the enriched signaling pathways of SPC24 with",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "differential expression, which were validated through cell experiments. The",
    "entities": []
  },
  {
    "text": "transcriptional regulatory relationship between E2F7 and SPC24 was also assessed",
    "entities": []
  },
  {
    "text": "through bioinformatics analysis, with validation completed by dual luciferase",
    "entities": []
  },
  {
    "text": "assay and chromatin immunoprecipitation (ChIP). To evaluate BC stemness, we",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "employed the western blot (WB) to detect the levels of CD44, CD133, Oct-4, and",
    "entities": [
      {
        "text": "WB",
        "label": "ORG"
      },
      {
        "text": "CD44",
        "label": "GPE"
      },
      {
        "text": "CD133",
        "label": "NORP"
      },
      {
        "text": "Oct-4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "ALDH1A1, and conducted the cell sphere formation. Flow cytometry was used to",
    "entities": []
  },
  {
    "text": "detect the proportion of stem cells. To assess the level of glycolysis in BC",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cells, we detected the expression of key proteins LDHA, HK2, and GLUT1 through",
    "entities": [
      {
        "text": "LDHA",
        "label": "PERSON"
      },
      {
        "text": "HK2",
        "label": "ORG"
      },
      {
        "text": "GLUT1",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "WB, and measured the extracellular acidification rate and oxygen consumption",
    "entities": [
      {
        "text": "WB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "rate with kits. Cell experiments combining bioinformatics analysis demonstrated",
    "entities": []
  },
  {
    "text": "that both E2F7 and SPC24 were greatly upregulated in BC, with SPC24 primarily",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "enriched in the glycolysis metabolic pathway. Further experiments manifested",
    "entities": []
  },
  {
    "text": "that SPC24 reinforced cell stemness through aerobic glycolysis reprogramming,",
    "entities": []
  },
  {
    "text": "and SPC24 was modulated by transcription factor E2F7. E2F7 transcriptionally",
    "entities": [
      {
        "text": "transcription",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "activates the upregulation of SPC24 in BC, which boosts stemness through aerobic",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "glycolysis reprogramming.",
    "entities": []
  },
  {
    "text": "participate: Not Applicable. Competing interests: The authors declare no",
    "entities": []
  },
  {
    "text": "SOX4 promotes triple-negative breast cancer progression by promoting",
    "entities": []
  },
  {
    "text": "SRPX2 transcription to regulate AKR1C1.",
    "entities": []
  },
  {
    "text": "(1)Department of Pathology, Rudong County Hospital of Traditional Chinese",
    "entities": [
      {
        "text": "Pathology",
        "label": "ORG"
      },
      {
        "text": "Rudong County Hospital of Traditional",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Rudong, China.",
    "entities": [
      {
        "text": "Rudong",
        "label": "PERSON"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Pathology, Nantong First People's Hospital, No. 666, Shengli",
    "entities": [
      {
        "text": "2)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Pathology",
        "label": "GPE"
      },
      {
        "text": "Nantong First People's Hospital",
        "label": "ORG"
      },
      {
        "text": "666",
        "label": "CARDINAL"
      },
      {
        "text": "Shengli",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Road, Guanyinshan Street, Nantong, 226001, China.",
    "entities": [
      {
        "text": "Nantong",
        "label": "GPE"
      },
      {
        "text": "226001",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Basic Medicine, Nanjing Medical University, Nanjing, China.",
    "entities": [
      {
        "text": "Basic Medicine",
        "label": "ORG"
      },
      {
        "text": "Nanjing Medical University",
        "label": "ORG"
      },
      {
        "text": "Nanjing",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Pathology, Nantong First People's Hospital, No. 666, Shengli",
    "entities": [
      {
        "text": "Pathology",
        "label": "GPE"
      },
      {
        "text": "Nantong First People's Hospital",
        "label": "ORG"
      },
      {
        "text": "666",
        "label": "CARDINAL"
      },
      {
        "text": "Shengli",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Road, Guanyinshan Street, Nantong, 226001, China. qjinfeng@ntu.edu.cn.",
    "entities": [
      {
        "text": "Nantong",
        "label": "GPE"
      },
      {
        "text": "226001",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer that",
    "entities": []
  },
  {
    "text": "poses a serious threat to women's health. The aldo-keto reductase type 1 C",
    "entities": []
  },
  {
    "text": "(AKR1C) family serves as a crucial ferroptosis defense system, catalyzing the",
    "entities": []
  },
  {
    "text": "conversion of aldehydes and ketones into their corresponding alcohols. SRY-Box4",
    "entities": [
      {
        "text": "SRY-Box4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(SOX4), a transcription factor of the SOX (sry-related HMG-box) family, is",
    "entities": [
      {
        "text": "SOX4",
        "label": "PERSON"
      },
      {
        "text": "transcription",
        "label": "CARDINAL"
      },
      {
        "text": "SOX",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "important in regulating tumor progression. This study aims to investigate the",
    "entities": []
  },
  {
    "text": "mechanism through which AKR1C1 mediates the growth, invasion, and ferroptosis of",
    "entities": []
  },
  {
    "text": "triple-negative breast cancer cells. SRPX2 was highly expressed in TNBC tissues",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and cells and was detrimental to patient prognosis. SRPX2 knockdown inhibited",
    "entities": []
  },
  {
    "text": "TNBC cell viability, invasion, and Stemness of tumor while promoting TNBC cell",
    "entities": [
      {
        "text": "Stemness",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "apoptosis and ferroptosis. SOX4 could bind to SRPX2 and was highly expressed in",
    "entities": [
      {
        "text": "SOX4",
        "label": "PERSON"
      },
      {
        "text": "SRPX2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "TNBC tissues and cells, down-regulation of SOX4 could inhibit the expression of",
    "entities": [
      {
        "text": "SOX4",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "SRPX2. Silencing SRPX2 inhibited the expression of AKR1C1. Up-regulating AKR1C1",
    "entities": []
  },
  {
    "text": "reversed the inhibitory effect of SRPX2 knockdown on cell viability, invasion,",
    "entities": [
      {
        "text": "SRPX2",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "and sphere formation abilities, and also reversed the promotive effect on",
    "entities": []
  },
  {
    "text": "apoptosis in TNBC cells. In vivo, SRPX2 knockdown suppressed tumor growth and",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "expression of Ki67 and AKR1C1 via down-regulated AKR1C1. SOX4 facilitates",
    "entities": []
  },
  {
    "text": "triple-negative breast cancer progression via promoting SRPX2 transcription to",
    "entities": []
  },
  {
    "text": "regulate AKR1C. This study is expected to explore potential therapeutic targets",
    "entities": []
  },
  {
    "text": "and strategies for the treatment of TNBC.",
    "entities": [
      {
        "text": "TNBC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "\u00a9 2025. The Author(s), under exclusive licence to Springer Nature B.V.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Springer Nature B.V.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40663167 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40663167",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "declare no competing interests. Ethics approval and consent to participate: The",
    "entities": []
  },
  {
    "text": "study had been authorized by the Ethics Committee of Nantong First People\u2019s",
    "entities": [
      {
        "text": "the Ethics Committee",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hospital. Each participant in this research gave their consent after being fully",
    "entities": []
  },
  {
    "text": "informed. Authorization for xenograft experiments was given by the Committee on",
    "entities": [
      {
        "text": "the Committee on\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Animal Welfare and Utilization of Nantong First People\u2019s Hospital. Consent for",
    "entities": [
      {
        "text": "Animal Welfare and Utilization of Nantong First People\u2019s Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "publication: Not applicable.",
    "entities": []
  },
  {
    "text": "Exploration of the Relationship between Macrophage-Related Proteins and the Risk",
    "entities": []
  },
  {
    "text": "and Prognosis of Breast Cancer.",
    "entities": [
      {
        "text": "Prognosis of Breast Cancer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Macrophage-related proteins play a crucial role in breast cancer.",
    "entities": []
  },
  {
    "text": "The present study explored the relationship between macrophage-related proteins",
    "entities": []
  },
  {
    "text": "and breast cancer using Mendelian randomization (MR) for genetic variations and",
    "entities": [
      {
        "text": "Mendelian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "bioinformatics methods for transcriptomics.",
    "entities": []
  },
  {
    "text": "METHODS: Genetic instruments associated with macrophage migration inhibitory",
    "entities": []
  },
  {
    "text": "factor (MIF), macrophage inflammatory protein 1\u03b1 (MIP-1\u03b1), macrophage",
    "entities": [
      {
        "text": "1\u03b1",
        "label": "CARDINAL"
      },
      {
        "text": "MIP-1\u03b1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "inflammatory protein 1\u03b2 (MIP-1\u03b2), and granulocyte macrophage colony-stimulating",
    "entities": [
      {
        "text": "1\u03b2",
        "label": "CARDINAL"
      },
      {
        "text": "MIP-1\u03b2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "factor (GM-CSF) were gathered from genome-wide association studies (GWAS). The",
    "entities": [
      {
        "text": "GM-CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "MR analysis was conducted using R software packages 'TwoSampleMR' and",
    "entities": []
  },
  {
    "text": "'MRPRESSO', employing MR-Egger, in-verse-variance weighted (IVW), weighted",
    "entities": []
  },
  {
    "text": "median, simple mode, and MR-PRESSO algorithms. In addition, data from the UCSC",
    "entities": [
      {
        "text": "UCSC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Xena database provided the TCGA BRCA dataset for a 5-year overall survival",
    "entities": [
      {
        "text": "Xena",
        "label": "ORG"
      },
      {
        "text": "5-year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "analysis of MIP-1\u03b1.",
    "entities": [
      {
        "text": "MIP-1\u03b1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "RESULTS: IVW analysis showed a significant positive association between MIP-1\u03b1",
    "entities": [
      {
        "text": "MIP-1\u03b1\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "and breast cancer incidence (OR = 1.0837, 95% CI: 1.0284 - 1.142), and the",
    "entities": [
      {
        "text": "1.0837",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.0284 - 1.142",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "MR-PRESSO result also confirmed a causal relationship between them (OR = 1.0789,",
    "entities": [
      {
        "text": "1.0789",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "95% CI: 1.0266 - 1.1338). There was no significant causal relationship found",
    "entities": [
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.0266 - 1.1338",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "between MIF, MIP-1B, GM-CSF, and breast cancer. Survival analysis revealed that",
    "entities": [
      {
        "text": "MIF",
        "label": "ORG"
      },
      {
        "text": "MIP-1B",
        "label": "PERSON"
      },
      {
        "text": "GM-CSF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CCL3 was associated with prognosis in breast cancer patients in the Cox",
    "entities": [
      {
        "text": "CCL3",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: Elevated levels of macrophage inflammatory protein 1A may increase",
    "entities": [
      {
        "text": "1A",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the risk of breast cancer and lead to poorer patient outcomes.",
    "entities": []
  },
  {
    "text": "PMID: 40663091 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40663091",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Pan-Cancer Bioinformatics Analysis of Matrix Metalloproteinase-9 (MMP9).",
    "entities": [
      {
        "text": "Pan-Cancer Bioinformatics Analysis of Matrix",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Matrix metalloproteinase-9 (MMP9) is a member of the matrix",
    "entities": []
  },
  {
    "text": "metalloproteinase family of proteases that have been linked to several major",
    "entities": [
      {
        "text": "metalloproteinase",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "normal and pathologic processes. Although cell-based, animal-based, or",
    "entities": []
  },
  {
    "text": "clinical-based evidence supports the relationship between MMP9 and cancers, the",
    "entities": []
  },
  {
    "text": "role of MMP9 in pan-cancer is still not fully understood.",
    "entities": []
  },
  {
    "text": "METHODS: We explored the prognostic value and potential immunological roles of",
    "entities": []
  },
  {
    "text": "MMP9 in 33 cancer types using the Cancer Genome Atlas datasets.",
    "entities": [
      {
        "text": "33",
        "label": "CARDINAL"
      },
      {
        "text": "the Cancer Genome Atlas",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: MMP9 is highly expressed at the RNA level in most cancers but is",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "present at a low protein level in breast cancer, liver cancer, lung",
    "entities": []
  },
  {
    "text": "adenocarcinoma, and ovarian cancer. Furthermore, there are distinct associations",
    "entities": []
  },
  {
    "text": "be-tween MMP9 expression and tumor patient prognosis. MMP9 expression was found",
    "entities": []
  },
  {
    "text": "to be associated with tumor mutational burden and microsatellite instability in",
    "entities": []
  },
  {
    "text": "eight cancer types, whereas it was associated with DNA methylation at multiple",
    "entities": [
      {
        "text": "eight",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "probes in 31 cancer types. Additionally, MMP9 expression was positively",
    "entities": [
      {
        "text": "31",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "associated with the infiltration levels of most immune cells in 33 cancer types.",
    "entities": [
      {
        "text": "33",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Moreover, extracellular matrix organizing-related and collagen",
    "entities": []
  },
  {
    "text": "metabolism-related functions are involved in the functional mechanism of MMP9.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: Our pancancer study offers a relatively comprehensive understanding",
    "entities": []
  },
  {
    "text": "of the role of MMP9 in tumorigenesis and tumor immunity in different tumors.",
    "entities": []
  },
  {
    "text": "PMID: 40663084 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "Cancer Detection in Breast MRI Screening via Explainable AI Anomaly Detection.",
    "entities": [
      {
        "text": "Explainable AI Anomaly Detection",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RA(4)(5), Kloft M(3), Blum E(2), Alessio AM(6), Li CI(7), Weeks WB(1), Dodhia",
    "entities": [
      {
        "text": "RA(4)(5",
        "label": "PERSON"
      },
      {
        "text": "Kloft M(3",
        "label": "PERSON"
      },
      {
        "text": "Alessio",
        "label": "PERSON"
      },
      {
        "text": "Li",
        "label": "PERSON"
      },
      {
        "text": "Weeks",
        "label": "DATE"
      },
      {
        "text": "Dodhia",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)AI for Good Lab, Microsoft, 1 Microsoft Way, 4330 150th Ave NE, Redmond, WA",
    "entities": [
      {
        "text": "1)AI",
        "label": "CARDINAL"
      },
      {
        "text": "Microsoft",
        "label": "ORG"
      },
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "Microsoft",
        "label": "ORG"
      },
      {
        "text": "4330",
        "label": "DATE"
      },
      {
        "text": "NE",
        "label": "GPE"
      },
      {
        "text": "Redmond",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Radiology, University of Washington School of Medicine,",
    "entities": [
      {
        "text": "Radiology, University of Washington School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Seattle, Wash.",
    "entities": [
      {
        "text": "Seattle",
        "label": "GPE"
      },
      {
        "text": "Wash.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)University of Kaiserslautern-Landau, Kaiserslautern, Germany.",
    "entities": [
      {
        "text": "Kaiserslautern-Landau",
        "label": "NORP"
      },
      {
        "text": "Kaiserslautern",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Berlin Institute for the Foundations of Learning and Data, Berlin, Germany.",
    "entities": [
      {
        "text": "Institute for the Foundations of Learning and Data",
        "label": "ORG"
      },
      {
        "text": "Berlin",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Machine Learning Group, Technical University of Berlin, Berlin, Germany.",
    "entities": [
      {
        "text": "5)Machine Learning Group,",
        "label": "ORG"
      },
      {
        "text": "Technical University",
        "label": "ORG"
      },
      {
        "text": "Berlin",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Biomedical Engineering, Michigan State University, East",
    "entities": [
      {
        "text": "Biomedical Engineering",
        "label": "ORG"
      },
      {
        "text": "Michigan State University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Fred Hutchinson Cancer Center, Seattle, Wash.",
    "entities": [
      {
        "text": "Hutchinson Cancer Center",
        "label": "ORG"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      },
      {
        "text": "Wash.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Background Artificial intelligence (AI) models hold potential to increase the",
    "entities": [
      {
        "text": "Background Artificial",
        "label": "ORG"
      },
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "accuracy and efficiency of breast MRI screening; however, existing models have",
    "entities": []
  },
  {
    "text": "not been rigorously evaluated in populations with low cancer prevalence and lack",
    "entities": []
  },
  {
    "text": "interpretability, both of which are essential for clinical adoption. Purpose To",
    "entities": []
  },
  {
    "text": "develop an explainable AI model for cancer detection at breast MRI that is",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "effective in both high- and low-cancer-prevalence settings. Materials and",
    "entities": []
  },
  {
    "text": "Methods This retrospective study included 9738 breast MRI examinations from a",
    "entities": [
      {
        "text": "9738",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "single institution (2005-2022), with external testing in a publicly available",
    "entities": [
      {
        "text": "2005-2022",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "multicenter dataset (221 examinations). In total, 9567 consecutive examinations",
    "entities": [
      {
        "text": "multicenter dataset",
        "label": "PERSON"
      },
      {
        "text": "221",
        "label": "CARDINAL"
      },
      {
        "text": "9567",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "were used to develop an explainable fully convolutional data description (FCDD)",
    "entities": [
      {
        "text": "FCDD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "anomaly detection model to detect malignancies on contrast-enhanced MRI scans.",
    "entities": [
      {
        "text": "anomaly detection",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Performance was evaluated in three cohorts: grouped cross-validation (for both",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "balanced [20.0% malignant] and imbalanced [1.85% malignant] detection tasks), an",
    "entities": [
      {
        "text": "20.0%",
        "label": "PERCENT"
      },
      {
        "text": "1.85%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "internal independent test set (171 examinations), and an external dataset.",
    "entities": [
      {
        "text": "171",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Explainability was assessed through pixelwise comparisons with",
    "entities": []
  },
  {
    "text": "reference-standard malignancy annotations. Statistical significance was assessed",
    "entities": []
  },
  {
    "text": "using the Wilcoxon signed rank test. Results FCDD outperformed the benchmark",
    "entities": [
      {
        "text": "Wilcoxon",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "binary cross-entropy (BCE) model in cross-validation for both balanced (mean",
    "entities": [
      {
        "text": "binary cross-entropy",
        "label": "ORG"
      },
      {
        "text": "BCE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "area under the receiver operating characteristic curve [AUC] = 0.84 \u00b1 0.01 [SD]",
    "entities": [
      {
        "text": "0.84",
        "label": "CARDINAL"
      },
      {
        "text": "0.01",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "vs 0.81 \u00b1 0.01; P < .001) and imbalanced (mean AUC = 0.72 \u00b1 0.03 vs 0.69 \u00b1 0.03;",
    "entities": [
      {
        "text": "0.81",
        "label": "CARDINAL"
      },
      {
        "text": "0.01",
        "label": "CARDINAL"
      },
      {
        "text": "P < .001",
        "label": "ORG"
      },
      {
        "text": "0.72",
        "label": "CARDINAL"
      },
      {
        "text": "0.03",
        "label": "CARDINAL"
      },
      {
        "text": "0.69",
        "label": "CARDINAL"
      },
      {
        "text": "0.03",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "P < .001) detection tasks. At a fixed 97% sensitivity in the imbalanced setting,",
    "entities": [
      {
        "text": "97%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "mean specificity across folds was 13% for FCDD and 9% for BCE (P = .02). In the",
    "entities": [
      {
        "text": "13%",
        "label": "PERCENT"
      },
      {
        "text": "FCDD",
        "label": "ORG"
      },
      {
        "text": "9%",
        "label": "PERCENT"
      },
      {
        "text": "BCE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "internal test set, FCDD outperformed BCE for balanced (mean AUC = 0.81 \u00b1 0.02 vs",
    "entities": [
      {
        "text": "FCDD",
        "label": "ORG"
      },
      {
        "text": "BCE",
        "label": "ORG"
      },
      {
        "text": "0.81",
        "label": "CARDINAL"
      },
      {
        "text": "0.02",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "0.72 \u00b1 0.02; P < .001) and imbalanced (mean AUC = 0.78 \u00b1 0.05 vs 0.76 \u00b1 0.01; P",
    "entities": [
      {
        "text": "0.72",
        "label": "CARDINAL"
      },
      {
        "text": "0.02",
        "label": "CARDINAL"
      },
      {
        "text": "P < .001",
        "label": "ORG"
      },
      {
        "text": "0.78",
        "label": "CARDINAL"
      },
      {
        "text": "0.05",
        "label": "CARDINAL"
      },
      {
        "text": "0.76",
        "label": "DATE"
      },
      {
        "text": "0.01",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "< .02) detection tasks. For model explainability, FCDD demonstrated better",
    "entities": [
      {
        "text": "FCDD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "spatial agreement with reference-standard annotations than BCE (internal test",
    "entities": [
      {
        "text": "BCE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "set: mean pixelwise AUC = 0.92 \u00b1 0.10 vs 0.81 \u00b1 0.13; P < .001). External",
    "entities": [
      {
        "text": "0.92",
        "label": "CARDINAL"
      },
      {
        "text": "0.10",
        "label": "CARDINAL"
      },
      {
        "text": "0.81",
        "label": "CARDINAL"
      },
      {
        "text": "0.13",
        "label": "CARDINAL"
      },
      {
        "text": "P < .001",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "testing confirmed that FCDD performed well, and better than BCE, in the balanced",
    "entities": [
      {
        "text": "FCDD",
        "label": "ORG"
      },
      {
        "text": "BCE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "detection task (AUC = 0.86 \u00b1 0.01 vs 0.79 \u00b1 0.01; P < .001). Conclusion The",
    "entities": [
      {
        "text": "0.86",
        "label": "CARDINAL"
      },
      {
        "text": "0.01",
        "label": "CARDINAL"
      },
      {
        "text": "0.79",
        "label": "CARDINAL"
      },
      {
        "text": "0.01",
        "label": "CARDINAL"
      },
      {
        "text": "P < .001",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "developed explainable AI model for cancer detection at breast MRI accurately",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "depicted tumor location and outperformed commonly used models in both high- and",
    "entities": []
  },
  {
    "text": "low-cancer-prevalence scenarios. \u00a9 RSNA, 2025 Supplemental material is available",
    "entities": [
      {
        "text": "RSNA",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "for this article. See also the editorial by Bae and Ham in this issue.",
    "entities": [
      {
        "text": "Bae and Ham",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40662973 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40662973",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Explainable AI in MRI for Breast Cancer Detection: Another Step Forward.",
    "entities": []
  },
  {
    "text": "(1)Department of Radiology, Korea University Ansan Hospital, Korea University",
    "entities": [
      {
        "text": "Radiology, Korea University Ansan Hospital",
        "label": "ORG"
      },
      {
        "text": "Korea University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "College of Medicine, 46 Gaeunsa 2-gil, Seongbuk-gu, Seoul 02842, South Korea.",
    "entities": [
      {
        "text": "College of Medicine",
        "label": "ORG"
      },
      {
        "text": "46",
        "label": "CARDINAL"
      },
      {
        "text": "Gaeunsa",
        "label": "PERSON"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "Seongbuk-gu",
        "label": "PERSON"
      },
      {
        "text": "South Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Healthcare Readiness Institute for Unified Korea, Korea University Ansan",
    "entities": [
      {
        "text": "Readiness Institute",
        "label": "ORG"
      },
      {
        "text": "Unified Korea",
        "label": "GPE"
      },
      {
        "text": "Korea University Ansan\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hospital, Korea University College of Medicine, Seoul, Korea.",
    "entities": [
      {
        "text": "Korea University College of Medicine",
        "label": "ORG"
      },
      {
        "text": "Seoul",
        "label": "GPE"
      },
      {
        "text": "Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "86. J Occup Environ Med. 2025 Jul 15. doi: 10.1097/JOM.0000000000003495. Online",
    "entities": [
      {
        "text": "86",
        "label": "CARDINAL"
      },
      {
        "text": "Occup Environ Med",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1097",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "The incidence of postmenopausal breast cancer in relation to occupational",
    "entities": []
  },
  {
    "text": "exposure to textile fibers and dusts in Montreal, Canada, 2008-2011.",
    "entities": [
      {
        "text": "Montreal",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      },
      {
        "text": "2008-2011",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(1)Department of Medicine, McGill University Health Center, Montr\u00e9al, Qu\u00e9bec,",
    "entities": [
      {
        "text": "Medicine, McGill University Health Center",
        "label": "ORG"
      },
      {
        "text": "Montr\u00e9al",
        "label": "GPE"
      },
      {
        "text": "Qu\u00e9bec",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "OBJECTIVE: To estimate the associations between occupational exposure to textile",
    "entities": []
  },
  {
    "text": "fibers/dusts, and incidence of postmenopausal invasive breast cancer.",
    "entities": []
  },
  {
    "text": "METHODS: A population-based case-control study conducted in Montreal (2008 -",
    "entities": [
      {
        "text": "Montreal",
        "label": "GPE"
      },
      {
        "text": "2008",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "2011) identified hospital cases (N = 695) and population controls (N = 608) from",
    "entities": [
      {
        "text": "2011",
        "label": "DATE"
      },
      {
        "text": "695",
        "label": "CARDINAL"
      },
      {
        "text": "608",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "the electoral list. Occupational hygienists examined participants' occupations",
    "entities": []
  },
  {
    "text": "and tasks, and attributed exposures to several textile fibers. For all tumors",
    "entities": []
  },
  {
    "text": "and according to biomolecular subtypes, odds ratios (OR) and 95% confidence",
    "entities": [
      {
        "text": "95%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "intervals (95%CI) were estimated using logistic regression models with different",
    "entities": []
  },
  {
    "text": "exposure indices, adjusting for potential confounders.",
    "entities": []
  },
  {
    "text": "RESULTS: Ever exposure to cotton dust was associated with an increased risk (OR",
    "entities": []
  },
  {
    "text": "= 1.42, 95%CI = 0.95-2.16) as was ever exposure to treated textile fibers before",
    "entities": [
      {
        "text": "1.42",
        "label": "CARDINAL"
      },
      {
        "text": "0.95-2.16",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "age 36 years and/or before first full-term pregnancy (OR = 1.39, 95%IC =",
    "entities": [
      {
        "text": "age 36 years",
        "label": "DATE"
      },
      {
        "text": "first",
        "label": "ORDINAL"
      },
      {
        "text": "1.39",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: These suggestive associations and the rapid evolution of textile",
    "entities": []
  },
  {
    "text": "fibers treatment warrant additional scrutiny, especially among younger women.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Wolters Kluwer Health, Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "behalf of the American College of Occupational and Environmental Medicine.",
    "entities": [
      {
        "text": "the American College of Occupational and Environmental Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Conflict of Interest: None Declared.",
    "entities": [
      {
        "text": "Conflict of Interest",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "An immunological mechanism of resistance to CDK4/6 inhibitors in HR(+) breast",
    "entities": [
      {
        "text": "CDK4/6",
        "label": "ORG"
      },
      {
        "text": "HR(+",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "(1)Department of Pharmacology, Weill Cornell Medical College, New York, NY, USA.",
    "entities": [
      {
        "text": "Weill Cornell Medical College",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Experimental and Clinical Medicine, University of Florence,",
    "entities": [
      {
        "text": "Experimental",
        "label": "ORG"
      },
      {
        "text": "Clinical Medicine",
        "label": "ORG"
      },
      {
        "text": "University of Florence",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Florence, Italy.",
    "entities": [
      {
        "text": "Florence",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles,",
    "entities": [
      {
        "text": "Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "Cedars-Sinai Medical Center",
        "label": "ORG"
      },
      {
        "text": "Los Angeles",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center,",
    "entities": [
      {
        "text": "4)Cancer",
        "label": "CARDINAL"
      },
      {
        "text": "Signaling",
        "label": "ORG"
      },
      {
        "text": "Microenvironment Program",
        "label": "ORG"
      },
      {
        "text": "Fox Chase Cancer Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CDK4/6 inhibitors are central to the clinical management of HR+HER2- breast",
    "entities": []
  },
  {
    "text": "cancer. We have recently demonstrated that immunosuppressive, IL17-secreting \u03b3\u03b4",
    "entities": []
  },
  {
    "text": "T cells recruited to the tumor microenvironment by a CCL2-dependent mechanism",
    "entities": []
  },
  {
    "text": "upon CDK4/6 inhibition can repolarize tumor-associated macrophages toward a",
    "entities": []
  },
  {
    "text": "CX3CR1+ phenotype associated with resistance to therapy.",
    "entities": []
  },
  {
    "text": "PMID: 40662849 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40662849",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1093/bioinformatics/btaf180.",
    "entities": [
      {
        "text": "10.1093",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "RVINN: a flexible modeling for inferring dynamic transcriptional and",
    "entities": []
  },
  {
    "text": "post-transcriptional regulation using physics-informed neural networks.",
    "entities": []
  },
  {
    "text": "(1)Division of Cancer Systems Biology, Aichi Cancer Center Research Institute,",
    "entities": [
      {
        "text": "Cancer Systems Biology",
        "label": "ORG"
      },
      {
        "text": "Aichi Cancer Center Research Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Division of Cancer Informatics, Nagoya University Graduate School of",
    "entities": [
      {
        "text": "Cancer Informatics",
        "label": "ORG"
      },
      {
        "text": "Nagoya University Graduate School of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "SUMMARY: Dynamic gene expression is controlled by transcriptional and",
    "entities": []
  },
  {
    "text": "post-transcriptional regulation. Recent studies on transcriptional bursting and",
    "entities": []
  },
  {
    "text": "buffering have increasingly highlighted the dynamic gene regulatory mechanisms.",
    "entities": []
  },
  {
    "text": "require complementary methodologies, which are both comprehensive and versatile.",
    "entities": []
  },
  {
    "text": "To address this issue, inference approaches based on transcriptome data and",
    "entities": []
  },
  {
    "text": "differential equation models representing the messenger RNA lifecycle have been",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "proposed. However, the inference of complex dynamics under diverse experimental",
    "entities": []
  },
  {
    "text": "conditions and biological scenarios remains challenging. In this study, we",
    "entities": []
  },
  {
    "text": "developed a flexible modeling using physics-informed neural networks and",
    "entities": []
  },
  {
    "text": "demonstrated its performance using simulation and experimental data. Our model",
    "entities": []
  },
  {
    "text": "has the ability to computationally revalidate and visualize dynamic biological",
    "entities": []
  },
  {
    "text": "phenomena, such as transcriptional ripple, co-bursting, and buffering in a",
    "entities": []
  },
  {
    "text": "breast cancer cell line. Furthermore, our results suggest putative molecular",
    "entities": []
  },
  {
    "text": "mechanisms underlying these phenomena. We propose a novel approach for inferring",
    "entities": []
  },
  {
    "text": "transcriptional and post-transcriptional regulation and expect to offer valuable",
    "entities": []
  },
  {
    "text": "insights for experimental and systems biology.",
    "entities": []
  },
  {
    "text": "DOI: 10.1093/bioinformatics/btaf180",
    "entities": [
      {
        "text": "10.1093",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40662812 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40662812",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1093/bioinformatics/btaf213.",
    "entities": [
      {
        "text": "10.1093",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "GRACKLE: an interpretable matrix factorization approach for biomedical",
    "entities": []
  },
  {
    "text": "representation learning.",
    "entities": []
  },
  {
    "text": "(1)Department of Pharmacology, University of Colorado Anschutz Medical Campus,",
    "entities": [
      {
        "text": "Pharmacology, University of Colorado Anschutz Medical Campus",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Aurora, CO, 80045, United States.",
    "entities": [
      {
        "text": "Aurora",
        "label": "ORG"
      },
      {
        "text": "CO",
        "label": "ORG"
      },
      {
        "text": "80045",
        "label": "DATE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Computational Bioscience Program, University of Colorado Anschutz Medical",
    "entities": [
      {
        "text": "2)Computational",
        "label": "CARDINAL"
      },
      {
        "text": "Bioscience Program",
        "label": "ORG"
      },
      {
        "text": "University of Colorado Anschutz Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Campus, Aurora, CO, 80045, United States.",
    "entities": [
      {
        "text": "Aurora",
        "label": "ORG"
      },
      {
        "text": "CO",
        "label": "ORG"
      },
      {
        "text": "80045",
        "label": "DATE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz",
    "entities": [
      {
        "text": "3)Linda",
        "label": "CARDINAL"
      },
      {
        "text": "Crnic Institute",
        "label": "ORG"
      },
      {
        "text": "University of Colorado",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medical Campus, Aurora, CO, 80045, United States.",
    "entities": [
      {
        "text": "Aurora",
        "label": "ORG"
      },
      {
        "text": "CO",
        "label": "ORG"
      },
      {
        "text": "80045",
        "label": "DATE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Pediatrics, University of Chicago, Chicago, IL, 60637, United",
    "entities": [
      {
        "text": "Pediatrics, University of Chicago",
        "label": "ORG"
      },
      {
        "text": "Chicago",
        "label": "GPE"
      },
      {
        "text": "IL",
        "label": "ORG"
      },
      {
        "text": "60637",
        "label": "DATE"
      },
      {
        "text": "United",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "States.",
    "entities": [
      {
        "text": "States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Biomedical Informatics, University of Colorado Anschutz Medical",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Biomedical Informatics",
        "label": "ORG"
      },
      {
        "text": "University of Colorado Anschutz Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "MOTIVATION: Disruption in normal gene expression can contribute to the",
    "entities": []
  },
  {
    "text": "development of diseases and chronic conditions. However, identifying",
    "entities": []
  },
  {
    "text": "disease-specific gene signatures can be challenging due to the presence of",
    "entities": []
  },
  {
    "text": "multiple co-occurring conditions and limited sample sizes. Unsupervised",
    "entities": []
  },
  {
    "text": "representation learning methods, such as matrix decomposition and deep learning,",
    "entities": []
  },
  {
    "text": "simplify high-dimensional data into understandable patterns, but often do not",
    "entities": []
  },
  {
    "text": "provide clear biological explanations. Incorporating prior biological knowledge",
    "entities": []
  },
  {
    "text": "directly can enhance understanding and address small sample sizes. Nevertheless,",
    "entities": []
  },
  {
    "text": "current models do not jointly consider prior knowledge of molecular interactions",
    "entities": []
  },
  {
    "text": "RESULTS: We present GRACKLE, a novel nonnegative matrix factorization approach",
    "entities": [
      {
        "text": "GRACKLE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "that applies Graph Regularization Across Contextual KnowLedgE. GRACKLE",
    "entities": [
      {
        "text": "GRACKLE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "integrates sample similarity and gene similarity matrices based on sample",
    "entities": []
  },
  {
    "text": "metadata and molecular relationships, respectively. Simulation studies show",
    "entities": []
  },
  {
    "text": "GRACKLE outperformed other NMF algorithms, especially with increased background",
    "entities": [
      {
        "text": "GRACKLE",
        "label": "ORG"
      },
      {
        "text": "NMF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "noise. GRACKLE effectively stratified breast tumor samples and identified",
    "entities": [
      {
        "text": "GRACKLE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "condition-enriched subgroups in individuals with Down syndrome. The model's",
    "entities": []
  },
  {
    "text": "latent representations aligned with known biological patterns, such as",
    "entities": []
  },
  {
    "text": "autoimmune conditions and sleep apnea in Down syndrome. GRACKLE's flexibility",
    "entities": [
      {
        "text": "GRACKLE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "allows application to various data modalities, offering a robust solution for",
    "entities": []
  },
  {
    "text": "identifying context-specific molecular mechanisms in biomedical research.",
    "entities": []
  },
  {
    "text": "AVAILABILITY AND IMPLEMENTATION: GRACKLE is available at:",
    "entities": [
      {
        "text": "AVAILABILITY",
        "label": "ORG"
      },
      {
        "text": "GRACKLE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DOI: 10.1093/bioinformatics/btaf213",
    "entities": [
      {
        "text": "10.1093",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40662804 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "10.1093/bioinformatics/btaf179.",
    "entities": [
      {
        "text": "10.1093",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "HIDE: hierarchical cell-type deconvolution.",
    "entities": []
  },
  {
    "text": "(1)Computational Biology Unit, Department of Informatics, University of Bergen,",
    "entities": [
      {
        "text": "Biology Unit",
        "label": "ORG"
      },
      {
        "text": "Department of Informatics, University of Bergen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Institute of Theoretical Physics, University of Regensburg, Regensburg 93053,",
    "entities": [
      {
        "text": "2)Institute",
        "label": "CARDINAL"
      },
      {
        "text": "Theoretical Physics",
        "label": "ORG"
      },
      {
        "text": "University of Regensburg",
        "label": "ORG"
      },
      {
        "text": "Regensburg 93053",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(3)Department of Medical Bioinformatics, University Medical Center G\u00f6ttingen,",
    "entities": [
      {
        "text": "Medical Bioinformatics, University Medical Center G\u00f6ttingen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Institute of Human Anatomy and Embryology, University of Regensburg,",
    "entities": [
      {
        "text": "Embryology, University of Regensburg",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hannover Medical School, Hannover Medical School, Hannover 30625, Germany.",
    "entities": [
      {
        "text": "Hannover Medical School",
        "label": "ORG"
      },
      {
        "text": "Hannover Medical School",
        "label": "ORG"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Biomedicine and Centre for Cancer Biomarkers, University of",
    "entities": [
      {
        "text": "Biomedicine and Centre for Cancer Biomarkers",
        "label": "ORG"
      },
      {
        "text": "University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "MOTIVATION: Cell-type deconvolution is a computational approach to infer",
    "entities": []
  },
  {
    "text": "cellular distributions from bulk transcriptomics data. Several methods have been",
    "entities": []
  },
  {
    "text": "proposed, each with its own advantages and disadvantages. Reference based",
    "entities": []
  },
  {
    "text": "approaches make use of archetypic transcriptomic profiles representing",
    "entities": []
  },
  {
    "text": "individual cell types. Those reference profiles are ideally chosen such that the",
    "entities": []
  },
  {
    "text": "observed bulks can be reconstructed as a linear combination thereof. This",
    "entities": []
  },
  {
    "text": "strategy, however, ignores the fact that cellular populations arise through the",
    "entities": []
  },
  {
    "text": "process of cellular differentiation, which entails the gradual emergence of cell",
    "entities": []
  },
  {
    "text": "groups with diverse morphological and functional characteristics.",
    "entities": []
  },
  {
    "text": "RESULTS: Here, we propose Hierarchical cell-type Deconvolution (HIDE), a",
    "entities": [
      {
        "text": "Hierarchical",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "cell-type deconvolution approach which incorporates a cell hierarchy for",
    "entities": []
  },
  {
    "text": "improved performance and interpretability. This is achieved by a hierarchical",
    "entities": []
  },
  {
    "text": "procedure that preserves estimates of major cell populations while inferring",
    "entities": []
  },
  {
    "text": "their respective subpopulations. We show in simulation studies that this",
    "entities": []
  },
  {
    "text": "procedure produces more reliable and more consistent results than other",
    "entities": []
  },
  {
    "text": "state-of-the-art approaches. Finally, we provide an example application of HIDE",
    "entities": []
  },
  {
    "text": "to explore breast cancer specimens from TCGA.",
    "entities": [
      {
        "text": "TCGA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "AVAILABILITY AND IMPLEMENTATION: A python implementation of HIDE is available at",
    "entities": [
      {
        "text": "AVAILABILITY",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DOI: 10.1093/bioinformatics/btaf179",
    "entities": [
      {
        "text": "10.1093",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40662776 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40662776",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "91. Nano Lett. 2025 Jul 15. doi: 10.1021/acs.nanolett.5c01830. Online ahead of",
    "entities": [
      {
        "text": "91",
        "label": "CARDINAL"
      },
      {
        "text": "Nano Lett",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1021",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "T-Cell-Derived Extracellular Vesicles with an Antitransferrin Receptor Antibody",
    "entities": [
      {
        "text": "Antitransferrin",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "for Multicancer Targeting.",
    "entities": [
      {
        "text": "Multicancer Targeting",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "MC(2).",
    "entities": [
      {
        "text": "MC(2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Biomedical Science, Kyungpook National University School of",
    "entities": [
      {
        "text": "Biomedical Science",
        "label": "ORG"
      },
      {
        "text": "Kyungpook National University School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Daegu 41944, Republic of Korea.",
    "entities": [
      {
        "text": "41944",
        "label": "DATE"
      },
      {
        "text": "Republic of Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Molecular Medicine, CMRI, Kyungpook National University School",
    "entities": [
      {
        "text": "Molecular Medicine",
        "label": "ORG"
      },
      {
        "text": "Kyungpook National University School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medicine, Daegu 41944, Republic of Korea.",
    "entities": [
      {
        "text": "41944",
        "label": "DATE"
      },
      {
        "text": "Republic of Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of New Biology, Daegu Gyeongbuk Institute of Science & Technology,",
    "entities": [
      {
        "text": "New Biology",
        "label": "ORG"
      },
      {
        "text": "Daegu Gyeongbuk Institute of Science & Technology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Daegu 42988, Republic of Korea.",
    "entities": [
      {
        "text": "Daegu 42988,",
        "label": "PERSON"
      },
      {
        "text": "Republic of Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Physics and Chemistry, Daegu Gyeongbuk Institute of Science &",
    "entities": [
      {
        "text": "Physics",
        "label": "ORG"
      },
      {
        "text": "Chemistry",
        "label": "ORG"
      },
      {
        "text": "Daegu Gyeongbuk Institute of Science &\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Technology, Daegu 42988, Republic of Korea.",
    "entities": [
      {
        "text": "42988",
        "label": "DATE"
      },
      {
        "text": "Republic of Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Section of Molecular Pharmacology and Toxicology, Laboratory of Membrane",
    "entities": [
      {
        "text": "Molecular Pharmacology and Toxicology, Laboratory of Membrane",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Biochemistry and Biophysics, National Institute on Alcohol Abuse and Alcoholism,",
    "entities": [
      {
        "text": "Biochemistry and Biophysics",
        "label": "ORG"
      },
      {
        "text": "National Institute on Alcohol Abuse",
        "label": "ORG"
      },
      {
        "text": "Alcoholism",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "National Institutes of Health (NIH), Bethesda, Maryland 20892, United States.",
    "entities": [
      {
        "text": "National Institutes of Health",
        "label": "ORG"
      },
      {
        "text": "NIH",
        "label": "ORG"
      },
      {
        "text": "Bethesda",
        "label": "GPE"
      },
      {
        "text": "Maryland",
        "label": "GPE"
      },
      {
        "text": "20892",
        "label": "DATE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Recent research has explored the anticancer properties of immune-cell-derived",
    "entities": []
  },
  {
    "text": "small extracellular vesicles (sEVs), but many challenges, like the need for",
    "entities": []
  },
  {
    "text": "improved targeting, remain. To address these challenges, we engineered",
    "entities": []
  },
  {
    "text": "T-cell-derived sEVs with antitransferrin receptor 1 (TfR1) antibodies (T-EVs).",
    "entities": []
  },
  {
    "text": "This modification enhanced the delivery of sEV to six types of cancer cells, as",
    "entities": [
      {
        "text": "six",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "confirmed by flow cytometry, immunocytochemistry, live cell imaging, and",
    "entities": []
  },
  {
    "text": "blocking experiments in vitro. The T-EVs also reduced PD-L1 and Rab27a levels,",
    "entities": []
  },
  {
    "text": "decreased sEV production from breast cancer cells, and increased susceptibility",
    "entities": []
  },
  {
    "text": "to CD8+ T-cell-mediated cytotoxicity. Systemically administered T-EVs",
    "entities": []
  },
  {
    "text": "efficiently targeted breast, lung, and skin tumors in mouse models. Notably,",
    "entities": []
  },
  {
    "text": "T-EVs significantly inhibited tumor growth without systemic toxicity.",
    "entities": []
  },
  {
    "text": "Additionally, T-EVs reduced PD-L1 and Rab27a levels in cancer cells while",
    "entities": []
  },
  {
    "text": "enhancing the CD8+ T-cell cytotoxicity and proliferation. Overall, this study",
    "entities": []
  },
  {
    "text": "highlights the anticancer effects of T-EVs against multiple cancer types,",
    "entities": []
  },
  {
    "text": "underscoring their potential in developing targeted cancer therapies.",
    "entities": []
  },
  {
    "text": "Robust Transfer Learning for High-Dimensional GLM Using \u03b3 -Divergence With",
    "entities": []
  },
  {
    "text": "Applications to Cancer Genomics.",
    "entities": []
  },
  {
    "text": "(1)International Institute of Finance, School of Management, University of",
    "entities": [
      {
        "text": "Institute of Finance",
        "label": "ORG"
      },
      {
        "text": "School of Management, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Science and Technology of China, Anhui, China.",
    "entities": [
      {
        "text": "Science and Technology of China",
        "label": "ORG"
      },
      {
        "text": "Anhui",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)The Wang Yanan Institute for Studies in Economics, Xiamen University, Fujian,",
    "entities": [
      {
        "text": "Wang Yanan Institute for Studies",
        "label": "ORG"
      },
      {
        "text": "Economics, Xiamen University",
        "label": "ORG"
      },
      {
        "text": "Fujian",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Biostatistics, Yale School of Public Health, New Haven,",
    "entities": [
      {
        "text": "Biostatistics, Yale School of Public Health",
        "label": "ORG"
      },
      {
        "text": "New Haven",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Statistics and Data Science, School of Economics, Xiamen",
    "entities": [
      {
        "text": "Statistics",
        "label": "ORG"
      },
      {
        "text": "Data Science, School of Economics",
        "label": "ORG"
      },
      {
        "text": "Xiamen",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University, Fujian, China.",
    "entities": [
      {
        "text": "Fujian",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)School of Public Health, Shanghai Jiao Tong University School of Medicine,",
    "entities": [
      {
        "text": "5)School of Public Health",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      },
      {
        "text": "Tong University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "In the analysis of complex diseases, high-dimensional profiling data is",
    "entities": []
  },
  {
    "text": "important for assessing risks and detecting biomarkers. With the increasing",
    "entities": []
  },
  {
    "text": "accessibility of cancer genomic data, the sample sizes remain limited in most",
    "entities": []
  },
  {
    "text": "studies. Hence, borrowing information from additional data sources is thus",
    "entities": []
  },
  {
    "text": "desirable to improve estimation and prediction. Transfer learning has been",
    "entities": []
  },
  {
    "text": "demonstrated to be flexible and effective in boosting modeling performance with",
    "entities": []
  },
  {
    "text": "a record in biomedical applications. In practice, outliers and even data",
    "entities": []
  },
  {
    "text": "contamination often occur. However, existing transfer learning methods often",
    "entities": []
  },
  {
    "text": "lack robustness to outliers and data contamination, issues commonly observed in",
    "entities": []
  },
  {
    "text": "real-world biomedical data. In this study, we propose a robust transfer learning",
    "entities": []
  },
  {
    "text": "approach based on the minimum \u03b3 -divergence under a generalized linear model",
    "entities": []
  },
  {
    "text": "(GLM) framework for high-dimensional data. Our method incorporates a data-driven",
    "entities": [
      {
        "text": "GLM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "source detection scheme that automatically identifies informative sources while",
    "entities": []
  },
  {
    "text": "mitigating the risk of negative transfer. We establish rigorous theoretical",
    "entities": []
  },
  {
    "text": "results, including consistency and high-dimensional estimation error bounds,",
    "entities": []
  },
  {
    "text": "ensuring robustness and reliable performance. A computationally efficient",
    "entities": []
  },
  {
    "text": "algorithm is developed based on proximal gradient descent to facilitate both the",
    "entities": []
  },
  {
    "text": "transfer and debiasing steps. Simulation demonstrates the superior and",
    "entities": []
  },
  {
    "text": "competitive performance of the proposed approach in selection and",
    "entities": []
  },
  {
    "text": "prediction/classification. We further validate its practical utility by",
    "entities": []
  },
  {
    "text": "analyzing data on breast cancer and glioblastoma, showcasing the method's",
    "entities": []
  },
  {
    "text": "effectiveness in real-world high-dimensional settings.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 John Wiley & Sons Ltd.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "John Wiley & Sons Ltd.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40662636 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40662636",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Recent Developments in Vesicular Nanocarriers for Targeted Drug Delivery in",
    "entities": []
  },
  {
    "text": "Breast Cancer.",
    "entities": [
      {
        "text": "Breast Cancer",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Quality Assurance, ISF College of Pharmacy, GT Road, Moga,",
    "entities": [
      {
        "text": "Quality Assurance",
        "label": "ORG"
      },
      {
        "text": "ISF College of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "GT Road",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "(2)Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001,",
    "entities": [
      {
        "text": "Pharmaceutics",
        "label": "ORG"
      },
      {
        "text": "ISF College of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "GT Road, Moga",
        "label": "FAC"
      },
      {
        "text": "142001",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(3)Department of Pharmaceutical Chemistry, ISF College of Pharmacy, GT Road,",
    "entities": [
      {
        "text": "Pharmaceutical Chemistry",
        "label": "ORG"
      },
      {
        "text": "ISF College of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "GT Road",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Breast cancer remains one of the most challenging malignancies worldwide due to",
    "entities": [
      {
        "text": "one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "its heterogeneity, which affects tumor behavior, progression, and treatment",
    "entities": []
  },
  {
    "text": "response. The complexity of breast cancer necessitates innovative therapeutic",
    "entities": []
  },
  {
    "text": "strategies to improve treatment outcomes. This review explores the potential of",
    "entities": []
  },
  {
    "text": "phytosomes, and transferosomes, in enhancing breast cancer treatment efficacy",
    "entities": []
  },
  {
    "text": "through targeted drug delivery. A detailed analysis of recent progress in the",
    "entities": []
  },
  {
    "text": "functionalization and application of vesicular nanocarriers is discussed,",
    "entities": []
  },
  {
    "text": "highlighting their contribution to enhancing pharmacokinetics, drug solubility,",
    "entities": []
  },
  {
    "text": "and targeted delivery. Both passive and active targeting strategies were",
    "entities": []
  },
  {
    "text": "assessed for their ability to enhance tumor-specific drug accumulation.",
    "entities": []
  },
  {
    "text": "Vesicular nanocarriers offer significant advantages, including reduced systemic",
    "entities": []
  },
  {
    "text": "toxicity, improved drug bioavailability, and precise delivery to cancer cells.",
    "entities": []
  },
  {
    "text": "Passive targeting utilizes the enhanced permeation and retention effect for",
    "entities": []
  },
  {
    "text": "tumor accumulation, while active targeting employs surface modifications with",
    "entities": []
  },
  {
    "text": "antibodies, aptamers, or peptides to enhance specificity. The integration of",
    "entities": []
  },
  {
    "text": "vesicular nanocarriers in breast cancer therapy presents a promising strategy",
    "entities": []
  },
  {
    "text": "for more effective and personalized treatment approaches. Their ability to",
    "entities": []
  },
  {
    "text": "optimize drug delivery and minimize off-target effects highlights their",
    "entities": []
  },
  {
    "text": "potential to revolutionize breast cancer treatment.",
    "entities": []
  },
  {
    "text": "Copyright\u00a9 Bentham Science Publishers; For any queries, please email at",
    "entities": [
      {
        "text": "Bentham Science Publishers",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Transfer Learning for Error-Contaminated Poisson Regression Models.",
    "entities": []
  },
  {
    "text": "(1)Department of Statistics, National Chengchi University, Taipei, Taiwan, ROC.",
    "entities": [
      {
        "text": "Statistics",
        "label": "ORG"
      },
      {
        "text": "National Chengchi University",
        "label": "ORG"
      },
      {
        "text": "Taipei",
        "label": "GPE"
      },
      {
        "text": "Taiwan",
        "label": "GPE"
      },
      {
        "text": "ROC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Poisson regression model has been a popular approach to characterize the count",
    "entities": [
      {
        "text": "Poisson",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "response and the covariates. With the rapid development of data collections, the",
    "entities": []
  },
  {
    "text": "additional source information can be easily recorded. To efficiently use the",
    "entities": []
  },
  {
    "text": "source data to improve the estimation under the original data, the transfer",
    "entities": []
  },
  {
    "text": "learning method is considered a strategy. However, challenging issues from the",
    "entities": []
  },
  {
    "text": "given datasets include measurement error and high-dimensionality in variables,",
    "entities": []
  },
  {
    "text": "which are not well explored in the context of transfer learning. In this paper,",
    "entities": []
  },
  {
    "text": "we propose a novel strategy to handle error-prone count responses and estimate",
    "entities": []
  },
  {
    "text": "the parameters in measurement error models by using the source data, and then",
    "entities": []
  },
  {
    "text": "employ the transfer learning method to derive the corrected estimator. Moreover,",
    "entities": []
  },
  {
    "text": "to improve the prediction and avoid the model uncertainty, we further establish",
    "entities": []
  },
  {
    "text": "the model averaging strategy. Simulation and breast cancer data studies verify",
    "entities": []
  },
  {
    "text": "the satisfactory performance of the proposed method and the validity of handling",
    "entities": []
  },
  {
    "text": "PMID: 40662525 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40662525",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "95. Expert Rev Anticancer Ther. 2025 Jul 15. doi: 10.1080/14737140.2025.2535656.",
    "entities": [
      {
        "text": "95",
        "label": "CARDINAL"
      },
      {
        "text": "Rev Anticancer Ther",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Risk-reducing surgical timing in BRCA1/2 carriers following breast cancer in the",
    "entities": [
      {
        "text": "BRCA1/2",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "era of PARP inhibitors.",
    "entities": []
  },
  {
    "text": "(1)Department of Medical Oncology, Bower Hospital, Diyarbak\u0131r, Turkey.",
    "entities": [
      {
        "text": "Medical Oncology",
        "label": "ORG"
      },
      {
        "text": "Bower Hospital",
        "label": "ORG"
      },
      {
        "text": "Diyarbak\u0131r",
        "label": "GPE"
      },
      {
        "text": "Turkey",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Correction to \"Circular RNA circHSPA8 Aggravates Metastasis by Acting as a",
    "entities": [
      {
        "text": "Aggravates Metastasis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Competitive Inhibitor of miR-195-5p to Upregulate WNT3A Expression in Breast",
    "entities": [
      {
        "text": "Competitive Inhibitor",
        "label": "ORG"
      },
      {
        "text": "Upregulate WNT3A Expression",
        "label": "ORG"
      },
      {
        "text": "Breast",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Cancer\".",
    "entities": []
  },
  {
    "text": "[No authors listed]",
    "entities": []
  },
  {
    "text": "Accounting for Patient Characteristics in a Model-Based Kappa of Agreement",
    "entities": []
  },
  {
    "text": "Nelson KP(1), Zhou TJ(2).",
    "entities": [
      {
        "text": "Nelson KP(1",
        "label": "PERSON"
      },
      {
        "text": "Zhou TJ(2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Biostatistics, Boston University, Boston, Massachusetts, USA.",
    "entities": [
      {
        "text": "Biostatistics, Boston University",
        "label": "ORG"
      },
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "Massachusetts",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Center for Biologics Evaluation and Research, Food and Drug Administration,",
    "entities": [
      {
        "text": "2)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Biologics Evaluation and Research, Food and Drug Administration",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Silver Springs, Maryland, USA.",
    "entities": [
      {
        "text": "Silver Springs",
        "label": "GPE"
      },
      {
        "text": "Maryland",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Cohen's kappa and other summary measures are often used in clinical studies to",
    "entities": [
      {
        "text": "Cohen",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "describe agreement and association between two experts' ordered categorical",
    "entities": [
      {
        "text": "between two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "ratings. However, a key limitation of Cohen's kappa and similar measures is",
    "entities": [
      {
        "text": "Cohen",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "their inability to evaluate the impact of patient-related factors such as family",
    "entities": []
  },
  {
    "text": "history and age on the agreement and association between experts. Strong",
    "entities": []
  },
  {
    "text": "agreement between experts is an essential component of effective clinical",
    "entities": []
  },
  {
    "text": "procedures where subjective interpretation of patients' images or test results",
    "entities": []
  },
  {
    "text": "by an expert is required, for example, in the visual assessment of breast",
    "entities": []
  },
  {
    "text": "density from a mammogram. Not accounting for important patient-related factors",
    "entities": []
  },
  {
    "text": "can lead to inflated and biased assessments of agreement and association. In",
    "entities": []
  },
  {
    "text": "this article, our objective is to propose novel model-based measures that",
    "entities": []
  },
  {
    "text": "appropriately account for the impact of patient-related covariates on",
    "entities": []
  },
  {
    "text": "chance-corrected agreement and association between two experts' ordinal ratings",
    "entities": [
      {
        "text": "between two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "that overcome limitations of existing measures. Our population-based approach is",
    "entities": []
  },
  {
    "text": "based on an ordinal generalized linear mixed model (GLMM). Rigorous simulation",
    "entities": [
      {
        "text": "linear",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "studies evaluating performance of the new model-based measures in a broad range",
    "entities": []
  },
  {
    "text": "of settings are reported. Existing and new measures are compared in two clinical",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "applications assessing breast density and multiple sclerosis. Key advantages of",
    "entities": []
  },
  {
    "text": "the new kappa measures over existing measures such as Cohen's kappa include",
    "entities": [
      {
        "text": "the new kappa",
        "label": "ORG"
      },
      {
        "text": "Cohen",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "incorporating patient-related factors, robustness to underlying disease",
    "entities": []
  },
  {
    "text": "prevalence and marginal distributions of experts' ratings, and appropriately",
    "entities": []
  },
  {
    "text": "correcting for chance agreement. Sample R code is provided by the authors for",
    "entities": []
  },
  {
    "text": "application of proposed measures in other studies.",
    "entities": []
  },
  {
    "text": "PMID: 40662445 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40662445",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "eCollection 2025 Jul 15.",
    "entities": [
      {
        "text": "15",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "First-generation and preclinical evaluation of an EphA5-targeted antibody-drug",
    "entities": [
      {
        "text": "First",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "conjugate in solid tumors.",
    "entities": []
  },
  {
    "text": "Markosian C(2)(3), Staquicini DI(2)(3), Wu Y(1), Parsons JK(1), Barnhart KF(1),",
    "entities": [
      {
        "text": "Markosian",
        "label": "NORP"
      },
      {
        "text": "Staquicini DI(2)(3",
        "label": "PERSON"
      },
      {
        "text": "Wu Y(1",
        "label": "PERSON"
      },
      {
        "text": "Parsons JK(1",
        "label": "PERSON"
      },
      {
        "text": "Barnhart KF(1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Alley SC(1), Chen I(1), Arap W(2)(4), Pasqualini R(2)(3).",
    "entities": [
      {
        "text": "Alley",
        "label": "ORG"
      },
      {
        "text": "Chen",
        "label": "PERSON"
      },
      {
        "text": "Arap",
        "label": "PERSON"
      },
      {
        "text": "Pasqualini",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)MBrace Therapeutics, San Diego, California, USA.",
    "entities": [
      {
        "text": "1)MBrace",
        "label": "CARDINAL"
      },
      {
        "text": "San Diego",
        "label": "GPE"
      },
      {
        "text": "California",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Rutgers Cancer Institute, Newark, New Jersey, USA.",
    "entities": [
      {
        "text": "Cancer Institute",
        "label": "ORG"
      },
      {
        "text": "Newark",
        "label": "GPE"
      },
      {
        "text": "New Jersey",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Division of Cancer Biology, Department of Radiation Oncology, and.",
    "entities": [
      {
        "text": "Cancer Biology, Department of Radiation Oncology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey",
    "entities": [
      {
        "text": "Hematology/Oncology",
        "label": "ORG"
      },
      {
        "text": "Department of Medicine, Rutgers",
        "label": "ORG"
      },
      {
        "text": "New Jersey",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Medical School, Newark, New Jersey, USA.",
    "entities": [
      {
        "text": "Medical School",
        "label": "ORG"
      },
      {
        "text": "Newark",
        "label": "GPE"
      },
      {
        "text": "New Jersey",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Contemporary cancer treatment strategies are shifting toward targeted therapies",
    "entities": []
  },
  {
    "text": "to improve efficacy and minimize toxicity. Here, we report the design and",
    "entities": []
  },
  {
    "text": "preclinical evaluation of MBRC-101, a first-in-class antibody-drug conjugate",
    "entities": [
      {
        "text": "MBRC-101",
        "label": "GPE"
      },
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "(ADC) targeting EphA5, a receptor tyrosine kinase with an established role in",
    "entities": []
  },
  {
    "text": "embryonic development but not extensively studied in cancer. We show that EphA5",
    "entities": []
  },
  {
    "text": "is expressed in multiple solid tumors, including cancers of the aerodigestive",
    "entities": []
  },
  {
    "text": "(non-small cell lung, head and neck, gastric, colon, and pancreatic) and",
    "entities": []
  },
  {
    "text": "genitourinary (bladder and ovary) tracts, as well as most breast cancer subsets",
    "entities": []
  },
  {
    "text": "(including triple-negative tumors), with limited expression in normal tissues.",
    "entities": []
  },
  {
    "text": "MBRC-101 is a humanized anti-EphA5 antibody conjugated to monomethyl auristatin",
    "entities": [
      {
        "text": "auristatin",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "E (MMAE) through a ThioBridge, thereby ensuring stable drug-to-antibody ratio",
    "entities": [
      {
        "text": "ThioBridge",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "and reducing off-target effects. MBRC-101 showed potent antitumor activity,",
    "entities": []
  },
  {
    "text": "achieving complete tumor regression in several patient-derived xenograft models.",
    "entities": []
  },
  {
    "text": "Preclinical Good Laboratory Practice-compliant toxicology studies in rats and",
    "entities": [
      {
        "text": "Preclinical Good Laboratory Practice",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "nonhuman primates demonstrated that MBRC-101 is well tolerated, with observed",
    "entities": []
  },
  {
    "text": "toxicities limited to known MMAE off-target effects. These findings establish",
    "entities": []
  },
  {
    "text": "EphA5 as a therapeutic target in cancer and support the translational",
    "entities": []
  },
  {
    "text": "development of MBRC-101 as a promising ADC candidate for clinical evaluation,",
    "entities": []
  },
  {
    "text": "currently in a first-in-human multicenter investigational trial for patients",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "with advanced solid tumors (ClinicalTrials.gov, NCT06014658).",
    "entities": []
  },
  {
    "text": "PMID: 40662373 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40662373",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "HIF-1 promotes murine breast cancer brain metastasis by increasing production of",
    "entities": []
  },
  {
    "text": "integrin \u03b23-containing extracellular vesicles.",
    "entities": []
  },
  {
    "text": "(1)Armstrong Oxygen Biology Research Center and Vascular Program, Institute for",
    "entities": [
      {
        "text": "1)Armstrong",
        "label": "CARDINAL"
      },
      {
        "text": "Oxygen Biology Research Center",
        "label": "ORG"
      },
      {
        "text": "Vascular Program",
        "label": "ORG"
      },
      {
        "text": "Institute for\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cell Engineering, Johns Hopkins University School of Medicine, Baltimore,",
    "entities": [
      {
        "text": "Cell Engineering",
        "label": "ORG"
      },
      {
        "text": "Johns Hopkins University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Baltimore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Maryland, USA.",
    "entities": [
      {
        "text": "Maryland",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore,",
    "entities": [
      {
        "text": "Kimmel Comprehensive Cancer Center",
        "label": "ORG"
      },
      {
        "text": "Johns Hopkins",
        "label": "ORG"
      },
      {
        "text": "Baltimore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Genetic Medicine and.",
    "entities": [
      {
        "text": "Genetic Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Molecular and Comparative Pathobiology, Johns Hopkins",
    "entities": [
      {
        "text": "Molecular and Comparative Pathobiology",
        "label": "ORG"
      },
      {
        "text": "Johns Hopkins",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University School of Medicine, Baltimore, Maryland, USA.",
    "entities": [
      {
        "text": "University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Baltimore",
        "label": "GPE"
      },
      {
        "text": "Maryland",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Johns Hopkins University, Baltimore, Maryland, USA.",
    "entities": [
      {
        "text": "Hopkins University",
        "label": "ORG"
      },
      {
        "text": "Baltimore",
        "label": "GPE"
      },
      {
        "text": "Maryland",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Brain metastasis is a major cause of breast cancer (BC) mortality, but the",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cellular and molecular mechanisms have not been fully elucidated. BC cells must",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "breach the blood-brain barrier in order to colonize the brain. Here, we",
    "entities": []
  },
  {
    "text": "determined that integrin \u03b23 (ITGB3) expression mediated by hypoxia-inducible",
    "entities": [
      {
        "text": "ITGB3",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "factor 1 (HIF-1) plays a critical role in metastasis of BC cells to the brain.",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hypoxia stimulated BC cell migration and invasion ex vivo and brain colonization",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "in vivo. Knockdown of either HIF-1\u03b1 or ITGB3 expression impaired brain",
    "entities": [
      {
        "text": "HIF-1\u03b1",
        "label": "ORG"
      },
      {
        "text": "ITGB3",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "colonization by human or mouse BC cells injected into the cardiac left",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "ventricle. Exposure of BC cells to hypoxia increased expression of ITGB3 and its",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      },
      {
        "text": "ITGB3",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "incorporation into small extracellular vesicles (EVs). EVs harvested from the",
    "entities": []
  },
  {
    "text": "conditioned medium of hypoxic BC cells showed increased retention in the brain",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "after intracardiac injection that was HIF-1\u03b1 and ITGB3 dependent. EVs from",
    "entities": [
      {
        "text": "HIF-1\u03b1",
        "label": "ORG"
      },
      {
        "text": "ITGB3",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "hypoxic BC cells showed binding to brain endothelial cells (ECs), leading to",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "increased EC-BC cell interaction, increased vascular endothelial growth factor",
    "entities": [
      {
        "text": "EC-BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "receptor 2 signaling, increased EC permeability, and increased transendothelial",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "EC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "migration of BC cells. Taken together, our studies implicate HIF-1-stimulated",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "production of ITGB3+ EVs as a key mechanism by which hypoxia promotes BC brain",
    "entities": [
      {
        "text": "ITGB3+ EVs",
        "label": "ORG"
      },
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40662366 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40662366",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "100. Org Biomol Chem. 2025 Jul 15. doi: 10.1039/d5ob00501a. Online ahead of",
    "entities": [
      {
        "text": "100",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1039",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Design of pyrrolo[2,3-d]pyrimidine-endoperoxide hybrids as first-in-class dual",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "degraders of cyclin D1/3 and CDK4/6 with potent antiproliferative effects.",
    "entities": [
      {
        "text": "CDK4/6",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)School of Pharmaceutical Sciences/Guizhou Engineering Laboratory for",
    "entities": [
      {
        "text": "1)School of Pharmaceutical Sciences/Guizhou Engineering Laboratory",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Synthetic Drugs, Guizhou University, Guiyang, China.",
    "entities": [
      {
        "text": "Guizhou University",
        "label": "ORG"
      },
      {
        "text": "Guiyang",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Chemical Engineering Center, Guizhou University, Guiyang, China.",
    "entities": [
      {
        "text": "2)Chemical Engineering Center",
        "label": "ORG"
      },
      {
        "text": "Guizhou University",
        "label": "ORG"
      },
      {
        "text": "Guiyang",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Guizhou Provincial Key Laboratory of Innovation and Manufacturing for",
    "entities": [
      {
        "text": "Provincial Key Laboratory of Innovation and Manufacturing",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pharmaceuticals, Zunyi Medical University, Zunyi, China.",
    "entities": [
      {
        "text": "Zunyi Medical University",
        "label": "ORG"
      },
      {
        "text": "Zunyi",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "The hyperactive Cyclin D-CDK4/6 heterodimer is a key cell cycle regulator in",
    "entities": [
      {
        "text": "Cyclin D-CDK4/6",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "breast cancer, and CDK4/6 inhibitors featuring pyridine/pyrrolo[2,3-d]pyrimidine",
    "entities": [
      {
        "text": "CDK4/6",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "scaffolds are clinically used treatments. In addition, numerous studies have",
    "entities": []
  },
  {
    "text": "reported the antitumor activity of endoperoxide compounds. In this study, we",
    "entities": []
  },
  {
    "text": "designed and synthesized a series of novel",
    "entities": []
  },
  {
    "text": "indicate that the C log P values (ranging from 2 to 4) for all target compounds",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "satisfy drug-likeness criteria, implying favorable solubility and membrane",
    "entities": []
  },
  {
    "text": "permeability. All synthesized compounds exhibited antiproliferative activities",
    "entities": []
  },
  {
    "text": "that were either superior to or comparable with the positive control drugs,",
    "entities": []
  },
  {
    "text": "Palbociclib and Ribociclib. Notably, compound E2 demonstrated enhanced",
    "entities": [
      {
        "text": "E2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "antiproliferative effects in MCF-7 and T47D cell lines (IC50 = 2.16 \u00b1 0.28",
    "entities": [
      {
        "text": "MCF-7",
        "label": "DATE"
      },
      {
        "text": "2.16",
        "label": "CARDINAL"
      },
      {
        "text": "0.28",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "\u03bcM/0.42 \u00b1 0.03 \u03bcM) compared to Palbociclib (IC50 = 4.13 \u00b1 0.13 \u03bcM/10.66 \u00b1 1.63",
    "entities": [
      {
        "text": "0.03",
        "label": "CARDINAL"
      },
      {
        "text": "Palbociclib",
        "label": "PERSON"
      },
      {
        "text": "4.13",
        "label": "CARDINAL"
      },
      {
        "text": "\u03bcM/10.66",
        "label": "DATE"
      },
      {
        "text": "1.63",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "\u03bcM), without exhibiting significant toxicity in normal breast cells MCF-10A.",
    "entities": []
  },
  {
    "text": "Kinase inhibition assays demonstrated that E2 exhibits an inhibitory activity",
    "entities": [
      {
        "text": "E2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "against CDK6/Cyclin D3 (IC50 = 6.1 nM), which is more than twice as potent as",
    "entities": [
      {
        "text": "CDK6",
        "label": "NORP"
      },
      {
        "text": "6.1 nM",
        "label": "QUANTITY"
      }
    ]
  },
  {
    "text": "that of Palbociclib (IC50 = 12.9 nM). Mechanistic studies revealed that, unlike",
    "entities": [
      {
        "text": "Palbociclib",
        "label": "PERSON"
      },
      {
        "text": "12.9 nM",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "traditional CDK4/6 inhibitors, compound E2 facilitates the targeted degradation",
    "entities": [
      {
        "text": "CDK4/6",
        "label": "ORG"
      },
      {
        "text": "E2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "of Cyclin D1/3 and CDK4/6 through the Ubiquitin-Proteasome System pathway.",
    "entities": [
      {
        "text": "Cyclin",
        "label": "NORP"
      },
      {
        "text": "CDK4/6",
        "label": "PERSON"
      },
      {
        "text": "Ubiquitin-Proteasome System",
        "label": "ORG"
      }
    ]
  }
]